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ABSTRACT
Chemoradiotherapy is not without risk of injury to the muscles and nerves associated
with swallowing function. Current research supports the use of prophylactic behavioral
swallowing exercise in the HNC population, however, wide variations in swallowing treatment
methodologies exist and no optimal SLP-patient visit frequency has been established. In
addition, poor patient adherence to swallowing exercise appears prevalent. The current study
explored the impact of speech language pathologist (SLP)-patient contact time, adherence to
prophylactic behavioral swallowing exercises, and explored effects of exercise intensity on
immediate post-radiation swallowing outcomes. Groups included a high frequency group (5
weekly SLP-patient visits, n = 15), a low frequency group (3 weekly SLP-patient visits, n = 15),
a 1day/week group (1 weekly SLP-patient visit, n = 25), and a current typical treatment group (34 SLP-patient visits during the 7 weeks of radiation treatment, n = 25). Results revealed that
higher frequency of SLP-patient contact time resulted in decreased aspiration risk, improved oral
diet levels, and reduced risk of feeding tube placement. This resulted in a new recommendation
to provide 2 weekly SLP-patient visits over the course of radiation therapy, for a total minimum
of 14 visits over 7 the course of radiation. Results also highlighted a potential for significant cost
savings associated with reduced feeding tube placements. Significant relationships were found
between adherence levels and maintenance of body mass index (BMI) level weight level, public
eating scores and normalcy of diet. Predictive equations determined that 60% adherence may
help maintain weight and stabilize BMI but 100% adherence of this study’s total exercise
regimen was needed to maximize subjects’ diet level. Results also highlighted new objective
measurement data and established a new range of salivary loss related to diet level or feeding
tube use. Findings revealed that a salivary loss of 74.85% - 88.68% was associated with feeding
tube dependence. Additionally, a salivary loss of 47.18% was associated with the ability to
vi

maintain a normal unaltered diet. This provided an objective level to measure the effectiveness
of methodologies designed to protect and/or restore salivary function in future studies.
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CHAPTER 1. INTRODUCTION
1.1 Statement of the Problem
Swallowing is a physiological function necessary for the safe passage of food, liquid, and
saliva into the stomach, while preventing infiltration of these materials into the airway. Radiation
therapy in the head and neck cancer population, with or without chemotherapy, is a known risk
factor for swallowing disorders (dysphagia) and increases risk of aspiration (1-11). Post-radiation
dysphagia may result in altered diet, decline in nutritional intake, reduced quality of life (QOL),
interruption to curative cancer treatment, and is linked to overall morbidity (1-11). Dysphagia
exists across a continuum, from mild to severe, and has the potential to cause malnutrition,
dehydration, pneumonia, and asphyxia (12). The life-threatening potential and impact to patient
health and safety make this a significant concern in the head/neck cancer (HNC) population (5).
Incidence of all combined new HNC estimates for the year 2016 was estimated at 71,760 (13).
Incidence rates of dysphagia following radiation for HNC may range up to 66%, with up to 33%
of dysphagic patients developing aspiration pneumonia (6), and silent aspiration rates up to 44%
(14).
Historical intervention for HNC involved surgical resection and subsequent radiation,
which fails to preserve the organs of swallowing (15). Studies conducted by the Veteran’s
Administration, beginning in 1984, and the Radiation Therapy Oncology Group produced
outcomes that demonstrated the organ preservation and curative potential of combined
chemotherapy and radiation treatment without surgical intervention (15, 16). Recognition of
these landmark studies has changed the standard of care for HNC, resulting in increased organ
preservation treatment modalities. Today, radiation is a widely accepted treatment approach for
stage II, III and IV head and neck cancers designed to cure the disease while preserving affected
organs, and may be performed in conjunction with chemotherapy, often referred to as
1

chemoradiotherapy (17). The use of chemoradiotherapy as an organ preservation tool in the
treatment of HNC has proven successful, but is not without risk of injury to the muscles and
nerves associated with swallowing function (4, 18-21). Chemoradiotherapy-induced dysphagia
and increased risk of aspiration are known to occur during and after chemoradiotherapy (1-11).
The current available research on chemoradiotherapy-induced dysphagia has sought to
identify specific causes and to examine swallowing-related outcomes in an effort to improve
both immediate and long-term swallowing function and QOL. Previous research has identified
the swallowing organs most at risk during and following radiation treatment (18). Also identified
are the acute and chronic dysphagia characteristics including aspiration, upper esophageal
sphincter (UES) dysfunction, reduced pharyngeal constriction, prolonged pharyngeal transit
time, and loss of appetite (9, 22-29). Additional treatment toxicity risks of chemoradiotherapy
include xerostomia (lack of sufficient salivary production) and mucositis (ulcerated and
edematous mucosal tissue of the mouth and throat), and their relationship to dysphagia and QOL
have been identified (30, 31). Toxicity effects are often considered a significant source of poor
adherence to treatment recommendations during swallowing interventions in the HNC
population. Adherence is typically reported as low, ranging from 21%-52%, based on patientreported completion of prescribed exercises (32). The possible consequences of non-adherence to
the recommended behavioral swallowing interventions may include extended feeding tube use
(PEG, percutaneous endoscopic gastronomy tube), increased risk of aspiration, and increased
morbidity (33). One study has suggested behavioral swallowing exercises and subsequent diet
level may have an indirect effect on salivary production (34). Oral hygiene protocols and oral
pain management have also been suggested to manage and reduce these toxicity symptoms
related to the cancer treatment modalities, potentially improving swallowing outcomes (30, 35).
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Better understanding of chemoradiotherapy’s effect on muscles, nerves, and the healing
process has expanded our understanding of associated dysphagia and dysphagia treatment.
Dysphagia interventions have been adapted to target the nutritional and swallowing-related
concerns in the HNC population. These interventions may begin between the initial cancer
diagnosis and the start of radiation treatment and continue for the duration of radiotherapy
(prophylactic treatment), or are prescribed in response to the occurrence of dysphagia symptoms
(reactive treatment). Recent research has highlighted the positive effect of prophylactic
swallowing exercise (14, 24, 34, 36-38). Currently, however, wide variations in swallowing
treatment methodologies exist and no optimal timeline for behavioral swallowing treatment has
been established. Intervention commonly begins at the start of radiation treatment, but some
preliminary data have indicated that starting behavioral swallowing exercise two weeks before
radiation begins (pre-treatment) may provide some advantage and result in better swallowing
outcomes (37, 39). A recent review determined that both prophylactic and reactive swallowing
intervention improved function and physiology of swallowing, but did not find improvements in
QOL (38). The need for further, high quality, study was highlighted due to the variations in
treatment timing and methodologies. Attempts to determine the optimal treatment timeline or
duration of swallowing treatment may also be premature given the lack of consensus regarding
other treatment factors including speech language pathologist (SLP)-patient visit frequency and
exercise intensity (sets and repetitions).
Principles of exercise science including intensity, duration, and frequency must be
considered in the preventative and rehabilitative process. While the current research supports the
use of behavioral swallowing exercise in the HNC population, the wide variations in
methodologies have led to a lack of consensus in dysphagia treatment protocols, and poor patient
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adherence appears prevalent. Virani, Kunduk, Fink, and McWhorter (24) experienced consistent
reductions in adherence to the prescribed exercise in the course of their prospective study, but
results established that exercise has a positive outcome on swallowing and feeding tube use in
the HNC population compared to performing extra swallows of saliva or water only. Feeding
tube use was not eliminated immediately following treatment for either study group, but only the
exercise group experienced a significant reduction in feeding tube use 3 months after
radiotherapy. In a retrospective study, Hutcheson, Bhayani, Beadle, Gold, Shinn et al. (14) also
determined that prophylactic treatment was associated with better long-term swallowing
outcomes, measured by final diet after treatment and duration of feeding tube use, but also found
treatment adherence (patient self-report, 58% reported adherence) to be a key factor in patient
outcome. Adherence was defined as performing more than four exercises per day. Patients, who
were more adherent to swallowing exercise, and maintained oral food intake, returned to the
highest-level diets and had the shortest duration of feeding tube use, compared to those who had
poor exercise adherence and no oral food consumption. Wall, Ward, Cartmill, Hill, and Porceddu
(40) also examined adherence to behavioral swallowing treatments, defined as the percentage of
exercises completed, and results demonstrated low mean adherence (27%) and high variability
with adherence ranging from 0-97%. Consistent with previous findings (e.g., Varani et al, 2015)
this study also noted declines in adherence after 4 weeks of intervention when toxicity effects are
increasing. Krisciunas, Castellano, McCulloch, Lazarus, Pauloski, et al. (41) also examined the
impact of adherence on swallowing outcomes in the HNC population reporting that 54% of
patients were considered adherent to behavioral swallowing exercise. Adherence was measured
as a percentage (performing10/12 possible exercise sessions per week). They found no
differences between adherent and non-adherent patients. To date, no optimal level of adherence
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has been determined and the consistent reduction in adherence often observed during
radiotherapy results in a lower intensity of exercise over the course of treatment. This result
raises questions about exercise intensity and exercise adherence during behavioral swallowing
treatment. It is plausible that the improvement adherence, resulting in higher intensity of exercise
and increased educational opportunities, may have further maximized the immediate and longterm swallowing function outcomes. Optimal levels of exercise force and intensity have been
recommended for specific lingual exercises (e.g., tongue-palate press) (42), but optimal levels of
force and intensity have not been well established, overall, for exercises used in behavioral
swallowing treatment.
Additional research in adherence, including HNC and other dysphagia populations,
revealed components of non-adherence, other than the direct effects of toxicity occurring during
chemoradiotherapy, including lack of knowledge, lack of skill, poor motivation or self-concept,
refusal of diet or exercise, poor satisfaction with diet, and denial of dysphagia by the patient (40,
43, 44). Additional external factors that may impact adherence include lack of knowledge within
members of the healthcare team or caregivers, team member or caregiver disagreement with
recommendations, improperly preparing foods and liquids, not valuing the SLP’s input, or
underestimating the needs of the patient (12). Findings illustrate how non-adherence, at all
levels, is related to inadequate education and constrained involvement in the care process.
To increase adherence, the SLP should understand the dynamic nature of the treatment
and recovery process, and ensure adequate education to patient and the caregiver. A recent
clinical trial by Carnaby-Mann, Crary, Schmalfuss, and Amdur (34) provided SLP-guided
swallowing treatments five days per week and demonstrated improved patient outcomes,
including reduced feeding-tube use and improved adherence to behavioral swallowing
5

intervention. This demonstrated the potential beneficial impact of increased skilled SLP-patient
contact time on adherence. However, the SLP-patient visit frequency related findings are limited
by the differing interventions in the comparison groups. Both the study exercise and sham groups
received 5-day per week SLP-visit frequencies, but received different exercises, making it
difficult to determine the specific contributions of increased SLP-patient contact time.
Furthermore, the recent work by Greco et al. (38) highlighted the potential bias and internal
validity concerns of the previous studies, that examined prophylactic swallowing interventions
for the HNC population, created by the wide variations in SLP-patient contact time. It was
reported that experimental groups in the meta-analysis often received greater SLP-patient contact
time compared to the non-experimental groups, potentially exaggerating any intervention effects.
To better assess the prophylactic swallowing interventions we need to determine the impact SLPpatient contact time has on patients’ swallowing-related outcomes. The proposed study will help
close this knowledge gap by examining the impact of SLP-patient contact time in groups
performing identical exercise protocols. Increasing the number of SLP-patient visits appears to
be a promising way to improve adherence to behavioral swallowing intervention. Increased SLPpatient contact time allows for greater monitoring of exercise performance, increased educational
opportunities, and problem solving opportunities, which have been suggested as mechanisms to
improve patient adherence. When non-adherence occurs, the SLP should not focus on the poor
adherence, but rather seek out underlying causes and offer solutions. The SLP should also work
to minimize the burden of treatment. Behavioral swallowing intervention including exercise and
postural interventions should be clearly described and targeted to the patient’s specific needs.
When needed, diet changes should be minimal and easy to carry out. The SLP has a significant
role in the initial and continued education of the patient and care team, but the frequency and
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duration of SLP-patient contact time needed to ensure high levels of education and adherence
have not been established.
Treatment tools using biofeedback may be one method to address the force of exercise in
behavioral swallowing treatment (45, 46). Crary, Carnaby, Groher, and Helseth (2004) (45)
demonstrated the potential benefits of biofeedback using surface electromyography (sEMG);
however, Humbert and Joel (2012) (46) indicated that sEMG can be overly sensitive to small
muscle movements not associated with the target activity. More recently, work by Malandraki
and Hutcheson (47) noted the potential limitations of sEMG-driven therapy when compared to
more food (bolus) based treatment approached, based on outcomes from a previous study
assessing the McNeil Dysphagia Therapy Program (48). It is plausible that the limitations of
sEMG may be overcome by other methods of biofeedback, or that a more organ-specific
biofeedback systems may provide a different outcome when compared to more traditional
swallowing interventions. Other instrumentation has been developed that provides biofeedback
and modulation of exercise force. The SwallowSTRONG system (SWST, Swallow Solutions,
Madison, WI) consists of small, moldable, oral pressure sensors and biofeedback display, and
allows the patient to visualize target pressures (force produced) during treatment. SWST
provides a means to monitor, measure, observe, and implement Isometric Progressive Resistance
Oropharyngeal [I-PRO] Therapy for lingual strengthening (tongue to palate presses) (49). It may
be hypothesized that exercise utilizing the SWST system will result in increased accuracy of the
desired exercise force resulting in improved swallowing outcomes. Rogus-Pila, Rusche, Hind,
Zielinski, Gangnon et al. (2015) reported that recent findings for I-PRO therapy with the SWST
system are positive with improved QOL scores, improved oral intake, and reduced incidence of
pneumonia (50). These findings are promising, and dysphagia etiologies in the study did include
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HNC, but there was no direct comparison group and treatment occurred post-radiation (50). No
studies were found that directly examined the feasibility and use of this device for lingual
strength exercises in the HNC population. This may be due to concern regarding the patient’s
ability to tolerate these devices due to toxicity-related pain and discomfort. However, findings of
the Rogus-Pila et al. (2015) study suggest the HNC patients may tolerate and benefit the use of
biofeedback devices that require oral placement. Further research is warranted to assess the role
of this device and determine feasibility in behavioral swallowing therapy provided
prophylactically during chemoradiotherapy, and to determine if the desired exercise force is
achieved and maintained.
The current body of evidence supports the use of prophylactic behavioral swallowing
interventions and the need for SLP involvement in the treatment of HNC (14, 24, 25, 34, 36, 45,
50, 51). However, to date, there is no guideline for optimal swallowing interventions in the HNC
population. Limited information exists regarding the effect that the frequency of SLP-patient
contact time on patients’ immediate and long term swallowing outcomes in the HNC population.
It is also unknown what impact increased SLP-patient contact time will have on cancer treatment
modality-related toxicities, immediate and long term swallowing outcomes, given increased
opportunity for education and counseling. This body of knowledge also highlights the lack of
patient adherence to swallowing interventions and the ongoing use/need for feeding tube
placement. Increased SLP-patient contact time may be one way to increased patients’ adherence
to swallowing-related interventions. However, it remains unknown if increased adherence to
swallowing exercises will decrease feeding tube use immediately upon completion of the
chemoradiation treatment and result in improved swallowing outcomes, or if the cancer
treatment modality-related toxicities are the most definitive factor of immediate swallowing-
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related outcomes. Feeding tube use may negatively affect QOL, but the current evidence has not
reached a consensus regarding the effects of feeding tube use on swallowing physiology. Some
evidence suggests a potential negative impact of feeding tube use on physiological swallowingrelated outcomes (e.g., upper esophageal sphincter dysfunction) or reduced likelihood for return
to full oral diets. These issues need further research to increase our understanding of swallowing
management in this population. Therefore, based on the current knowledge and the available
literature, the following research questions were developed, and the specific aims of this study
are to investigate the following:
Primary research questions:
If increased SLP-patient contact time (high frequency), compared to reduced SLP contact time
(low frequency), during prophylactic behavioral swallowing intervention will result in improved
immediate post-treatment swallow physiology, swallow function, and swallow-related QOL.
If increased SLP-patient contact time during prophylactic behavioral swallowing exercise
intervention, compared to the current common treatment, will result in improved immediate posttreatment swallow physiology, swallow function, and swallow-related QOL.
Secondary research questions:
Does increased SLP-patient contact time result in improved treatment exercise adherence?
Does increased adherence with behavioral intervention result in decreased reactive PEG
placement, weight loss, improved post-treatment swallow physiology, swallow function, and
swallowing-related QOL?
Are patients undergoing chemoradiotherapy for HNC able to tolerate a biofeedback device that
requires oral placement?

9

How does salivary production (salivary weight) during chemoradiotherapy relate to diet level?
Does the level of toxicity (measured by salivary weight, mucositis scale score, pain level, and
Cancer Fatigue Scale score) correlate to the level of swallowing function and/or swallowing
QOL-related scores?
1.2 Research Hypotheses
The research hypotheses for this study, based on previously published literature include:
1. The high frequency (HF) group will exhibit significantly higher levels of swallowing function
compared to the low frequency (LF) group based on the following:
Physiological outcomes measured by the PAS scores, DIGEST, maximal UES opening
(centimeters, cm), and maximal isometric tongue pressure (kilopascals, kPa), maximal upper
esophageal sphincter (UES) opening, maximal pharyngeal constriction, maximal hyolaryngeal
excursion, maximal isometric tongue palate pressure, time to airway closure, pharyngeal
constriction ratio, pharyngeal residue ratio
Functional swallow outcomes measurements: PEG tube use, FOIS, weight loss percentage, and
MNA-SF scores
Quality-of-life: MD Anderson Dysphagia Inventory (MDADI) scores and the Performance
Status Scale Head and Neck (PSS H&N) (normalcy of diet and public eating) scores
2. Higher frequency treatment (HF or LF) will result in better swallowing ability postchemoradiotherapy than the 1day/week group or current common treatment (CCT) group based
on the following:
Physiological outcomes measured by the PAS scores, DIGEST
Functional swallow outcomes measurements: PEG tube use, FOIS, weight loss percentage
Quality-of-life: MD Anderson Dysphagia Inventory (MDADI) scores
10

CHAPTER 2. RADIATION TREATMENT IN HEAD/NECK CANCER, DELIVERY,
AND IMPLICATIONS FOR SWALLOWING
2.1 Defining Head/Neck Cancer
Madsen (52) reports that HNC accounts for 3 to 5% of all cancers and is defined as
cancers occurring in the head or neck region; this includes cancers of the mouth, larynx, pharynx,
salivary glands, oral cavity, and sinus cavities. Cancers of the skin, bones, eyes, brain, and
thyroid are not included. Risk factors of HNC include smoking tobacco, oral tobacco, betel and
mate consumption. Leukoplakia, white patches or spots within the mucosal lining of the oral
cavity, are also a known risk factor with approximately one-third becoming cancerous. Other
factors which increase risk include asbestos, paint fumes, poor diet, weakened immune system,
gastroesophageal reflux, human papilloma virus (HPV), Epstein-Barr virus, and secondhand
smoke (2, 53).
HNCs typically originate from the mucosal tissues of the mouth and throat as squamous
cell carcinoma (17, 52-54). Other types of cancerous cells include lymphomas (developing from
lymphocytes), adenocarcinomas (developing from glands within the body), and sarcomas
(developing from cartilage, bone, or blood vessel tissues) (55). Squamous cell carcinoma makes
up over 90% of all head and neck cancer and is by far the most common (55). Historically,
squamous cell carcinomas of the head and neck were related to tobacco and alcohol exposure but
currently 25% of all HNCs are non-tobacco related (56). Today, up to 70% of oropharyngeal
cancer in the United States is HPV-mediated (56). There has been a rapid rise in HPV-mediated
HNC, which appears linked to the slow epidemic-like rise of overall HPV incidence (57). HPV is
associated with increased overall risk of oropharyngeal cancers, and a specific subtype (HPV16)
is strongly linked to development of HNC (58). The HPV-related HNC population is also
younger and experiences less comorbid disease than the historic tobacco-related HNC population
11

(57). Despite the reduction in comorbid disease and potentially favorable age, recent findings for
HPV-related HNC demonstrated that these cancers result in the same swallowing-related decline
in QOL as non-HPV HNCs (57, 59). The rise of HPV-related HNC indicates that treatmentrelated dysphagia will continue to be a concern for many years to come (60). Additionally, recent
research has suggested that HPV-related HNC may have a lower mortality rate than non-HPV
cancers (61). This group of findings suggests that HPV-mediated cancer survivors may live for
decades with the negative effects of chemoradiation.
2.2 Diagnosis and Staging of Head/Neck Cancer
Squamous cell cancer is categorized as carcinoma in situ when cancerous cells are
limited to mucosal tissues, and invasive squamous cell carcinoma when cancerous cells move
into deeper tissues (52). Initial diagnosis of suspected cancerous tissue requires biopsy, and may
require additional surgery to determine if cancerous cells have spread to lymph nodes of the neck
before a cancer stage can be assigned (52).
Cancer staging, known as the TNM system, accounts for tumor size (T), lymph nodes
involvement (N), and if the tumor has metastasized into other areas of the body (M) (52). Tumor
size is measured in centimeters (cm) and assigned a ranking 1-4; lymph node involvement is
measured in centimeters and assigned a ranking 0-3; and metastasis is measured as spread or no
spread and assigned a ranking of 0-1 (52). Once the TNM ranking is assigned, the overall cancer
is assigned a stage (0-IV), but having the cancer stage without the associated TNM rankings may
lead to confusion as stage III and stage IV cancers allow multiple combinations of TNM
rankings (52). It should be noted that up to 50% of HNCs are considered advanced (stage III, IV)
by the time of diagnosis, and advanced stage may play a role in treatment outcomes and
symptom severity (52). Stage 0 and 1 tumors are smaller and do not involve other areas of the
12

body, and may be successfully removed surgically with minimal damage to surrounding tissue
eliminating the need for chemoradiotherapy. Larger tumors or those with metastasis and lymph
node involvement (stage II, III, and IV) most often receive chemoradiation as a means to cure the
cancer while preserving the affected tissues. Table 1 provides detailed descriptions of the TNM
and cancer stage ranking criteria.
Table 1. TNM (Tumor, Lymph Node, and Metastasis) and Cancer Tumor Staging Systems
TNM System
Cancer
Stage
Tumor Size
Stage
Tis
In situ
0
Cancer in situ only
T1
2 cm or smaller
I
T1N0M0 tumor
T2
2-4 cm
II
T2N0M0 Tumor
T3
4 cm or larger, or spread to a
III
T3N0M0 or T1-T3N1M0
single lymph node
tumor
T4
4 cm or greater
IV
Any T4, Any N2-3, and Any
M1 tumor
Lymph Node
Involvement
N0
Absent from regional lymph
nodes
N1
Tumor less than 3 cm with
spread to one lymph node on
same side
N2
Tumor of 3-6 CM with spread
to same side, less than 6 cm
with multiple spread on same
side, 6 cm or less with spread to
both sides
N3
6 cm or greater spread to any
lymph node
Metastasis
M0
None
M1
Disease in another area of the
body
cm: centimeter
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2.3 Radiation in Head/Neck Cancer
Radiation therapy utilizes high-energy radiation particles directed at the cancerous tissue
to break apart small pieces of the cell’s deoxyribonucleic acid (DNA) in order to prevent cell
replication, ultimately killing off cancerous tissues (17, 62). Radiation can be delivered through
external beam radiotherapy, interstitial radiotherapy (brachytherapy), 3-D conformal
radiotherapy (tomotherapy), intensity modulated radiotherapy (IMRT), and proton beam
radiation therapy (PBRT).
External beam radiation sends high-energy particles from the outside of the body into the
affected tissues, but will infiltrate surrounding healthy tissues covered by the beam potentially
resulting in more severe and wide spread tissue damage and toxicity (62). Brachytherapy places
radioactive material directly into a target area(s) and does not appear to be routinely used to treat
HNC (63). 3-D conformal radiotherapy projects three separate external beams into the affected
area in an attempt to spare surrounding tissues, but lacks the ability to modulate the treatment
dose to healthy tissue within the field leading to greater toxicity and radiation damaged tissue
(55). A newer form of external beam radiation, intensity modulated radiation therapy (IMRT)
which uses photons, allows a tumor-shaped beam of radiation to be passed into the body in
similar fashion to 3-D conformal beams (62). IMRT also allows varying strengths within the
radiation beam to deliver in higher dosage to the tumor and lower dosage to outlying areas which
may lessen the damage to these healthy body tissues. The potential tissue saving function of
IMRT has made it the previous and current standard of care for HNCs (4, 10, 17, 21, 54, 64, 65).
PBRT, which uses protons, is the most recent advancement in radiation delivery using
multiple beams, similar to IMRT, to target only the tumor and marginal tissues (60). New
evidence suggests that PBRT may take the place of traditional IMRT due to the potential
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reduction, but not elimination, of treatment associated toxicity (60). The reduction of toxicity
appears to be a function of the physical properties of protons used in PBRT, which may have less
radiation beam overlap into healthy tissues, compared to the photons of traditional radiation (60).
Currently PBRT does not appear to be widely used and limited research exists in this area, but
research efforts are ongoing.
In IMRT, a process known as contouring produces a three-dimensional model of the
tumor or tumors using computerized tomography (CT) scans or magnetic resonance imaging
(MRI) (10, 64, 66). Contouring is performed using computerized software (e.g., ECLIPSE
planning system, Varian Medical Systems, Palo Alto, CA) (64). Following contouring, the
margins (the areas of tissue around the identified tumor) are expanded to capture any subclinical
cancerous tissues ensuring eradication of the tumor (10, 64). Expansion of the radiation beam
into these marginal tissues is reported to range from 5 mm to 1.5 cm in depth (10, 64).
Additionally, each patient receives a cast-like mask designed to reduce patient movement during
treatment (e.g., thermoplastic immobilization system, S-type, Medtec, Orange City, IA) (62, 64),
and the skin is often marked outlining the area where radiation is introduced into the body (62).
IMRT may reduce radiation to surrounding healthy tissues; however, the large dose
required for treating squamous cell cancers in the head/neck often results in higher total radiation
accumulation (17). Radiation dosage and delivery are determined by the radiation oncologist and
will vary based on tumor size, location, and severity (62). However, a recent review of the
literature by King, Dunlap, Tennant, and Pitts (67) revealed that head/neck squamous cell
cancers require highly aggressive radiation resulting in a high total prescribed doses of 60–70
Gray (Gy, x100, e.g., 70=7,000). A high total dose also results in a rapid dose accumulation.
During IMRT the total dose of radiation (referred to as the accumulated dose) is broken into
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small increments (fractionation) which are delivered daily over a period lasting from 5 to 8
weeks (10, 17, 62, 64). Fractionation can be delivered in multiple methods including
conventional fractionation (equal doses), accelerated fractionation (delivery of the total dosage at
twice the rate), hyperfractionation (delivery of multiple small doses per day in place of one large
dose), and hypofractionation (delivering larger doses per day to reduce the number of days per
week) (31). Fractionation is commonly delivered using the conventional method with treatment
once per day, five days per week, until the total dosage is administered, typically 35
fractionations (10, 64, 68). A retrospective study analyzed the IMRT regimen of 141 patients
and reported an average fractionation dosage of 2.1Gy equaling a total accumulation dosage of
69.3 for the primary tumor, and fractionation of 1.7Gy equaling a total accumulation of 56.1Gy
for the prophylactic (marginal) treatment area (10).
Radiation is delivered using a linear accelerator machine overseen by the radiation
physicist, dosimetrist, and radiation therapist (62). The radiation physicist ensures the radiation
equipment delivers the prescribed dosage; the dosimetrist assists the radiation oncologist in
developing the treatment plan; and the radiation therapist operates the radiation equipment and
positions the patient during treatment (62). Radiation treatment begins once tumor contouring is
complete and the dosages have been prescribed, and complicating factors including pre-radiation
surgeries and dental work have been completed (17).
Dosimetric and Tumor Related Factors of Dysphagia
The severity of swallowing changes is dependent on multiple dosimetric factors including
tumor size and location, the dose volume and fractionation, and the volume of tissue radiated (1,
4, 8, 10, 54, 64, 67, 69-71). Starmer, Quon, Kumar, Alcorn, Murano, et al. (72) found a mean
radiation dosage of 69.6 Gy was associated with high levels of aspiration (32%), and slowed
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swallow kinematics occurred when radiation was in the supraglottic region. Timing measures
included duration of laryngeal vestibule closure, time to vestibule closure, duration of hyoid
excursion, pharyngeal transit time, swallow onset delay, and UES opening time. Patients with
aspiration had delayed vestibular closure, shorter transit, and shorter UES opening times. These
findings support the previous findings of Steele and Cichero (73) who reported that the risk of
aspiration increased with decreased hyoid movement, which may reduce UES opening times, and
delayed closure of the airway (delayed closure of the laryngeal vestibule).
Teguh, Levendag, Sewnaik, Hakkesteegt, Noever, et al. (8) used FEES along with quality
of life (QOL) measurements [MD Anderson Dysphagia Inventory, MDADI (74); Performance
Status Scale (75), and EORTC H&N35 (76)] to examine the relationship between radiation dose
and SWOARs in a prospective study. Results demonstrated that higher doses to the superior
PCM area result in more severe dysphagia. The pattern of higher doses resulting in more severe
outcomes is consistent with other findings. However, tumor site was limited to tonsillar fossa and
base of tongue and, while it may be plausible that larger radiation doses to all SWOARs will
result in more severe dysphagia, this remains unclear.
Kumar, Madanikia, Starmer, Yang, Murano, et al. (1) examined dosage and tumor stage
in floor of mouth cancer (SWOAR = Base of tongue) for their relationship to dysphagia using the
Penetration Aspiration Scale (PAS). Results concluded that tumor size was not predictive of
patient outcomes, but dosage (70 Gy) was a significant predictor with increased risk of
penetration/aspiration. A prospective 2009 study collected dosage and QOL data (MDADI), oneyear post radiation, examined the superior, middle, and inferior PCM, and found no correlation
between dose and tumor site for chronic dysphagia (71).
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A 2009 retrospective study, examining dosimetric factors in 250 patients having a wide
range of tumor sites and stages, found that higher tumor stage (III, IV) was predictive of
dysphagia, and that higher dosage volume (60 Gy) to the larynx increased the risk of feeding
tube use (67). Additional findings revealed a dose of 65 Gy to the pharyngeal constrictors
increased risk of UES stricture (67). More recent findings continued to demonstrate that
advanced tumor stage was related to dysphagia and associated decreased QOL (77, 78). A 2016
study examined the two-year longitudinal outcomes of the MDADI related to the use of IMRT
finding that higher cancer stages (III, IV) and high total accumulated radiation dose appeared to
result in longer duration of swallowing impairment and low QOL (78). These findings support
dosage as a significant predictor of acute and chronic dysphagia. The effect of tumor size is
mixed, but it does appear that stage III and IV are more predictive of dysphagia. The impact of
tumor size may relate to the prescribed dosage and volume, ultimately increasing the dose to the
SWOARs. Acute dysphagia characteristics (e.g., severity) do not appear to predict chronic
dysphagia.
While tumor site may not directly predict dysphagia or severity, it may be predictive of
specific functional deficits associated with dysphagia. Logemann, Rademaker, Pauloski, Lazarus,
Mittal, et al. (79) examined tumor site and swallowing function outcomes. Findings revealed that
the characteristics of dysphagia observed 3 months after chemoradiotherapy varied by primary
tumor location (e.g., nasopharyngeal cancer), and the frequency of dysphagia symptoms reported
also increased after curative treatment. Results also found deficits including reduced tongue
strength/retraction and reduced/slowed laryngeal closure occurred across all tumor sites. These
findings indicate that function may vary based on the SWOAR region impacted, but tongue
strength and laryngeal closure appear consistent across tumor site.
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Controlling radiation levels may offer some protection to swallowing organs. However,
prescribed radiation thresholds were found only for the salivary glands, ≤ 26 Gy (54). Findings
of the same study reveal that dosages to the salivary glands were lower than the level prescribed
to the primary tumor, but the recommended dose was exceeded in all cases with the exception of
the parotid glands in unilateral tumor cases (54). These findings, and those of additional studies
indicate that, despite the potential benefits for IMRT, the thresholds for adverse effects may still
be exceeded resulting in dysphagia (54, 69, 70, 80). IMRT does not appear to mitigate undesired
radiation, despite the advances in technology, and the higher doses needed to cure advanced
disease appear to result in higher total dosage to the marginal areas.
2.4 Chemotherapy
Chemotherapy, a drug-based treatment capable of preventing cell division targeting
rapidly dividing cells, is administered in conjunction with radiation therapy in more advanced
cancers (stage III, IV) to increase treatment effectiveness, improve cancer eradication, and
survival rates (17, 64). The use of chemotherapy with radiation has also been called chemoIMRT (81). One delivery method, induction chemotherapy, infuses the patient with a large
dosage, 1000 mg, prior to the start of radiation treatments followed by a concomitant dose of 100
mg on days 1 and 29 during radiotherapy (81). Chemotherapy that does not include an induction
phase has varying chemotherapy regimens including a 100 mg dosage every three weeks or 150
mg dosages given on days 2, 9, 16, 23 (64). The use of chemotherapy in conjunction with
radiation appears common for more advanced tumors (stage III, IV) and is reported throughout
the available literature. Chemotherapy is also associated with treatment toxicity (mucositis and
xerostomia); and while delivery protocol does not appear to have a significant effect on
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swallowing outcomes, use in conjunction with radiation may result in faster onset or severity of
toxicity symptoms (79, 81).
2.5 Impact of Wound Healing and Recovery from Chemoradiotherapy
Wound healing from trauma caused by the cancer treatment modalities is different from
the wound healing processes from other tissue trauma (82). Mucositis-related wounds may not
begin healing until two weeks after chemoradiotherapy ends (31). Denham and Hauer-Jensen
(82) reported on radiation-induced wounds and the healing processes of these damaged tissues
compared to typical healing processes. Typical wound healing follows a five-step sequence
outlined as follows:
1. homeostasis is achieved through coagulation and vasoconstriction;
2. inflammation of tissues allows for vasodilation, increased tissue permeability, and leucocyte
infiltration;
3. granulation tissue forms, activation of fibroblasts and collagen formation for the extracellular
matrix, and infiltration of neutrophils and macrophages;
4. tissue restoration through the cessation of fibronectin and collagen production, the wound
closes and re-epitheliasation occurs;
5. remodeling of the wound, balancing the structures of the tissues and restoring normal
properties.
The effects of radiation on wound healing were described as follows:
1. homeostasis is prevented by the repetitive nature of radiation therapy and vasoconstriction
may not occur due to the associated increased tissue permeability;
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2. inflammatory responses are suppressed by low radiation doses and high radiation doses
increase inflammation while suppressing tissue repair;
3. dispersion and formation of granulation tissue, activation and levels of fibroblasts and
collagen formation for the extracellular matrix, and infiltration of neutrophils and macrophages
are all disrupted by the repetitive insult of radiation;
4. tissue restoration is prohibited or dampened by the continued destruction of cells during
treatment;
5. remodeling of the wound may be impaired due to the underlying vascular and cellular (DNA)
changes, and chronic manifestation of these changes may have long-term effects on future
wounds.
The disrupted mechanisms of healing directly influence the mechanisms of excess
fibrinogen and collagen, resulting in poor cellular organization, which produces fibrotic and
immobile tissues of the head/neck. Fibrotic tissue formation can occur in the superficial
epithelial layers or extend into the deeper lamina or connective tissues surrounding the
swallowing organs and nerves (83). Fibrotic tissue formation is reported to be common, and high
total radiation dose is reported as a predictive factor for the development of this tissue (83).
Despite the reported common occurrence of fibrosis, incidence data do not appear to be
available. It is unclear if fibrotic tissue development can be fully avoided in the HNC population,
but it is plausible that minimizing the extent or severity of chemoradiotherapy-induced wounds
may reduce the risk of developing fibrotic tissues. The SLP must be aware of the potential for
fibrotic tissue development during wound healing and understand the potential impact on
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swallowing physiology. Education regarding oral hygiene for prevention of wounds and wound
care, if wounds appear, is an important aspect of the treatment process in the HNC population.
Surgical wounds including neck dissection (removal of the lymph nodes) is also a
significant contributor to lymphedema (collection of intracellular fluids in the affected tissues)
(84). The presence of lymphedema, if left untreated, has been linked to later formation of fibrotic
tissue, which may result in dysphagia from immobilization of the organs of swallowing (84).
Given the nature of some cancers (involvement of the lymph nodes), these surgical interventions
may be unavoidable, and the SLP should be aware of the potential exacerbating and negative
impact they may have on the prognosis for patient-related swallowing outcomes. Lymphedema
intervention is available (performed by the SLP, patient, or lymphedema therapist), and
lymphedema education and treatment should be implemented as soon as lymphedema is
observed.
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CHAPTER 3. ORGANS OF SWALLOWING, EFFECTS OF RADIATION AND
CHEMOTHERAPY ON SWALLOWING ORGANS, AND CURRENT DYSPHAGIA
TREATMENT IN HEAD/NECK CANCER
3.1 The Intact Swallow
Normal swallowing function is controlled by sensory and motor cortical pathways, and
relies on intact structures of the oral cavity, pharynx, larynx, pulmonary system, and esophagus
(46). The muscles and neurological pathways of swallowing are well established (85-89). Cranial
nerve (CN) I, olfactory, is responsible for smell and the initiation of salivation (85, 86, 88, 89).
CN V, trigeminal, provides both sensory afferents including light and deep sensation,
temperature, proprioception and taste of the anterior 2/3 of the tongue, and proprioception of jaw
muscles (85-89). The motor pathway of CN V includes the muscles of jaw (masseter, temporalis)
and assists with mastication and bolus propulsion (85-89). CN VII, facial, is responsible for
sensation on the anterior 2/3 of the tongue and stimulation of salivary glands, and motor
innervation of the face including the buccals and lips (85-89). Approximately 80% of saliva is
produced by the parotid and submandibular glands which are also stimulated by the sense of
sight and taste (30). Saliva is an important component of efficient swallowing moistening the
bolus and lubricating the organs of swallowing. Decreased salivary production has been linked to
reduced QOL and patient perception of decreased swallowing performance (90). CN IX,
glossopharyngeal, provides sensory input for taste in the posterior 1/3 of the tongue and pharynx,
and motor innervation to the pharynx for elevation (85-89). CN X, vagus, provides sensory and
motor function to the larynx, pharynx, nasopharynx, velum, esophagus, and stomach (85-89). CN
XII, hypoglossal, provides motor innervation to the tongue assisting in bolus containment,
mastication, and bolus propulsion (85-89). CN V, VII, IX, X, and XII have afferent and efferent
pathways to and from the brainstem (85-89). These pathways work together to influence the
forces, pressure, direction, speed, initial positioning, and integration of environmental
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information for the pathophysiology of safe and efficient swallowing (85-88). Neurological
control of motor function has been described as hierarchical, relying on delivery of sensory
information to cortical areas, which, in turn, provide instruction to the brainstem (upper motor
neurons), cranial nerves (lower motor neurons), and finally the effectors (muscles of swallowing)
(86).
3.2 Delineation of Organs at Risk for Dysphagia
The identification of specific organs or anatomical regions associated with swallowing
function that are at risk during radiotherapy may offer guidance during the curative cancer
treatment and radiotherapy-related dysphagia. Swallowing organs at risk (SWOARs) include
superior pharyngeal constrictor muscles, middle pharyngeal constrictor muscles, inferior
pharyngeal constrictor muscles, cricopharyngeal muscle, esophagus inlet (upper 1 cm of the
esophagus), cervical esophagus, base of tongue, supraglottic larynx, and glottic larynx (4, 18,
21).
Due to the incidence of xerostomia, the salivary glands should be considered an
additional organ at risk (54). Both the submandibular and parotid glands may suffer a significant
reduction in output over the course of the cancer-related treatment (54). Table 2 provides an
overview of the SWOARs, swallowing muscles, nerves, functions, and associated dysfunctions.
A visual representation of the SWOARS is presented in Figure 1.
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Table 2. Cancer Site and Corresponding Swallowing Organs at Risk (SWOAR), Muscles, Nerves, Function, and Dysfunction
Reported in the Head/Neck Literature
Cancer Site
SWOARs
Muscle(s)
Cranial
Function(s)
Dysfunction(s)
Nerve(s)
Oral Cavity
Superior PCM
Tongue (longitudinal, V, VII,
Mastication
Reduced Tongue
(including floor of Base Of Tongue
transverse, and
IX, XII
Bolus Formation
Based Retraction
mouth)
vertical)
Oral Bolus Transit Reduced
Mylohyoid
Oral Bolus
Mastication
Glossopharyngeal
Containment
Reduced Taste
Hypoglossal
Taste
Velum
Masseter
Temporalis
Buccals
Orbicularis Oris
Pharyngeal Cavity Superior PCM
Superior, Middle,
V, IX, X, Bolus Transit
Residue of Bolus
Middle PCM
Inferior Constrictors
XII
Stripping/Clearance Stenosis/
Inferior PCM
Stylopharyngeus
of Bolus
Incomplete
Cricopharyngeous
Salpingopharyngeus
Propulsion of
Opening of UES
Esophageal Inlet
Palatopharyngeus
Bolus into UES
Cervical Esophagus
Cricopharyngeous
Supraglottic Larynx
Glottic Larynx
Larynx
Supraglottic Larynx
Thyroarytenoid
X; RLN, Protection of
Aspiration
(including
Glottic Larynx
Lateral
SLN
Airway
Penetration
laryngeal
Cricopharyngeous
Cricoarytenoid
Reflexive
Incomplete
elevation)
Esophageal Inlet
Transverse Arytenoid
Cough/Redirection Opening of UES
Cervical Esophagus
Geniohyiod
of Bolus
Incomplete Glottic
Inferior PCM
Mylohyoid
Glottic Seal
Closure
Digastric
Opening Of UES
(Table 2. Continued)
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Cancer Site

SWOARs

Muscle(s)

Salivary Glands

Salivary(Parotid,
Submandibular)
Superior Pharyngeal
Constrictor Muscles

N/A

Nasal cavity

Cranial
Nerve(s)
VII, XI,
or X
X, I

NA
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Function(s)

Dysfunction(s)

Salivation

Xerostomia

Seal
Nasopharyngeal
Port
Smell

Nasal
Regurgitation
Reduced/Loss of
Smell
Excitation Of
Salivation

3.3 Evaluation of Dysphagia in Head/Neck Cancer Population
Assessment of chemoradiotherapy-related dysphagia is performed by the speechlanguage pathologist (SLP) and may include the use of an oral mechanism exam, bedside
swallow study, videofluoroscopy (modified barium swallow study, MBSS), fiberoptic
endoscopic examination of swallowing (FEES), or some combination of the preceding (7, 8, 91-
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94). One reported standard assessment protocol used by the SLP to evaluate patients in the HNC
population included a baseline assessment prior to surgery or radiation, and again at 1, 3, 6, and
12 months post-treatment (93). The standard assessment protocol included oral outcome
variables (e.g., tongue strength), performance status rated by the SLP (e.g., PSS H&N), and
patient-rated QOL (e.g., MDADI) (93). The oral mechanism exam and bedside swallow study
include measures of tongue strength, jaw range of motion, tongue range of motion, and signs of
possible aspiration (2, 93). An additional oral measurement may include salivary weight (2, 30,
31, 93), commonly taken using the Saxon test (93). The Saxon test involves placing 4 x 4 gauze
in the patient’s mouth, allowing the patient to chew for two minutes, and subtracting the original
dry weight from the weight post chewing (93, 95). Quality of life measurements completed by
the patient often include the MD Anderson Dysphagia Inventory (MDADI) (74), and EORTC
H&N35 (2, 93). Functional ratings often made by the SLP include the Karnofsky Performance
Status Scale (measures overall functional impairment) (96) and Performance Status Scale Head
and Neck (measures normalcy of diet, intelligibility, and public eating) (75).
The MBSS is used to assess coordination and physiology of the swallow and UES
function (92, 94). Variables assessed in the MBSS include laryngeal penetration and aspiration,
epiglottis function, pharyngeal wall contraction, velar function, oral tongue movement and
tongue-base retraction, hyoid and laryngeal elevation, UES opening, pharyngeal sensation (e.g.,
cough), and residue of the oral/pharyngeal cavity (92). FEES exams have been used to assess
mucous status, penetration and aspiration, and residue after the swallow (8). The use of CT is
found in the HNC research literature; however, it is primarily used for the diagnosis and planning
of radiation therapy for the HNC patient (18, 21, 66). Lazarus, Husaini, Jacobson, Mojica,
Buchbinder, Okay et al. (93) evaluated jaw ROM using the Therabite measuring disk. Normative
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data in the HNC population were established and compared to data from healthy controls, and
the scale was validated against both objective measurement and quality of life indicators.
3.4 Radiation and Chemoradiotherapy-Induced Dysphagia
Dysphagia resulting from the cancer treatment modalities is the set of signs and
symptoms including weakness, fatigue, reduced efficiency of bolus transit, and reduced mobility,
which may result in difficulty with oral intake, aspiration, malnutrition, feeding tube dependence,
and increased morbidity (26, 67, 97, 98).
Eisbruch, Schwartz, Rasch, Vineberg, Damen, and Van As (21) reported dysphagia signs
associated with HNC included:
residue in the oropharynx and hypopharynx indicating reduced pharyngeal constriction or poor
coordination with other functions of swallowing, and reduced or absent tongue-base retraction
resulting in vallecular residue;
slow or reduced closure of the supraglottic larynx which may lead to aspiration, reduced or
absent hyoid/laryngeal movement which may result in aspiration and/or reduced opening of the
upper esophageal sphincter (UES);
slow opening of the UES which may indicate stenosis or reduced relaxation leading to aspiration
during the swallowing.
Despite these reported changes in the physiology of the swallowing mechanism (e.g.,
slow laryngeal closure) resulting from radiation therapy, scarce research exists on the potential
clinical value for the quantitative measurements of swallowing timing and displacement
variables in the HNC population. One additional prospective study examined the effect of
radiation dose on aspiration and swallowing timing (7). Modified barium swallow studies
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(MBSS) were used to examine duration of laryngeal vestibule closure, time to vestibule closure,
duration of hyoid excursion, pharyngeal transit time, swallow onset delay, and duration of upper
esophageal sphincter (UES) opening time. Longer vestibular closure times, prolonged transit
times, and shorter UES opening times were associated with increased risk of aspiration. These
previous findings highlight the potential clinical benefit of timing and displacement
measurements in the identification and rehabilitation of HNC-related dysphagia. Recent work by
Leonard and Kendall (99) which established timing and displacement measures associated with
the physiological events of swallowing has been used to establish a method to quantify these
physiological events. Quantification of these underlying physiological changes may help
clinicians determine the most salient features of swallowing function or dysfunction, and provide
added prognostic and therapeutic benefits. Assessment and quantification of these changes may
be of significant importance in the HNC population due to the reported timing and physiological
changes of the swallowing system (e.g. pharyngeal transit time or UES opening).
The work by Leonard and Kendall (99) demonstrating the ability to measure timing and
displacement of swallowing events has been adapted into a computer-based program to allow
real-time and frame-by-frame analysis of the swallowing events using the MBSS imaging data.
Swallowtail Software Version 2 (Belldev Medical, Arlington Heights, IL) was developed using
the timing and displacement measures established by Leonard and Kendall. This tool provides a
method to quantify the timing and displacement measurements of swallowing observed during
the MBSS. The Swallowtail measurements include 16 timing and 5 displacement variables
which exist across 5 anatomical structures associated with the pharyngeal swallowing
mechanism including: the pharynx, larynx, hyoid, UES, and the soft palate. Variables and
definitions can be found in Table 3. The quantification of the measures may aid in determining if
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Table 3. Swallowtail Timing and Displacement Variables and Definitions
Variable
Structure
Definition
Timing
Spstart
Soft Palate
first movement of the soft palate towards the posterior
pharyngeal wall
SPMax
Soft Palate
maximal elevation of the soft palate to the posterior
pharyngeal wall during the swallow
Aes
Larynx
time of the first approximation of the arytenoids and
epiglottis coming together to close off airway
Aec
Larynx
time of contact (if occurs) between arytenoids and
epiglottis indicating airway (vestibule) closure
BV1
Pharynx
first entry of bolus head into vallecula (identify
contact near lingual base of vallecula if possible
BV2
Pharynx
first exit of bolus head from vallecula
Pop
Upper
first opening of the lumen at the UES during swallow
Esophageal
Sphincter
BP1
Upper
first entrance of bolus head into UES
Esophageal
Sphincter
PES Max
Upper
maximal distention during a swallow of the narrowest
Esophageal
point between C4 and C6
Sphincter
HL Max
Larynx
point of maximum displacement of hyoid, relative to
“Hold.”
PA Max
Pharynx
point of maximum constriction of the pharynx during
the swallow
Pcl
Upper
closure of the superior portion of the UES (PES) at the
Esophageal
lumen
Sphincter
BP2
Upper
bolus tail clears UES
Esophageal
Sphincter
H1
Hyoid
time of first superior/anterior movement of hyoid
(from “Hold”) that leads to a swallow
H2
Hyoid
time hyoid achieves maximum anterior/superior
displacement
H3
Hyoid
first relaxation of hyoid back to rest position
Displacement
Hmax+HL
Hyoid
combination of Hmax and HL
Hmax
Hyoid
maximum displacement of hyoid relative to hold
position
(Table 3. Continued)
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Variable
Structure
Displacement
PESmax
Upper
Esophageal
Sphincter
PCR
Pharynx

Definition
measure of the narrowest point between c4 and c6
when it is maximally distended during the swallow

ratio of 2-dimensional area of pharynx (including any
residual bolus and air space) maximally constricted to
area of pharynx
PRR
Pharynx
Ratio of bolus post-swallow compared to pharynx at
rest
BCR
Pharynx
Bolus remaining in pharynx post-swallow minus clear
pharynx at rest
UES, upper esophageal sphincter; C4 and C6, cervical spine 4 and 6

specific changes in the swallowing events can discriminate among the functional swallowing
outcomes in the HNC population. While all variables will be calculated when using the
Swallowtail software, those most salient to the HNC population will be highlighted in
this study. These include maximal UES opening (PESmax), maximal pharyngeal constriction
(PCR), maximal hyolaryngeal excursion (HL), time to airway closure (AEC), total transit time
(BP2), bolus clearance (BCR), pharyngeal residue/clearance (PRR). A more accurate and
complete assessment of swallowing physiology should improve the precision of clinical
interventions and rehabilitation of swallowing function. A more complete physiological
assessment may offer an increased prognostic and assessment value when paired with
perceptual/observational evaluation methods.
Dysphagia and the associated muscular and nerve changes appear to be exacerbated by
the cancer treatment associated toxicity (xerostomia, mucositis) observed during treatment, and
these occur at varying timeframes (11, 17, 26, 67, 97). Muscular and physiological changes
associated with dysphagia and increased aspiration risk may include reduced tongue strength,
reduced hyoid movement, and extended bolus transit times (73). Patients may experience
increased difficulty swallowing, but not have symptoms of coughing and choking commonly
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associated with potential aspiration (100). This may be due to treatment-related toxicities or
reduced swallowing efficiency in the absence of aspiration. Delineating between toxicity and
underlying pathological dysfunction may be difficult due to their overlapping occurrence, but it
appears that mucositis and xerostomia may worsen perception of dysphagia (101). Reduced
saliva associated with xerostomia may also impact the physiology of swallowing. A recent
review of radiation-induced dysphagia reported on the multiple terms used to describe the onset
or duration of dysfunction, demonstrating a lack of consistency among researchers and
professions (67). Terms most frequently used included early or acute (< 3months), sub-acute (3-6
months), long-term or chronic (>1 year) (17), and late-Rad (>5 years) (102). For the purpose of
this text the following terms will be used: acute (<3 months), subacute (3-12 months), and
chronic (>12 months). The proposed study will primarily focus on the acute dysphagia-related
outcomes following the completion of chemoradiotherapy. King, Dunlap, Tennant, and Pitts (67)
report that the acute phase is associated with the cancer treatment modality related toxicity
effects and muscular and physiological changes to the swallowing systems (e.g., atrophy, fatigue,
delayed closure of the airway, xerostomia). Subacute dysphagia factors also include these same
toxicity and swallowing-related changes, but may also include a latent period with no apparent,
overt, swallowing-related symptoms. The chronic phase included the long-term changes
associated with the cancer treatment modalities including increased fibrotic tissue formation and
chronic loss of salivary production or sensation. A summary of radiation and chemotherapyrelated dysphagia characteristics is provided in Table 4.
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Table 4. Summary of Radiation and Chemotherapy-Related Dysphagia Characteristics
Source
Findings
Starmer et al. (72)
 High levels of radiation (69gray) are
associated with high levels of
aspiration
 Slowed swallowing kinematics
associated with supraglottic radiation
Eisbruch et al. (21)
 Radiation is associated increased
bolus residue, slowed closure of the
airway, and slowed upper esophageal
opening
King et al. (67)
 Radiation is associated with muscle
atrophy, swallowing-related fatigue,
delayed airway closure, xerostomia
Steele and Cichero (73)
 Radiation is associated with decreased
tongue strength, decreased hyoid
movement
Kumar et al. (1)
 Radiation (70 gray) is a predictor of
aspiration and penetration risk
Starmer et al. (7)
 Radiation associated with longer
vestibular closure times, prolonged
transit times, and shorter UES opening
times were associated with increased
risk of aspiration
Bhide et al. (81)
 Chemotherapy results in increased
Logemann et al. (79)
toxicity (mucositis, xerostomia) but
does not directly result in dysphagia
 Chemotherapy may result in faster
onset of toxicity symptoms

Effects of Cancer Treatment Modalities on the Muscle and Nerves of Swallowing
Decline in swallowing function, weakness or atrophy, reduced range of motion (ROM) in
swallowing organs, and potential damage to nerves are all known complaints following
chemoradiotherapy (26, 67, 97). Swallowing is a muscular function controlled by the nerves,
with the individual parts relying on actions that occur at a cellular level. The damage to DNA
within the cells may result in altered cellular pathways impeding adenosine triphosphate (ATP)
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production, may cause an increase in cellular waste resulting in oxidative stress or reduced signal
conduction (6, 103, 104), and may ultimately end in cell death (67).
The muscles of the swallowing system are primarily type II muscle fibers (commonly
called fast-twitch), which have fewer mitochondria per cell and are more reliant on the glycolytic
energy system (67, 103, 105). Glycolysis produces waste by-products at a higher rate, and
reduced number of mitochondria means these tissues are more susceptible to the oxidative stress
associated with chemoradiotherapy (67, 103, 105).
Swallowing ability often remains functional during the first weeks of chemoradiotherapy,
but nausea and acute mucositis often occur and may result in malnutrition despite this functional
swallowing ability (31, 67, 101, 106). Malnutrition will result in overall fatigue (67), but will
also limit the available substrate available to the metabolic systems muscle cells (105). Though
evidence is minimal, there is a probable link between these factors and acute muscle atrophy.
The limited information regarding muscular changes may be due to the invasive nature required
to examine muscular changes (surgery, biopsy); however, it may be possible to evaluate
muscular changes using strength measurements [e.g., IOPI or SWST (107-109)], or by
measuring muscle thickness changes using MRI (34). Information gained may help determine if
underlying muscular and physiological changes (e.g., atrophy and reduced UES opening) or only
the toxicity effects of the chemoradiotherapy cause acute swallowing difficulties, observed in the
HNC population.
Changes to skeletal muscle due to periods of inactivity or disuse, which may occur in this
acute phase as a result of toxicity, have been linked to muscle atrophy (110). One study found
approximately a 1/3 reduction in overall strength and significant loss of lean muscle over a 28day period of bed rest in a healthy individuals (110). Animal modeling has demonstrated
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radiation-related changes to the muscle fibers and vascular system supplying radiated areas
within first 24 hours of exposure, and these models also demonstrate a cumulative effect during
treatment leading to atrophy (67, 111). If we assume that these changes also occur in a human
undergoing radiation, then exercise may help reduce the amount or rate of muscle loss by
stimulating the growth or repair of muscle cells. It may also be plausible to build a functional
reserve reducing the impact of atrophy on the swallowing by beginning behavioral swallowing
exercises before or when radiotherapy begins, before the cumulative effects of radiotherapy are
evident.
Sensory impairments often begin in the acute phase, however, they are often considered a
secondary change related to mucositis, xerostomia, or edema (30, 81). Loss of taste is a common
acute, sub-acute, and chronic complaint and lack of adequate saliva will further impair taste
perception (30). Acute pain is attributed to mucositis and the inflamed and ulcerated, raw, burned
tissues associated with chemoradiotherapy (30, 31, 93). Sensory changes and/or pain may impact
quality of life, reduce oral intake, or increase the potential for non-adherence to swallowing
intervention. Recent studies using Gabapentin prophylactically in conjunction with the cancer
treatment modalities (radiation with or without chemotherapy) have attempted to minimize these
toxicity effects, and the results are promising with a reduction in symptoms and improved
swallow-related outcomes (72, 112).
Chronic and sub-acute changes appear to occur independent to the degree and severity of
acute symptoms, resulting from chronic ill-adaptations manifesting from radiation (67). Acute
symptoms (xerostomia and acute dysphagia) have been reported as significant predictors of
chronic dysphagia, but chronic dysphagia was assessed at 6 months when many patients are still
recovering (113). This result may not accurately reflect truly chronic changes.
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Ill-adaptations may occur from disruptions to the healing process and include excess
production of fibrinogen, collagen, and overall disorganization of these cellular building blocks
resulting in hard and immobile tissues (67, 83, 114). One factor attributed to this poor
organization is the perpetuation of broken DNA as the mucosal and skeletal muscle cells
regenerate following organ preservation therapy (67). Recent work in breast cancer has identified
specific gene expressions resulting from radiation that are predictive of chronic fibrotic tissue
development (115). Additional work in gene expression in HNC has identified genes that both
upregulate (increase) and downregulate (decrease) aspects of cellular responses to stimuli
including stress, oxidation, DNA repair, and many other homeostatic factors (116). It appears
unknown if, or how much, these gene expressions can be manipulated by the cancer treatment
modalities, but findings are promising for the use of these gene expressions as prognostic
indicators for long-term cancer diagnosis outcomes and possible re-occurrence of head/neck
tumors (117, 118). Work in vocal fold wound healing following surgical interventions has
demonstrated a positive influence of exercise and voice use in the wound healing process, as
compared to total rest (119). These are promising findings, but it remains unclear how these gene
expressions or exercise may influence curative treatments or wound healing post-radiation in the
HNC population.
Fibrotic tissue development has the potential to expand, covering the SWOARs, and
entrapping the blood vessels and nerve supply from the initial months following
chemoradiotherapy up to 30 years (67, 83). This would lead to chronic reduced metabolic
function and poor cellular resilience. Fibrosis associated with radiation is known to cause soft
tissue changes including pharyngeal-esophageal strictures, reduced ROM, edema, and reduced
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constriction of the swallowing chambers culminating in the signs of dysphagia, including
aspiration (67).
Nerves can be damaged from the invasion of fibrotic tissue as previously mentioned, but
may also suffer direct damage from the radiation itself, with permanent damage being rare (20,
67). Intense and often uncontrollable pain is reported, and this may be symptomatic of mucositis
in the acute phase, but underlying chronic oxidative stress can lead to a depolarization of pain
fibers leading to a more chronic condition (67). Additionally, collagen and fibronectin deposits
along with microvascular changes may result in neuropathy within the affected regions (20, 67).
It is plausible that chronic dysphagia may occur in the absence of acute symptoms if the sensory
and motor aspects of the swallowing nerves are damaged.
In the sub-acute period there may be a latency of radiation effects. The latent period may
go undetected for years while underlying tissue changes accumulate slowly, allowing a patient to
function normally for a period of time (67, 83). During this time there may be asymptomatic but
progressive increases in fibrotic tissue, progressive oxidative stress on cells, and progressive
atrophy (62, 67). It is plausible that a reduced diet or continued feeding tube use may exacerbate
these underlying changes (use it or lose it) further disabling the swallowing function. Continued
feeding tube use would result in the absence of oral intake, reducing the use and load on the
swallowing muscles, and may be associated with dis-use atrophy. A reduced diet (e.g., full liquid
or puree) may also result in changes to the muscles of swallowing. Reducing the diet level
minimizes the load placed in the swallowing system and, over time, it may adapt to this new
limited diet making a transition to more solid foods difficult.
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Behavioral Treatment Strategies for Chemoradiotherapy-Related Dysphagia
The first step in swallowing intervention for HNC patients is education, and a recent
qualitative analysis of chemoradiotherapy, with associated dysphagia, revealed that the patients
desired verbal communication about their condition, did not fully understand the severity or
timing of symptoms, and did not fully comprehend all information during the first delivery (120).
The implication of these findings reveals that more than one education session is needed, and
written information should be provided to back-up verbalized information (120). This supports
the idea that increasing the number of SLP-patient visits may be needed to provide optimal
intervention.
Behavioral swallowing treatments using exercise or compensation (positioning or
swallowing strategies) have been indicated to address the dysphagia associated with cancerrelated organ preservation therapies (22). These interventions may be provided prior to, during,
or after chemoradiotherapy, as needed (22). Limited research has also examined pre-treatment
(beginning 2 weeks prior to radiation); however, while findings indicate some improvement in
QOL scores, there does not appear to be significant improvement in feeding tube use (39, 121).
These limited and mixed findings highlight the need to establish the optimal use of swallowing
exercises in prophylactic behavioral swallowing treatments before examining the potential
benefits of pre-treatment. Swallowing exercises for rehabilitation should target the organs at risk
during chemoradiotherapy (SWOARs). A review of the available literature reveals that tongue
strength and retraction, delayed closure of the laryngeal vestibule, reduced laryngeal elevation,
reduced opening of the mouth, and UES dysfunction are the most common muscular/structural
impairments (9, 22-29). Exercises should consider principles of exercise science including
intensity, frequency, duration, and timing (24, 42, 122, 123). Strengthening exercises are
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intended either to rebuild lost muscle mass (atrophy) or to build strength in existing muscle as a
preventative mechanism, in this case against dysphagia. Conditioning, or increasing the mass and
strength of a muscle, may have a preventative effect against deconditioning (123). Since atrophy
and loss of muscle strength occur during chemoradiotherapy, improving the condition of the
swallowing system may have a protective or beneficial effect.
Additionally, the force (difficulty or weight of exercise), intensity (duration, sets and
repetitions), and specificity of exercise will affect the exercise outcomes (42, 122-124). The
prevailing recommendation for exercise force is to work at 60% of the 1-repetition maximum (1repetition max; the maximal force that a muscle or group of muscles can generate) (42).
Establishing a 1-repetition max may be difficult and some protocols have used a range of 6080% of maximal effort (42). Duration and volume of exercise are less concrete, with wide
variations in the swallowing literature based on exercise and purpose (122), and there does not
appear to be consensus. Common durations include repetitions and sets (5 repetitions for 5 sets
per day) or times (1 hour per day) with treatment occurring from 3-7 days per week for 2-8
weeks (122). The specificity of the exercise should match the targeted goal (e.g., tongue
strengthening for tongue-based retraction), and exercise science has demonstrated the largest
gains when exercise is specific to a part of the whole task (123). The wide variations in treatment
duration and volume support the need for additional research of behavioral swallowing exercises
in the HNC population to provide further guidelines for optimal treatment.
The mechanisms that increase muscle mass (hyperplasia and hypertrophy) have been
reported to occur at a meaningful level (measureable difference in force) in the muscles of
swallowing 5 weeks after exercise begins (42). However, treatment declines associated with
toxicity may have an impact on these processes. One study examined changes in muscle size
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resulting from radiation using fMRI and reported reduced loss of muscle mass across all study
groups (exercise group, sham exercise, and control group), but the authors noted the degree of
muscle loss was least in the exercise group (34). If treatment levels are maintained, it may
increase the level of functional reserve within the swallowing system, and increase swallowing
outcomes post-chemoradiotherapy. However, studies examining the muscular changes that occur
as a result of behavioral swallowing exercise in HNC are scarce. Including physiological
outcomes measures (e.g., lingual pressure measurements) will help to fill knowledge gaps
regarding the physiological impacts of swallowing exercises during prophylactic treatment of
HNC patients.
The current trend in swallowing intervention related to chemoradiotherapy-related
dysphagia is to begin behavioral swallowing treatment when chemoradiotherapy begins,
following an educational/counseling session provided during the first visit or pre-treatment
(125). However, this does not appear to be a widely used standard of care and swallowing
interventions continue to vary by exercise type, treatment intensity, and SLP-patient contact
frequency. Common interventions for swallowing include Masako, tongue resistance exercise,
Shaker, super-supraglottic and supraglottic swallow, effortful swallow, pharyngeal squeeze,
electrical stimulation therapy, jaw exercises/stretches and Therabite treatment
(CranioMandibular Rehab, Inc., Denver, CO), and Mendelsohn maneuver (23-25, 28, 51, 126128). A description of each exercise used in this study protocol follows.
Tongue-palate press exercise, SWST
These exercises are intended to increase general tongue strength for bolus manipulation
and propulsion into the pharynx. The exercises are performed by pressing the tongue against a
device or object (e.g., SwallowSTRONG, IOPI, or tongue depressor) and holding a desired
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pressure for a period of time, usually measured in seconds, followed by a rest/relaxation period
(29, 107, 108, 129, 130). There is potential benefit from these more generalized tongue strength
exercises in the HNC population, and devices like SWST and IOPI may offer a way to ensure
that the level of exercise force is sufficient to be meaningful for post-radiation swallowing
outcomes (109, 131). SWST exercise for increasing tongue strength is performed by pressing the
tongue, at a specified percentage of maximal effort, against an intra-oral pressure monitoring
device to increase tongue strength and endurance. SwallowSTRONG was chosen over the Iowa
Oral Performance Instrument (IOPI) for use in this study. Both the SwallowSTRONG and IOPI
devices can be used for tongue-palate press exercise and measure tongue strength in similar ways
(109). However, the design of the SwallowSTRONG allows the mouthpiece to be custom
molded to the patient’s mouth. This should allow consistent replication of oral placement and
increased consistency of measurement. The IOPI uses a single air-filled bulb placed within the
oral cavity, at the desired locations for measurements and exercise. This single bulb design
makes exact replication of placement unrealistic. For this reason, the SwallowSTRONG system
was chosen over the IPOI. The currently available, effective, protocol consists of ten lingual
presses per session per placement (anterior, posterior, left lateral, right lateral), three sessions per
day, three days per week, for a total of eight weeks (50). This results in a total exercise volume
of 120 repetitions per day. The current evidence suggest that anterior and posterior tongue
strength are most significantly affected by the radiation-related atrophy observed during
radiation treatment (3, 132, 133). Therefore, only the anterior and posterior placements will be
targeted during treatment in this study. To maintain the same exercise load as the previous
effective study and published protocol used in the HNC population, 120 repetitions per day, the
number of repetitions will be increased from 10 to 20 per placement per exercise session. In
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addition, exercise principles highlight the need to work at 60-80% of maximal effort (42).
Patients will be instructed to push as hard as they can during each exercise session with SWST to
determine if they can achieve and maintain this level of exercise effort over the course of
radiation treatment.
The use of devices like SWST and IOPI appears promising, but there is limited evidence
related to their use in HNC. It is possible that the toxicity and sensory changes associated with
the cancer treatment modalities will make the use of these devices difficult to use in the HNC
population. If the patient has significant pain the oral placement of the intra-oral sensors may not
be tolerated, and if there is reduced or loss of oral sensation targeting the sensors may be
difficult. While these are promising systems, further research is needed to evaluate the benefit
and feasibility of use of these systems and general tongue strength in the HNC population.
Furthermore, the current behavioral swallowing treatment protocol must assume that the SWST
system may not be tolerated, which would be an important finding, and ensure that adequate
exercises are in place to provide the appropriate level of evidence-based care. For this reason, the
Masako exercise will also be included in the study protocol.
Masako exercise
The Masako exercise increases the contact of the tongue base to the posterior pharyngeal
wall (134). The exercise is performed by advancing the tongue tip beyond the teeth, holding it
gently between the teeth, while swallowing (134). The expected benefit includes improved bolus
clearance of the vallecular and upper pharyngeal space. This exercise has been incorporated in a
treatment protocol for HNC-related dysphagia with positive outcomes (24). However, since this
exercise is specific to the tongue base, if the Masako exercise is used alone, it may fail to target
the generalized weakness noted in the tongue as a result of chemoradiotherapy (135).
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Shaker exercise
The Shaker exercise is intended to improve opening of the UES and increase
hyolaryngeal elevation by increasing strength in the suprahyoid muscles (136). The exercise is
completed in two parts: first a series of sustained head lifts held for 60-seconds with a 60-second
rest between each, followed by 30 consecutive head lifts all in a supine position (136). This
exercise has shown significant promise in the HNC population with reduced aspiration and
increased UES opening (51, 137). This is an evidence-based treatment with known
improvements to function, and given the reduction in UES function during radiotherapy, it
should be considered as part of any swallowing therapy protocol in this population.
Pharyngeal squeeze
The pharyngeal squeeze, also called falsetto voice, is used to increase function of the
pharyngeal constrictors and laryngeal excursion (138, 139). The pharyngeal squeeze is
performed by gliding quickly up the pitch scale to the highest possible pitch and sustaining that
pitch for the longest duration possible. This appears to be an important exercise for the HNC
population due to the association of reduced pharyngeal constriction and the increased risk of
aspiration of pharyngeal residue (140).
A 2013 review of swallowing interventions used in HNC reveals that the previously
discussed behavioral swallowing exercises have been performed alone, or paired with electrical
stimulation, biofeedback, and jaw exercises (127). Additionally there is a wide variation of
methodology, timing, and interventions used across published studies (127). An overview of
these swallowing exercises, expected exercise outcomes, and reported frequency is available in
Table 5. Common groupings of exercise and treatment tools are given in Figure 2.
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Table 5. Swallowing Exercises, Expected Treatment Outcome, and Reported Frequency
Exercise
Expected Outcome
Exercise Frequency
Mendelsohn
Increase duration of upper
10 repetitions, 3 sets per day,
esophageal sphincter (UES)
daily (36)
opening and laryngeal
10 repetitions, 5 sets per day,
elevation
5 days per week for 6 weeks
(25, 39)
Masako or Tongue Hold
Increase tongue base
8-12 repetitions 5 sets per
retraction and bolus clearance day, daily (51)
10 repetitions, 7 sets per day,
daily
(24)
10 repetitions, 5 sets per day,
5 days per week for 6 weeks
(25, 39)
10 repetitions, 4 sets per
session, 2 sessions per day,
daily for 6 weeks
(34)
Shaker
Strengthen the suprahyoid
3 repetitions of part 1 and
muscles and improve opening part 2 per day, daily
of the UES
(24, 39, 51)
Pharyngeal Squeeze or
Improve constriction and
10 repetitions, 7 sets per day,
Falsetto
medialization of the
daily (24)
pharyngeal constrictors
10 repetitions, 4 sets per
session, 2 sessions per day,
daily for 6 weeks
(34)
Super- or Supraglottic
Provide and maintain
8-12 repetitions, 5 sets per
Swallow
volitional airway closure
day, daily (51)
Effortful Swallow
Increase tongue base
8-12 repetitions, 5 sets per
retraction and pharyngeal
day, daily (51)
constriction
10 repetitions, 4 sets per
session, 2 sessions per day,
daily for 6 weeks
(34)
Neuromuscular Electrical
Increase tongue based
30 minutes, 15 sessions
Stimulation
retraction and pharyngeal
(128)
strengthening
Therabite or Jaw Range of
Improve and maintain
30 seconds per stretch, 10
Motion Stretches
opening and strength of the
repetitions, 3 sets per day,
jaw
daily
(126)
10 repetitions, 4 sets per
session, 2 sessions per day,
daily for 6 weeks (34)
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Figure 2. The Reported Behavioral Swallowing Interventions and Their
Common Groupings for Head/Neck Cancer (24, 25, 34, 36, 39, 51,
126)

Previous Literature in Behavioral Swallowing Intervention in Head/Neck Cancer
Population
A 2009 randomized clinical trial found reduced aspiration with use of Shaker exercise
compared to traditional therapy (super-supraglottic swallow, Mendelsohn, and tongue-based
retraction) but no difference in pharyngeal residue or diet (51). This finding indicates that other
non-behavioral factors may influence diet level and swallowing efficiency (e.g., salivation or
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pain), or that the intervention chosen did not adequately target all underlying causes of residue
(e.g., reduced pharyngeal squeeze). Consideration should be given to the need for multiple
exercises targeting hyolaryngeal excursion, reduced UES opening, reduced laryngeal closure,
reduced pharyngeal squeeze, and loss of tongue strength. Additionally, intensity and timing of
exercise may potentially alter the outcomes.
A 2012 randomized controlled trial compared prophylactic swallowing exercise to a
control group who received no prophylactic exercise (36). Patients performed tongue-base
exercise, super-supraglottic swallow, and Mendelsohn Maneuver (each 10 repetitions, 3 sets per
day) with no significant difference in Functional Oral Intake Scale (FOIS) scores immediately
following chemoradiotherapy completion, but there were improvements in FOIS scores at 3 and
6 months for the prophylactic exercise group (36). At 9 and 12 months there were no differences
between the prophylactic and the control group (36) which may be due to differences between
acute and chronic manifestations of chemoradiotherapy-induced dysphagia. In contrast, a 2013
retrospective study of 497 patients found that prophylactic treatment was associated with better
long-term outcomes, measured by final diet after treatment and duration of feeding tube use, but
also found treatment adherence to be a key factor in patient outcome (14). These findings further
support the need to identify methods to improve adherence to swallowing exercises in the HNC
population, and highlight the potential relationships between increased adherence and positive
swallowing outcomes.
A study by van der Molen, van Rossum, Burkhead, Smeele, Rasch, et al. (126) sought to
assess the preventative ability of two swallowing therapy programs. One group performed gargle
(10 seconds, 3xs per day), jaw stretch (3xs per day), Masako (8-12 repetitions, 5 sets per day),
effortful swallow (8-12 repetitions, 5 sets per day), and super-supraglottic swallow (8-12
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repetitions, 5 sets per day). The second group performed Therabite stretches (each 30 seconds)
and exercise (10 swallows per session) each three times per day. Mean adherence for
interventions was 4/7 days per week; and outcome variables included maximum jaw opening,
body mass index (BMI), FOIS, and a visual analog scale for pain. Findings, measured 10 weeks
after radiation therapy began, demonstrated acute changes in jaw opening, body weight, and oral
intake all declined during treatment despite intervention method. The lack of improvement may
have been due to the limited adherence noted in both intervention groups. As previously
discussed, adherence is a key factor in the success of swallowing interventions.
Another prospective study examined two different swallow regimens prophylactically
(24). One group performed only swallows with saliva or water (34 swallows, 7 sets) while the
other performed Masako (10 repetitions, 7 sets), pharyngeal squeeze (10 repetitions, 7 sets), and
Shaker exercise (part 1 and 2, 3 times per day) (24). All groups performed exercise 7 days per
week for 7-8 weeks (24). Outcome measures included FOIS and PEG dependence, and results
indicated that the exercise group had significant reduction in PEG tube dependence compared to
swallow-only group 3 months following chemoradiotherapy completion, but there were no
significant differences immediately after treatment (24). The average percentage of exercise
completed reached only 70-80% of the recommended level and dropped to approximately 30%
by the end of the treatment, with a notable drop in week 3 to 4 weeks into treatment as toxicity
effects increased (24). Positive gains were made, with patients returning to oral diet, despite not
achieving the intensity prescribed. The lack of findings immediately following completion of
chemoradiotherapy may be related to cancer treatment-related toxicity and/or poor adherence to
swallowing treatment. The pain and discomfort associated with treatment toxicity may limit the
patient’s ability or willingness to consume more advanced diets or complete behavioral exercise.
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Poor adherence may have resulted in less than the desired exercise volume, and reduced time to
PEG tube removal in the exercise group highlights the importance of swallowing exercise in this
population. It may be possible to further reduce or eliminate the need for PEG placement if
exercise adherence remains high for the duration of treatment.
A 2014 randomized clinical study reported that no study had examined the efficacy of
tongue strengthening in the HNC population and sought to compare tongue strengthening
(resistance against tongue depressor) paired with traditional exercises (Mendelsohn and tongue
ROM) compared to traditional exercise alone (25). Exercise began 1 month after
chemoradiotherapy started and was performed 10 repetitions, 5 sets per day, 5 days per week for
6 weeks (25). Adherence with duration and intensity of exercise was reported as only fair, and
results did not yield any difference between groups (25). Tongue strength was measured using
the Iowa Oral Pressure Instrument (IOPI) (25, 107). The lack of findings makes it unclear if the
intensity and duration of exercise was sufficient to obtain the desired strength training effects, or
if adherence and other toxicity factors limited the results. The use of visual biofeedback will
provide a method to ensure exercise intensity, and provide insight into the relationship between
adherence and exercise intensity, and their impact on swallowing ability, filling this gap in our
knowledge.
Another study by Carnaby-Mann, Crary, Schmalfuss, and Amdur (34), a randomized
controlled design, examined pharyngocise (high falsetto, tongue press, effortful swallow, and
Therabite; along with appropriate diet modification) compared to a sham group (puffing out
cheeks and appropriate diet modification) and standard care (ensuring safe swallow and postural
changes, as needed). Each exercise in the pharyngocise and sham group was performed daily
during chemoradiotherapy, 10 repetitions for 4 sets with 5 SLP-visits per week, with a primary
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outcome variable of muscle size and composition (measures by T2-weighted magnetic resonance
imaging). Additional variables included functional swallow ability, mouth opening, taste,
salivation, and nutrition. Results indicated that exercise performed during chemoradiotherapy
reduced muscle loss, maintained higher levels of mouth opening, and functional swallow ability.
Another interesting result in this study was greater preservation of taste, smell, and salivation.
This finding may be accounted for by the higher levels of oral intake and more normalized intake
in the pharyngocise group. Patients in the pharyngocise and sham groups received 2 sessions per
day, 5 days per week. Increased SLP contact may have improved adherence with exercise and
outcomes, however, levels of adherence are not clearly reported. The pharyngocise group also
experienced less PEG-tube use than the control group (usual care), 3 vs. 6 patients used PEGtube, respectively. These adherence and PEG-tube related findings support the potential benefit
of more frequent SLP contact time, but the treatment groups did not receive the same
interventions (behavioral exercise vs. sham exercise). It remains unclear if the exercise group
would have maintained the same effectiveness with reduced visits. Furthermore, the twice-daily
treatment is likely unrealistic in the clinical setting due to time and cost restraints. The American
Speech-Language and Hearing Association reports the current Medicare rate for dysphagia
treatment is $87.71 per day (141). Twice daily treatment would yield the same revenue as once
daily SLP treatments (5 days x 7 weeks = $3069.85). If the lesser number of SLP-visit days
proposed in the current study, 3 days per week, is as effective as 5 days per week, the cost and
time savings would be significant (3 days x 7 weeks = $1841.91). The current proposed study
will examine high and low visit frequency across matched exercise regimes. This design will
allows for direct comparisons regarding the potential positive impact of high frequency SLPvisits in the HNC population.
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The use of neuromuscular electrical stimulation (NMES) has also been examined in the
HNC population (127, 128, 142, 143). The first was a double blind randomized study with one
group performing 30 minutes of NMES to the pharyngeal musculature (Vital Stim, Chattanooga
Group, Hixon, TN) combined with 30 minutes traditional exercise (oral motor exercise, thermal
stimulation, Mendelsohn), and the other group performing sham NMES and traditional exercise
(128). Results for Functional Dysphagia Score (FDS) were significantly higher for the NMES
group than the sham group, but there was no significant improvement in the MDADI, clinical
dysphagia scale, or ASHA NOMS Indicating a potential limited effect of NMES in HNC-related
dysphagia. The second study examined electrical stimulation compared to a home therapy
program (Shaker, tongue hold, tongue resistance, effortful swallow, and ROM) (142). Results
indicated there was improvement in the electrical stimulation group and no improvement of the
home exercise group; however, the electrical stimulation group received 15 treatments and the
home group was only phoned once in a two-week period to “encourage” participation (142).
Studies have also demonstrated potential positive and negative effects of NMES on
laryngeal elevation (144, 145). Burnett, Mann, Cornell, and Ludlow (144) examined the effect of
hooked wire (small wires inserted directly into the target muscle) electrical stimulation on
laryngeal elevation in healthy men. Findings indicated increased elevation with paired muscle
stimulation. Ludlow, Humbert, Saxon, Poletto, Sonies, et al. (145) examined surface-based
electrical stimulation in patients having long-term dysphagia revealing that electrical stimulation
may inhibit hyoid movement and even increase risk of aspiration. Findings revealed probable
differences between electrical stimulation delivery methods leading to potential confusion
regarding their efficacy and safety. The most common NMES units available to SLPs use surface
electrodes. A study examining the efficacy of NMES in HNC patients using surface electrodes
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combined with swallowing exercises (Mendelsohn, effortful swallow, and super-supraglottic
swallow) revealed both groups reported increased quality of life (performance status scale and
Head Neck Cancer Inventory), but the NMES group exhibited significantly worse swallowing
performance (Penetration Aspiration Scale scores) than the sham group (143). Overall, results
indicated a negative relationship between NMES and dysphagia treatment with HNC and
recommendations were made not to use this modality (143).
Behavioral treatment (e.g., Shaker) for UES dysfunction after chemoradiotherapy is the
common initial treatment step, but two additional treatments include Botox injection and dilation
(146, 147). These are medical interventions and may be used after behavioral intervention has
not been effective. Botox is delivered to the cricopharyngeous muscle to reduce tone allowing
for more effective opening of the sphincter (146). Dilation requires the insertion and inflation of
a balloon into the UES to re-open and regain function of the UES (147).
Despite the previously reviewed positive findings related to prophylactic swallowing
exercise in HNC, recent findings including meta-analysis data have demonstrated that the use of
swallowing exercise may perform no better than no exercise or therapy-as-usual (reactive or no
dysphagia treatment) (148-150). Messing, Ward, Lazarus, Kim, Zhou, et al. (149) reported no
significant difference between an exercise group and control group; however, they did report that
the exercise group had a non-significant increase in levels of oral intake at 3-months postradiation. The lack of significant findings may be due to the choice and intensity of swallowing
exercise. To date no optimal exercise protocol has been established. Other studies using different
exercises and higher intensity of exercise have been able to demonstrate significant
improvements at 3-months (24). Heijnen, Speyer, Kertscher, Cordier, Koetsenruijter, et al. (148)
performed a systematic review of 60 articles to examine the impact of swallowing intervention in
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HNC. Of these articles, only 14 included SLP provided swallowing interventions and findings
revealed that QOL and dysphagia related scores continue to decline during and after radiation
despite intervention. These findings appear limited by the scope of the review. In the 14 articles,
the methods varied widely, not all outcome measures were validated, and only six studies
included described the intervention processes. Perry, Lee, Cotton, and Kennedy (150) also
performed a review to determine the effects of therapeutic swallowing exercise in the HNC
population. They reported that swallowing exercise performed during or after radiation had no
more effect than therapy-as-usual. Therapy-as-usual was defined as receiving a typical course of
care, which may mean prophylactic PEG-placement or swallowing-related treatment when
difficulties arise. Here again these findings are limited by both the inclusion criteria and the
review methodology. They limited inclusion to only randomized controlled trials resulting in
only 6 studies, and were unable to pool the included outcome data due to the variations in the
included studies’ outcome tools. In addition, comparing outcomes to therapy-as-usual may be a
limiting factor. Patients who received swallowing-related therapy-as-usual may have received
very similar swallowing interventions compared to patients who received prophylactic
behavioral swallowing treatments, if reactive intervention began very early during radiation
therapy.
A recent study by Malandraki and Hutcheson (47) explored two differing treatment
options for radiation-related dysphagia, intensive therapy versus a dysphagia boot camp
approach. Patients included in this study were an average of 5 years post-radiation therapy. The
intensive therapy for dysphagia incorporated evidence-based swallowing training, targeted
swallowing practice, and adherence-inducing factors (e.g., health literacy or exercise tracking).
The swallowing boot camp approach included an intense series of targeted therapy based on
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massed practice and were either bolus-driven or device-driven. For both intervention groups the
swallowing interventions were individualized and may vary from patient to patient. Findings for
this study were preliminary and revealed potential improvement in aspiration risk and diet levels
for the intensive therapy group and improved QOL but not aspiration risk in the boot camp
group. No direct comparisons were made between the study groups. Additionally, despite the
importance of adherence raised by the authors, no adherence data were made available. The
authors indicated that this reactive form of intervention was not intended to replace the
prophylactic intervention, but rather to offer a mechanism to help those who did not respond to
the initial prophylactic interventions. This lack of response to the initial prophylactic treatments
highlights the need to further assess the quality of prophylactic dysphagia care, which may
further reduce the need for these reactive interventions. This study also highlighted the potential
importance of adherence, citing health literacy or awareness as a potential factor in improving
adherence. While the authors did not address the impact of adherence within the current paper,
other researchers have recently begun to examine ways to facilitate and track adherence to
dysphagia interventions in the HNC population. Starmer et al. (151) recently assessed the
feasibility of a mobile application to assist in the delivery and tracking of patients’ adherence to
swallowing-related interventions. While not all patients (80%) used the application and overall
completion of exercises was limited, based on the information logged into the application, these
findings highlight the ongoing need to offer patients an easy and clear method to monitor
progress or interact with the SLP during treatment. One of the most important findings of this
study was that 70% of patients reported that they forgot to log the exercise, not that they did not
engage in exercise. A common limitation of the available literature is the assertion that poor
adherence may be limiting patient outcomes, but it appears that we may not be adequately
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tracking these data. Overall, this group of findings is limited by the wide and varied exercises,
potential importance of intervention adherence, study methodologies, and study designs used
across the HNC swallowing literature. It appears premature, based on the available literature, to
conclude that prophylactic swallowing exercise provided no benefit over only reactive
intervention.
In contrast, despite these negative findings, prophylactic swallowing intervention appears
both beneficial and promising. However, the current available research does demonstrate
inconsistency and lack of information regarding swallow exercise timing, duration, and
frequency. The optimal timing, frequency, and duration of SLP involvement in treatment is
unknown. Currently, the current common treatment appears to be prophylactic treatment with
patients receiving swallowing intervention visit with the SLP, with or without a pre-radiation
instrumental evaluation of swallowing (e.g., MBSS), at least once at the beginning of radiation
treatment; the potential for at least one SLP-visit during treatment; and a potential post-radiation
SLP-visit with a swallowing evaluation (e.g., MBSS) (14, 24, 121, 126, 132, 152-154). More
consistent treatment may be provided if significant dysphagia occurs. An overview of
swallowing intervention timing and exercise protocol is available in Table 6. Establishment of
optimal swallowing exercises, frequencies, and intensities is needed. In addition, determining the
impact of SLP contact time on adherence to exercise levels, and clearly defining the level of
adherence needed to achieve optimal results are needed. Once these are established, replication
in randomized controlled trials appears needed to close the gap between current preliminary
findings and meta-analyses that are more robust. The current study is designed to examine the
potential benefit of increased SLP-visit frequency on patient-related swallowing outcomes. The
development of a historical cohort group, based on the current standard of care (prophylactic
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intervention as previously described), would provide the needed data to examine if increasing the
SLP-visit frequency to three or five visits per week results in greater post-radiation swallowing
function.
Table 6. Previously Reported Exercise Timing, Exercise Frequency, Exercise
Protocols, and PEG Tube Use Percentage and Reported Timing
Authors
Study Type
Timing/Frequency
Exercises

Virani et al.
(24)

CarnabyMann et al.
(132)

Kotz et al.
(154)

Hutcheson et
al. (14)

Prospective

Prospective

Prospective

Prophylactic, 1
weekly SLP visit
during radiation
Exercise 7 days per
week during
radiation (7 weeks)
Prophylactic, 5
weekly SLP visits
Exercise performed 5
days per week during
radiation
Prophylactic, 1
weekly SLP visit

Masako
Shaker
Pharyngeal squeeze

Pharyngeal squeeze,
Tongue press,
Effortful swallow, and
Therabite

Effortful swallow,
Super-supraglottic
swallow, Masako,
Exercise performed
Tongue retraction,
daily during radiation Mendelsohn
Retrospective Prophylactic, preShaker exercise, jaw
radiation (at least 1
stretch, supraglottic,
SLP visit)
Valsalva maneuver,
falsetto, lingual
Exercise performed
protrusion and
daily during radiation retraction, yawn,
gargle, Masako
maneuver, and
effortful swallows

(Table 6. Continued)
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PEG Tube
Percent
(Timing)
42%
(Immediately
postradiation)

20%
(Immediately
postradiation)

46%
(Immediately
postradiation)
60%
(Various)

Authors

Study Type

Timing/Frequency

Exercises

van der
Molen et al.
(126)

Prospective

Prophylactic, 1 preradiation SLP visit

Gargle, Jaw stretch,
Masako, Effortful
swallow, Supersupraglottic swallow,
Therabite, Dry
Swallows
Tongue depressor
presses, Mendelsohn,
Tongue range of
motion,
Mendelsohn, Masako,
Effortful swallow,
Shaker

Exercise daily during
radiation
Lazarus et al.
(25)

Carroll et al.
(153)

Logemann et
al. (51)

Prospective

Post-radiation (1month after
completion), 5 days
per week, 6 weeks
Retrospective Prophylactic and
post-radiation,
Number of total SLP
visits unknown
(prophylactic group
received at least 1
pre-radiation SLP
visit)
Prospective
Post-radiation, 2 SLP
visits per week for 6
weeks

Ryu et al.
(128)

Prospective

Post-radiation, 5 SLP
visits per week for 2
weeks

Kulbersh et
al. (121)

Prospective

Prophylactic, 1 visit
pre-radiation, 1
during, and 1 post
radiation

(Table 6. Continued)
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Shaker or the
following :
Mendelsohn, Tongue
base exercise
(including yawn,
pretending to gargle,
tongue retraction)
Electrical stimulation
combined with oral
motor exercises
(undefined),
pharyngeal
swallowing exercises
(undefined),
thermal/tactile
stimulation,
Mendelsohn
Mendelsohn, Masako,
Shaker, Pharyngeal
Squeeze

PEG Tube
Percent
(Timing)
37%
(Immediately
postradiation)

NA

33% (12monts postradiation)

73%
(minimum 3
months postradiation)

NA

NA

Authors

Study Type

Ahlberg et al.
(152)

Prospective

Timing/Frequency

Exercises

Prophylactic, 1 SLP
Mendelsohn, Tongue
visit prior to
range of motion
radiation
Malandraki et Prospective
Post-radiation (5
Unspecified, but
al. (47)
years), Intensive
examples provided
group 3 hours daily
include Shaker and
over 4 weeks, Boot
Mendelsohn, and
Camp group daily
McNeil Dysphagia
sessions for 2-3
Therapy Program
weeks
(SLP) speech-language pathologist, (NA) Not applicable or not reported

PEG Tube
Percent
(Timing)
31.4% (3
months postradiation)
NA

Nutrition and Nutritional Intervention in the Head/Neck Cancer Population
Malnutrition has been associated with poor rehabilitation outcomes in the HNC
population (155). Prevalence of pre-existing malnutrition in patients experiencing new onset
dysphagia was not found, but prevalence in patients experiencing hip fractures has been reported
as 37.5%, and presence of malnutrition has been linked to morbidity (155). Many factors
influence malnutrition including food cost, availability, convenience, and physical ability to
prepare meals. However, malnutrition as a pre-existing condition likely remains unknown until
the patient has a significant health-related event. This situation highlights the importance of
nutritional assessment prior to, or in coordination with rehabilitation. Given the important link
between dysphagia and nutrition, many studies include nutritional measures (e.g., weight loss) as
outcome variables. However, if the pre-treatment status is unknown, the outcomes may be
misinterpreted. Future studies should examine differences of patients experiencing pre-treatment
malnutrition.
Diet modification is a common initial step in management of dysphagia (156-158).
Shim, Oh, and Han. (156) reported that 43.5% of individuals on viscosity modified diets were
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noncompliant. Complaints of non-compliant patients included dissatisfaction with the taste and
texture of meals, difficulty in meal preparation, and increased difficulty in swallowing the
recommended foods and liquids. It has been reported that some patients look at altered diets and
do not consider them real food (159). This perception presents an ethical issue regarding a
patient’s right to eat, desire to have a normal diet, cultural needs, and patient safety. Patient
attitudes toward the use of thickened liquids and altered diets are negative, and often become
more negative over time (160).
Potential complications of non-adherence with diet recommendations are dehydration
and/or malnutrition (12). Cichero (158) discussed the bioavailability of water and satiety in
thickened liquids and reported that non-adherence equals inadequate intake of liquids. Thirst and
dissatisfaction increase with more viscous liquids, and flavor diminishes regardless of the
thickening agent used. Gracia, Chambers, Clark, Helverson, and Mattaet (157) found that liquids
prepared by medical staff were frequently too thick or thin and did not meet the prescribed
viscosity. This inaccuracy of prescribed viscosity leads to dissatisfaction and confusion for the
patient. Either situation may lead to decreased adherence, inadequate intake, or increased risk of
aspiration. Diet modification cannot be taken lightly and justification changes should be clearly
stated. Despite recommendations and the potential negative implications or refusal on patient
health, some patients will refuse the prescribed “safe” diet. These patients are taking a
“calculated risk” based on their beliefs and knowledge (159). Clear justification and education
regarding the need for an altered diet have been shown to increase acceptance (160), and thus
may improve adherence.
The SLP must consider the ethical implications of restricting a patient’s foods and intake,
and the implications this has on the patient’s autonomy (161). When faced with non-adherence
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of dietary recommendations, the SLP should use shared decision-making to improve patient
understanding and increase adherence. The SLP, patient, other professionals, and family
members should be included in the shared decision-making process. Each member can share
concerns and discuss the pros and cons of the recommendations (161). This is an educationfocused approach and allows the patient to exercise informed choice. But this informed choice
may not result in patient adherence with SLP recommendations for optimal dysphagia treatment.
In HNC, failure to maintain adequate nutritional levels may result in increased toxicity,
and malnutrition is also associated with chronic dysphagia (162). A study that examined overall
nutritional status (Performance Status Scale for Head and Neck, Malnutrition Universal
Screening Tool, and weight loss) following chemoradiotherapy concluded that nutritional
intervention and education are needed for years after treatment completion (162). The frequency
and timing of education required to increase or maintain patient nutrition/hydration and safety in
this population has not been described, and further research in this area is warranted.
Nutrition, hydration, and overall energy balance are important factors for quality of life
during and after treatment, consideration of feeding tube placement, and mortality (20, 163, 164).
Due to the importance of nutrition for wound healing, energy level, and quality of life during
curative treatment of HNC, aspects of nutrition including weight loss/maintenance, feeding tube
use, and nutritional intake need to be considered. Weight loss independently predicts mortality in
stage III and IV cancers, negatively affects metabolic function, and may have a proinflammatory effect (20). In the HNC population unintentional weight loss is reported beginning
1 week after treatment occurring in up to 82% of patients, ranging from 6-12% of pre-treatment
weight (20). Loss of appetite, difficulty chewing, dry mouth or thick saliva, and oral pain
(mucositis) are all associated with significant weight loss and, as the number of symptoms
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increase, significant nutritional deficits increase (163). Prophylactic feeding tubes, placed after
cancer diagnosis, before or at the start of chemoradiotherapy, are often used to ensure adequate
weight maintenance and nutrition during treatment (165). For many, the prophylactic feeding
tube appears to continue as the standard of care.
The SLP has a valuable role in weight maintenance. Dysphagia management may have
the potential to mitigate the high levels of undesirable weight loss observed in the HNC
population and reduce feeding tube use. During treatment many patients receive and maintain
prophylactic feeding tube placement in an effort to ensure nutritional levels, as previously
discussed (163, 165-170). Feeding tube use does not mean that patients cease to eat by mouth
during chemoradiotherapy, but risk of complete non-oral intake increases with feeding tube use
(169). Many patients will receive feeding tubes when they are unable to consume >50% of their
nutritional needs by mouth and have a significant weight loss, but many refuse placement until
malnutrition deems it absolutely necessary (169).
A 2006 study prospectively examined the use of prophylactic feeding tube use in the
HNC population, and found that 98% of patients had weight loss (average loss 21.5 lbs.) despite
feeding tube use (165). The lack of a comparative control makes it unclear if weight loss was
minimized by feeding tube use. A 2010 study concluded that feeding tube use significantly
reduced the weight loss; however, both non-feeding tube and feeding tube users had wide ranges
of weight loss, 0-76 lbs. and 0-51 lbs. respectively (170). It is unclear how clinically significant
these findings are, and further examination revealed that 41% of patients who received feeding
tubes still used them 6 months after treatment (170). The duration of feeding tube placement is a
significant concern in this population since prolonged use leads to disuse atrophy of the
swallowing organs complicating recovery (169). The use of prophylactic feeding tube placement
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has also been found to increase time to feeding-tube removal (171). While radiation treatments
last 7-8 weeks, feeding tubes (gastronomy tube, PEG) remain in place an average of 21 weeks
(169). Risk of atrophy and upper esophageal sphincter (UES) stricture stenosis make it plausible
that feeding tube use may also increase the risk of late onset/chronic dysphagia, but this
relationship remains unclear.
A prospective study examined prophylactic nasogastric tube (NG) and PEG use found
that NG patients had significantly better swallowing outcomes than the PEG patients (168). The
difference in outcomes may be due to the typical short-term use of NG tubes compared to longer
length of PEG use, though length of use was not disclosed (168). Another recent study
examining NG and PEG-tube use in patients who received feeding tube placements
prophylactically and found no statistical differences in swallowing outcomes between these two
delivery methods (172). They did report a one-year trend in the data that may indicate the
potential for more favorable outcomes for NG use, but these finding are limited by the nonsignificance of the statistical outcomes (172). Two additional studies examined prophylactic
PEG placement finding that it did not lead to increased swallowing difficulty or tube dependence
(166, 167). However, one study examined patients at 6 months when chronic or late-radiation
induced difficulties may not be apparent (166). The second study did follow patients for 3 years
finding 3% (3 enrolled patients) use after this time, but 45% of patients remained on puree or
liquid diets indicating high levels of chronic dysphagia (167). Overall, this group of findings
indicates the removal of feeding tubes does not represent improvement in or normalcy of diet. In
the HNC population avoidance of feeding tube use appears to decrease some risk of swallowing
deficits (e.g., weakness and UES dysfunction). The use of PEG as an outcome variable is
important, but cannot take the place of information regarding diet level and nutritional status.
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Knowing the nutritional status of a patient prior to cancer diagnosis and referral to the
SLP for intervention is rarely feasible, if not impossible. Studies have linked low intake of fruits
and vegetables to higher risk of HNC (173). The available studies examine prophylactic
nutritional interventions (e.g., specific diet, supplementation) in patients receiving
chemoradiotherapy (174-176). Poor nutritional status has been linked to reduced muscle
function, wound development and poor healing, respiratory difficulty, and immune system
compromise (177). A prospective study reported nutritional support (oral supplementation)
provided 7-10 days before surgical intervention for HNC reduced postoperative complications
(infection, continued or new malnutrition) by 10%, for patients reporting pre-diagnosis weight
loss (177). It is unclear if there is a relationship to swallowing function, and the results are not
directly comparable to chemoradiotherapy patients. This study highlights ability to implement
intervention prior to treatment and the time limitations faced for nutritional and other
interventions between cancer diagnosis and the initiation of chemoradiotherapy treatment.
A 2013 review that examined nutritional support interventions used during
chemoradiotherapy treatments found that individualized nutritional counseling resulted in higher
QOL measurements compared to no counseling (164). The study also found the use of nutritional
supplements (e.g., Ensure) was inconsistent in its ability to improve nutrition, and found that NG
tube for supplementation may perform better than nutritional supplements alone (164). This
result may be due to the potential non-adherence of oral supplementation due to oral pain.
Wen-Xing and colleagues reported on a prospective study comparing nutritional
counseling during chemoradiotherapy in HNC (176). Findings revealed a net increase of calories
(~600 calories) for those receiving counseling, but timing and frequency of counseling were not
reported. A study of nutritional supplementation examined the use of liquid supplements finding
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that supplementation did not prevent weight loss, but the supplementation group did have
increases in total protein levels and caloric intake (178). However, one recent study found that
nutritional counseling paired with nutritional supplements did improve post-radiation weight
compared to the use of supplements alone (179). Two additional studies have shown
improvements with supplementation including increased weight and body biometrics (e.g., skin
fold test) (164, 180, 181).
Nutritional intervention following chemoradiotherapy must also be considered due to the
association of chronic dysphagia. A study that examined overall nutritional status (Performance
Status Scale for Head and Neck, Malnutrition Universal Screening Tool, and weight loss)
following chemoradiotherapy and concluded that nutritional intervention and education were
needed years after treatment was completed, and these findings highlighted the lack of any
regular diet consumption found in the study group (162). There appears to be some level of longterm dysphagia risk associated with feeding tube placement and malnutrition, but the underlying
factors to improve nutritional status remain unclear.
Overall, there is limited information about the type and benefit of oral supplementation,
and limited information about the timing and role of nutritional counseling (174). These
interventions show promise for maintaining nutritional status, but further research is needed to
identify the optimal protocol for intervention. Swallowing counseling, including nutritional and
weight management counseling, and intervention appear important and should be considered to
address patient’s nutritional status when radiation treatment is initiated. A summary of nutritionrelated findings is provided in Table 7.
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Table 7. Summary of Nutrition-Related Dysphagia Characteristics in the Head and Neck
Cancer Population
Source
Findings
van den Berg et al. (162)
 Reduced nutrition results in increased
chemotherapy and radiation-related
toxicity
 Malnutrition is associated with
chronic dysphagia
Wakabayashi et al. (155)
 Malnutrition is linked to patient
morbidity
Silver et al. (20)
 Weight loss independently predicts
mortality in stage III and IV head and
neck cancer patients
Farhangfa et al. (163)
 Loss of appetite, difficulty chewing,
dry mouth or thick saliva
(xerostomia), and oral pain (mucositis)
are all associated with significant
weight loss
Nguyen et al. (165)
 98% of head and neck cancer patients
had weight loss (average loss 21.5
lbs.) despite feeding tube use
Chen et al. (170)
 Feeding tube use significantly reduced
the weight loss; however, both nonfeeding tube and feeding tube users
had wide ranges of weight loss, 0-76
lbs. and 0-51 lbs. respectively
Brown et al. (171)
 Prophylactic feeding tube placement
has also been found to increase time to
feeding-tube removal
Prestwich et al. (166)
 Feeding tube placement did not lead to
increased swallowing difficulty or
tube dependence 6-months postradiation
Crombie et al. (167)
 45% of patients who received a
feeding tube in conjunction with
radiation remained on puree or liquid
diets indicating high levels of chronic
dysphagia 3-years post-radiation
Cereda et al. (179)
 Nutritional counseling paired with
nutritional supplements did improve
post-radiation weight compared to the
use of supplements alone
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3.5 Cancer Treatment Toxicities: Mucositis and Xerostomia and Their Management
Mucositis, a painful inflamed ulceration of the mucosal lining, is the most common acute
toxicity of radiation treatment in HNC affecting up to 100% of patients (31, 101). Mucositis is
caused by the depletion and destruction of mucosal cells during the organ preservation
treatments and starts as an inflammation of the mucosal lining progressing into an edematous
ulcerated sore (31). Mucosal cells, which have a rapid repopulation potential, are unable to
completely heal these damaged linings due to the continuous and cumulative nature of radiation
treatment (31). Another side effect of radiation, xerostomia, can exacerbate or prolong the
mucositis healing process (30). Severe mucositis may lead to reduced nutritional intake, or
dysphagia (poor tolerance of certain foods) requiring a reduced diet (e.g., puree diet) (31).
Specific dysphagia symptoms associated with mucositis are not well defined in the available
literature. Severe pain and discomfort may reduce patient adherence in dysphagia treatment, and
resistance to oral intake may exacerbate radiation effects on the muscles of swallowing resulting
in an accelerated decline.
In addition to the negative impact of mucositis on swallowing, the economic implications
are great. Mucositis treatment cost may be up to $2400.00 during initial hospitalization and
treatment (35). Once factors including subsequent infection, medications, and enteral feedings
are included, treatment cost for chemoradiotherapy may increase by an additional $25000.00
(35).
Severity and duration of mucositis reactions are observed to be based on the dosage
intensity and accumulation of radiation, which is partially determined by the fractionation
schedule (31, 82). Mucositis typically occurs between 3 and 14 days after the beginning of
radiation treatment (31). Mucositis tolerance thresholds range from 25.2 Gy-38.3 Gy (182). Once
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mucositis occurs it follows a pattern of increasing severity, followed by a plateau of symptoms,
and finally a healing and recovery phase (31). A 2010 review examined the impact of radiation
duration and accumulation on mucositis in 4,649 patients grouped by tumor stage (182). Results
demonstrated that total accumulated radiation was a more significant factor than the length of
treatment time (182). Conventional and accelerated fractionation demonstrated continual
increases in severity of mucositis for the duration of radiotherapy in approximately 25% of
patients; however, plateau and decreasing rates were seen in the remaining patients (31).
Hyperfractionation appears to result in a plateau for the majority of patients with no decrease in
symptoms, and hypofractionation has demonstrated an equal division between increasing and
plateaued severity over the course of radiation treatments (31). Overall, most patients will
experience a continuous increase or ultimate plateau of symptoms during treatment, but only
25% will experience any reduction despite the choice of fractionation (31).
The addition of chemotherapy to radiation treatment may increase the incidence of mucositis
threefold due to increased toxicity associated with combined cancer treatment modalities (81).
Mucositis is often graded using the Dische Scoring System ranging from 0-24, with 24 being the
most severe (31, 183). This system is detailed in Table 8.
Mucositis is treated during chemoradiotherapy after it appears (30, 35, 184, 185).
However, treatment with growth factor (naturally occurring substances that stimulate cellular
growth) is used as a potential preventive intervention pre-treatment (184). Growth factor may
improve oral mucositis by stimulating production of new epithelial cells, but there is concern
regarding the effect it may have on active tumors (35). Growth factor’s effectiveness remains
unclear. Some forms of growth factor (e.g., growth factor-2) appear to have no significant effect
in severe cases of mucositis (35), but other forms have demonstrated a decrease in symptoms and
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severity (184). Growth factor does not appear to prevent mucositis and the research cited only
studied chemotherapy-related mucositis (184). Therefore no definitive recommendation for use
appears currently available.
Table 8. Dische Scoring System [Wygoda et al.,(31)]
Areas
Scores
Mucosal Reactions
0: none; 1: mild erythema; 2: significant
erythema; 3: spotted mucositis; 4: consistent
mucositis
Area Involved
0: none; 1: up to 25%; 2: 25-50%; 3: 50100%
Edema
0: none; 1: mild ; 2: moderate; 3: severe
Bleeding
0: none; 1: incidental; 2: multifocal; 3: regular
Ulceration
0: none; 1: single, surface; 2: multifocal,
surface; 3: single, deep; 4: multifocal, deep
Diet
0: normal; 1: avoidance of certain foods; 2:
soft or puree only; 3: liquids only; 4: NPO
Pain
0: none; 1: while eating only; 2: constant,
moderate; topical medication 3: constant,
severe, narcotic prescribed

Oral care has been demonstrated as an effective part of mucositis management, and
should use non-alcohol based cleansers, mechanical cleaning with soft toothbrushes, and flossing
(30, 35). This oral hygiene may minimize the side effects of xerostomia and mucositis including
accelerated tooth decay (30). Minimizing the toxicity effects of the organ preservation treatments
may improve overall swallow function in HNC patients as well as the quality-of-life
measurements. Reduced toxicity during treatment may improve nutrition status and increase
patient treatment adherence.
Additional therapeutic aids that may have some benefit to management of mucositis
symptoms include cryotherapy (ice chips), infusion of growth factor, anti-oxidant therapy, and
anti-inflammatory therapy (35). Cryotherapy protocols during chemotherapy recommend placing
the ice chips in the mouth from 5-30 minutes prior to treatment and maintaining them until 30
68

minutes-6 hours following chemotherapy treatment (35, 184). Ice chips may reduce the flow of
chemotherapy drugs into the oral mucosa via vasoconstriction (35), but it is unclear what effect
this treatment may have during radiation treatment. A recent double blind placebo study
examined the use of vitamin E oil against placebo in 18 patients. Results indicated that 6 of 9
patients who receive vitamin E oil had complete resolution in 5 days compared to none having
resolution in the placebo group (186). However, given the small number of patients, it is difficult
to generalize these results (186). Anti-inflammatory medications (e.g., benzydamine
hydocholride) may have a preventative effect on mucositis formation by reducing the amount of
pro-inflammatory compounds released by the damaged cells (35). Anti-oxidant treatment may
also reduce or improve mucositis by minimizing the oxidative stress placed on cells during
chemoradiotherapy, but specific guidelines for anti-inflammatory and anti-oxidant treatments
were not found (35, 83). To ensure adequate education and work as an effective member of the
care team the SLP must be aware of the potential benefit of these anti-inflammatory and antioxidant treatments. Optimal management of treatment toxicity may improve overall adherence to
behavioral swallowing exercise and help maintain the highest levels of oral intake.
Fluoride treatments are also recommended during chemoradiotherapy and for the
remainder of the patient’s life, but may not be tolerated if mucositis-related pain is present (30).
Pain is the primary symptom of oral mucositis (35). Management typically requires systemic use
of oral analgesics (e.g., lidocaine, magic mouthwash), and the most severe mucositis may require
opioid or narcotic-based pain management (35, 184). One prospective study reported oral pain
creams (e.g., dioctahedral smectite) performed better than oral rinses, and also reported a
reduced time to healing in oral mucositis (185). A 2016 review examined the use of honey to
treat or prevent oral mucositis in radiation patients indicating that honey delayed time to onset,
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reduced weight loss, and minimized interruption to treatments due to mucositis, but was unable
to reduce the overall severity (184).
The pain associated with mucositis often leads to reduced nutritional intake, and the
patient’s nutritional status should be monitored during this time (35). If nutrition is not
maintained, diet modification (soft or full liquid diet) may be needed to improve food tolerance,
and in more severe cases feeding tube placement may be warranted (35). The treatment of
mucositis should include pain management, nutritional management, quality oral care,
behavioral interventions, and medications, if needed (30, 35). The treating physician will control
pain management in the current study, and no specific medication regimen will be used.
However, the SLP should be aware of the reported levels of pain and prescribed treatments. This
will ensure that appropriate consultation or referral will be made, as needed, ensuring the patient
receives consistent pain management.
Xerostomia is defined as dry mouth or lack of normal salivary production and affects up
to 95% of radiation patients leading to dental caries or ill-fitting dentures, oral pain or yeast,
reduced or changed taste, dysphagia, and overall reduction in nutritional status (30). Changes to
salivation appear to fall in acute, sub-acute, and chronic time frames with reports of 49% and
58% reductions in saliva at 3 and 6 months, respectively (2).
Previous research reported a mean salivary weight of 5.1g (grams) pre-radiation and 1.4g
three months post organ preservation treatment, and an additional investigation revealed
xerostomia resulted in higher levels of dysphagia (90). These findings suggest that xerostomia
may affect comfort and quality of life factors (e.g., taste), but may not have a significant effect
on the mechanical process of swallowing if foods are sufficiently moistened, based on MBSS
data.
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Bruce (30) reported that xerostomia may begin in week 1 of treatment or when the dose
accumulation reaches 10 Gy. Other findings indicated that patients who receive less than a 30-35
Gy cumulative dose will have some degree of salivary return; however, if the dose reached 40-60
Gy, only 1/5 of patients will experience some salivary return. The amount of salivary return for
these groups has not been defined. Salivary return typically occurs around 6 months after
cessation of radiotherapy. Damage to the blood vessels and nerves surrounding the salivary
glands may account for the loss of salivary function, with both acute and late effects. Acute
changes were reported as early as 12 hours after the initial radiation treatment with patients
experiencing parotiditis, an acute enlargement of the salivary gland. These findings highlight the
importance of reducing or avoiding radiation to the salivary glands whenever possible.
Xerostomia does not manifest until after radiation treatment begins, usually about 1 week
into radiation, and salivary production may not return until 6 months post treatment (30). A
literature search found no pre-treatment or preventative literature available for xerostomia, but
only reactive treatments. Xerostomia treatment focuses on increasing natural salivary production
by maintaining good hydration, chewing gum or sucking on sugar free candies, ensuring moist
foods through sauces or cooking methods, or using artificial saliva replacements) (30). These
modifications are meant to improve comfort, but are not curative (30). Medications such as
Salagen (MGI Pharma, Inc., Hopkins, MN) may be prescribed to stimulate the remaining
functional salivary production. One study reported a positive effect of Salagen with improved
salivation and oral food intake after 12 weeks of medications use (187). However, there was
significant dropout due to side-effects including sweating and nausea (187.) Additional
cytoprotective medications (e.g., Ethyol, MedImmune Oncology, INC., Gathersburg, MD), may
offer some protection from chemoradiotherapy by preventing damage to the cellular DNA, but
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there is little information on the use of these medications (30). Consistent with the SLP role in
mucositis intervention, the SLP must also ensure adequate education regarding xerostomia,
including differences between patient perception and patient ability.
Mucositis and xerostomia have the potential to diminish quality of life, interrupt both the
chemoradiotherapy and swallowing treatment process, reduce overall adherence, and reduce the
social and psychological well-being of HNC patients. They also exacerbate the perceived
severity of chemoradiotherapy-related dysphagia (90). Prevention does not appear possible.
Treatment of mucositis may be in place for weeks after chemoradiotherapy ends due to the
expected healing times (31), and xerostomia treatment often continues for life because many
patients will not have full return of salivary function (30). Compensation (sipping on water
throughout the day) is the most widely used approach to help maintain oral hydration for
swallowing and talking, as well as overall QOL. This treatment appears safe despite a risk of
aspiration in this population (188). However, oral care has been advocated as an additional
component to reduce further reduce toxicity and risk of infiltration of non-water items (e.g., oral
and pharyngeal residue of foods and medications) (189, 190).
There is limited information regarding the long-term outcomes of mucositis and
xerostomia treatments despite their apparent relationship to dysphagia (191). Reduced pain and
improved oral comfort associated with mucositis and xerostomia treatment could have a
multifaceted effect on patient swallowing performance during chemoradiotherapy. Improved oral
intake may help maintain weight levels, reduce levels of muscle atrophy in the swallowing
organs occurring from disuse, and allow patients to eat a more varied diet leading to higher QOL.
Patient education regarding the use of oral hygiene protocols, along with referral for pain
management when appropriate, appears to be an appropriate part of dysphagia management in
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the HNC population. The current literature reveals that, at present, toxicity effects associated
with HNC treatment cannot be prevented or easily resolved. This conclusion highlights the need
to focus on other factors to improve patient adherence to swallowing interventions and oral diet
maintenance. This would include the use of increased SLP-visit frequency, allowing for
increased educational, motivational, and problem-solving opportunities, included in the current
study.
Starmer, Yang, Raval, Gourin, Richardson, et al. (72) reported on the use of Gabapentin
(Neurontin) administered prophylactically (2700 mg daily) for pain management and toxicity
control. Outcomes demonstrated decreased rates of aspiration, more normalized diets, and
reduced dependence on feeding tubes compared to narcotic-only pain management (72). In the
Gabapentin group only 13% needed no additional pain management; all others required
additional narcotic pain therapy (72). A retrospective study found that Gabapentin is also
associated with reduced, but not eliminated, PEG tube dependence (192). This finding indicates
that reduction of toxicity may have a positive effect on swallowing outcomes, but does not fully
eliminate associated dysphagia risk. Starmer, Yang, Gourin, Kumar, Jones, et al. (112) reported
on the one-year outcomes of patients who received Gabapentin finding elimination of PEG-tube
use, decreased aspiration risk, improved oral diet (FOIS 6.83), and minimal impact to QOL.
These findings are promising but, to date, the use of Gabapentin does not appear to be part of the
standard of care and further prospective study has been suggested.
There are no clearly reported rationales for the lack of Gabapentin use for toxicity control
in HNC patients undergoing chemoradiotherapy. The National Institute of Health U.S. National
Library of Medicine reports Gabapentin is prescribed as a medication to control epilepsy, pain
related to neuralgia (after shingles or diabetic-related nerve pain), and restless leg syndrome
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(193). There are many reported common side effects, and perhaps those most salient to the HNC
population include drowsiness, tiredness or weakness, nausea, vomiting, and heartburn (193).
The use of Gabapentin for prophylactic use related to the toxicity effects of chemoradiotherapy
on the HNC population appears to be new and off-label. The side effects may complicate and
potentially exacerbate those already associated with toxicity in this population. Furthermore,
PubMed Health reports the maximal dose for nerve pain is 1800 mg/day in adults, which is far
less than the dose used in the previously mentioned study (194). It is plausible that these factors
paired with the limited number of studies, restricted study sample sizes, and use of additional
narcotic pain medications by 87% of study participants would make medical practitioners
hesitant to prescribe this medication for HNC patients, for prophylactic use. Given these
considerations, the widespread use of Gabapentin may be premature. A summary of mucositis
and xerostomia findings are provided in Table 9.
Table 9. Summary of Mucositis and Xerostomia Findings in the Head and Neck Cancer
Population
Source
Findings
Pauloski et al. (101)
 Mucositis is the most common acute
toxicity of radiation treatment
affecting up to 100% of patients
Wygoda et al. (31)
 Mucositis may lead to reduced
nutritional intake, or dysphagia (poor
tolerance of certain foods) requiring a
reduced diet (e.g., puree diet)
Lalla et al. (35)
 Mucositis-related and associated
factors may increase treatment cost
between $2,400 and $25,000
 Pain associated with mucositis often
leads to reduced nutritional intake
Bruce et al. (30)
 Xerostomia affects up to 95% of
radiation patients
 Xerostomia may begin in week 1 of
treatment or when the dose
accumulation reaches 10 Gy (gray)
(Table 9. Continued)
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Source
Husaini et al. (90)



Robbins et al. (188)



Starmer et al. (72)







Starmer et al. (112)
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Findings
Reported a mean salivary weight of
5.1g (grams) pre-radiation and 1.4g
three months post organ preservation
treatment
Compensation (sipping on water
throughout the day) is the most widely
used approach to help maintain oral
hydration for swallowing and talking
Reported on the use of Gabapentin
(Neurontin) administered
prophylactically (2700 mg daily) for
pain management and toxicity control
Finding indicates that reduction of
toxicity may have a positive effect on
swallowing outcomes, but does not
fully eliminate associated dysphagia
risk
Reported on the one-year outcomes of
patients who received Gabapentin
finding elimination of feeding-tube
use, decreased aspiration risk,
improved oral diet (Functional Oral
Intake Scale score, FOIS 6.83), and
minimal –related quality of life

CHAPTER 4. PATIENT-RELATED FACTORS AFFECTING SWALLOWING
OUTCOMES
4.1 Age and Sex
The aging process is a progressive decline of the body’s cellular, molecular, and organ
functions (195). These progressive declines result in decreased performance across all
physiological systems and are characterized by atrophy, dystrophy, edema, reduced elasticity of
tissues, and demyelination (195). These changes are reported to result in slower and weaker
muscles with reduced coordination, stability, and endurance; all of the preceding are important to
swallowing (195).
Somatosensory function and muscular function are known to decline with age and may
result in age-associated changes in swallowing (195-201). Decline in olfactory and taste
receptors occur with age but are rarely self-reported, and often missed by healthcare
professionals irrespective of the important role they play in swallowing (197). Malandraki,
Perlman, Karampinos, and Sutton (196) assessed somatosensory activation changes with age and
found activation of the primary motor areas appeared to remain intact. Findings of intact cortical
function have been confirmed by additional studies (202, 203). Therefore, swallowing
differences within the proposed study should not vary based on age due to cortical differences,
but more aged patients may have greater declines in taste and smell compared to younger
participants.
Swallowing changes have been reported in those 60+ years of age including longer apnea
periods during swallowing episodes and longer duration of laryngeal/hyoid movements (201,
204). Studies have demonstrated lower maximal isometric tongue pressure in the older
individuals (60+ years of age), but no differences in actual swallowing pressures (200, 205, 206).
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However, older individuals use a higher percentage of their maximal strength during swallowing
tasks (38.8% for younger, 53.8% for older) (206). Further examination of age-related changes
revealed increased pharyngeal transit time, reduced laryngeal elevation, and reduced UES
relaxation/transit times, but these differences are not indicative of disorder (207). Another agerelated difference is increased incidence in penetration (infiltration of food or liquids into the
laryngeal vestibule that remains above the true vocal folds) with age (60+) in non-pathological
patients (199).
Additional age-associated changes reported by Leonard (208) include poor oral hygiene
and dentition, and decreased salivary output which may increase risk of toxicity. Toxicity is a
known complication of treatment and aged persons have more frequent and severe
chemotherapy-associated toxicity (209, 210). Using videofluoroscopy, Leonard (208) revealed
prolonged pharyngeal transit time in the pharynx of just 2-5 seconds increased risk of
pneumonia. Other timing differences were observed in hyoid movement and UES opening, with
the aged having increased duration between events. There is also higher pressure associated with
UES opening with advanced age, which may increase risk for UES dysfunction during and after
chemoradiotherapy.
Sex differences include larger bolus volumes in males compared to females (211).
Volume differences are likely the result of anatomical differences (larger cavities in men) (212).
Longer UES opening duration and slower total transit time were seen in women than men, and
have been attributed to differences in size of anatomical structures (212).
This group of findings indicate that in healthy individuals, while age and Sex differences
exist, they do not appear to result in dysphagia. However, given the changes to pharyngeal
constriction, UES function, and laryngeal elevation in patients receiving chemoradiotherapy,
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these may be important findings. It may be plausible that chemoradiotherapy patients of more
advanced age (60+) have increased risk of developing dysphagia secondary to treatment-related
changes in these structures. Despite this potential connection, the current body of evidence
revealed no age differences in post-chemoradiation swallowing outcomes. A retrospective study
of 407 patients with post-chemoradiotherapy dysphagia in three age groups (<55, 55-69, and
70+) revealed age was not a strong predictor of dysphagia severity or presence of aspiration, but
being female was a strong predictor (213). This finding may be related to underlying anatomical
Sex and physiological differences observed between men and women, but no definitive rationale
for this difference was given. With the rise in HPV-mediated cancers, this potential Sex
difference may become an important factor. Recent prevalence information for any type of HPV
transmission was 45.2% for men and high-risk genital HPV was 25.1% for men aged 18–59, and
for women aged 18-59 was 39.9% and 20.4%, respectively (214). Sex differences reveal that
men are at higher risk of contracting HPV. Given the sexually transmitted nature of HPV and the
implementation of new HPV-targeted vaccines it is unclear if these HPV-related differences will
change, affecting one Sex disproportionately when compared to the other. The SLP must be
aware of the relationship between Sex and HPV, and the potential relationship between Sex and
severity of chemoradiotherapy-related dysphagia.
4.2 Pre-existing Conditions and Medication Use
Pre-existing medical conditions and comorbidity have the potential to create or
exacerbate swallowing disorders in the HNC population (215, 216). Comorbidity is the
occurrence of a co-existing, but unrelated, disease (61). Overall lower numbers of comorbidities
(2 or less) are associated with higher survival rates (215). Surgical intervention often occurs prior
to referral for swallowing therapy, and may have the potential to exacerbate swallowing
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dysfunction. In HNC surgical interventions have the potential to change the anatomical
structures of swallowing resulting in dysphagia (5, 15, 26). Surgical intervention prior to
dysphagia treatment has resulted in more severe dysphagia and reduced patient outcomes (26).
Awareness of previous surgical interventions is needed to ensure optimal care. This information
will also lead to improved study design for inclusion and exclusion criteria. The current study
will exclude patients who received any previous surgical interventions that resulted in dysphagia
requiring feeding tube placement. This will eliminate these surgical interventions as a potential
study limitation.
In non-malignant disease, common surgical interventions which may affect the
swallowing systems include anterior cervical spine surgery (ACSS) and fusion, partial or total
thyroidectomy, laryngeal and pulmonary surgery, cardiac surgery, esophageal procedures and
fundoplication, gastric and bariatric surgery, and neurological or cortical surgeries (217). In nonmalignant disease, injuries during surgery include loss of sensation and motor control (damage to
the superior laryngeal branch of the vagus nerve, pharyngeal plexus, or hypoglossal nerve), or
direct damage to the anatomical structures (218). Other factors may include tethering of muscle
and tissue to the surgical hardware which may reduce mobility of swallowing structures (219). If
patients have a history of surgical procedures for non-malignant disease prior to
chemoradiotherapy, the severity and prognosis may be affected, but this has not been examined.
The most common comorbid diseases in the HNC population include hypertension
(HTN), diabetes (DM), and respiratory disease (61). HTN is the most common with reported
prevalence of 47.6%; DM follows with 14.6%; and respiratory disease occurs in 11.1% of
patients (61). One potential complication of these comorbid diseases, which may lead to
complications including infection or hospitalization and increase morbidity, is the prioritization
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of the cancer treatment and subsequent neglecting of the comorbid disease (61). DM care
management, in particular, has been found to decline when patients are faced with cancer
treatments (220). Furthermore, a known complication of DM is neuropathy; however, this more
commonly occurs in the peripheral areas of the body (e.g., feet) and neuropathy in the head/neck
area appears to be rare (221). DM can also negatively affect wound healing, but a recent study
examining post-surgical wound healing for cancer treatment found no difference between
patients with DM compared to those without DM (222). The impact of DM on wound healing
from radiation appears to be unknown.
Smoking, alcoholism, and depression are also important factors to consider in the HNC
population (223-225). Smoking and alcohol consumption have demonstrated increased risk of
HNC, but are also associated with depression and decreased QOL scores (225). Depressive
symptoms occur in up to 50% of HNC patients, and are related to weight loss, cognitive
impairment, reduced appetite, and have the potential to exacerbate the effects of
chemoradiotherapy (223, 225). Smoking and alcohol use are independently linked to mortality
during chemoradiotherapy (215). Alcohol use rates are reported at 16% and smoking at 30%
(225). High levels of use within a study group may negatively bias QOL scores. Additionally,
some settings (e.g., VA hospitals) have greater prevalence of usage compared to others (e.g.,
university setting) (226). Higher prevalence than the general population may limit the
generalizability of study findings.
Additional pre-existing conditions may include disease processes resulting in frailty (e.g.,
sarcopenia and dynapenia, both muscle wasting diseases) (155, 208, 227). Other common
conditions resulting in dysphagia include neurogenic diseases (e.g., Parkinson’s, dementia)
which result in decline to the central nervous system affecting motor and sensory functions (22880

231). The existing research examining chemoradiotherapy-induced dysphagia does not appear to
examine the relationship between pre-existing diseases, frailty, and swallow outcomes. If these
progressive neuromuscular and muscular diseases are present, more severe and chronic
dysphagia is likely.
Medications with potential to affect swallowing function include antihistamine and antidepressants (anticholinergics), psychotropics, and narcotic pain medications (232). Medications
and polypharmacy (the use of multiple medications) have the potential to exacerbate or create a
swallowing disorder, and can impact the anticipation and motor functions of swallowing (210,
233). Polypharmacy may also exacerbate treatment toxicities associated with chemoradiotherapy
(210). Side effects of prescribed medications can adversely affect swallowing physiology by
acting upon the laryngeal system, general motor function, cognition, alertness, and/or
emotional/mood status (232). Additional medicinal interactions may occur with respiration,
salivation, and nutrition/digestion (232). Medications that act as depressants to the central
nervous system (sedatives) may reduce alertness, muscle response to stimulation (sensory input),
and reduce or alter smell/taste (233). Medications may exacerbate or predispose patients to
toxicity or dysphagia, but to date the relationship between these medications and swallowing
outcomes following chemoradiotherapy appears to be unknown. It may be impractical or
dangerous to eliminate prescribed medications in patients undergoing treatment for associated
conditions.
Many HNC patients may be taking medications that have a potential negative or positive
effect on swallowing. The available information regarding potential effects of medication
illustrate the need to further consider these factors when treating dysphagia in this population.
Additional consideration should be given to the potential beneficial effects of medications in the
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dysphagic population. Medications including atropine and levodopa have been shown to improve
swallowing function resulting from neurogenic disease (233). Gabapentin and pain medications
have demonstrated a potential for toxicity management in the HNC population, but do not appear
to be a current standard of care (72, 192). Additionally, the importance of medication timing to
optimize swallowing outcomes has been highlighted (234). The SLP must be aware of comorbid
conditions and medication usage to ensure adequate patient education and make referrals to the
treating physician, or other treatment team members as needed, throughout the intervention
process. Knowledge of these conditions is also important to the study design. Significantly
limiting the study sample pool due to factors including comorbid disease would likely yield a
clinically irrelevant sample, or make the study required sample size impossible to achieve.
However, the researcher must be able to discuss these potential relationships.
4.3 Adherence
Compliance and adherence appear to be used interchangeably within the HNC literature.
A simple definition of compliance is following the instructions and recommendations made by
the appropriate professional (43). However, adherence refers to the actual completion of the
recommended tasks and is reported to account for the multiple external factors that must be in
place to ensure the success (235). SLP recommendations during dysphagia management include
dietary changes, specialized exercise and maneuvers, behavioral and positioning strategies, and
non-oral feeding (12, 43, 159, 160). Adherence has been highlighted as a potential way to
improve swallow exercise use, and improve swallowing outcomes in return (235). However, the
effects of chemoradiotherapy appear to have a direct impact on adherence with levels of exercise
completion diminishing as the negative impact of radiation increases (236). Poor adherence may
have serious consequences on overall health and may result in a significant financial burden.
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Non-compliant individuals have more hospital re-admissions due to pulmonary infection, receive
more medications, and experience higher rates of aspiration pneumonia than compliant patients
(33).
Rogus-Pulia and Hind (43) outlined factors that may influence adherence in patients with
dysphagia.
1. Self-efficacy includes insight into one’s condition, possession of task or condition-related
skills, and confidence or self-motivation. Factors underlying self-efficacy appear to be highly
moldable and not fixed. It can be postulated that low levels of self-efficacy may influence nonadherence while high levels would improve adherence. The SLP appears to be able to influence
the underlying traits through the therapeutic model. For example, education of condition or taskrelated skill performance may improve insight, knowledge of skills, and motivation in a positive
way.
2. Knowledge of the condition, also referred to as health literacy, appears to be a crucial
component of adherence. For many patients denial of disorder is common and may occur due to
lack of knowledge, or as a coping mechanism due to the loss of a function (43, 159). If the
patient denies the existence of dysphagia the patient will not maintain adherence with orders for
thickening liquids or modified diet, and often may refuse therapeutic interventions. This situation
highlights the positive impact that adequate education regarding the patient’s condition can have
on adherence.
3. Adequate education, including verbal and visual materials during the initial treatment and
when any change in condition occurs, should improve and maintain the patient’s knowledge,
having a positive impact on adherence.
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4. Skill development is also required to maintain adherence. Implementing a new strategy or
technique without ensuring adequate training will result in an inability to comply. Skill
acquisition requires motor learning, or change occurring with practice that persists over time
(237). The use of feedback may have a positive effect of learning and may include knowledge of
performance and/or results (43). One promising method to improve skill acquisition and
accuracy, biofeedback, is reported as beneficial component of behavioral treatment and
demonstrates an immediate effect on function (46). Biofeedback provides the patient insight into
the underlying muscle activity, and provides a way to understand an individual task ensuring
accuracy (238).
Rogus-Pulia and Hind (43) reported on the role of self-motivation, confidence, and skill
acquisition. If patients are intellectually and cognitively intact, imparting knowledge to improve
motivation and confidence may be relatively straight forward. In HNC it is possible that a preexisting concomitant neurological condition (e.g., previous stroke) or psychological conditions
(depression, alcohol and tobacco withdrawal) will exist. Care should be taken to screen or
ascertain if such a disorder does exist due to the potential impact on education and adherence.
Chadwick, Jolliffe, Goldbart, and Burton (12) reported on barriers to adherence in dysphagia
treatment for those having intellectual disabilities. Findings suggested that external assistance
from caregivers is often needed to ensure adequate use of skills and safety in dysphagia
management. We should assume that any factor that may affect a person’s intellectual or
communication capacity in the HNC population would also benefit from increased assistance,
but it appears no studies have examined these interactions within HNC populations.
Another recent study examined the effect of adherence on swallowing outcomes after
treatment in the HNC population (130). Krisciunas, Castellano, McCulloch, Lazarus, Pauloski,
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et al. (41) reported that 54% of patients were considered compliant. Adherence was defined as
completing at least 10 swallowing exercise sessions per week; there were 12 possible sessions
per week. Level of adherence was calculated as the number of possible sessions minus the total
completed. Patients were grouped by compliant and non-complaint, but no significant
differences in swallowing-related outcomes emerged. The original intent of the study was not to
assess adherence, and thus lack of specific planning to address the outcomes related to adherence
limit these findings. The measurement of adherence also does not account for adherence within a
session. It is unclear if all compliant patients, as measured in this study, actually performed the
same level of exercise. Further study, with careful planning regarding adherence factors, is
needed to further explore these relationships.
Patients with dysphagia ultimately face a life changing circumstance, whether acute or
chronic, that has both nutritional and social consequences (44). Lack of adherence has been
described as a main barrier to effective management of dysphagia (44). Patients experience
swallowing difficulties following a wide range of neurological or disease events (e.g., stroke or
HNC) (44, 159, 239-241). With a spectrum of etiologies, there are many possible sources of nonadherence in dysphagic individuals. Dysphagia changes the physical ability to swallow, but also
impacts the social and psychological function of the individual (44). For example, changes in
eating ability can create anxiety and behavioral changes at meals reducing opportunity for social
interaction (44). Social behavior appears to impact adherence in healthcare decisions (e.g., a
social support network) (242). Knowing that dysphagia affects both physical and social function
highlights the need for more research to explore these aspects of adherence. These findings
highlight the need to maintain high levels of support from the SLP and to normalize diet and
eating habits as much as possible, during chemoradiotherapy.
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It appears that knowledge and timing of education are crucial for self-motivation and
confidence. Patients often receive education at the beginning of prophylactic dysphagia treatment
related to HNC. The amount and frequency of ongoing education from the SLP is poorly
reported (40), but increasing the level and type of education may be beneficial to adherence and
subsequently patient outcomes. Wall, Ward, Cartmill, Hill, and Porceddu (40) examined three
separate service delivery models to determine their effect on patient adherence to swallowing
therapy programs for HNC. Models included face-to-face therapy with the SLP [5 weekly
treatments based on previous work by Carnaby-Mann et al. (34)], technology assisted therapy
[electronic therapy application], and patient-directed intervention [5 weekly treatments, no
clinician direction]. Adherence to treatments was defined as the percentage of exercises
completed, and results demonstrated low mean adherence (27%) across all groups with noted
declines after 4-weeks of intervention. Further analysis revealed high variability among
individuals ranging from 0-97% adherence. Overall, the SLP-directed treatment yielded the
highest results. These results highlight a drop in adherence at 4 weeks, a time when toxicity
effects are increasing. The current study will seek to find a balance between SLP-directed
intervention and patient-directed (home-based) intervention. While direct SLP interaction
appears key to patient adherence and swallowing-related outcomes, the intensity or volume of
behavioral swallowing exercise recommended in the current literature prevents the completion of
all exercises in the presence of the SLP. The current study will examine a higher level of SLPpatient interaction (e.g., 5 SLP-visits per week) combined with additional home-based patientdirected behavioral swallowing interventions.
Recent studies have highlighted the need for improved adherence and have built on the
earlier work by Rogus-Pulia and Hind (235, 243, 244). They provide some consensus regarding
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the need to mitigate the burden of treatment, ensure adequate education to patients and
caregivers, provide adequate support during the treatment process, provide feedback about
exercise, and motivate patients (235, 243, 244). Recent work by Starmer et al. (151) has
examined the feasibly of a mobile application to provide a potential method for increased
swallowing intervention health literacy and adherence to prophylactic swallowing exercises.
While initial outcomes for adherence were limited, the data revealed that patients reported
forgetting to do exercises to be the most significant barrier to adherence. Patients also reported
that they benefited from feeling like they were receiving more interaction from the SLP and had
a method to track progress. It may be plausible that increased SLP-patient interaction may
provide a platform to improve overall adherence. Adherence may be affected by increased
opportunity for education (health literacy) and increased opportunity for coaching and
performance of exercise in the presence of the SLP. Further studies are needed to determine if
more structured SLP-driven protocols will further increase adherence.
4.4 Caregiver and Environmental Factors
It has been reported that we underestimate the occurrence of non-dysphagia related meal
time difficulty faced by patients (240). Findings suggested that as many as 87% of patients are
experiencing some meal time challenge (240) creating greater risk of non-adherence with
dysphagia or nutritional related recommendations. These difficulties, when compounded by
layers of additional dysphagia recommendations, may over burden the patient resulting in poor
adherence.
Due to the level of difficulty faced with meal preparation and consumption, patients are
often dependent on their caregiver. Chadwick et al. (12) found that caregivers viewed food and
liquid preparation for altered diets difficult, struggled with maintaining appropriate patient
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positioning during meals, and had difficulty providing adequate verbal support. They cited time
constraint and rapid turn-over in staff as causal factors. However, the more important finding
was inadequate training and education from the SLP. They concluded the SLP needed to increase
educational opportunities and be more integrated in the process. Work by Smith-Tamaray,
Wilson, and McAllister (245) offered some insight into increasing adherence of other healthcare
staff. They discussed the importance of healthcare team membership including increasing value
in the SLP’s role in the healthcare setting, earning respect as an individual provider, and
increasing the credibility of the profession. Lack of professional credibility is a clear source of
non-adherence from both the caregiver and patient. Consistent and accurate education, problem
solving and training, and increasing the SLP availability during the treatment process are
important to adherence and the potential success of intervention. Furthermore, it appears that
increasing, not reducing these opportunities may offer better outcomes. There is currently no
standard regarding the timing and frequency of SLP-patient interaction during prophylactic or
rehabilitative treatment in the HNC population.
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CHAPTER 5. DESIGN AND METHODS
To evaluate the proposed hypotheses, a prospective study using a two-group cohort
design and one retrospective cohort group was undertaken at the Mary Bird Perkins Cancer
Center (MBPCC), Baton Rouge, Louisiana. An additional group was formed using existing data
from a previous study completed at MBPCC (24). Institutional Review Board (IRB) approval
was obtained from Louisiana State University (LSU), Louisiana State University Health Science
Center (LSUHSC), and the Our Lady of the Lake Regional Medical Center (OLOLRMC) for
both the prospective study groups and the retrospective group obtained through chart review.
Approved IRB documents are available in Appendix A.
5.1 Recruitment of Patients into Treatment Groups
Four groups were examined in this study (high frequency, HF; low frequency, LF;
1day/week; and current common treatment, CTT). For the prospective study groups, patients (18
year of age or older) with newly diagnosed HNC (base of tongue, pharyngeal, and/or laryngeal
cancer) who began radiation therapy with or without chemotherapy between September 1, 2017
and December 21, 2018, at MBPCC, were referred to the Our Lady of the Lake Regional
Medical Center-Voice Center (OLOLVC) for a routine baseline assessment modified barium
swallow study (MBSS). The MBSS was completed by the primary investigator (M.V.) or a SLP
employed at the OLOLVC as part of standard care. MBSS outcomes and screening of patient
medical history were used to determine patient eligibility for the prospective study group.
Inclusion and exclusion criteria for the study are found in Table 10.
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If the patient met eligibility for the study, a short meeting was held with the patient in a
private room to recruit the patient into one of the experimental groups. During this meeting the
procedures and objectives of the study were explained. These procedures and objectives are
Table 10. Inclusion Criteria and Exclusion Criteria for Prospective Patient Recruitment
Inclusion Criteria
Exclusion Criteria
1. Diagnosis of cancers of the base of tongue, 1. Dysphagia warranting PEG tube placement
oropharynx, nasopharynx, hypopharynx,
prior to the initiation of radiation therapy
larynx and/or nodal disease
2. Evidence of functional oral swallowing
abilities based on the pre-HNC treatment
MBSS study, defined as no use or
recommendation for non-oral feeding, prior to
the initiation of radiation

2. Evidence of or reported diminished ability
to comprehend and perform therapy tasks,
due to any reason which may include
previous neurological damage (stroke, brain
injury, disease) included in the medical
record or subject reported history

3. No PEG tube placement prior to the
initiation of radiation therapy

3. Patients who will not undergo radiation
treatment

4. Signed Informed Consent

4. Pregnancy

5. Newly diagnosis cancer

5. Previous surgeries to the head and neck
resulting in PEG use or any associated
dysphagia, or any surgery related to the
cancer treatment process prior to radiation
(other than biopsy)
6. Any previous radiation treatment to the
head/neck area
7. Any reoccurrence of head/neck cancer
8. Subjects with an unknown primary
head/neck cancer

9. Tracheostomy
PEG: Percutaneous Endoscopic Gastronomy feeding tube; MBSS: Modified Barium Swallow
Study; HNC: Head and Neck Cancer

outlined in the Informed Consent. The Informed Consent is available as part of the IRB-related
documents in Appendix A. If the patient desired to participate in the study, the patient was asked
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to read the Informed Consent. Once the patient had agreed to participate in the study, the patient
was asked to sign the LSUHSC IRB-approved Informed Consent along with the LSUHSC
Health Insurance Portability and Accountability Act (HIPAA) Statement. The HIPAA Statement
is available with the IRB-related forms in Appendix A.
The retrospective cohort group was obtained through a retrospective chart review.
Subjects with diagnosis of HNC (oral, pharyngeal, and/or laryngeal cancer) who began radiation
therapy with or without chemotherapy between January 1, 2013 and September 30, 2017 at
OLOL-RMC and MBPCC were reviewed for potential inclusion. Inclusion and exclusion criteria
for the retrospective group are also found in Table 8. Informed consent along with the LSUHSC
Health Insurance Portability and Accountability Act (HIPAA) Statement waivers were requested
due to the retrospective nature of this study. Subjects who met the inclusion criteria were placed
into a retrospective current common treatment (CCT) group.
An additional study group was formed using subject data available from previously
completed clinical study examining the effects of two different behavioral swallowing exercise
regimens delivered prophylactically (repetitive swallowing or behavioral exercise including
Masako, Shaker exercise, and pharyngeal squeeze) while undergoing radiation therapy with or
without chemotherapy (24). This previous study was also performed at MBPCC, and the subjects
received similar behavioral dysphagia-related interventions, but only 1 day a week SLP visit
during course of radiation therapy. The inclusion and exclusion criteria found in Table 11 were
also applied to these subjects. If the inclusion criteria were met subjects were placed into a 1
day/week group.
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Table 11. Criteria for Inclusion and Exclusion of Retrospective Patients
Inclusion Criteria
Exclusion Criteria
1. Diagnosis of cancers of the base of tongue, 1. Dysphagia warranting PEG tube placement
oropharynx, nasopharynx, hypopharynx,
prior to the initiation of radiation therapy
larynx and/or nodal disease
2. Evidence of functional oral swallowing
abilities based on the existing MBSS study,
defined as no use or recommendation for nonoral feeding, prior to the initiation of radiation

2. Evidence of or reported diminished ability
to comprehend and perform therapy tasks, due
to any reason which may include previous
neurological damage (stroke, brain injury,
disease) included in the medical record or
subject reported history

3. No PEG tube placement prior to the
initiation of radiation therapy

3. Patients who did not undergo or complete
radiation treatment

4. Existence of both pre- and post-radiation
MBSS

5. Previous surgeries to the head and neck
resulting in PEG use or any associated
dysphagia, or any surgery related to the
cancer treatment process prior to radiation
(other than biopsy)
6. Any previous radiation treatment to the
head/neck area prior to the reviewed period
7. Subjects with an unknown primary
head/neck cancer

8. Tracheostomy
PEG: feeding tube; MBSS: Modified Barium Swallow Study

Chemotherapy provided before radiation therapy (induction) or during (concurrent) is a
common organ preservation treatment practice in HNC population; however, not all patients
received chemotherapy. Chemotherapy, as discussed earlier, does not result in dysphagia but
does cause treatment toxicities (mucositis and xerostomia), which also occur with radiation
treatment. Due to the presence of these toxicities across cancer treatment modalities, there does
not appear to be a rationale for excluding any chemoradiotherapy combination, or absence of
chemotherapy (radiation only), from the study. Additionally, surgical interventions are often
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performed to de-bulk or biopsy tumors prior to radiation treatment with or without
chemotherapy. De-bulking surgery may pose some risk to swallowing function. This study
excluded any surgery, other than biopsy, to eliminate the potential of surgery-related dysphagia.
Final enrollment of study participants revealed no inclusion of subjects with any surgical
interventions other than biopsy.
5.2 Rationale for Retrospective Data
The first two groups (HF and LF) in this study were collected prospectively, a level II
form of experimental research (246). This allowed for increased control of group selection and
minimization of confounding factors during the research process (247), and is a widely used
research methodology within the field of dysphagia research. In contrast, the third study group
(CCT) was be collected as a retrospective cohort group from the existing medical records, a level
III form of experimental research (248). This methodology is also widely used in dysphagia
research. Previous studies using retrospective data collection methods to examine radiationrelated dysphagia in the HNC population including Hutcheson et al. (14) and Carroll et al. (153)
have been previously discussed in Chapter 3 of this document. Findings of these studies revealed
similar SLP-patient visit frequencies, prophylactic treatment methods, and similar exercises
compared to the retrospective group planned for this study. Retrospective group data are often
collected from existing medical records to identify risk factors associated with certain disease or
conditions, even if the original intent of the medical data was not designed for research (246,
247, 249). The use of historical or retrospective cohort groups allows the researcher to establish a
control population, based on a desired set of characteristics (248). In this study, the use of a
retrospective group, which received a SLP-patient contact frequency based on the current
common treatment, acted as a control group, allowing the comparison of higher SLP-patient
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contact frequency to the current common prophylactic behavioral swallowing treatment
approach. It has been suggested that a control group is needed to validate study-related results in
clinical research (248). The use of a historical retrospective cohort allowed for the comparison of
population-related risks between the study groups based on the study variables (249, 250). It is
not possible to compare risks without a comparative cohort.
While retrospective data collection is a common research methodology, it may be more
restrictive or increase the risk of confounding factors when compared to the prospectively
collected data (246). If care is not taken in the methodology of group design and data collection,
the retrospectively collected data may be invalid or unusable. There are, however, both
advantages and disadvantages to the use of retrospectively collected group data, found in
Table 12.
Table 12. Advantages and Disadvantages of Retrospective Data Collection (247-250)
Advantages
Disadvantages
 Existing records limit the time and
 All needed data may not be stored or
cost of data collection
present
 No exposure to newly discovered risk
 May not be representative of the
factors
desired population
 Timeline/sequence related to risk
 Little control of original data
factors is the same when compared to
collection methods
prospective groups
 Limited data sets may allow for
findings of association between
 Minimized risk to subjects
factors, but prevent findings of
 Risk to a specific population can be
causation
assessed
 Limited ability to control for possible
 Unique cohorts can be established
confounding factors via statistical
methodology

Many potential disadvantages or pitfalls exist in the collection of retrospective data;
however, using the appropriate methodology can minimize or eliminate these problems. The
initial problem, missing data in the medical chart, can be reduced in many cases. For the current
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study, missing data included MDADI values if these values were not recorded or if the original
methodology of data collection did not match the current study’s needs. Other missing values
(e.g., FOIS or PAS scores) can also be determined based on written descriptions of patient’s diet
or condition documented in the relevant swallowing-related notes, or with the existing MBSS
videos. It is unlikely that all missing values can be recreated. Missing data can increase risk of
bias (247, 249). Bias is only an issue, however, if the data are systematically missing within all
or a portion of the study population. Randomly missing data would not constitute such a bias in
the statistical analysis (247). Since the potential study population for the retrospective CCT
group received their treatment at the same facility using many of the same assessment tools and
methodologies as the planned prospective groups, there is little chance of bias and missing data,
for the data collected. However, newer tools including the Saxon test, MINI-SF, and H&N PSS
forms were not available or used for the retrospective group. Therefore, the analyses between the
prospective groups and the CCT groups was limited to the previously available data.
Retrospective data collection was limited to PEG use, PAS, FOIS/diet level, weight loss
percentage, and patient reported QOL (MDADI). Information related to cancer type, tumor site,
cancer stage, age, Sex, radiation type, radiation dose, and use of chemotherapy were also
available. These data are important for the study of swallowing-related outcomes in the HNC
population, and allowed for direct comparison of functional, physiological, and QOL data. These
data were also directly comparable to other previously published studies which used similar,
previously available, data collection methods.
To ensure that the retrospective group was matched to the desired population, and to
eliminate this potential limitation, the group included the same range of cancer tumor sites and
cancer stages as the prospectively collected groups. If the retrospectively collected data
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represents all of the potential tumor sites and stages for the HNC population, it would be
representative of the desired study population (247, 249). If the retrospective group represents
the population and the group was well matched to the prospectively collected groups, inference
of causation, not just association, would be appropriate (247). However, potential causation must
be discussed with an understanding that all confounding or causal variables cannot be identified
or controlled with this retrospective methodology. Based on these criteria and methodological
guidelines a retrospectively collected cohort group was created. This, as previously mentioned,
allowed for comparison between the HF and LF groups, 1 day/a week group, and the CCT group.
These comparisons highlighted the potential impact of treatment frequency during prophylactic
swallowing intervention methodology on HNC-related risk of dysphagia and related outcomes
including PEG use, diet level, aspiration risk, and QOL.
5.3 Selection of Sample Size and Group Placement
A power analysis for sample size was performed for the main outcome variable, PEG
tube use or no PEG tube use, for comparison between the treatment parameters. A historical
research group was used to establish a 35% post radiation PEG-use level (24). This historical
group was chosen because it represents a group of HNC patients who received prophylactic
behavioral swallowing interventions while undergoing radiation treatment with or without
chemotherapy. The following statistical equation was used to determine the appropriate sample
size for each study group: n = (Zα/2+Zβ)2 * (p1(1-p1) + p2(1-p2)) / (p1-p2)2. Analysis revealed a
recommended sample size of 15 per group, 30 total for the prospective groups and 15 total for
retrospective recruitment (total study n = 45), for a power of .80 (effect size) and significance
p = .05. A statistician in the Department of Experimental Statistics at LSU confirmed these
sample size findings for the proposed study design. Attrition in HNC-related research is a known
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factor that needs to be considered when planning study sample size (251). To account for
possible attrition, recruitment of 17 patients per prospective group (total n = 34) was completed;
however, only 30 subjects (n = 15 HF and n = 15 LF) were included in the final study analysis.
One of the 30 patients included in the current study’s prospective groups did pass away prior to
the completion of the post-radiation MBSS. This subject did complete the treatment portion of
the study. This resulted in missing post-radiation MBSS-related data for this patient (PAS scores,
Swallowtail-related timing and displacement variables). Two additional enrolled patients passed
away prior to the completion of radiation therapy and were not included in the study analysis,
one subject received an accelerated version of radiation and experienced surgery requiring
removal from the study analysis, and a fourth subject was removed due to violence against
treatment staff. Due to the potential for missing or incomplete data in the retrospective group 25
subjects’ data were included into the CCT group. The initial patient pool from the previously
completed study (24) was 56 patients. However, once the inclusion and exclusion criteria for this
study were applied, the final number of included subjects for the 1day/week group was 47. This
n was greater than the power analysis result of 15. The total n for this study was 102 patients.
Upon enrollment into the study, patients recruited into the prospective groups were
placed into one of two treatment groups (High Frequency or Low Frequency). The consecutive
enrollment of new patients, as cancer diagnoses were made, meant that random assignment into
treatment groups would likely yield unmatched groups for tumor site and tumor stage. In
addition, due to the reported prevalence of stage III and IV tumors, at least 50% (52) of the
participants in each group needed to fall within these stages. This enrollment method ensured a
clinically relevant sample. To ensure well-matched and clinically representative groups, the first
16 patients were alternately enrolled into each of the two groups, and the remaining 18 were
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enrolled with intent based on tumor site and tumor stage factors. The CCT group also included a
varied mix of tumor sites and cancer stages. Due to the retrospective nature of the 1day/week
group, the enrollment methodology could not be controlled. However, the previous study did
include a wide range of tumor sites and stages, with more than 50% coming from stage III and
IV cancers. This enrollment method for the HF, LF, and CCT groups, paired with the similar
variety of the tumor sites and stages found in the 1day/week group, increased the likelihood of
well-balanced groups.
5.4 Assessment of Group Differences
The influence of patient characteristics (e.g., age, cancer stage, HPV status) has
previously been discussed in Chapter 4 of this document. The potential role of Sex in
swallowing-related outcome severity (213); the potential impact of smoking, alcoholism, and
depression on treatment adherence and QOL (223-225); and the potential impact of
antihistamine and anti-depressants (anticholinergics), psychotropics, narcotic pain medications,
and polypharmacy make these important factors to explore within the study groups (210, 232,
233). The enrollment methods for group placement were undertaken in an attempt to ensure the
balance of these characteristics within the study groups. However, the enrollment methodology
did not guarantee that group differences would not occur. To explore potential group differences
between the treatment groups and to explain the potential impact of these differences, should
they occur, a series of statistical analyses were performed prior to the main study analyses.
Analysis of group characteristics included age, Sex, HPV status, pain and nausea medication
type, smoking and alcohol use, tumor site, cancer stage, pre-treatment patient QOL measures,
pre-treatment function measures, and pre-treatment physiological measures.
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Table 13 provides information summarizing subjects’ demographics for age and Sex.
Enrollment criteria and retrospective analysis techniques were used in an effort to match the age
and Sex of these HF, LF, and CCT treatment groups. The enrollment techniques of the existing
1day/week group data were not able to be controlled. Statistical analysis using ANOVA revealed
no age or Sex differences across the four study groups with p = .837 and p = .911, respectively.
Table 13. Demographics of Subjects’ Age and Sex for the HF, LF, 1day/week, and CCT
Groups
Demographic
HF
LF
1day/week
CCT
P value
n = 15
n = 15
n = 50
n = 25
Age (years)
Mean
63.5
59.6
62.7
62.1
.837
Range
44-76
44-76
40-90
40-81
Sex
Male
12
14
39
21
.911
Female
3
1
8
4
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits per week;
(1day/week) 1 SLP-visit per week; (CCT) current common treatment, 3-4 visits over 6 weeks
or radiation treatment

Table 14 provides a summary of the chi-square analysis, using Kruskal-Wallis test, of
HPV status, medication type, smoking, and alcohol use during/at the start of radiation treatment
for the HF and LF groups only. These data were not available for the CCT or 1day/week group.
The analysis revealed no pre-radiation differences based on HPV status (p = .472). Medication
differences were not observed with all subjects receiving Norco as the initial pain medication.
Two subjects from the HF and four subjects from the LF group received a secondary pain
medication. These were either Demerol, Demerol patch, or morphine (pill form). Due to the
limited frequency of these additional pain medications, they were grouped together for the
analysis and no between group differences emerged (p = .369). All study subjects received both
Phenergan and Zofran for nausea. Overall, there was limited variation in the pain and nausea
medications used across the prospective study groups. Additionally, all subjects who received
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chemotherapy received the same chemotherapy medication, Cisplatin. There were also no
radiation, chemotherapy, or medication-related differences observed between patients with a
HPV diagnosis and patients without a HVP diagnosis. Three subjects for the HF and two from
the LF group continued to smoke during radiation treatment, but no between group difference
was evident (p = .630). Additionally, one HF subject and three LF subjects consumed alcohol
during radiation treatment, but again there was no significant between group difference (p =
.291).
Table 14. HPV status, Medication Type, Smoking, and Alcohol
Use for the HF and LF groups
Variable
Status/Type
HF
LF
p Value
n = 15
n = 15
HPV
Positive
8
6
.472
Negative
7
9
Medication

Smoking

Norco
(pain)
Demerol or
Morphine
(pain)
Zofran
(nausea)
Phenergan
(nausea)

15

15

-

2

4

.369

15

15

-

15

15

-

Positive
Negative

3
12

2
13

.630

Alcohol

Positive
1
3
.291
Negative
14
12
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3
SLP-visits per week; (-) unable to compute, all subjects received
Analysis of tumor characteristics are reported in Table 15. Tumor sites included oral
tongue plus base of tongue, base of tongue only, tonsil, larynx, pharynx, and lymph node plus
neck. Oral tongue was only present in the 1day/week group, and each of these subjects also had
base of tongue tumor. Given that there were four subjects with oral tumor plus base of tongue
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and five with base of tongue tumor only, and to ensure clarity of data reporting, these were
treated as separate tumor sites. Chi-square revealed that there was no difference between the
groups based on tumor location
Table 15. Tumor site and Tumor/Cancer Stage for the HF, LF, 1day/week, and CCT groups
Variable
HF
LF
1day/week
CCT
P value
n = 15
n = 15
n = 47
n = 25
Tumor site
Oral
4
.188
Tongue
with Base
of Tongue
Base of
5
4
5
4
Tongue
only
Tonsil
4
8
13
8
Larynx
4
2
15
6
Pharynx
2
1
4
7
Lymph
6
Node/Neck
Tumor/Cancer
I
1
5
1
.430
Stage, Based
II
2
1
7
3
on TNM score
III
10
8
12
12
(Tumor size,
IV
2
6
22
9
Nodal
involvement,
Metastasis)
Percentage of
80%
93%
72%
84%
Stage III and
IV Tumors
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits per week;
(1day/week) 1 SLP-visit per week; (CCT) current common treatment, 3-4 visits over 6 weeks
of radiation treatment

(Kruskal-Wallis, p = .188). Tumor stage (I, II, III, IV), also known as cancer stage, was based on
the TNM system which has been described previously (Table 1). Staging ranged for I (least
severe) to IV (most severe) for the HF, 1day/week, and CCT groups. The LF group ranges from
stage II to IV. There were no between group differences observed (Kruskal-Wallis, p = .43). In
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addition, stage III and IV tumors constituted greater than 50% of the total tumors in each group
representing a more clinically relevant sample. It was noted that while no statistical significance
was found for cancer stage there was a higher prevalence of stage IV tumors in the 1day/week
group. This difference may be due to the variations in group size, with the 1day/week group
having a larger total n. The proportion of stage III and IV cancers is similar across all groups.
Analysis of pre-treatment function summarized in Table 16 includes PEG use, FOIS
scores, BMI, and nutritional risk assessed using the MNA-SF. Given that the inclusion criteria
required no PEG use prior to study enrollment or the start of radiation, no subjects in any group
had a PEG tube in place.
Table 16. Pre-radiation PEG use, Mean FOIS Score, Mean BMI, Mean MINI-SF score for the
HF, LF, 1day/week, and CCT groups
Variable
HF
LF
1day/week
CCT
P value
n = 15
n = 15
n = 50
n = 25
PEG Use
% used
0
0
0
0
FOIS
Range
7
7
5-7
5-7
BMI**
Mean
27.47
30.44
NA
NA
.290
MNA-SF**
Mean
6.53
5.60
NA
NA
.496
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits per week;
(1day/week) 1 SLP-visit per week; (CCT) current common treatment, 3-4 visits over 6 weeks
or radiation treatment, (PEG) percutaneous endoscopic gastronomy tube-feeding tube; (FOIS)
Functional Oral Intake Scale; (BMI) body mass index; (MNA-SF) Mini Nutritional
Assessment-Short Form; (**) indicates that this comparison was only available between the
HF and LF groups

FOIS levels range from 1 (lowest, PEG use) to 7 (highest, normal diet). The mean levels
for the HF and LF groups were both 7, and the levels for the 1day/week and CCT groups were
6.62 and 6.84, respectively. The range of pre-radiation FOIS scores across all groups was 5-7,
indicating that all subjects were on a full oral diet with only minor changes (e.g., soft or tender
cooked solids). This is an expected range of textures given the likelihood of pre-radiation dental
extractions experienced in this population and does not constitute a true group difference.
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Analysis of pre-treatment physiology included PAS and DIGEST scores. Additional
physiological variables included measurement of saliva production in grams (Saxon test);
maximal UES opening (UESMax/cm); maximal pharyngeal constriction (PCR); maximal
hyolaryngeal excursion (Hyolaryngeal); time of the first approximation of the arytenoids and
epiglottis coming together to close off airway (Airwayclose); total pharyngeal swallowing transit
time (TPST); pharyngeal residue ratio (PRR); and bolus clearance ratio (BCR). Findings for preradiation physiology scores assessed are reported in Table 17.
Examination of the mean pre PAS data for combined thin and pudding bolus types
revealed that mean PAS scores ranged from 1 to 3 in the 1day/week and CTT groups, and all
scores were 1 for the HF and LF groups. This examination of the PAS range data indicated that,
while the some penetration was present across retrospective study groups, there was no
aspiration present. The lack of penetration observed in the prospective HF and LF groups may be
due to the selective nature of inclusion criteria. Additionally, due to the potential invasive nature
of HNC-related tumors in the swallowing mechanism some level of penetration may be
expected. These instances of penetration did not result in altered diet or diagnosis of dysphagia
prior to radiation therapy. Therefore, there did not appear to prevent further examination of postradiation group differences. Repeated measure design was also used to examine for PAS
differences between the HF and LF groups. The prospective nature of these groups allowed the
collection of PAS data across multiple trials by bolus type. Results indicated no group
differences, consistent with the previous analysis of the mean data, for thin (p = .212) or pudding
(p = .448) bolus types. Additionally, DIGEST scores were examined across the HF and LF
groups with no significant difference noted, with both groups having a mean of 0. As discussed
previously, DIGEST is a new assessment method quantifying both aspiration risk and reduced
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swallowing efficiency into combined score (scores range from 0, meaning no risk to 3, meaning
the most severe risk). Mean pre-radiation data for the HF and LF groups was 0, indicating no
aspiration risk or reduced swallowing efficiency.
Table 17. Pre-radiation PAS, DIGEST, Saliva, Timing and Displacement Values for the HF,
LF, 1day/week, and CCT groups
Variable
Bolus Mean HF Mean LF 1day/week
CTT
P value
Type
n = 15
n = 15
N=47
N=25
PASmean
1
1
1.53
1.08
(range)
(1-3)
(1-3)
PASrepeated
Thin
1
1
.212
PASrepeated
Pudding
1
1
.448
DIGEST
0
0
Saliva
4.14 g
4.42 g
.650
UESMax/cm
Thin
.83
1.0
.042
Pudding
.90
.94
.533
TPST
Thin
.98
1.34
.463
Pudding
1.59
1.16
.136
PCR
Thin
.17
.07
.104
Pudding
.07
.10
.733
PRR
Thin
2.81
1.22
.148
Pudding
1.38
1.6
.828
BCR
Thin
12.1
8.72
.245
Pudding
9.33
5.19
.176
Airwayclose
Thin
.18
.15
.696
Pudding
.24
.30
.696
Hyolaryngeal/cm
Thin
2.56
1.86
.035
Pudding
1.93
2.31
.183
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits per week;
(QOL) quality-of-life, (PASmean) penetration aspiration scale mean combined data,
(PASrepeated) penetration aspiration scale repeated trials data, (DIGEST) Dynamic Image
Grade of Swallowing Toxicity scale, (UESMax/cm) maximal displacement of upper
esophageal opening in centimeters, (TPST) total pharyngeal swallow time, (PCR) pharyngeal
constriction ration, (PRR) pharyngeal residue ratio, (BCR) bolus constriction ratio,
(Airwayclose) time of the first approximation of the arytenoids and epiglottis coming together
to close off airway, (Hyolaryngeal/cm) maximal hyolaryngeal excursion in centimeters

Analysis of saliva function revealed no pre-radiation group differences. For timing and
displacement values no pre-radiation differences were observed for UESMax/cm, PCR,
Hyolaryngeal/cm, Airwayclose, TPST, PRR, or BCR for pudding bolus type. For thin bolus type,
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no pre-radiation differences were observed for PCR, Airwayclose, TPST, PRR, or BCR. For thin
bolus type there were observed differences for UESMax/cm and Hyolaryngeal/cm. However,
when comparing the group means for UESMax/cm and Hyolaryngeal/cm to the available
normative values (99, 252), it was observed that each group mean fell within the normal range
and did not prevent any between group comparisons.
In addition to examination of pre-treatment Swallowtail timing and displacement
variables and PAS data, reliability test was performed on the swallowtail-related variables and
prospectively collected PAS ratings. Both inter-rater and intra-rater reliability was calculated
using intraclass correlation coefficients (ICC). Twenty percent (n = 6) of patient’s MBSS’s were
randomly selected and the swallowtail variables were re-analyzed by the primary researcher
(M.V.) and one additional SLP with two plus years MBSS experience. The same patients MBSS
data were also used for the PAS reliability assessment. Swallowtail reliability analysis was
completed using both thin and pudding bolus types. Inter-rater and Intra-rater ICC ratings both
reached high levels of reliability, ICC = .92 and ICC = .96 respectively. MANOVA was also
used to assess for a rater effect, but revealed no significant rater difference (p = .285). Overall
ICC reliability levels and ICC reliability levels for individual Swallowtail variables can be found
in Table 18. Reliability testing for aspiration risk using the PAS for both pudding and thin liquid
boluses revealed perfect correlations for both inter-rater reliability (ICC 1.0) and intra-rater
reliability (ICC 1.0) for PAS scores.
Analysis of pre-treatment QOL-related scores are summarized in Table 19. Findings
indicate no overall group differences, based on the available data. MDADI data, which is patient
derived information, were available for the HF, LF, and 1day/week groups only. The MDADI
was not routinely collected or not available in the electronic medical record for the CCT group.
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Table 18. Intraclass Correlation Coefficients, Reliability Measurements for Swallowtail-Based
Variables
Variable
Inter-rater Reliability
Intra-rater Reliability
UESMax/cm
.88
.84
TPST
.95
.83
PCR
.91
.95
PRR
.87
.94
BCR
.86
.94
Airwayclose
.93
.76
Hyolaryngeal/cm
.74
.89
Overall
.92
.96
(UESMax/cm) maximal displacement of upper esophageal opening in centimeters, (TPST)
total pharyngeal swallow time, (PCR) pharyngeal constriction ration, (PRR) pharyngeal
residue ratio, (BCR) bolus constriction ratio, (Airwayclose) time of the first approximation of
the arytenoids and epiglottis coming together to close off airway, (Hyolaryngeal/cm) maximal
hyolaryngeal excursion in centimeters

The MDADI is provided as a composite score and ranges for 0 (worst) to 100 (best). Mean data
for the available groups indicate a high level of patient-perceived QOL prior to radiation. The
NOD and PE are subsections of the PSS H&N and are SLP measured ratings. The scores range
from 0 (worst) to 100 (best) and mean data for both NOD and PE scores were 100, indicating
normal diet and no restriction to place or people the subject was willing to eat with. Subject
fatigue was measured with the CFS, and scores were subject generated. Scores range from 0
(best) to 60 (worst), with higher scores revealing more fatigue. These score were available to the
HF and LF groups and no significant difference was observed (ANOVA, p = .159). Means for
the HF and LF groups were 3.07 and 8.47, respectively, indicating very low levels of fatigue.
General pain and swallowing-related pain were also assessed using a 0 (no pain) to 10 (worst
pain) scale. No significant difference was observed in general pain (ANOVA, p = .261) or
swallowing pain (ANOVA, p = .454). Additionally, there were very low levels of pain reported
with the means across the HF and LF groups for general and swallowing-related pain ranging
from .20 to .87.
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Table 19. Pre-radiation MDADI, PSS H&N NOD and PE Scores, CFS Scores, General Pain,
Swallowing-related pain scores for the HF, LF, 1day/week, and CCT groups
Variable
HF
LF
1day/week CCT
P value
n = 15
n = 15
n = 47
n = 25
ANOVA
MDADI***
Mean
96.9
93.5
93.4
NA
.481
NOD**
Mean
100
100
PE**
Mean
100
100
CFS**
Mean
3.07
8.47
.159
General Pain** Mean
.20
.73
.261
Swallow Pain** Mean
.87
.40
.454
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits per week;
(1day/week) 1 SLP-visit per week; (CCT) current common treatment, 3-4 visits over 6 weeks
or radiation treatment; (MDADI) M.D. Anderson Dysphagia Inventory; (PSS H&N)
Performance Status Scale for Head and Neck Cancer; (NOD) Normalcy of Diet portion of the
PSS H&N; (PE) Eating in Public portion of the PSS H&N; (CFS) Cancer Fatigue Scale;
General Pain, pain in the head and neck area; Swallow Pain, Pain associated with the act of
swallowing; (**) indicates that this comparison was only available between the HF and LF
groups; (***) indicates that this comparison was only available for the HF, LF, and 1day/week
groups; (NA) indicates not available, (-) indicated unable to perform analysis because of no
group variance

5.5 Therapeutic Interventions and Rationale
The prospective study groups were designed to explore the effects of SLP visit frequency.
The groups were divided by SLP visit frequency (High Frequency, HF; Low Frequency, LF). All
swallowing treatments began at the start of radiation treatment. The HF group had a SLP visit
frequency of 5 days per week, and the LF group had a SLP visit frequency of 3 days per week.
Three days per week was the minimum number of days required to complete the established
protocol for tongue-palate press exercise. Each group performed tongue-palate press exercises
for tongue resistance exercise based on the I-Pro approach using the Swallow STRONG system
(without visual biofeedback), Masako exercise, Shaker exercise, and pharyngeal squeeze
exercises. Each group also performed exercises with identical repetitions, sets, and frequencies.
The retrospective group was designed to explore the potential benefits of increased SLP-patient
visit frequency compared to the current common treatment. Patients included in the retrospective
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groups, CCT and 1day/week, were all treated at the OLOL-MBP Cancer Center. The CCT and
the exercise group portion of the 1day/week group received the Masako, pharyngeal squeeze,
and Shaker exercises with recommended volumes similar to those in this study’s prospective
group design. The swallow-only group portion of the 1day/week group performed 34
water/saliva swallows 7 times per day. Both the exercise and swallow-only groups of the
1day/week retrospective group received 1 weekly SLP session per week during radiation
therapy. The CCT group routinely received a pre-radiation and post-radiation MBSS and one or
two swallowing therapy sessions during radiation therapy, consistent with the current standard
care provided to the HNC population. Table 20 provides an overview of the therapeutic tasks for
each prospective group.
Table 20. 7-week Prophylactic Exercise Plan, Total n = 30 (HF n = 15, LF n = 15)
High Frequency Group (HF)
Low Frequency Group (LF)
5 SLP visits per week
3 SLP visits per week
Tongue-Palate Press (AP placements)
Tongue-Palate Press (AP placements)
20 repetitions per placement (NB)
20 repetitions per placement (NB)
3 set per day, 3 days per week
3 set per day, 3 days per week
Masako exercise
10 repetitions, 7 sets per day, 7 days per week

Masako exercise
10 repetitions, 7 sets per day, 7 days per week

Pharyngeal Squeeze
10 repetitions, 7 sets per day, 7 days per week

Pharyngeal Squeeze
10 repetitions, 7 sets per day, 7 days per week

Shaker
Shaker
Part 1, 2; 3 times per day, 7 days per week
Part 1, 2; 3 times per day, 7 days per week
SWST: SwallowSTRONG, SLP: Speech Language Pathologist, NB: No visual biofeedback, n:
number of participants AP: anterior and posterior placement

Intervention Exercises
Pharyngeal squeeze maneuver is considered a valid exercise to improve the muscles of
pharyngeal constriction and laryngeal elevation, and reduced pharyngeal constriction or
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elevation may increase risk of aspiration in the HNC population (138, 139). Shaker exercise is an
evidence-based treatment improving hyolaryngeal excursion and UES function (51). UES
function is diminished or restricted as a result of radiation, and poor UES function is also
predictive of more chronic dysphagia (67). Generalized weakness is noted in the tongue as a
result of chemoradiotherapy (135). Tongue resistance exercises, SWST and Masako, are
intended to increase general tongue strength for bolus manipulation and propulsion. Tonguepalate press exercises using SWST offers a method to perform the isometric exercise needed to
improve/increase tongue strength. Specific recommendations exist regarding the level of exercise
force for this type of intervention (e.g., 60% of maximal effort). While both tongue-related
exercise methods have reported success, only SWST offers a method to verify that patients are
exercising at the desired force during treatment. The SWST exercises were performed using the
previously discussed protocol (3 sets per day, 20 repetitions per set for anterior and posterior
placement only, 3 days per week during the 7 weeks of radiation), but without the use of visual
biofeedback. The removal of visual biofeedback (discussed in section 7.5) enabled the researcher
to answer questions regarding the feasibility of use, patient tolerance, and to determine if patients
achieved the desired accuracy of exercise intensity based on only verbal feedback and
instruction. Pt were instructed to press the tongue to the roof of the mouth as hard as possible.
This SWST protocol also enabled future research to compare the potential changes or benefits
related to the inclusion of the visual biofeedback component. The Masako exercise provides a
method to improve tongue base and posterior pharyngeal wall contact, which may increase bolus
clearance and oral to pharyngeal bolus transit (134). Additionally, since the feasibility of use for
the SWST devices was unknown in the HNC population, it was possible that patients included in
this study would not tolerate the intraoral device (SWST) required to complete tongue-palate
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press exercises due to the pain and toxicity effects of the cancer treatment modalities. The
inclusion of the Masako exercise within the behavioral swallowing exercise protocol ensured
consistent availability of a targeted tongue strengthening exercise.
Increased SLP-patient visit frequency has been suggested to increase treatment
adherence, and increased adherence may improve overall swallow-related outcomes (34, 40).
Increased SLP-patient visit frequency provided more opportunities for the completion of
exercises in the presence of the SLP, more opportunities to motivate the patient, and more
opportunities to answer questions and educate the patient. The standardized SLP-patient exercise
protocol, home exercise protocol, and related percentage of total exercise can be found in
Table 21.
Each session lasted approximately 45 minutes. During this treatment session the patients
in the HF completed 56% of their weekly exercise, and the LF group completed 44% of their
weekly exercise. The remaining exercises were completed as part of the patients’ home exercise
program. Both the amount of exercise completed in the therapeutic session and at home were
tracked. The SLP tracked exercise complete for SLP-guided session and patients completed and
exercise log at home. In addition, the amount of exercise completed within a SLP-patient visit
was standardized to prevent variations in the total amount of SLP-directed treatment. Once per
week, all patients completed the needed QOL and functional outcome measures. These were
collected at the beginning of each week to ensure consistency of data collection across time. The
SWST device automatically collected tongue pressure measured in kilopascals (kPa) (109).
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Table 21. Exercise Regimen by Environment
Treatment with SLP

Home

Tongue-Palate Press (AP placements)
20 repetitions per placement (NB)
3 set per day, 3 days per week

No Tongue-Palate press performed

Masako exercise
10 repetitions, 4 sets per day

Masako exercise
10 repetitions, 3 sets per day on SLP-visit
days, 7 sets per day on non-SLP-visit days

Pharyngeal Squeeze
10 repetitions, 4 sets per day

Pharyngeal Squeeze
10 repetitions, 3 sets per day on SLP-visit
days, 7 sets per day on non-SLP-visit days

Shaker
Parts 1 and 2; 1 time

Shaker
Parts 1 and 2; 2 times per day on SLP-visit
days, 3 times per day on non-SLP-visit days
Percentage of Total Exercise Protocol
Completed at Home

Percentage of Total Exercise Protocol
Completed with the SLP
5 weekly SLP visits: 56%

5 weekly SLP visits: 44%

3 weekly SLP visits: 44%
AP: anterior and posterior; %: percentage

3 weekly SLP visits: 56%

5.6 Data Collection and Rationale for Outcome Measures
Data Collection
The following data were obtained from the patient’s Electronic Medical Record (EMR):
Sex, age in years, tumor site, TNM classification, Tumor stage, previous head/neck surgery
(excluding biopsy), cancer treatment plan (radiation or chemoradiation, surgical management),
HPV status, and pre-treatment weight. In addition, the following were obtained from the MBSS
results or by the SLP during the initial/final swallowing treatment visits (or in previous SLP
notes for the retrospective group) as pre/post data:
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Functional outcomes: PEG tube use and date of placement, Functional Oral Intake Scale (FOIS)
scores, weight loss percentage, and Mini Nutritional Assessment Short Form (MNA-SF) tool
scores;
Physiological outcomes from the MBSS: Penetration Aspiration Scale (PAS) for 10 milliliter
thin liquid and pudding boluses, Dynamic Imaging Grade of Swallowing Toxicity (DIGEST);
Physiological outcomes from Swallowtail: UES opening, maximal pharyngeal constriction,
maximal hyolaryngeal excursion, time of the first approximation of the arytenoids and epiglottis
coming together to close off airway, total pharyngeal swallowing transit time, pharyngeal residue
ratio, bolus clearance ratio;
Physiological outcomes from SWST: maximal isometric tongue palate pressure
Quality-of-life: MD Anderson Dysphagia Inventory (MDADI) scores and the Performance
Status Scale Head and Neck (PSS H&N) (normalcy of diet and public eating) scores;
Adherence measurement: percentage of swallowing exercises completed with the SLP,
percentage of exercise completed at home;
Adherence measurement from SWST: accuracy of exercise force with SWST, percentage of
SWST exercise completed, duration (number of visits and weeks) of SWST use;
Toxicity measurements: salivary weight (Saxon test), mucositis scale (Dische Scale), and the
Cancer Fatigue Scale.
For the prospective groups, the following were assessed weekly or when changes in
status occurred: PEG placement data (with change), salivary weight (weekly), Dische scores
(mucositis, weekly), Cancer Fatigue Scale (weekly), MNA-SF (weekly), and QOL measurements
(weekly). Weekly data were collected on a tracking sheet completed by the SLP. The tracking
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sheet is available in Appendix B. Table 22 provides an overview of the independent and
dependent variables.
Table 22. Independent and Dependent Variables
Independent Variables
Dependent Variables
SLP-Visit Frequency
Functional Variables:
PEG tube use
Functional Oral Intake Scale (FOIS) scores
Weight loss percentage
Mini Nutritional Assessment Short Form
(MNA-SF) tool scores
Physiological Variables:
Penetration Aspiration Scale (PAS) Dynamic
Imaging Grade of Swallowing Toxicity
(DIGEST)
Maximal upper esophageal sphincter (UES)
opening
Maximal pharyngeal constriction
Maximal hyolaryngeal excursion
Maximal isometric tongue palate pressure
Total swallow transit time
Time to arytenoid approximation and airway
closure
Pharyngeal residue ratio
Bolus clearance ratio
Quality of Life Variables:
MD Anderson Dysphagia Inventory
(MDADI) scores
Performance Status Scale Head and Neck
(PSS H&N) (normalcy of diet and public
eating) scores
Adherence Variable:
Percentage of swallowing exercises
completed
Toxicity Variables:
Salivary weight (Saxon test)
Mucositis scale score (Dische Scale)
Cancer Fatigue Scale

For the retrospective groups weekly data were not available, so in this case only preradiation and post-radiation data were collected, along with swallowing-related data related to
any changes that occurred during radiation therapy (e.g., rationale for PEG placements). In
113

addition, not all data points were available from the retrospective data including DIGEST,
Cancer Fatigue Scale, salivary weight, or Dische mucositis rating scale scores. This was due to
the addition of these data collection tools to prospective groups based on recent data collection
recommendations for research in the HNC population.
Rationale for Dependent Measurements
Functional outcome measures:
PEG use: PEG dependence indicates a more severe level of dysphagia and is one of only
a few predictors of chronic dysphagia with a reduction in UES function.
Functional Oral Intake Scale (FOIS): Originally published by Crary, Mann, and Groher
(2005) (45), FOIS is a 7-point scale that indicates the level of oral intake a patient is capable of at
a given time. It can be used to show change over time, and accounts for patients using a PEG
tube while maintaining some level of oral intake. Scores ranging 1-3 indicate non-oral feeding,
4-6 indicate limited oral feeding, and 7 represents a regular oral diet. Reliability and validity
have been established. In the current study the SLP will assess the FOIS level at baseline,
weekly, and post-treatment. The FOIS scale is available in Appendix C.
Mini Nutritional Assessment Short Form (MNA-SF) tool: The MNA-SF is a validated
nutritional assessment tool, completed in 4 minutes or less, used to establish if a person is well
nourished, at risk of malnutrition, or malnourished (253). Due to the risk of malnutrition
associated with HNC, and the impact malnutrition has on overall morbidity, nutritional status
should be included. The MNA-SF is available in Appendix D.
Physiological Measurements:
Penetration Aspiration Scale (PAS): The PAS is a valid and reliable 8-point scale
developed by Rosenbek and colleagues in 1996 to provide an objective grade for penetration and
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aspiration (254). It has been widely used to assess aspiration risk in the HNC population. Scores
of 6-8 indicate aspiration, 2-5 indicate penetration, and a score of 1 indicates no penetration or
aspiration. The PAS score is assigned by the SLP based on the MBSS data for each bolus type
administered. High percentages of aspiration reported in the HNC population make this an
important outcome measure for swallowing intervention. New methods have been suggested to
examine the potential study related outcomes based on the PAS including analyzing individual
trials (e.g., repeated measures design) rather than mean data (255). Therefore, the PAS scores
were collected on 10 milliliter (ml) thin and solid boluses (1 teaspoon pudding) separately, and
across two bolus trials per consistency. These bolus sizes and consistencies were present across
all pre- and post-radiation MBSS images. Thin and solid boluses were compared separately to
determine if any consistency-based differences existed. The PAS is available in Appendix E.
Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Hutcheson and colleagues
(2017) developed DIGEST, a severity scale, designed to use the PAS levels and pharyngeal
residue scale to provide an objective grade of dysphagia severity in HNC. This scale was
developed to meet the universal framework of the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (CTCAE). It is both reliable and valid, and given the
potential benefit of including swallowing efficiency along with penetration and aspiration scores,
it may offer additional insight into swallowing outcomes in this unique population (256, 257).
The DIGEST form is available in Appendix F.
Maximal upper esophageal sphincter (UES) opening: UES function is highlighted by the
available literature as both an organ at risk of impairment and one, which if impaired, is
predictive of reduced swallowing ability and potential chronic dysphagia (67). Measurement was
obtained from MBSS imaging data using SwallowTail software (Belldev Medical, Arlington
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Heights, IL). Emerging software applications, such as SwallowTail, offer quantification of
swallowing timing and displacement events observed during the MBSS. The SLP measured
maximal UES opening pre- and post-radiation to assess the level of change among treatment
groups.
Maximal pharyngeal constriction, pharyngeal residue ratio, and bolus clearance ratio:
Reduced pharyngeal constriction has been linked to pharyngeal residue (bolus material
remaining in the pharynx after the swallow) with increased risk of aspiration and reduced QOL
scores in the HNC population, as a result of chemoradiation treatment (138-140, 258, 259).
Measurement of pharyngeal constriction and residue were obtained using SwallowTail software.
These measurements enabled the comparison of pharyngeal constriction ability across the study
groups.
Maximal hyolaryngeal excursion: Reduced laryngeal excursion is associated with
reduced airway protection and reduced UES opening in the HNC population during and
following chemoradiotherapy (21). These measurements, obtained using the SwallowTail
software, further enabled the comparison of hyolaryngeal excursion across the study groups.
Maximal isometric tongue palate pressure: Loss of tongue strength is commonly reported
in the HNC literature and has been correlated with reduced swallow efficiency and safety (25).
Maximal tongue strength can be used to measure the preventative nature of swallowing exercise
on this at-risk organ.
Time to airway closure: Airway closure is important for the prevention of aspiration.
Delayed closure of the laryngeal vestibule (airway closure, time of the first approximation of the
arytenoids and epiglottis coming together to close off airway) is associated with increased risk of
aspiration in HNC patients that receive chemoradiotherapy (21). Aspiration may also result in
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PEG tube placement. The measurement of time to airway closure, obtained using SwallowTail
software, allowed the comparison of these timing data across study groups.
Quality-of-life:
MD Anderson Dysphagia Inventory (MDADI) scores: Reduced QOL is a common
complaint associated with dysphagia in this population, and understanding how treatment affects
QOL is important. Chen et al. (2001) originally published the MDADI, a reliable and valid
measure quantifying the patient representation of QOL associated with dysphagia specific to the
HNC population. QOL is measured via global score (single question) and composite score
comprised of functional, physical, and emotional subscales scores. The composite score was
used for this study in order to capture a more holistic view of the patient’s QOL. The MDADI is
available in Appendix G.
Performance Status Scale Head and Neck (PSS H&N) (normalcy of diet and public
eating) scores: We know that patient-reported QOL and SLP-rated QOL measures do not
correlate significantly, and patients may report more difficulty than is perceived upon
physiological examination (260). To provide a more complete illustration of patient performance
and ability the PSS H&N, a SLP-completed QOL scale, was included. List, Ritter-Sterr, and
Lansky (2006) (75) reported the measure as reliable and valid. It contains three subscales
quantifying areas related to QOL, each scored separately, including normalcy of diet, eating in
public, and understandability of speech. For the purpose of this study, only the scores assessing
normalcy of diet and eating in public were used, since the study was not designed to treat or
evaluate the patient’s speech or voice. The PSS H&N is available in Appendix H.
Adherence measurement:
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Percentage of swallowing exercises completed were obtained by dividing the total
completed by the total prescribed. Patients completed a daily tracking of home exercise and
turned the tracking form in at the beginning of the following week, to the SLP. The SLP tracked
exercise completed during treatment sessions. One goal of this study was to examine how visit
frequency may increase adherence, and how differences in adherence may affect swallowing
outcomes. The quantification of adherence allowed these questions to be explored. The patient
tracking form is available in Appendix I.
SWST related adherence measurements: The accuracy of exercise force (exercise target
pressure) with SWST, percentage of SWST exercise completed, and duration (number of visits
and weeks) of SWST use were tracked. These data allowed the researcher to investigate the
potential use and feasibility of the intraoral device, and explored within or between group
differences based on usability across study patients. This helped determine the overall feasibility
and usefulness of the device.
Toxicity measurements:
Saxon test: Kohler and Winter (1985) (261) described this simple and cost-effective
method to assess salivary output. The measurement of saliva production is an important toxicity
factor in the HNC population due to the high prevalence of xerostomia and the potential negative
impact on patient swallowing perception and physiology. The protocol for the Saxon test is
found in Appendix J.
Dische Scale: The Dische scale for grading severity of mucositis has been validated, and
serves as a reliable way to quantify severity (31). It assesses the area involved, edema, bleeding,
ulceration, diet, and pain, with a score ranging from 0-24, with a higher score representing more
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severity. Measurement of mucositis is necessary due to the potential negative impact of this
toxicity on swallowing and QOL.
Cancer Fatigue Scale (CFS): Okuyama, Akechi, Kugaya, Okamura, Shima, et al. (2000)
(262) developed the CFS, a reliable and valid 15-item scale, containing three subscales (physical,
affective, and cognitive). The three subscale scores combine to provide an overall measure of
fatigue, with scores ranging from 0-60. Scores of 0 represents no fatigue, scores of 1 or more
represent some level of fatigue, and higher scores represent greater levels of fatigue. This scale
quantified the level of fatigue experienced during the treatment process, allowing for group
comparison. The scale is available in Appendix K.
5.7 Data Analysis
Chi-square, a nonparametric statistic, was employed to analyze PEG use data for each
hypothesis. The PEG data were treated as dichotomous frequency data scored as either present or
absent. For all other statistics parametric statistics were used. Analysis of hypothesis 1 (HF vs.
LF) and hypothesis 2 (HF vs. LF vs. 1day/week vs. CCT) examined effects of SLP-patient visit
frequency. These statistical analyses compared mean data from a single independent variable
(visit frequency) to multiple dependent variables (physiological outcomes, functional outcomes,
and QOL outcomes), with the exception of PEG use (count data). Based on this statistical design
an multiple analysis of variance (MANOVA) and chi-square were used to examine the study
hypotheses (263). Table 23 includes test statistics for the study hypotheses.
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Table 23. List Of Variables And Test Statistics For Post-Radiation Comparison Between The
High Frequency (HF ), Low Frequency (LF), 1day/week, and Current Common Treatment
(CCT) Groups
Hypothesis
Variables
Test Statistic
Hypothesis 1a and 2a
Physiological Outcomes:
MANOVA
PAS Repeated Measure ANOVA
DIGEST
MANOVA
Maximal UES opening
MANOVA
Total swallow transit time
MANOVA
Tongue-palate pressure
MANOVA
Maximal pharyngeal
MANOVA
constriction
Hypothesis
Variables
Test Statistic
Maximal hyolaryngeal
MANOVA
excursion

Hypothesis 1c and 2c

Bolus clearance ratio
Pharyngeal residue ratio
Time to airway closure
QOL:
MDADI

MANOVA
MANOVA
MANOVA

MANOVA
Correlation/Regression
PSS H&N NOD
MANOVA
Correlation/Regression
PSS H&N PE
MANOVA
Correlation/Regression
(ANOVA) analysis of variance; (PAS) Penetration Aspiration Scale; (MDADI) M.D. Anderson
Dysphagia Inventory; (PSS H&N) Performance Status Scale for Head and Neck Cancer;
(NOD) Normalcy of Diet portion of the PSS H&N; (PE) Public Eating portion of the PSS
H&N; (UES) upper esophageal sphincter
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CHAPTER 6. RESULTS
IBM SPSS Statistics version 25 was used to conduct all analyses in this study. Analysis
methods included descriptive statistics, parametric tests including multivariate analysis of
variance (MANOVA) and repeated measures ANOVA, correlation, and regression. Nonparametric tests including chi-square Mann-Whitney U and Kruskal-Wallis. The specific
hypothesis and variable-related statistics used can be found in the data analysis section of
Chapter 5, Table 23.
6.1 Post-radiation treatment variables
The HF, LF, 1day/week, and CCT groups were each analyzed to assess potential postradiation between group treatment differences. Variables assessed included total radiation dose
(raddose), the addition of chemotherapy (+/-chemo, concurrent and/or neoadjuvant). Raddose
was assessed using ANOVA, and +/-chemo was assessed using chi-square Kruskal-Wallis. The
number of missed SLP visits was also analyzed for the HF and LF groups using chi-square
Mann-Whittney U. Table 24 summarizes the finding for raddose, +/-chemo, and HF vs. LF group
missed SLP-visits.
Total Radiation Dose
Findings reveal a significant difference in total radiation dose based on group (ANOVA,
p = .034). Further examination of group means revealed the 1day/week group to be significantly
different compared to the HF, LF, and CCT groups. The HF and LF groups each had a mean
radiation dose of 70Gy and the 1day/week group had a total radiation dose of 68.68Gy. The CCT
group had similar total radiation dose of 65.83Gy. While the mean doses are similar, it was noted
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that the 1day/week group had a wider range of total radiation doses (30Gy-70Gy) and that 6 of
the 47 subjects in this group received radiation doses below 60Gy.
Table 24. Post-radiation Group Characteristics for Raddose, +/-chemo, and Missed Visits for
the HF, LF, 1day/week, and CCT groups
Variable
HF
LF
1day/week
CCT
P value
n = 15
n = 15
n = 50
n = 25
Raddose
Mean
70Gy
70Gy
65.83Gy
68.68Gy
.034
Range
70Gy
70Gy
30-70Gy
60-70Gy
(6 subjects
≤ 30Gy)
+/-chemo

Yes
No

12
3

13
2

33
14

20
5

.775

Missed Visits**

Mean
.089
Range
0-4
0-4
NA
NA
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits per week;
(1day/week) 1 SLP-visit per week; (CCT) current common treatment, 3 visits over 6 weeks or
radiation treatment; (Raddose) total radiation dose; (+/-chemo) addition of concurrent or
neoadjuvant chemotherapy; (Gy) gray, unit of measurement for radiation; (**) indicated the
analysis was only completed for the HF and LF group; (NA) indicated the data were not
available

Previous findings have revealed that radiation doses ≤ 26Gy (54) are associated with
reduced saliva function, and radiation doses above 60Gy are associated with increased risk of

feeding tube placement and dysphagia (including UES dysfunction) (67). There does not appear
to be specific evidence linking radiation dose levels to other factors associated with radiationrelated dysphagia (e.g., weight loss, nutrition, aspiration risk). Given the wide variation of
radiation dose associated with features of swallowing function/dysfunction (e.g., saliva or UES
function), there does not appear to be a rationale to remove any subjects from the 1day/week
group, based on lower radiation dosage. In addition, all study subjects received the same form of
radiation, IMRT with fractionation. Given that no group differences in immediate post-radiation
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outcomes were noted in the original study (24), it appears that this variation in total radiation
dose does not prevent a group comparison in the current study.
Chemotherapy
There was no statistical difference in the frequency of concurrent or neoadjuvant
chemotherapy (+/-chemo, Kruskal-Wallis p = .775) between the HF, LF, 1day/week, or CCT
groups.
SLP Visits
The number of missed SLP-visits observed between the HF and LF groups did not differ
in frequency (Mann-Whitney U, p = .089). Groups did differ in the number of SLP-visits
received based on the research design. The HF group had a mean SLP-visit number of 32.84, LF
group had a mean SLP-visit number of 18.53, 1day/week group received 7 SLP-visits, and CCT
group received a mean of 3 SLP-visits per subject while undergoing radiation treatment. Missed
visits were not observed in the 1day/week group. The data collection methods for the CCT
group, counting the number of visits received during the course of radiation treatment, which
were not based on specific weekly visits, made missed visits not applicable for this group.
6.2 Pre and Post-radiation High Frequency and Low Frequency Group Differences
To assess for radiation-related changes within the prospective HF and LF groups, the preand post-radiation differences were analyzed within each group separately and as a combined
group. Variables included FOIS, BMI, DIGEST scores, PAS, tongue pressure measurements
(ATP, PTP), weight, saliva (Saxon Test measurements), CFS, MINI, mucositis scores, PSS NOD
and PE scores, and pain-related scores. Analyses of the HF pre and post-radiation comparisons
are available in Table 25.
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Table 25. Pre-radiation and Post-radiation Comparisons for Swallowing
Outcome Values for the High Frequency (HF) Group; n = 15
Variable
Pre-radiation
Post-radiation
p Value
Mean
Mean
FOIS
7
3.73
0.000
BMI
27.47
25.5
0.000
DIGEST Safety
0
0.64
0.002
DIGEST
Efficiency
0
0.29
0.104
DIGEST
Composite
0
0.79
0.001
PASmean
1
1.21
0.336
ATP
125.7kPa
79.49kPa
0.003
PTP
128.48kPa
47.61kPa
0.000
Weight
186.68lb
173.25lb
0.000
Saliva Output
4.14g
1.26g
0.000
CFS
3.07
25.13
0.000
MINI
11.07
6.53
0.000
Mucositis Score
0
16.8
0.000
MDADI
96.95
52.34
0.000
PSS NOD
100
28
0.000
PSS PE
100
38.33
0.000
General Pain
0.2
6.27
0.000
Swallowing Pain
0.87
6.87
0.000
(PASmean) penetration aspiration scale mean combined data, (DIGEST)
Dynamic Image Grade of Swallowing Toxicity scale, (MDADI) M.D.
Anderson Dysphagia Inventory, (PEG) percutaneous endoscopic
gastronomy tube, (BMI) Body Mass Index, (FOIS) Functional Oral Intake
Scale, (NOD) Normalcy of Diet score, (PE) Public Eating score, (CFS)
Cancer Fatigue Scale, (kPA) kilopascal, (lb) pound, (g) gram
Analysis revealed a significant difference in all values except for DIGEST efficiency
score and PAS scores. Overall these results reveal a significant radiation effect on the
swallowing-related outcomes. Analysis of the LF group was similar with all variables revealing a
significant difference except DIGEST Safety and PAS. These data are available in Table 26.

124

Table 26. Pre-radiation and Post-radiation Comparisons for Swallowing
Outcome Values for the Low Frequency (LF) Group, n = 15
Variable
Pre-radiation
Post-radiation
p Value
Mean
Mean
FOIS
7
3.73
0.000
BMI
30.44
27.36
0.000
DIGEST Safety
0
0.67
0.065
DIGEST
Efficiency
0
0.73
0.016
DIGEST
Composite
0
0.93
0.010
PASmean
1
1.33
0.136
ATP
126.69kPa
88.02kPa
0.001
PTP
109.03kPa
48.81kPa
0.000
Weight
215.93lb
193.09lb
0.000
Saliva Output
4.42g
1.16g
0.000
CFS
8.47
23.2
0.000
MINI
11.47
5.6
0.000
Mucositis Score
0
18.8
0.000
MDADI
93.58
55.69
0.000
PSS NOD
100
22.33
0.000
PSS PE
100
26.66
0.000
General Pain
0.73
6.4
0.000
Swallowing Pain
0.4
7.2
0.000
(PASmean) penetration aspiration scale mean combined data, (DIGEST)
Dynamic Image Grade of Swallowing Toxicity scale, (MDADI) M.D.
Anderson Dysphagia Inventory, (PEG) percutaneous endoscopic
gastronomy tube, (BMI) Body Mass Index, (FOIS) Functional Oral Intake
Scale, (NOD) Normalcy of Diet score, (PE) Public Eating score, (CFS)
Cancer Fatigue Scale, (kPA) kilopascal, (lb) pound, (g) gram
Both groups were combined (HF+LF, n = 30) and analysis revealed a significant
difference across all variables except PASmean, available in Table 27. These data continue to
reveal a significant radiation-related swallowing effect observed across all patients. However,
PASmean values remained non-significant for pre-post radiation differences and this may be an
important finding when assessing post-radiation group differences.
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Table 27. Pre-radiation and Post-radiation Comparisons for Swallowing
Outcome Values for the Combined Low Frequency (LF) and High
Frequency (HF) Groups, n = 30
Variable
Pre-radiation
Post-radiation
p Value
Mean
Mean
FOIS
7.00
3.73
0.000
BMI
28.96
26.43
0.000
DIGEST Safety
0.00
0.66
0.002
DIGEST
Efficiency
0.00
0.52
0.003
DIGEST
Composite
0.00
0.86
0.000
PASmean
1.00
1.28
0.073
ATP
126.19kPa
83.61kPa
0.000
PTP
118.76kPa
48.22kPa
0.000
Weight
201.31lb
183.17lb
0.000
Saliva Output
4.29g
1.21g
0.000
CFS
5.77
24.17
0.000
MINI
11.27
6.07
0.000
Mucositis Score
0.00
17.80
0.000
MDADI
95.27
54.02
0.000
PSS NOD
100.00
25.17
0.000
PSS PE
100.00
32.50
0.000
General Pain
0.47
6.33
0.000
Swallowing Pain
0.63
7.03
0.000
(PASmean) penetration aspiration scale mean combined data, (DIGEST)
Dynamic Image Grade of Swallowing Toxicity scale, (MDADI) M.D.
Anderson Dysphagia Inventory, (PEG) percutaneous endoscopic
gastronomy tube, (BMI) Body Mass Index, (FOIS) Functional Oral Intake
Scale, (NOD) Normalcy of Diet score, (PE) Public Eating score, (CFS)
Cancer Fatigue Scale, (kPA) kilopascal, (lb) pound, (g) gram

Finally, pre- and post-radiation PEG use was assessed across groups HF, LF, and
combined HF+LF. Findings reveal a significant radiation effect for PEG placement within the
combined HF+LF groups (p = ,008). These findings are available in Table 28.

126

Table 28. Pre-radiation and Post-radiation Chi-Square Comparisons
(Wilcoxon Rank) for PEG Use for the HF, LF, and Combined Low
Frequency (LF) and High Frequency (HF) Groups, n = 30
Group
Pre-radiation
Post-radiation
p Value
Count
Count
HF, n = 15
0
3
.083
LF, n = 15

0

4

.046

HF+LF, n = 30

0

7

.008

6.3 Hypothesis Testing, Hypothesis 1
The prospective data collection in the HF and LF groups enabled a greater number of
variables to be assessed across subjects’ swallowing function, physiology, and QOL. This greater
amount of available data necessitated the separate initial post-radiation comparison of the HF
and LF groups to determine what differences might exist, prior to exploring HF or LF group
differences compared to the 1day/week and CCT groups. The research question guiding these
statistical analyses asked if increased SLP-patient contact time (HF), compared to reduced SLPpatient contact time (LF), during prophylactic behavioral swallowing intervention, would result
in improved immediate post-radiation treatment swallow physiology, swallow function, and
swallow-related QOL. Results of the statistical analysis for between group post-radiation
differences in swallowing physiology, swallowing function, and swallowing-related QOL
variables are found in Table 29.
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Table 29. Post-Radiation Comparison of HF (n = 15) and LF Group (n = 15)
Differences for Physiological, Functional, and QOL Variables
Variable
Bolus Type Mean (SD) HF
Mean (SD) LF P value
Group
Group
Physiology
PASmean
Thin and
1.21 (.802)
1.33 (.816)
.695
Pudding
PASrepeated
Thin only
1.36 (.82)
1.73 (1.79)
.448
PASrepeated
Pudding
1.43 (1.57)
1.80 (2.07)
.212
only
DIGEST
.79 (.69)
.93 (1.22)
.696
UESMax/cm
Thin
.061 (.18)
.103 (.13)
.229
Pudding
-.148 (.34)
-.188 (.21)
.683
TPST
Thin
-.022 (.26)
-.044 (1.8)
.966
Pudding
.107 (.92)
.294 (1.14)
.634
PCR
Thin
.061 (.18)
.103 (.12)
.472
Pudding
.106 (.15)
.349 (.87)
.315
PRR
Thin
2.34 (.62)
2.28 (.58)
.341
Pudding
1.40 (2.37)
6.24 (16.52)
.287
BCR
Thin
2.79 (11.9)
11.5 (15.36)
.100
Pudding
9.27 (13.9)
14.97 (19.23)
.371
Airwayclose
Thin
-.023 (18)
.026 (.26)
.555
Pudding
.145 (.61)
-.144 (.34)
.125
Hyolaryngeal/cm
Thin
-.577 (1.33)
.288 (.95)
.053
Pudding
.229 (1.22)
-.168 (1.20)
.387
Anterior Tongue
Pressure %
change
Posterior Tongue
Pressure %
change
Functional
PEG Use
FOIS
BMI% change
Weight% change
MNA-SF
(Table 29 Continued)

-.226 (.68)

-.274 (.27)

.803

-.564 (.334)

-.217 (1.41)

.364

3 (count)
3.73 (1.1)
-.071 (.051)
-.07 (.05)
6.53 (2.2)

4 (count)
3.73 (1.03)
-.101 (.055)
-.099 (.048)
5.6 (1.05)

.775
1.0
.142
.118
.159
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Variable

Bolus Type

Mean (SD) HF
Group

Mean (SD) LF
Group

P value

Quality of Life
MDADI
52.34 (12.57)
55.69 (10.06)
.427
NOD
28.0 (14.7)
22.33 (12.08)
.259
PE
38.33 (20.84)
26.66 (17.59)
.109
CFS
25.13 (8.5)
23.2 (8.4)
.539
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLP-visits
per week; (QOL) quality-of-life, (PASmean) penetration aspiration scale mean
combined data, (PASrepeated) penetration aspiration scale repeated trials data,
(DIGEST) Dynamic Image Grade of Swallowing Toxicity scale, (UESMax/cm)
maximal displacement of upper esophageal opening in centimeters, (TPST) total
pharyngeal swallow time, (PCR) pharyngeal constriction ration, (PRR)
pharyngeal residue ratio, (BCR) bolus constriction ratio, (Airwayclose) time of
the first approximation of the arytenoids and epiglottis coming together to close
off airway, (Hyolaryngeal/cm) maximal hyolaryngeal excursion in centimeters,
(SD) standard deviation, (MDADI) M.D. Anderson Dysphagia Inventory, (PEG)
percutaneous endoscopic gastronomy tube, (BMI) Body Mass Index, (FOIS)
Functional Oral Intake Scale, (NOD) Normalcy of Diet score, (PE) Public
Eating score, (CFS) Cancer Fatigue Scale

Physiology
For the HF and LF group comparisons, the post-radiation MBSS was used to assess postradiation aspiration risk (PAS scores), aspiration plus efficiency risk (DIGEST scores) and to
analyze the Swallowtail-related timing and displacement variables. Swallowtail variables
included maximal opening of the UES (UESMax/cm), total pharyngeal swallow transit time
(TPST), pharyngeal constriction ratio (PCR), pharyngeal residue ratio (PRR), bolus constriction
ratio (BCR), time of the first approximation of the arytenoids and epiglottis coming together to
close off airway (Airwayclose), and maximal hyolaryngeal excursion (hyolaryngeal/cm).
Additionally, the SwallowSTRONG system was used to obtain measurements of anterior and
posterior tongue-palate pressure measurements. Swallowtail based measurements were obtained
using the pre-radiation and post-radiation MBSS videos
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The hypothesis-related statistical analysis was completed using the post-radiation difference
(pre-radiation minus post-radiation value) in each variable value as measurement of swallowingrelated change. Post-radiation MBSS studies were completed within three weeks of the final
radiation treatment for 27 of the 30 subjects. The 2 subjects’ MBSS studies were completed
within 6 weeks of the final radiation treatment. This delay resulted from the subjects canceling
an earlier MBSS appointment due to concerns for pain and discomfort during the exam. The final
subject did not receive a post-radiation MBSS. This subject passed away two weeks postradiation from sepsis. SwallowSTRONG tongue-palate pressure measurements were obtained
pre-radiation, once weekly during radiation, and post-radiation (final day of radiation treatment).
The pre-radiation minus post-radiation value was also used in the statistical analysis as a measure
of tongue-palate pressure change.
Aspiration and Efficiency
Findings for aspiration risk based on the PAS were assessed using two separate methods
including mean across bolus types and repeated measure analysis for thin and pudding bolus
types separately. Comparison was made across 29 subjects, 14 HF and 15 LF subjects. One
subject, as previously discussed, completed radiation therapy but passed away before the MBSS
was complete resulting in an inability to assess post-radiation aspiration risk in that subject.
Results for comparison between HF and LF groups using mean across bolus types revealed no
significant post-radiation differences (ANOVA, p = .695). Results for between group comparison
using repeated measure analysis for thin bolus (ANOVA, p = .448) and pudding bolus (ANOVA,
p = .212) also revealed no significant differences between the HF and LF groups.
Post-radiation DIGEST scores were based on the post-radiation MBSS. Scores were
assessed using the combination of a subject’s aspiration risk score and swallowing-related
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efficiency score to create a composite score quantifying overall swallowing risk. Due to the
missing MBSS data discussed previously, this analysis was also performed on 29 of the 30
subjects’ data (14 HF and 15 LF). Results found no between group differences based on
DIGEST composite scores (ANOVA, p = .696).
Swallowtail Timing and Displacement Measures
Swallowtail timing and displacement analysis was completed using the pre-radiation
minus post-radiation difference for each variable, as a measure of swallowing-related change.
Each timing and displacement variable included in this study was assessed for thin liquid bolus
type and pudding bolus type separately (Varibar thin and pudding, (Varibar®, E-Z-EM, Inc.).
There were a total of 116 MBSS video segments analyzed (29 pre-radiation thin, 29 postradiation thin, 29 pre-radiation pudding, 29 post-radiation pudding). All segments were analyzed
by the author who has extensive experience with this program.
For thin liquid bolus type, there were no significant group differences for maximal UES
opening (UESMax/cm, p = .229); total pharyngeal swallow transit time (TPST, p = .996);
pharyngeal constriction ratio (PCR, p = .472); pharyngeal residue ratio (PRR, p = .341); bolus
constriction ratio (BCR, p = .100); time of the first approximation of the arytenoids and epiglottis
coming together to close off airway (Airwayclose, p = .555); or maximal hyolaryngeal excursion
(hyolaryngeal/cm, p = .053). Similarly, for pudding bolus type, there were no significant group
differences for maximal UES opening (UESMax/cm, p = .683); total pharyngeal swallow transit
time (TPST, p = .634); pharyngeal constriction ratio (PCR, p = .315); pharyngeal residue ratio
(PRR, p = .287); bolus constriction ratio (BCR, p = .371); time of the first approximation of the
arytenoids and epiglottis coming together to close off airway (Airwayclose, p = .125); or
maximal hyolaryngeal excursion (hyolaryngeal/cm, p = .387).
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SwallowSTRONG Tongue-palate Pressure Measurements
Tongue-palate pressure measurements were collected for all 30 study subjects using the
SwallowSTRONG system. Measurements were taken in kilopascals (kPa). Tongue-palate
pressure measurement data were collected separate from any SwallowSTRONG-related exercise
attempts. Difficulty with device tolerance did result in some missing data across subjects. These
missing data points occurred on days when intra-oral radiation-related pain resulted in a refusal
or failed attempt to obtain the measurements. Missing data were present in 3.3% of the total
observed cases and were random in nature. The type and nature of the missing data did not
appear to prevent further analysis of between group differences. The between group analysis was
performed using the percentage of tongue-palate pressure change taken as the post-radiation
pressure divided by the pre-radiation pressure. Results for percentage of change in anterior and
posterior tongue-palate pressure were not significant between the HF and LF groups (anterior, p
= .803; posterior, p = .364). Examination of the group means revealed a decline in tongue-palate
pressure during radiation. The HF group had a mean loss in anterior pressure of 22.6% and a
posterior pressure decline of 56.4%. The LF group had a mean anterior pressure decline of
27.4% and a posterior pressure decline of 21.7%. A minimum level of 60 kPa has been reported
as normal for healthy adults, and a loss of approximately 50% has been suggested to correspond
with swallowing impairments in the HNC population (26). This study’s findings reveal
reductions of 50% or greater for posterior and reductions approaching 50% for the anterior
placements. These radiation-related changes are summarized in Figure 3 using the mean weekly
tongue-palate pressure measurements taken in kPa, and the mean weekly data for each group are
summarized in Table 30.
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Figure 3. Weekly Tounge-to-Palate Pressure for High Frequency (HF) and
Low Frequency (LF) Groups, n = 30

Table 30. Mean and Standard Deviation for Anterior and Posterior Tongue-palate pressures
by HF and LF groups, n = 30
Group
Week
PreWeek Week Week Week Week Week
radiati Week 1
2
3
4
5
6
7
on
HF
Ant Mean 125.70 118.13 107.5 98.58 105.5 89.86 81.60 79.49
6
9
(SD) 45.72
28.71
29.91 29.07 25.31 40.84 35.08 33.81
LF

Ant

Mean
(SD)

123.84
43.59

117.98
37.85

96.40
47.11

97.64
41.48

91.22
57.83

77.14
40.16

68.29
36.98

88.02
37.87

HF

Post Mean
(SD)

126.27
43.83

91.33
53.48

91.41
49.97

79.10
46.45

92.44
51.09

67.43
51.31

59.80
50.64

47.61
37.75

LF

Post Mean 110.73 96.63
78.48 82.40 60.23 55.53 53.72 48.81
(SD) 50.39
50.02
39.61 41.51 38.17 36.69 43.47 34.67
(SD) standard deviation, (HF) high frequency group, (LF) low frequency group, (Ant)
anterior, (Post) posterior
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Functional
For the HF and LF group comparisons, post-radiation count and ratio data were used to
assess PEG use (+/-PEG). FOIS scores were assessed using the mean post-radiation FOIS level.
BMI and weight were both assessed using the same methodology. To examine the potential
impact of group placement on subject weight, and to account for the wide variation in individual
starting weights and BMI scores, the percentage of change in weight (weight% change) and the
percentage of change in BMI (BMI% change) were calculated. These were calculated by taking
the post-radiation values and dividing these by the pre-radiation value for each subject. In
addition to these measures of functional outcome, the nutritional status of each subject was
tracked using the Mini Nutritional Assessment – Short Form (MNS-SF). The mean postradiation value was used to assess between group differences. Data for each variable were
available across all 30 subjects with no missing values. The summary of these data and their
statistical analysis are available in Table 29.
PEG Outcomes
There were a total of 7 PEG tubes placed during radiation over the course of this study.
The HF group received 3 PEG tubes (2%) and the LF group received 4 PEG tubes (2.66%).
There was no statistical difference in the ratio of PEG placement between the two groups (MannWhitney U, p = .775).
FOIS Outcomes
The mean post-radiation FOIS level for the HF and LF groups were identical, 3.73. This
mean level does not directly correspond to any specific FOIS diet level. To further examine the
FOIS levels across the groups a distribution frequency table was developed. The distribution
revealed minimal variation between groups, with no patients tolerating unaltered diets and only 1
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patient who was completely feeding tube dependent. Examination of the feeding tube dependent
patients revealed that 3 of the 4 LF patients only had minimal oral intake. In the HF group 1
patient was completely feeding tube dependent, 1 patient had only minimal oral intake, and the
remaining patient had consistent oral intake. These findings are summarized in Table 31.
Table 31. Post-Radiation FOIS Count and Frequency Data by HF and LF Groups, n = 30
Group
FOIS Level
1
2
3
4
5
6
7
HF
Frequency
1
1
1
8
4
0
0
Ratio
6.66%
6.66%
6.66%
53.33% 26.66%
0%
0%
LF
Frequency
0
3
1
8
3
0
0
Ratio
0%
20%
6.66%
53.33%
20%
0%
0%
(HF) high frequency group, (LF) low frequency group, (FOIS) Functional Oral Intake Scale
BMI and Weight Outcomes
Post-radiation BMI loss (BMI% change) and weight loss (weight% change) were
analyzed and no significant between group differences emerged. The mean post-radiation BMI
loss for the HF group was 7.1% and the LF group was 10.1%. The mean post-radiation weight
loss for the HF group was 7% and the LF group was 9.9%. Figure 4 provides a visual summary
of findings for percentage of weight loss (pounds, lbs) and percentage of loss for BMI, n = 30.
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Percentage Lost by Group and Variable
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Figure 4. Percentage of Weight Loss and Body Mass Index (BMI) Loss for the
High Frequency (HF) and Low Frequency (LF) Groups, n = 30

Mini Nutritional Assessment – Short Form Outcomes
Comparison between the mean MNA-SF scores of the HF and LF groups revealed no
significant difference (p = .159). The Mean MNA-SF score for the HF group was 6.53 and the
LF group was 5.6. These scores do not directly represent MNA-SF scores, which are
summarized as whole numbers and correspond to individual nutritional risk categories. Scores of
0-7 indicate malnourishment; 8-11 indicate risk of malnutrition; and 12-14 indicate normal
nutritional status. To ensure that the clinical implications of these values could be fully assessed
a frequency distribution was also developed. The frequency and ratio data for individual MNASF scores are provided in Table 32. The frequency data revealed that all patients in the LF group
were in a state of malnutrition, while 73.33% of the HF group entered a state of malnutrition.
This level of malnutrition existed despite both groups experiencing less than 10% weight loss.
The MNA-SF relies on several factors including change in diet and medical diagnosis in addition
to weight loss to assess nutritional risk. Additionally, the level of weight loss assessed buy the
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MNA-SF is measured in pounds, not percentage of starting body weight, and these factors appear
influence the differences observed between weight loss percentage and nutritional risk observed
with the MNA-SF.
Table 32. Post-Radiation MNA-SF Frequency Data by HF and
LF Groups, n = 30
Group
MNS-SF level
0-7
8-11
12-14
Malnutrition
Risk
Normal
HF
Frequency
11
4
0
Ratio
73.33%
26.66%
0%
LF
Frequency
15
0
0
Ratio
100%
0%
0%
(MNA-SF) Mini Nutritional Assessment – Short Form, (HF)
high frequency group, (LF) low frequency group
Quality of Life
QOL outcomes were assessed using post-radiation patient-generated MDADI composite
scores. The MDADI was completed weekly during the course of radiation by each subject. In
addition to the patient-generated score, the NOD and PE QOL-related scores were assessed by
the treating SLP (author) weekly. To further assess QOL, and due to the reported occurrence of
fatigue in the cancer population, the CFS was administered. The CFS provided a weekly, patientgenerated, score related to the patient’s fatigue level. Data for each variable were available
across all 30 subjects with no missing values. The summary of these data and their statistical
analysis are available in Table 29.
MDADI, NOD, and PE Outcomes
The MDADI was assessed using the mean post-radiation composite scores of the HF and
LF groups. The composite score is derived from the functional, physical, and emotional
swallowing-related scores assessed by the MDADI. Scores range from 0-100, with 100 being the
best. There was no significant difference observed (p = .427) between the HF and LF groups.
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The mean score for the HF group was 53.34 and the mean score for LF group was 55.69. Each of
these MDADI levels represents a moderate decline in swallowing-related QOL. The NOD and
the PE scores are both derived from subtests of the PSS H&N. NOD represents the normalcy of
the study subject’s diet and PE represents the patient’s restriction to eating environment. Each
subtest ranges from 0-100, with 100 representing normal diet or no restriction to eating
environment. There were no observed differences between the HF and LF groups for NOD (p =
.259) or PE (p = .109). Mean NOD diet score for the HF group was 28 and the LF group was
22.33, both scores indicating a level between liquid and puree diets. The mean PE score for the
HF group was 38.33 and for the LF group was 26.66 indicating the both groups eat only with
select people or in select places. These outcomes are summarized in Figure 5.
These mean NOD, and PE scores represent a significant decline in swallowing-related
QOL, but they do not directly relate to the levels described within the assessment, falling
between levels on the assessment. To further explore the clinical meaning of these scores, a
frequency distribution was developed. These scores are summarized in Table 33. Frequency
distribution for Nod revealed that both groups had diets ranging from feeding tube dependence to
soft chewable foods, there was a trend for greater acceptance of puree foods (8 of 15 subjects) in
the HF group. This was compared to a trend for liquids only in the LF group (10 of 15 subjects).
Frequency of PE revealed that both the HF and LF groups had similar ranged of PE scores from
eating at home with select people to No restriction of person/place, but restriction of foods they
may choose. There was an observed trend in the LF group to eat only at home with select people
(10 of 15 patients).
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Figure 5. Mean Post-radiation NOD, PE, and MDADI Scores for
the High Frequency (HF) and (Low Frequency) LF Groups, n = 30

Table 33. Post-Radiation PE and NOD Count and Frequency Data by HF and LF Groups, n =
30
Group
NOD Level (Higher is Better)
0
10-20
30-40
50
60-100
HF
Frequency
2
3
8
2
0
Ratio
13.33%
20%
53.33%
13.33%
0%
LF

Frequency
Ratio

1
6.66%

Frequency
Ratio

In
Hospital
0
0%

10
66.66%

3
20%

1
6.66%

0
0%

PE Level (Higher is Better)

HF

0
1
6.66%

LF

25
7
46.66%

50
5
33.33%

75
2
13.33%

100
0
0%

Frequency
0
2
11
1
1
0
Ratio
0%
13.33%
73.33%
6.66%
6.66%
0%
(HF) high frequency group, (LF) low frequency group, (NOD) Normalcy of Diet score, (PE)
Public Eating
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Additionally, while there was no between group difference in MDADI scores, there was a
decline in MDADI scores over the course of radiation. This MDADI-related change is
represented in Figure 6. Review of Figure 6 reveals no observable variations between these two

MDADI Score Range

groups.
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0

Week of Radiation Treatment
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Figure 6. Mean Weekly MDADI Scores for High
Frequency (HF) and Low Frequency (LF) Groups

Cancer Fatigue Score Outcomes
The CFS was completed by all subjects weekly. CFS scores range from 0, no fatigue, to
60, significant fatigue. Comparison between the HF and LF groups found no significant
difference for fatigue scores (CFS, p = .539). The mean CFS score for the HF group was 25.13
and the LF group was 23.2, both representing a moderate level of fatigue. While CFS scores did
not vary between the groups, there was a noted increase in the reported level of fatigue over the
course of radiation treatment. This change in fatigue level over time is represented in Figure 7.
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Figure 7. Mean Cancer Fatigue Score (CFS) for the High
Frequency (HF) and Low Frequency (LF) Groups, n = 30

Assessment of SLP-patient Contact Time and Exercise Adherence
To assess the impact of SLP-patient contact time on exercise adherence the following
question was asked: does increased SLP-patient contact time result in improved treatment
exercise adherence? SLP-patient contact time was determined by group placement and adherence
was measured as the percentage of prescribed exercise completed. Adherence data was available
across multiple categories including SLP-guided (the exercise completed in the presence of the
SLP during treatment sessions), home-based exercise (the exercise completed as part of the home
program), and the combination of SLP-guided and home-based exercise. The original study
intervention called for the inclusion of SwallowSTRONG I-Pro exercise (tongue-palate press
exercise). However, based on feasibility findings, which will be discussed later in this document,
any SwallowSTRONG-based exercise completed was excluded from these analyses. This means
that any percentage of adherence was calculated based on the total prescribed Shaker exercise,
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Masako exercise, and pharyngeal squeeze exercise. Between group analyses of adherence
revealed a significant difference based on SLP-guided exercise (p = .049) and the combined
SLP-guided plus home-based exercise (p = .010). Examination of group means revealed the HF
group had a mean adherence of 89.96% and the LF group had a mean adherence of 80.61% for
the SLP-guided intervention. The HF group had a mean of 79.01% and the LF group had a mean
of 64.89% for the combined SLP-guided and home-based exercise. These findings are
summarized in Table 34.
Table 34. Group Adherence for SLP-guided treatment and Combined SLPguided Plus Home-based Intervention for HF and LF Groups, n = 30
Variable
HF
LF
P value
n = 15
n = 15
% complete
% complete
SLP-guided
Mean
89.96%
80.61%
.049
Range
71.07-100%
42.86-96.03%
Home-based

Mean
Range

68.07%
32.75-100%

49.6%
20.35-81.44%

.014

Combined SLP- Mean
79.01%
64.89%
.010
guided Plus
Range
51.8-100%
34.41-88.73%
Home-based
(HF) high frequency, 5 SLP-visits per week; (LF) low frequency, 3 SLPvisits per week; (1day/week) 1 SLP-visit per week; (CCT) current common
treatment, 3-4 visits over 6 weeks or radiation treatment; (Raddose) total
radiation dose; (+/-chemo) addition of concurrent or neoadjuvant
chemotherapy; (Gy) gray, unit of measurement for radiation, (ANOVA)
Analysis of variance

The range of the mean data, provided in Table 34, indicated that there was a greater
variation in the amount of exercise completed across subjects and exercise environment. It was
additionally important to examine how the adherence to exercise changed over the course of
radiation. The following figure, Figure 8, provides visual representation of the mean weekly
adherence by groups for the SLP-guided, home-based, and combined exercises. These graphs
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visually demonstrate that the HF group generally maintained higher levels of exercise adherence
than the LF group.
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Figure 8. Weekly Percentage of Adherence for SLP-guided, Home-based,
and Combined for High Frequency (HF) and Low Frequency (LF) Groups,
n = 30
(Figure 8. Continued)
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Assessment of Adherence on PEG use, Physiology, Function, and QOL
As discussed in the previous section within this chapter, there is significant difference
between group differences in exercise adherence. Based on this difference the following question
was asked: does increased adherence with behavioral intervention (exercise) result in decreased
post-radiation PEG placement, weight loss (weight% change, BMI% change), improved posttreatment swallow physiology (PAS), swallow function (FOIS), and swallowing-related QOL
(MDADI, NOD, PE) scores? To assess for differences based on adherence level, two new groups
(high adherence and low adherence) were created from the available HF and LF groups’
adherence data. Criteria for establishment of the two adherence groups was based on the mean
level of adherence across the subjects, n = 30. The mean adherence was determined to be 88%
for combined SLP-guided and home-based exercise. Therefore, groups were divided into high
adherence, 88% to 100%, and low adherence, 87% or below. To assess all possible adherence
differences, high and low adherence group differences were assessed within the HF group, LF
group, and between the high adherence group and low adherence group created from the
combined HF+LF groups. The findings for the within group analysis for the HF group are
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summarized in Table 35 and findings for within group analysis for the LF group are found in
Table 36.
Table 35 Post-Radiation Comparison of High adherence (n = 9) and Low
Adherence (n = 6) Groups Differences for the HF Group, n = 15
Variable
Mean (SD)
Mean (SD)
F value
P value
Low
High
Adherence
Adherence
Group
Group
Physiology
PASmean
1.0 (0)
1.33 (1.0)
.536
.139
PASrepeated
Pudding
PASrepeated
Thin
DIGEST
1.4 (.54)
.44 (.52)
10.291
.008
Functional
PEG Use
FOIS
BMI% change
Weight%
change
MNA-SF

2
33.33%
3.33 (1.5)
5.5 (4.6)
5.7 (5.0)

1
11.11%
4.22 (.66)
8.2 (5.4)
7.9 (5.0)

.000
.139
.987
.678

.139
.339
.439

6 (3.4)

6.89 (1.1)

.537

.447

Quality of Life
MDADI
55.7 (10.49)
50.1 (13.92)
.698
.418
NOD
21.66 (17.22) 32.22 (12.01)
1.976
.183
PE
20.83 (10.20
50.0 (17.6)
13.1
.003
(PASmean) penetration aspiration scale mean combined data, (PASrepeated)
penetration aspiration scale repeated trials data, (DIGEST) Dynamic Image
Grade of Swallowing Toxicity scale, (SD) standard deviation, (ANOVA)
analysis if variance, (MDADI) M.D. Anderson Dysphagia Inventory, (PEG)
percutaneous endoscopic gastronomy tube, (BMI) Body Mass Index, (FOIS)
Functional Oral Intake Scale, (MNS-SF) Mini Nutritional Assessment - Short
Form(NOD) Normalcy of Diet score, (PE) Public Eating score, (CFS) Cancer
Fatigue Scale
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Table 36. Post-Radiation Comparison of High Adherence (n = 6) and Low
Adherence (n = 9) Groups Differences for the LF Group, n = 15
Variable
Mean (SD)
Mean (SD)
F value
P value
Low
High
Adherence
Adherence
Group
Group
Physiology
PASmean
1.33 (1.0)
1.33 (.51)
.000
1.0
PASrepeated
Pudding
PASrepeated
Thin
DIGEST
1.11 (1.45)
.65 (.81)
.457
.511
Functional
PEG Use
FOIS
BMI% change
Weight%
change
MNA-SF

2 count
22.22%
3.89 (.92)
-11.7 (4.7)
-11.6 (4.0)

2 count
33.33%
3.5 (1.22)
-7.6 (6.1)
7.5(5.3)

.000
.492
2.11
2.84

.495
.170
.115

5.78 (1.09)

5.33 (1.03)

.621

.445

Quality of Life
MDADI
51.73 (7.04) 61.63 (11.56)
4.30
.058
NOD
19.44 (8.07) 26.66 (16.32)
1.31
.272
PE
22.22 (15.02) 33.33 (20.41)
1.486
.245
(PASmean) penetration aspiration scale mean combined data, (PASrepeated)
penetration aspiration scale repeated trials data, (DIGEST) Dynamic Image
Grade of Swallowing Toxicity scale, (SD) standard deviation, (ANOVA)
analysis if variance, (MDADI) M.D. Anderson Dysphagia Inventory, (PEG)
percutaneous endoscopic gastronomy tube, (BMI) Body Mass Index, (FOIS)
Functional Oral Intake Scale, (MNS-SF) Mini Nutritional Assessment - Short
Form(NOD) Normalcy of Diet score, (PE) Public Eating score, (CFS) Cancer
Fatigue Scale

Findings for within group analysis of adherence for the HF group revealed significant
difference in DIGEST scores (p = .008), PEG use (p = .000), and PE (p = .008). Findings for
within group analysis of adherence for the HF group revealed significant a significant difference
for PEG use (p = .000). To further explore differences in PEG use among group by adherence
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level a distribution table was developed. The distribution, available in Table 37, revealed similar
rates of PEG use across adherence levels.
Table 37. Distribution of Patients and Percutaneous Endoscopic Gastronomy Tube (PEG) Use
by Adherence Level, n = 30
Level of Adherence
Group
Variable
88% or above
87% or below
HF
# of Patients
9
6
# of PEG tubes
1
2
LF

# of Patients
# of PEG tubes

6
2

9
2

Within group analyses of adherence for the HF and LF groups revealed potential
adherence-based differences. To further assess adherence-based differences analysis was
completed for between group differences for the high adherence and low adherence groups
created from the combined HF and LF group data. Analysis revealed a significant difference
between groups based on NOD and PE scores. NOD was significant (p = .049) with the low
adherence group mean of 20.33 and the high adherence group of 30.0. PE was significant (p =
.001) with the low adherence group mean of 21.66 and the high adherence group mean of 43.33.
No other physiological or functional variables were significantly different between the groups.
These findings are summarized in Table 38.
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Table 38. Post-Radiation Comparison of High adherence and Low Adherence
Group Differences, n = 30
Variable
Mean (SD)
Mean (SD)
F value
P value
Low
High
Adherence
Adherence
Group
Group
Physiology
PASmean
1.21 (.80)
1.33 (.81)
.157
.695
PASrepeated
.448
Pudding
PASrepeated
.212
Thin
DIGEST
1.21 (1.18)
.53 (.64)
3.763
.063
Functional
PEG Use
FOIS
BMI% change
Weight%
change
MNA-SF

4
(26.66%)
3.67 (1.17)
-.092 (.05)
-.092 (.05)

3
(20%)
3.80 (.941)
-.80 (.55)
-.07 (.05)

.775
.118
.387
.627

.734
.539
.435

Quality of Life
MDADI
53.31 (8.47) 54.71 (13.88)
.111
.742
NOD
20.33 (12.02)
30.0 (13.62)
4.244
.049
PE
21.66 (12.9) 43.33 (19.97)
12.45
.001
(PASmean) penetration aspiration scale mean combined data, (PASrepeated)
penetration aspiration scale repeated trials data, (DIGEST) Dynamic Image
Grade of Swallowing Toxicity scale, (SD) standard deviation, (ANOVA)
analysis if variance, (MDADI) M.D. Anderson Dysphagia Inventory, (PEG)
percutaneous endoscopic gastronomy tube, (BMI) Body Mass Index, (FOIS)
Functional Oral Intake Scale, (MNS-SF) Mini Nutritional Assessment - Short
Form(NOD) Normalcy of Diet score, (PE) Public Eating score, (CFS) Cancer
Fatigue Scale

Additional methods to explore the potential relationship between the level of adherence
and subjects’ physiological, functional, and QOL include correlation and regression. Therefore a
correlation matrix was developed for subjects’ adherence and these outcome measures. These are
summarized in Table 39.
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Correlation analysis was performed on each of the three possible measurements of
adherence (SLP-guided, home-based, and combined SLP-guided plus home-based exercise).
Significant correlations were found between %BMI change and each adherence group (SLPguided, r = .39, p = .017; home-based, r = .391, p = .016; combined, r = .436, p = .008). Weight
loss (%Weight Change) was also significant across each adherence group (SLP-guided, r = .425,
p = .010; home-based, r = .443, p = .007; combined, r = .487, p = .003). NOD was significant for
SLP-guided adherence only (r = .314, p = .046). PE was significant for all adherence groups
(SLP-guided, r = .595, p = .003; home-based, r = .345, p = ≤.000; Combined, r = .491, p =
.031).No other variable had a significant relationship with any of the adherence measurements.
It was an original intent of this study to investigate what level of exercise adherence was
needed to reduce the likelihood of a PEG placement, aspiration risk (PAS score), decreased diet
level (FOIS), weight loss, and reduced QOL scores. However, as observed in Table 39, there are
no significant linear relationships between exercise adherence and PEG placement, FOIS, or
PAS scores. This is an important assumption that must be met prior to undertaking the statistical
methods, including linear regression, to further define such a relationship. There was a
significant relationship between measures of percent weight loss, percent BMI change, PE and
NOD scores, which met the statistical assumption. To further investigate the potential interaction
between percent weight loss, percent BMI change, PE and NOD scores and exercise adherence,
linear regression was performed. For the linear regression analysis the SLP-guided exercise
adherence and total combined exercise adherence (SLP-guided plus home based exercise) were
each input into a model along with percent weight loss, percent BMI change, NOD, and PE
scores. These two measurements of adherence, SLP-guided and combined exercises, were
chosen because the SLP-guided exercises represent approximately 50% of the prescribed daily
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Table 39. Correlation Analysis Outcomes for Exercise Adherence Relationships to Post-radiation
PEG use, PAS Scores, FOIS Scores, %BMI Change, %Weight Loss., and QOL Scores, n = 30
Variable
SLP-guided
Home-based
Combined SLPExercise
Exercise
guided and Home
based Exercise
+/-PEG
r value
-.078
-.019
-.046
p value
.404
.341
.460
PAS

r value
p value

-.005
.498

.237
.108

.162
.201

FOIS

r value
p value

.092
.315

.012
.475

.047
.403

% BMI Change

r value
p value

.390
.017

.391
.016

.436
.008

% Weight Loss

r value
p value

.425
.010

.443
.007

.487
.003

MDADI

r value
p value

.147
.219

.167
.190

.178
.174

NOD

r value
p value

.314
.046

.179
.172

.257
.086

PE

r value
.595
.345
.491
p value
.003
≤ .000
.031
(PEG) Percutaneous Endoscopic Gastronomy Tube, (PASmean) penetration aspiration scale mean
combined data, (MDADI) M.D. Anderson Dysphagia Inventory, (BMI) Body Mass Index, (FOIS)
Functional Oral Intake Scale, (NOD) Normalcy of Diet score, (PE) Public Eating score

amount of exercise and the combined exercise measurements account for the maximal possible
exercise and adherence. Table 40 summarizes the findings of the linear regressions for these
adherence measurements and percent weight loss, percent BMI change, NOD, and PE.
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Table 40. Post-Radiation Linear Correlation Models and Coefficients for Adherence by SLPguided only exercise and Combined SLP and Home-Based Exercise for Weight loss, BMI,
NOD, PE, n = 30
Model Variables
R value
F value
P value
Combined SLP and Home-based exercise adherence
%Weight Loss, % BMI change,
.661
4.85
NOD, and PE

.005

SLP-based Exercise adherence only
%Weight Loss, % BMI change ,
.682
5.420
.003
NOD, and PE
(BMI) Body Mass Index, (NOD) Normalcy of Diet score, (PE) Public Eating score

Results for combined SLP-guided and home-based exercise were significant (p = .005) with r =
.661, and SLP-guided adherence was significant (p = .003) with r = .682. Coefficients of the
individual variables included within the model are provided in Table 41.
Table 41. Post-Radiation Linear Correlation Coefficients by SLP-guided only
exercise and Combined SLP and Home-Based Exercise for Adherence and
%Weight Loss, % BMI Change, NOD, and PE Scores, n = 30
Variable
Coefficients
B
Combined SLP and Home-based exercise adherence
Constant
-.201
%Weight Loss
.002
Constant
%BMI Change

-.197
.002
9.11

Constant
NOD
Constant
PE
Constant
%Weight Loss

.223
-12.47
.625
SLP-based Exercise adherence only
-.227
.002

Constant
%BMI Change
(Table 41. Continued)

-.225
.002
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Variable
NOD

Coefficients
B
.324

Constant
-44.20
PE
.899
(BMI) Body Mass Index, (NOD) Normalcy of Diet score, (PE) Public Eating Score
Based on the significant results of the linear regression analyses, a prediction model was
created using the following equation: predicted outcome = (variable coefficient * predicted
adherence level) + constant. Outcomes were predicted across %Weight Loss, %BMI Change,
NOD, and PE for both SLP-guided exercise and combined exercise. These findings revealed that
60% of combined exercise and 70% of the SLP-guided exercise prevented greater than 10%
weight loss. Combined exercise adherence of 100% was predictive of maximized diet level and
diet-related QOL. Results are summarized in Table 42.
Table 42. Predicted Outcomes for %Weight Loss, %BMI Change, NOD, PE Scores
Based on Percentage of Exercise Adherence , n = 30
Variable
Percentage of Adherence
50% 60%
70%
80%
90%
100%
Combined SLP and Home-Based Exercise
%Weight Loss 10.1 8.1
6.1
4.1
2.1
.1
%BMI Change 9.7
7.7
5.7
3.7
1.7
.3
NOD
20.26 22.49
24.72
26.95
29.18
31.41
PE
18.78 25.03
31.28
37.53
43.78
50.03
SLP-Based Exercise Only
%Weight Loss 12.7 10.7
8.7
6.7
4.7
2.7
%BMI Change 12.5 10.5
8.5
6.5
4.5
2.5
NOD
13.73 16.97
20.21
23.45
26.69
29.93
PE
.75
9.74
18.73
27.72
36.71
45.7
(BMI) Body Mass Index, (NOD) Normalcy of Diet score, (PE) Public Eating score
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Feasibility of SwallowSTRONG Biofeedback
An original intent of this study was to explore the potential benefits of biofeedback using
the SwallowSTRONG system. Examination of the feasibility of this device was guided by the
following question: are subjects undergoing chemoradiotherapy for HNC able to tolerate a
biofeedback device that requires oral placement? The initial step in analyzing feasibility was to
determine if any SwallowSTRONG-related differences occurred between the original HF and LF
groups. SwallowSTRONG-related variables included percentage of exercise completed, number
of possible exercise sessions possible and completed, rationale for discontinued use, and the
duration of use. Chi-square Mann-Whitney U was used to assess each analysis and no significant
differences were found. Findings are summarized in Table 43.
Table 43. SwallowSTRONG (SWST) Comparison for
Group Differences Between HF and LF Groups, n = 30
Comparison
P value
Comparison of SWST Usage
% of SWST complete
.653
% of SWST not
.174
performed
Number of total
.137
possible SWST visits
Duration of Use
.870
Comparison of Rationale for Discontinuing SWST
Pain
1.00
Nausea / Vomiting
.367
Gag
.775
Subject Declined
.775
(SWST) SwallowSTRONG, (HF) High frequency
group, (LF) Low frequency group, (%) percentage
Results of the between group comparison found no significant differences for the SWST
usage. There were also no significant group differences for the rationale for discontinuing the
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SWST exercise. Based on lack of between group differences the HF and LF group data were
pooled to calculate the overall mean use of the SWST exercise, available in Table 44.
Table 44. SwallowSTRONG Exercise Frequency and Participation-Related Values, n = 30
Total Subjects
n = 30
Mean sessions completed
3.33
Participated
n = 27
Mean Session Incomplete
1.03
Mean Total session attempted
4.37
Declined
n=3
Mean Session possible
19.03
Optimal number of Sessions
21
A visual summary of the rationale for discontinued use of the SwallowSTRONG-based exercise,
and the average percentage of possible or desired SwallowSTRONG-related exercise of provided
in Figure 9.

Figure 9. Summary of the Rationale for Discontinued use of SwallowSTRONG-Based
Exercise and the Average Percentage of Possible or Desired SwallowSTRONG-Related
Exercise, n = 30
(Figure 9. Continued)
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Average Percentage of SwallowSTRONG Complete for Total
Possible and Total Desired Exercise
100

Percentage Complete

90
80
70
60
50
40
30
20

16.05

16.95

Percentage of Possible

Percentage of Desired

10
0

Total Possible and Total Desired Exercise

Saliva Production During Radiation Therapy With or Without Chemotherapy
To assess the relationship between salivary production the following question was asked:
how does salivary production (salivary weight) during chemoradiotherapy relate to diet level?
Data available for this question was taken for the HF and LF groups from the Saxon test of
salivary weight. The original data were converted into the percentage of salivary function loss by
dividing the post-radiation salivary weight by the pre-radiation saliva weight. Potential between
group differences for HF and LF groups were evaluated using ANOVA and no significant
difference was found (p = .536). Mean loss for the HF groups was 66.7% and the mean for the
LF group was 72.9%, summarized in Figure 10. Based on the lack of significant between groups,
groups were combined for remaining analysis of salivary loss data. To explore the relationship
between salivary loss and diet level, correlation and regression were used with variables FOIS
and NOD. As previously discussed, it is necessary to establish a linear relationship
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Percentage of Salivary Loss
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Figure 10. Average Percentage of Salivary Function
Loss Post-Radiation By Group, n = 30

before using regression analysis. The correlation findings are summarized in Table 45. Findings
indicate a significant linear relationship for FOIS (r = .395, p = .031), but no linear relationship
with NOD.
Table 45. Correlation Results for Salivary Loss by FOIS and NOD, n = 30
Variable
r value
P Value
FOIS
.395
.031
NOD
.166
.381
(FOIS) Functional Oral Intake Scale, (NOD) Normalcy of Diet
Based on the significant results for FOIS, a linear regression was performed to further
explore the relationship between salivary loss and diet level. Regression was significant (p =
.031) and has been summarized in Table 46.
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Table 46. Post-Radiation Linear Correlation Model for Salivary Loss and FOIS, n = 30
Regression Model
Model
R value
F value
P value
FOIS
Variable
Constant
FOIS
(FOIS) Functional Oral Intake Scale

.395
Coefficients
B
-95.602
69.17

5.189

.031

T value
-7.832
2.278

P value
.000
.031

Based on the significant relationship, the linear regression coefficients were used to
develop a predictive equation to predict the level of salivary loss associated with each FOIS
level. These results are summarized in Table 47. It was noted that a loss of 88.68% was
predictive of total PEG dependence compared to a 47.18% loss, which was predictive of
continued normal dietary intake.
Table 47. Predicted Percentage of Salivary Loss for FOIS Levels, n = 30
FOIS Level
% of Predicted
Saliva Loss

1

2

3

4

5

6

7

88.68

81.76

74.85

67.96

61.01

54.1

47.18

(FOIS) Functional Oral Intake Scale, (%) Percentage
Toxicity Relationship with Function and QOL
A final area this study needed to explore was the relationship between the radiation and
chemotherapy-related toxicities and swallowing function or QOL. These analyses were guided
by the following question: does the level of toxicity (measured by saliva weight, mucositis scale
score, and Cancer Fatigue Scale score, and pain level) correlate to the level of swallowing
function and/or swallowing QOL-related scores? Table 48 provided a summary of the
correlation matrix for toxicity, functional, and swallowing-related QOL scores.
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Table 48. Correlation Analysis Outcomes for Toxicity Level to Post-radiation PEG
use, FOIS Scores, Pain Level, and QOL Scores, n = 30
Swallow% Saliva
General
Related
Mucositis
Variable
Loss
Pain
Pain
CFS
Score
+/-PEG
r value
-.403
-.239
-.284
.189
.065
p value
.027
.203
.128
.317
.734
FOIS

r value
p value

.395
.031

.196
.299

.278
.137

-.132
.488

-.195
.303

MDADI

r value
p value

-.099
.604

.014
.940

-.063
.741

-.445
.014

-.287
.124

NOD

r value
p value

.166
.381

.226
.230

.224
.234

.139
.464

-.440
.015

PE

r value
-.075
.307
.270
.132
-.411
p value
.694
.099
.149
.488
.024
(PEG) Percutaneous Endoscopic Gastronomy Tube, (MDADI) M.D. Anderson
Dysphagia Inventory, (FOIS) Functional Oral Intake Scale, (NOD) Normalcy of
Diet score, (PE) Public Eating score

As previously reported, there were no between group differences for post-radiation
outcomes across the functional and swallowing-related QOL. Functional outcomes included
post-radiation PEG use and FOIS score. Swallowing-related QOL variables included MDADI,
NOD, and PE scores.
Significant correlations were found between % salivary loss and PEG use (r = -.403, p =
.027) and % salivary loss and FOIS level, which has previously been discussed. Significant
correlations were also found between mucositis scores and NOD (r = -.440, p = .015) and
mucositis and PE (r = -.411, p = .024). No other significant relationships were found. For all
other significant correlations linear regression was used to further examine these relationships.
Linear correlations results are summarized in Table 49.
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Table 49. Post-Radiation Linear Correlation Results and Coefficients for % Salivary Loss and
+/-PEG, % Salivary Loss and FOIS, Mucositis and NOD, and Mucositis and PE, n = 30
Model
R value
F value
P value
% Saliva Loss Regression
+/-PEG
.403
5.426
.027
% Saliva Loss Coefficients
B
T value
-61.18
-10.389
-22.066
-2.329

P value
.000
.027

Model
NOD
PE

Mucositis Regression
R value
F value
.440
-6.706
.441
-5.70

P value
.015
.024

Variable
Constant
NOD

Mucositis Coefficients
B
T value
20.230
19.057
-.097
-2.590

P value
.000
.015

Variable
Constant
+/-PEG

Constant
19.803
20.237
.000
PE
-.062
-2.388
.024
(PEG) Percutaneous Endoscopic Gastronomy Tube, (NOD) Normalcy of Diet score, (PE)
Public Eating score

Results of these linear regressions were significant for % salivary loss and +/- PEG (r =
.403, p = .027), mucositis and NOD (r = .440, p = .015), and mucositis and PE (r = .441, p =
.024). Due to the importance of PEG use, the linear regression coefficients were used to create an
equation for the percentage of salivary loss predictive of PEG tube use. The equation used was %
salivary loss = +/-PEG coefficient value multiplied by the post-radiation PEG value plus the
constant value. Results of the predictive equation found that salivary losses of 83.25% or below
were associated with post-radiation PEG use.
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6.4 Hypothesis testing, Hypothesis 2
The research question guiding these statistical analyses asked if increased SLP-patient
contact time provided during prophylactic behavioral swallowing exercise intervention,
compared to the current common treatment, will result in improved immediate post-treatment
swallow physiology, swallow function, and swallow-related QOL. The available groups for these
analyses included the HF, LF, 1day/week, and CCT groups. Findings for Hypothesis 1,
previously examined in this chapter, indicated that the HF and LF groups had no statistically
significant post-radiation differences. Given the lack of significant differences, the HF and LF
groups were pooled to create a new HF+LF group, n = 30. This allowed for a more robust
analysis of SLP-patient contact time in Hypothesis 2. Two of the groups in these analyses,
1day/week and CCT, were collected retrospectively. This limited the number of available
variables; however, variables were available for swallow physiology and swallow function for all
groups. Results of the statistical analysis are found in Table 50.
Table 50. Post-Radiation Comparison of HF+LF, 1day/week, and CCT Group Differences
Variable
Mean (SD)
Mean (SD)
Mean (SD)
P value
Statistic
HF+LF
1day/week
CCT Group
Group
Group
N = 30
N = 47
N = 25
Physiology
PASmean
1.28 (.79)
3.35 (2.65)
1.88 (1.94)
≤.000
ANOVA
Functional
PEG Use
7 (count)
20 (count)
13 (count)
.080
Kruskal23.3%
42.5%
52%
Wallis
FOIS
3.73 (1.04)
3.79 (1.57)
3.60 (1.95)
.021
ANOVA
%Weight
-.084 (.05)
-.082 (.05)
-.073 (.04)
.718
ANOVA
Change
Quality of Life
MDADI
54.01 (11.3)
62.82 (12.98)
NA
.481
ANOVA
(PASmean) Penetration Aspiration Scale mean across bolus types, (PEG) Percutaneous
Endoscopic Gastronomy tube, (FOIS) Functional Oral Intake Scale, (MDADI) MD Anderson
Dysphagia Inventory, (ANOVA) Analysis of Variance, (HF + LF) Combined High Frequency
and Low Frequency Groups, (1day/week) 1 day per week group, (CCT) Current Typical
Treatment
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Physiology
Aspiration Risk Outcomes
PAS data were available as means across thin liquid and solid bolus for all groups. While
the potential benefits of analyzing these data by bolus type across multiple trials have been
previously discussed, the retrospective data collection prevented these types of analyses.
Comparison of PAS data revealed a statically significant (p = ≤ .000) difference between the
HF+LF, 1day/week, and CCT groups. Examination of mean data revealed that the 1day/week
group had a mean of 3.35, indicating higher risk of penetration but not aspiration. The HF+LF
group and CCT group had means of 1.28 and 1.88, respectively, indicating reduced risk of
aspiration or penetration. Frequency data revealed that the HF+LF group had no occurrence of
aspiration using the mean across bolus data, while the 1day/week experienced 22.5% aspiration
and the CTT experienced 8%. To further explore the frequency and distribution of PAS mean
scores Table 51 was developed.
Table 51. Post-Radiation Mean Across Bolus Type, PAS Frequency Data, HF+LF (n = 30),
1day/week (n = 47), and CTT (n = 25)
Group
PAS Level
1
2
3
4
5
6
7
8
HF+LF
83.3%
6.6%
0%
6.6%
0%
0%
0%
0%
1day/week

35.0%

22.5%

7.5%

2.5%

10.0%

0%

7.5%

15.0%

CTT
40.0%
32.0%
8.0%
8.0%
4.0%
8.0%
0%
0%
(PAS) Penetration Aspiration Scale, (HF+LF) high frequency plus low frequency combined
group, (1day/week) one day per week group, (CTT) current typical treatment group

Functional Outcomes
Post-radiation PEG tube use data were available as count and ratio data for each group.
Chi-square was used to examine between group differences and no significant difference were
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observed (Kruskal-Wallis, p = .080). However, there were notable differences in percentage of
PEG use across groups (HF+LF, 23.3%; 1day/week, 42.5%; CCT, 52%). To further analyze PEG
use across study groups, correlation and linear regression analyses were used to determine if a
relationship was present, and if group placement and the number of SLP visits could be
predictive of PEG placement. Bivariate correlation was used to first determine if the assumption
of linearity was met between group placement and post-radiation PEG use, and the number of
SLP-patient visits and PEG use. Bivariate analysis, Pearson r, indicated a significant correlation
among the group placement and post-radiation PEG use (r = .224, p = .024), and among SLPpatient visits and PEG use (r = -.216, p = .029). These findings indicate that a relationship exist
between SLP contact time and feeding tube placement.
Based on the bivariate analysis, the assumption of linearity was met and linear regression
was performed. Findings of linear regression analyses are available in Table 52.
Table 52. Post-Radiation Linear Correlation Models for Group Placement and
SLP-Patient Contact Time by PEG Use, n = 102
R value
F value
P
value

PEG Use

Group Placement
.224

SLP-Patient Contact Time
PEG Use
.216
(PEG) Percutaneous Endoscopic Gastronomy Tube

5.27

.024

4.91

.029

The coefficient data, available in Table 53, for SLP-patient contact time
(number of visits) were then used to calculate the estimated minimum number of SLP-visits
needed to avoid a PEG tube placement. The following calculation method was used: Predicted
number of visits = (Post radiation PEG coefficient value * predicted outcome, 0 = no PEG) + the
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constant [visits = (-4.583*0) + 13.258]. This equation resulted in a prediction of 13.258 SLPvisits associated with no PEG use.
Table 53. Post-Radiation Linear Correlation Coefficients for SLP-Patient Contact Time and
PEG Use, n = 102
Variable
Coefficients
t value
P value
B
Constant
13.258
10.237
.000
SLP-Patient
-4.583
-2.216
Contact Time
(PEG) Percutaneous Endoscopic Gastronomy Tube

.029

Functional Oral Intake Scale (FOIS)
Post-Radiation FOIS scale scores were used to quantify subjects’ diet levels. Mean FOIS
score for the HF+LF group was 3.73, for the 1day/week group was 3.79, and for the CCT group
was 3.60. As previously discussed, the scale ranges from 1, corresponding total no oral intake, to
7, corresponding to oral intake with no restrictions. Means ranging between 3 and 4 fall between
PEG use with consistent oral intake and total oral intake of a single consistency. Initial analysis
of between group means found a significant difference (p = .021). These findings have been
previously summarized in Table 42. Given the lack of obvious clinical variation between the
group means, a frequency distribution was created to further assess group differences,
summarized in Table 54. The frequency distribution showed that while each group had FOIS
scores ranging from 0 to 7, the 1day/week and CCT group had a larger proportion of total PEG
use (FOIS 0, no oral intake) compared to the HF+LF group. The HF+LF group had no subjects
with an unrestricted diet (FOIS 7) while the 1day/week and CCT groups had 4.2% and 12%,
respectively. No groups had a FOIS level 6, normal diet with specific food avoidances.

163

Table 54. Post-Radiation FOIS Count and Frequency Data by HF+LF (n = 30), 1day/week (n
= 47), and CCT Group (n = 25)
Group
FOIS Level
1
2
3
4
5
6
7
HF+LF
1
4
2
16
7
0
0
3.3%
13.3%
6.6%
53.3%
23.3%
0%
0%
1day/week

7
14.9%

4
8.5%

3
6.3%

15
31.9%

16
34.0%

0
0%

2
4.2%

CCT

4
5
5
0
8
0
3
16.0%
20%
20%
0%
32%
0%
12%
(FOIS) Functional Oral Intake Scale, (HF + LF) Combined High Frequency and Low
Frequency Groups, (1day/week) 1 day per week group, (CCT) Current Typical Treatment
Weight
Post-radiation weight loss was measured as the percentage of weight loss over the
subjects’ course of radiation. This was measured as the post-radiation weight in pounds divided
by the pre-radiation weight in pounds. Mean weight loss for the HF+LF group was -.084%
(8.4%), the 1day/week group mean weight loss was -.082% (8.2%), and the CCT group
experienced weight loss of -.073% (7.3%). Analysis of mean differences between the groups
revealed no significant differences (p = .718). These findings have been summarized in Table 50.
Quality of Life
As previously discussed, MDADI data were only available for the HF+LF and 1day/week
groups. For the CCT group it was initially expected that the MDADI would be available. The
MDADI is a routine QOL questionnaire given to subjects at the data collection site. However,
when data collection began, it was determined that a combination of changes to the electronic
medical record system and subject refusal to complete forms during routine care prevented any
meaningful data collection of MDADI scores from the CCT group. Therefore, the comparison of
QOL between groups could only be completed the MDADI scores for the HF+LF and 1day/week
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groups. The mean post-radiation MDADI composite score for the HF+LF groups was 54.01 and
the mean for the 1day/week group was 62.82. Clinically relevant change, based on MDADI
composite score, is 10 points in either direction (e.g., 60 + or - 10) (264). Both means indicate a
moderate decline in overall swallowing-related QOL. Between group comparison found no
significant difference (p = .481). These findings are summarized in Table 50.
6.5 Secondary Research Questions
Assessment of PEG Users compared to No PEG Users
In addition to the primary research hypothesis of this study, the following question was
asked: do post-radiation PEG (+PEG) users differ from non-PEG users (-PEG) across treatment,
physiological, functional, or QOL variables? To answer this question, two new groups were
formed from the existing data set (combined HF, LF, 1day/week, CTT groups, n = 102), + PEG
and –PEG. Prior to analyzing the potential treatment, physiological, functional, or swallowingrelated QOL differences possible, differences in radiation dose, use of chemotherapy, and group
demographics were assessed. These findings are summarized in Table 55.
Findings for group differences in post-radiation dose (Raddose) were not significant (p =
.470). However, chemotherapy (+/-chemo) use was significantly (p = .002) different between
groups. Further examination of the data revealed that 21 patients (33.8%) in the –PEG group 3
patients (7.5%) in the +PEG group received no chemotherapy. No significant between group
differences were noted for tumor site (p = .940) or cancer stage (.074). To assess difference for
+PEG and –PEG physiology PASmean, FOIS, BMI% change, Weight% change, and MDADI
scores analyzed. Findings revealed a significant difference based on FOIS scores with PEG users
experiencing lower overall diet levels. Findings are summarized in Table 56.
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Table 55. Post-radiation Group Characteristics including Raddose, +/-chemo, and
Missed Visits for the +PEG and -PEG groups
Variable
+PEG
-PEG
P value
n = 40
n = 62
Dose (Gy)
Dose (Gy)
Raddose
Mean
68.40Gy
67.34Gy
.470
Range
31-70Gy
30-70Gy
+/-chemo

Tumor site

Yes

37

41

No

3

21

Count
0

Count
4

7

11

15
6
7
4

18
21
6
2

Oral Tongue with
Base of Tongue
Base of Tongue
only
Tonsil
Larynx
Pharynx
Lymph Node/Neck

.002

.940

Tumor/Cancer
I
1
6
.074
Stage, Based on
TNM score
II
3
10
(Tumor size,
III
17
25
Nodal
IV
18
21
involvement,
Metastasis)
(Raddose) total radiation dose; (+/-chemo) addition of concurrent or neoadjuvant
chemotherapy; (Gy) gray, unit of measurement for radiation, (ANOVA) analysis
of variance
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Table 56. Post-Radiation Comparison for +PEG and -PEG Group
Differences
Variable
Bolus Type Mean (SD)
Mean (SD)
+PEG Group -PEG Group
n = 62
n = 40
Physiology
PASmean
2.46 (2.61)
2.23 (1.94)
Functional
FOIS
2.38 (1.31)
4.60 (.91)
BMI% change
-10.80 (5.74) -7.97 (5.36)
Weight% change
-8.84 (4.77)
-7.69 (5.5)
Quality of Life
MDADI**

n = 27
59.54 (11.72)

n = 50
59.31
(13.79)
**MDADI data was unavailable for 25 subjects (CTT group)

P value

.626
≤.000
.239
.304

.940

Further assessment of PAS repeated measures by bolus type, DIGEST, Swallowtail
timing and displacement variable, and SwallowSTRONG anterior and posterior tongue-palate
pressure variables were examined using the original data from the HF and LF groups. This
yielded a n = 30 for these further analyses. These findings are summarized in Table 57.Findings
for PAS mean were not significant (p = .626); however, PASrepeated for thin liquid bolus type
and for pudding bolus type were both significant (PASrepeated thin, p = .005; pudding, p =
.010). The repeated measure analysis examined two trials per bolus type per subject, equaling 58
total observations per bolus type. To further assess the clinical relevance of these findings, a
frequency distribution table, Table 58, was developed. Findings of the frequency distribution
reveal that the +PEG group experienced 0% aspiration of thin liquid trials (PAS 6, 7, or 8) and
the –PEG group experienced 4.5% aspiration of thin liquid trials. For pudding bolus type, the
+PEG group experienced 28.5% aspiration and the –PEG group experienced 4.5% aspiration. No
group experienced penetration only (PAS 2, 3, 4, or 5) of
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Table 57. Post-Radiation Comparison for +PEG and -PEG Group Differences
Variable
Bolus Mean (SD)
Mean (SD)
Type +PEG Group
-PEG Group
n=7
n = 23
Physiology
PASrepeated**
Thin 1.86 (1.16)
1.45 (1.48)
PASrepeated**
DIGEST
UESMax/cm
TPST
PCR

PRR
BCR

Airwayclose
Hyolaryngeal/cm
Anterior Tongue%
change
Posterior Tongue%
change
Functional
MNA-SF
Quality of Life
NOD

Pudding
Thin
Pudding
Thin
Pudding
Thin
Pudding
Thin
Pudding
Thin
Pudding
Thin
Pudding
Thin
Pudding

P value

.005

2.71 (2.81)

1.27 (1.26)

.010

1.0 (1.26)
.81 (.16)
.82 (.23)
1.18 (.62)
1.72 (1.59)
41.9 (53.88)
18.17
(28.35)
6.31 (7.68 )
2.90 (3.87)
24.44 (19.0)
16.16
(17.70)
.30 (.16)
.26 (.35)
1.98 (1.03)
2.20 (1.27)
-6.07
(98.89)
-53.19
(33.72)

.83 (.93)
.78 (.09)
.74 (.19)
1.12 (.58)
1.41 (.66)
13. 29 (9.34)
37.01
(99.32)
2.11 (1.3)
.23 (16.4)
15.03 (7.13)
20.72
(14.61)
.124 (.08)
.27 (.31)
2.08 (.82)
2.11 (.85)
-30.81
(25.48)
-58.08
(30.08)

.709
.669
.601
.603
.291
.009
.679

4.71 (1.49)

6.48 (1.70)

.020

10.0 (11.54)

.007
.710
.051
.547
.053
.547
.133
.535
.270
.066

29.78
.000
(10.49)
PE
21.42
35.86
.092
(17.25)
(19.96)
CFS
27.0 (7.91) 23.30 (8.54)
.317
(PASrepeated) penetration aspiration scale repeated trials data, (DIGEST) Dynamic Image
Grade of Swallowing Toxicity scale, (UESMax/cm) maximal displacement of upper esophageal
opening in centimeters, (TPST) total pharyngeal swallow time, (PCR) pharyngeal constriction
ration, (PRR) pharyngeal residue ratio, (BCR) bolus constriction ratio, (Airwayclose) time of
the first approximation of the arytenoids and epiglottis coming together to close off airway,
(Hyolaryngeal/cm) maximal hyolaryngeal excursion in centimeters, (NOD) Normalcy of Diet
score, (PE) Public Eating score, (CFS) Cancer Fatigue Scale
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pudding bolus type. The +PEG group experienced 42.6% penetration for thin liquid bolus trials
and the –PEG group experienced 13.6% penetration for thin liquids.
Overall, while both groups experienced some aspiration, the +PEG group experienced
greater levels of aspiration and penetration across bolus types compared to the –PEG group. This
finding also highlights the difference in aspiration risk based on bolus type observed within these
patients.
Table 58. Post-Radiation Repeated Measures PAS Count and Frequency Data by +PEG and PEG Groups and Bolus Type
Group
PAS Level
1
2
3
4
5
6
7
8
Thin Bolus Type
+PEG
8
2
2
2
0
0
0
0
57.14%
14.2%
14.2%
14.2%
0%
0%
0%
0%
-PEG

36
81.8%

6
13.6%

0
0%

+PEG

10
71.4%

0
0%

0
0%

-PEG

42
0
0
95.4%
0%
0%
(PAS) Penetration Aspiration Scale

0
0
0%
0%
Pudding Bolus Type
0
0
0%
0%
0
0%

0
0%

0
0%

0
0%

2
4.5%

0
0%

4
28.5%

0
0%

0
0%

2
4.5%

0
0%

Pharyngeal constriction ratio (PCR, .009) and pharyngeal residue ratio (PRR, p = .007)
were also significant between the + PEG and –PEG groups. Swallowtail-based measurements, as
previously discussed, were obtained using the pre-radiation and post-radiation MBSS. The
statistical analysis was completed using the difference (pre-radiation minus post-radiation value)
in each variable’s value as measurement or swallowing-related change. Both PCR and PRR are
ratio measurements. Examination of the mean data revealed that for PCR there was 41.9%
reduction in maximal pharyngeal constriction for PEG users and only a 13.29% reduction for
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non-PEG users. Additionally, for PRR there was a 6.31% increase in total pharyngeal residue
(stasis) compared to a 2.11% increase in pharyngeal residue for non-PEG users. No other
physiological measure was significant for any group difference.
Functional Outcomes
The MNA-SF was significantly different between the +PEG and –PEG groups (p = .020).
The MNA-SF, as previously discussed, measures nutritional risk. Examination of the mean data
for the +PEG group reveals a mean of 4.71 and the –PEG group reveals a mean of 6.48. Both of
these mean scores fall within the malnourished category of the MNA-SF. To further analyze the
distribution of nutritional risk between these two groups, a frequency distribution was developed.
Findings reveal that 100% of the +PEG group fell into malnutrition, while only 69.5% of the –
PEG group was in malnutrition. Of the remaining –PEG group, 30.5%, fell into risk of
malnutrition. No group had subjects in a normal nutritional state. Frequency distribution findings
are summarized in Table 59. No other functional measurement was significant between the
+PEG and –PEG groups.
Table 59. Post-Radiation MNA-SF Count and Frequency Data by +PEG and -PEG Groups,
n = 30
Group
MNS-SF level
0-7
8-11
12-14
-PEG
Frequency
16
4
0
Ratio
69.5%
30.5%
0%
+PEG

Frequency
7
0
Ratio
100%
0%
(MNA-SF) Mini Nutritional Assessment – Short Form
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0
0%

QOL Outcomes
For the between group comparison of QOL measures, NOD was significant (p = ≤.000).
Examination of the mean data revealed a mean NOD score of 10.0 for the +PEG group which
indicated intake of cold or room temperature liquids only. The mean for the –PEG group, 29.78,
indicated that it fell between the level for warmed liquids (NOD level 20) and pureed solids
(NOD level 30). To further expand the relationship between diet levels and PEG use, a frequency
distribution was developed. The frequency distribution reveals that the +PEG group had 42.8%
with no oral intake, 42.8% with only intake of liquids, and 14.2% with intake of pureed foods.
The –PEG group had 43.4% consumption of only liquids, 43.4% consumption of pureed foods
and liquids, and 13.0% of subjects consuming a soft diet. These findings are summarized in
Table 60. No other QOL measure was significant between the +PEG or –PEG groups.
Table 60. Post-Radiation NOD Count and Frequency Data by +PEG and -PEG Groups, n = 30
Group
NOD Level
0
10-20
30-40
50
60-100
+PEG Frequency
3
3
1
0
0
Ratio
42.8%
42.8%
14.2%
0%
0%
-PEG

Frequency
0
10
10
3
0
Ratio
0%
43.4%
43.4%
13.0%
0%
(NOD) Normalcy of Diet, (PEG) Percutaneous Endoscopic Gastronomy Tube, (+PEG)
subjects with PEG, (-PEG) subjects with no PEG
6.6 Summary of Results
The significant post-radiation results of this study are summarized in Table 61. Results
are organized by hypothesis/research question and include a description and reference to the
clinical and/or statistical significance.
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Table 61. Significant Post-radiation Study Results, Variables, Descriptions, and Statistical, and
Clinical Values
Area of
Variable
Description
Statistical/Clinical
Analysis
Value
Hypothesis 1
Adherence
Adherence to Exercise
The High Frequency
SLP-guided exercise, p
(HF) group
= .049; Home-based
maintained
exercise, p = .014;
significantly higher
Combined exercise, p =
levels of exercise
.010
adherence compared
to the Low Frequency
(LF) group. Combined
exercise adherence for
the HF group was
79.01% and the LF
group was 64.89%.
Normalcy of Diet
When comparing high NOD, p = .049
(NOD) and Public
and low adherent
PE, p = .001
Eating (PE)
patients, the NOD and
PE scores were
consistency better in
the high adherence
group (those
performing 88% or
more of the total
exercise).
%Body Mass Index
Regression for
Regression analysis:
(BMI) Change,
adherence was
Combined exercise;
%Weight Loss,
significant SLPweight loss, change in
Normalcy of Diet
guided, Home-based,
BMI, NOD, and PE, p =
(NOD), and Public
and Combined
.005
Eating (PE)
exercise except NOD,
which was only
weight loss, change in
significant with SLPBMI, and PE, p = .003
guided exercise.
(Table 61. Continued)
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Area of
Analysis

Diet Level and
PEG (feeding
tube) use

Variable

Description

Prediction of needed
exercise adherence

Exercise adherence
outcomes predicative
of less than 10%
weight loss or
maintenance of the
highest possible oral
diet level.

Salivary function

Correlation and
regression were
significant for diet
level (FOIS) and PEG
use.
Salivary function were
able to predict the
possible diet
outcomes, based on
FOIS levels.

Prediction of diet level
(Functional Oral Intake
Scale, FOIS) and PEG
use based on salivary
function

Chemoradiation
Treatment
Differences

Raddose (Total
Radiation Dose)

Hypothesis 2
The 1day/week group
had a wider range of
radiation dose when
compared to the high
Frequency (HF), Low
Frequency (LF), or
Current Common
Treatment (CTT)
groups.

(Table 61. Continued)
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Statistical/Clinical
Value
Combined exercise:
60% adherence to
minimize weight and
BMI change, 100% to
maximize diet levels
SLP-guided exercise:
70% to minimize weight
loss and 100% was
needed to maximize diet
level.
FOIS, p = .031
PEG, p = .027

Loss of salivary output
associated with FOIS 3
was 74.85%, loss
associated with FOIS 7
was 47.48%. FOIS 1
was associated with an
88.68% loss.
Loss of saliva associated
with PEG use was
83.25%.
p = .034
The range for all groups
met the minimum dose
associated with some
swallowing-related
radiation change.

Area of
Analysis
Diet and
Feeding Tube
Use

Variable

Description

Feeding Tube (PEG)
use

Correlation and
regression for PEG
use was significant
across the combined
High and Low
Frequency groups
(HF+LF), 1day/week
group, or Current
Common Treatment
(CTT) group, based
on group placement.
Regression for PEG
use and SLP-patient
contact time (number
of SLP-patient visits)
was also significant.
Prediction of PEG use
A prediction model
based on SLP-patient
was developed based
contact time
on the significant
relationship between
number of SLP visits
and PEG use.
Functional Oral intake
Diet level, based on
Scale (FOIS)
FOIS scores, was
significantly different
across groups. The
HF+LF groups had the
highest proportion of
patients on multiconsistency diets.
Feeding Tube (Peg) Use
Chemoradiation Chemotherapy
PEG users were more
Treatment
likely to receive
Differences
chemotherapy than
non-PEG users.
Diet
Functional Oral
FOIS level was also
Inventory Score (FOIS) consistently lower in
PEG users, and
expected finding.
(Table 61. Continued)

174

Statistical/Clinical
Value
p = .024

p = .029

13.258 visits or
approximately 2 SLP
visits per week were
predictive of no PEG
use.
p = .021

p = .002

p = ≤.000

Area of
Analysis

Variable

Description

Normalcy of Diet
(NOD)

Treatment
Toxicity

Aspiration Risk
and Swallow
Efficiency

Peg users had a
significantly lower
Nod level (liquids
only) compared to
non-PEG users.
Mucositis Score
Correlation and
regression were
significant for Nod
and PE.
Mini Nutritional
All subjects using a
Assessment-Short Form PEG were in a state of
(MNS-SF)
malnutrition compared
to 69.5% of non-PEG
users.
Penetration Aspiration
PEG users were more
Scale (PAS) repeated
likely to experience
measures design
aspiration, and this
aspiration was more
likely to occur with
pudding boluses
compared to thin
liquids.
Pharyngeal Constriction PCR and BRR were
Ratio (PCR) and
all significant with
Pharyngeal Residue
PEG users
Ratio (PRR)
experiencing greater
levels of residue and
reduced pharyngeal
efficiency.
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Statistical/Clinical
Value
p = ≤.000

NOD, p = .015
PE, p = .024

p = .020

Thin, p = .005
Pudding, p = .010

PCR, p = .009
BRR, p = .007

CHAPTER 7. DISCUSSION
The current study set out to investigate the effects of SLP-patient contact time on
immediate post-radiation swallowing outcomes for HNC patients receiving organ preservation
treatment. Swallowing function was assessed across physiological, functional, and QOL
measurements. In addition, organ preservation treatment-related toxicities were assessed for their
relationship to the observed swallowing outcomes. The study was conducted using 4 groups
totaling 102 total subjects: two prospective prophylactic behavioral swallowing exercise groups
(HF n = 15 and LF n = 15), a retrospective historical group (1day/week group n = 47), and a
retrospectively collected group (CTT group n = 25). There were no significant pre-radiation
differences across subjects’ demographics, tumor site and stage characteristics, cancer treatment
characteristics, swallowing function, swallowing physiology, or swallowing-related QOL. The
prospectively collected HF and LF groups also revealed significant pre-radiation to postradiation declines across all variables, except PAS (mean across bolus), revealing the expected
swallowing-related radiation effects. In addition to these group-based analyses, to fully explore
possible differences or relationships among subjects who received a PEG, post-radiation analyses
were also carried out between PEG users (+PEG n= 40) and non-PEG users (-PEG n=62).
Finally, a series of additional research questions were used to guide the analyses of various
behavioral swallowing intervention-related and cancer treatment-related relationships to further
understand the differences observed.
In summary, there were no observed differences across immediate post-radiation
swallowing-related physiology, function, or QOL between the HF and LF groups. A trend
toward higher diet level and diet-related QOL (NOD and PE scores) was noted but this did not
reach a level of statistical significance. There were no cancer treatment-related (radiation dose,
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use of chemotherapy, or missed SLP visits) differences between the HF and LF groups. The HF
group received 5 weekly SLP visits and the LF group received 3 weekly SLP visits. The study
hypothesis (Hypothesis 1) anticipated that the HF group would have significantly better postradiation outcomes compared to the LF group. The absence of any post-radiation group
differences for swallowing physiology, function, and QOL do not support this hypothesis. It
appears that 5-day per week SLP-patient contact time is not advantageous to post-radiation
swallowing outcomes, when compared to 3-day per week SLP-patient contact time. An
underlying rationale for Hypothesis 1 was that increasing the number of SLP visits would
increase the adherence of the patients to behavioral swallowing interventions. Previously
literature had indicated that increased adherence might lead to improved post-radiation
swallowing outcomes (34, 40). Differences between the HF and LF groups, based on adherence,
were observed but did not result in differences in swallowing outcomes (e.g., PEG use). In fact,
within the LF group, the patient with the lowest adherence for combined home-based and SLPguided exercise was 34.41%, and this patient did not receive a feeding tube. This level of
adherence is compared to 51.88% combined adherence in the HF group, also not resulting in
PEG placement. Despite these differences in group-based SLP-patient contact time and
adherence levels, PEG use, swallowing function, swallowing physiology, and swallowing-related
QOL were similar across the groups. Both 3 and 5 SLP-patient visits per week (HF or LF, 21-35
visits) are far greater than the 1 day per week or fewer weekly visits (CTT or 1day/week, 4-7
visits) of the remaining study groups. Therefore, due to the lack of HF and LF group differences,
the HF and LF groups’ data were pooled (HF+LF) into a new group (HF+LF, n = 30) for further
analysis of SLP-patient contact time. Further analysis of SLP-patient contact time was guided by
Hypothesis 2 to further explore the relationship with post-radiation swallowing outcomes.
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Hypothesis 2 analyses were performed using the newly formed HF+LF group, 1day/week
group, and CTT group data. While the analyses were completed for post-radiation swallowingrelated physiology, function, and QOL, the number of available variables was reduced by the
retrospective nature of the 1day/week and CTT groups. Statistical data were available for PEG
use, PAS scores, FOIS scores, and percentage of weight loss across all groups. However, QOL
data (MDADI scores) were only available for the HF+LF group and 1day/week group, limiting
comparison. In summary, findings of the analyses revealed a significant difference between
groups for PAS scores with both the 1day/week and CTT groups experiencing greater risk of
penetration or aspiration than the HF+LF group. Use of the PEG-related count/ratio data revealed
no statistical significance (chi square) between group differences for PEG use. However,
frequency distribution revealed clinically relevant differences based on PEG use among the
groups. Additionally, there was a significant correlation between group, SLP-patient visit
frequency, and PEG use. The HF+LF group experienced approximately one-half the frequency
of PEG placement compared to the 1day/week and CTT groups. The variations in PEG use
frequency also represented a relevant difference in total PEG-related healthcare cost among the
groups. These variations highlighted the potential to save significant healthcare dollars with the
reduction in PEG placements, in addition to the improved function and related QOL experienced
by the patients.
This clinical relevance in PEG use rates among these groups represented a significant
health care cost difference. The yearly cost associated with a new PEG placement has been
reported at $31,832 (265). Assuming a PEG is used for 1 year, the HF+LF group would have a
related cost of $222,824 compared to $413,816 and $636,640 for the CTT and 1day/week
groups, respectively. This reduction in PEG use yields a significant savings in health care
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dollars. In the original study by Virani et al. (24) the swallow exercise group eliminated all
feeding tubes by 3-months post-radiation. Of the $31,832 per patient reported by Callahan et al.,
approximately 25% ($7958) of the cost was associated with the enteral formula. Therefore, for 3
months PEG use, the surgical placement, associated hospital costs, and formula would be
approximately $25,864. Using this new cost and assuming that all subjects eliminate feeding
tube use after 3 months, the group costs are as follows: HF+LF = $181,048, CTT = $336,232,
and the 1day/week = $517,280. Even with the elimination of PEG use after 3 months, there are
still large health care cost savings associated with increased SLP-patient contact time. This
increased need for SLP-patient contact time raises questions about clinical feasibility and
caseload/workload. Do the SLPs in the cancer treatment facility or treating hospitals have the
time to provide at least twice weekly care per patient, and, if not, staffing must be increased to
meet this need. The American Speech-Language and Hearing Association (ASHA) reported that
the annual median salary of an SLP is $78,000 (266). Based on this salary 4.3 SLPs could be
employed using the cost savings associated with reduced PEG use between the HF+LF and
1day/week groups.
At the current study’s treatment site, the recommended intervention practice is suggested
to be 1 weekly SLP visit per patient. This is carried out by 2 fulltime and 1 part-time SLP, when
the site is fully staffed. If it is assumed that double the number of visits required doubling the
staff, then salary cost would increase by $195,000 using ASHA salary data. This is roughly the
same cost estimated for PEG use in the HF+LF group. However, each visit would generate
additional revenue as discussed in Chapter 3. Based on the reported reimbursement of $87.71
per day (141), twice weekly visits would increase the revenue generated by the SLP by $613.97,
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per patient. This additional revenue would further offset the cost associated with increased
staffing.
FOIS scores were also significantly different between the HF+LF, 1day/week, and CTT
groups. Frequency distribution for FOIS revealed that the 1day/week and CTT groups had
greater proportions of complete PEG tube dependence, based on FOIS level, when compared to
the HF+LF group. Greater levels of complete PEG dependence may be related to reduced
likelihood of or return to maintenance of a full oral diet following radiation (14). There were no
significant differences in QOL, based on MDADI, between the HF+LF and 1day/week groups.
The evaluation of the available data revealed differences between the groups based on aspiration
risk (PAS), PEG dependence, and oral diet levels (FOIS). The HF+LF group had consistently
better levels of the swallowing-related physiological and functional measurements, compared to
the remaining groups. These higher levels of swallowing-related outcomes support Hypothesis 2
indicating that higher SLP-patient contact time, when compared to 1day/week per week (7 visits)
or CTT (3-4 visits), is advantageous.
Comparison of the PEG dependent (+PEG) and non-PEG user (–PEG) groups revealed
between group differences for post-radiation swallowing-related physiology, function, and QOL.
There were no significant pre-radiation differences noted in any physiological, functional, or
QOL value available for all subjects. Use of repeated means analysis for the prospective groups
revealed statistically significant differences between +PEG and –PEG for both thin liquid and
pudding bolus types for PAS scores. PEG users exhibited higher risk of aspiration associated
with pudding boluses. In addition to PAS differences, there were statistically significant
differences for both pharyngeal constriction ratio (PCR) and pharyngeal residue ratio (PRR). The
+PEG group had significantly reduced pharyngeal constriction paired with significantly
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increased pharyngeal residue indicating poor swallowing efficiency compared to the –PEG
group. Reduced PCR and increased PRR resulted in higher a rate of aspiration in the +PEG
group. Statistically significant differences were also noted in nutritional risk (MNA-SF) and
normalcy of diet (NOD). The +PEG group’s MNA-SF scores placed 100% of PEG users in a
state of malnutrition, and NOD findings revealed that, when oral intake occurred, it was
restricted to liquids only, with only 1 subject tolerating any pureed solids. These findings
revealed significant underlying swallowing-related physiological, functional, and QOL
differences experienced by those subjects using a PEG. These are important findings which are
strengthened by the original statistical calculations performed for sample size, which indicated
these analysis would have the sufficient power to assess both Hypothesis 1 and Hypothesis 2.
Findings revealed underlying physiological challenges related to swallowing efficiency,
increased safety risks associated with more solid bolus material, and overall greater restriction of
diet with reduced QOL associated with PEG use. In addition, despite the use of PEG, PEG users
completed radiation in a state of malnutrition, based on the MNA-SF. While malnutrition was
also present for a portion of non-PEG users, all (100%) of PEG users reached a state of
malnutrition.
Further analysis found a statistically significant linear relationship between PEG use and
the SLP-patient contact time. This finding resulted in a prediction equation suggesting that 13.25
SLP-patient visits, or 2 visits per week during radiation treatment, are associated with reduced
likelihood of PEG placement. This prediction is a significant finding, having the potential to
change current radiation-related prophylactic behavioral swallowing treatment practices.
Overall, these findings indicated that PEG users experienced significant hardships and
reduced swallowing outcomes following radiation treatment. Findings also indicated that higher
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frequency of SLP-patient contact time, 3-5 visits or the predicted 2 visits per week, were
associated with reduced likelihood of PEG placements. While increasing the total number of
SLP-patient visits may be recommended, and does appear to further reduce risk of PEG
placement, we should not expect this to eliminate PEG use. In fact, the HF+LF group yielded 7
total PEG users. The proportion of PEG users in the current study’s prospective groups fell
within a similar range to other studies which also provided prophylactic treatment outline in
Table 6. This result highlighted that other remaining factors existed which resulted in PEG
placements that increased SLP-patient contact time did not overcome. The following sections
discuss, in detail, the study hypotheses and subsequent secondary research questions’ findings
and these findings’ relationships to the literature, where available.
7.1 Hypothesis Testing, High Frequency vs. Low Frequency
This study sought to investigate two hypotheses: Hypothesis 1, that higher SLP-patient
contact time (5 SLP-patient visits per week), compared to lower SLP-patient contact time (3
SLP-patient visits per week), would result in better immediate post-radiation swallowing
outcomes, and Hypothesis 2, that higher SLP-patient contact time (3 or 5 SLP-patient visits per
week), compared to lower frequency SLP-patient contact time (1 or fewer SLP-patient visits per
week), would result in better immediate post-radiation swallowing outcomes. Hypotheses 1 and
2 both examined the potential positive effects of higher SLP-patient contact time on postradiation swallowing outcomes across different levels of patient contact frequency. The 5-day
(HF) and 3-day (LF) treatment groups were combined (HF+LF) due to lack of significant
differences across any available outcome or treatment variables. Therefore, the discussion of
hypothesis testing examined the swallowing-related physiology, function, and QOL based on the
results of testing from Hypothesis 2 (HF+LF vs. 1day/week vs. CTT). This hypothesis was
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accepted based on the significant findings for between group comparisons across the HF+LF,
1day/week, and CTT groups. These findings illustrated a significantly lower aspiration risk score
(PAS), reduced PEG use, and higher diet levels (FOIS) among the HF+LF group.
Physiology
This study examined aspiration risk using the PAS scores as a mean across bolus types.
This methodology was used due to the retrospective nature of data collection for two of the three
groups used in this analysis. For the 1day/week group, PAS data were provided as a mean across
bolus types, thereby limiting other potential methodologies including repeated measures or
comparison by bolus type. While it might have been possible to obtain PAS scores for differing
boluses for the 1day/week group from the MBSS videos, these videos were no longer available
or were unusable for greater than 40% of these subjects. Additionally, the MBSS protocols for
both the 1day/week and CTT groups did not include the specific multiple trials per bolus needed
to perform a repeated measures analysis.
The PAS scores between groups in this study were significantly different (p = ≤.000).
PAS scores range form 1-8, with 1 indicating bolus material not entering the airway, 2-5
indicating penetration of bolus material into the airway, and 6-8 indicating aspiration of bolus
material has occurring (254). The mean data revealed that the HF+LF group had a lower risk of
penetration or aspiration risk compared to the 1day/week and CTT groups. The 1day/week group
experienced the greatest rate of penetration or aspiration. The mean data used in the analysis
represented a greater chance of penetration and that no group experienced a mean PAS level that
would indicate significant risk of aspiration. However, previous work has suggested that
potentially half of post-radiation dysphagic patients may experience aspiration, and that up to
44% of those aspirating may experience silent aspiration (6, 14). This discrepancy between the
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previous literature and what the current study’s mean PAS data highlights a limitation to the
interpretation of mean PAS data. For example, if 10 subjects experience aspiration (PAS level 8)
and 10 experience no penetration or aspiration (PAS level 1), then the mean PAS value would be
4.5, indicating a general risk of penetration despite no subjects experiencing penetration only. In
the current study, frequency distribution revealed that the HF+LF group had no occurrence of
aspiration using the combined bolus type data, while the 1day/week experienced 22.5%
aspiration, and the CTT experienced 8%. These available data suggested that aspiration occurred
in the 1day/week and CTT groups post-radiation, and fell within the previously described levels
(14). This finding also highlights the observed reduction in aspiration risk seen in those who
received more SLP-patient contact. Every subject within this study received prophylactic
behavioral swallowing intervention, which has been shown to decrease dysphagia risk postradiation including aspiration risk (14, 24). Each group had an aspiration risk that fell within, but
below, the possible rate of 50% aspiration. It is plausible that lower levels of aspiration may be
evident across each of the groups used in this study due to the prophylactic intervention;
however, only the HF+LF experienced no aspiration based on these data. Each group within the
current study also received the same exercise prescription reducing the potential for varying
exercise protocols influencing the results. This finding illustrates a significant decrease in risk
associated with the increase in SLP-patient contact time. However, the adherence to exercise
observed in the HF+LF group appears to be greater than that reported in the 1day/week group
(24) and the low adherence commonly reported in the previous literature (14, 25, 126, 151). In
addition the adherence level in the CTT group is unknown, and while exercises may be similar,
adherence cannot be ruled out as an influencing factor.
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Functional Outcomes
PEG use, FOIS, and percentage of weight loss were assessed across the HF+LF,
1day/week, and CTT groups to explore between group differences in functional post-radiation
swallowing outcomes. PEG data were provided as count (ratio) data and initial analyses, using
chi-square, and revealed no significant differences. However, when examining the count and
ratio of PEG use among the groups, there appeared to be a near doubling of PEG usage within
the 1day/week and CTT groups compared to the HF+LF groups. Percentage of PEG use is the
most effective way to compare these data due to the variation in group n number. Comparison of
the group ratio data revealed that the HF+LF group experienced about one half the rate of PEG
use compared to the 1day/week and CTT groups. This increased rate of PEG users constituted a
significant clinical difference despite the lack of statistical significance. A review of the available
literature revealed that post-radiation PEG use ranges from 20-73% (24, 25, 34, 36, 39, 51, 126,
128). These reported ranges vary based on time of data collection from immediately postradiation to 12 months post-radiation, or undefined timing. This variation in data collection
timing limited direct comparison of this study’s results with the previous studies. However,
previous work by Carnaby-Mann et al. (132) yielded the lowest rate of PEG tube use, 20%, and
was also the only other study to provide 5 day per week SLP-patient contact. The rate of PEG
use in the current study’s HF+LF group was similar to the findings of Carnaby-Mann et al.
(132), and the current findings appear to support the previous study’s findings that lower PEG
tube use is associated with increased SLP-patient contact time. Furthermore, the PEG data in this
previous study was collected immediately post-radiation, similar to the current study, and all
subjects participated in prophylactic swallowing exercise. Carnaby-Mann et al. (132) did not set
out to determine if specific SLP-patient contact times (e.g., 5 days per week) would result in
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lower PEG usage, but rather they wanted to assess a specific intervention approach. Their
findings did, however, highlight the potential relationship between interaction time and
swallowing outcomes. Additionally, there were differences between the current studies
behavioral swallowing exercise protocol and the Carnaby-Mann et al. study including the
exercise type and intensity. The current study appears to be the first to directly assess the
potential relationship between SLP-patient contact time and swallowing function post-radiation.
The current study did not cover all possible interaction times (e.g., 2 days or 4 days per week),
and further analysis of these data are warranted in future research. While this analysis comparing
between group outcomes revealed key differences based in SLP-patient contact time, further
analysis using regression revealed the potential impact of 2-day per week intervention. This
regression analysis was reported in Chapter 6. The potential of reducing PEG use through
increased SLP-patient contact is an important finding that will have long lasting implications for
patients’ post-radiation swallowing function and QOL. Furthermore, the previous literature has
also found that reducing PEG usage may result in a return to higher level diets post-radiation
compared to patients who received a PEG (14). The goal of any swallowing intervention is to
maintain the least restrictive and highest level oral diet possible, making SLP-patient contact
time an important variable to consider.
To further investigate the relationship between PEG use and SLP-patient contact time,
linear regression was used to build a predictive model for the number of SLP-patient visits
associated with no PEG use. This task was accomplished by inputting the number of actual visits
(e.g., 35, 18, 7, and 4 visits) into the model, instead of inputting the group placement. The use of
the actual visit count allowed for the prediction of an exact number of visits and was necessary,
due to the variation in actual visits days, within the HF+LF group. The statistically significant
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bivariate relationship and statistically significant linear regression analysis made this prediction
possible, and to the best of the author’s knowledge, this relationship has not been demonstrated
previously in the literature. The outcome for the prediction indicated that 13.25 SLP-patient
visits were associated with an expected outcome of no PEG use. This result means that 2 SLPvisits per week during the 7 weeks of radiation may be sufficient to further reduce the risk of
PEG placement during radiation. While this predicated SLP-patient contact time is less that the
21 visits possible in the original LF 3-day per week group, it represents a substantial increase
when compared to the current typical SLP-patient contact times recommended for HNC
population. In the current study, the 1day/week group experienced 43.5% PEG use immediately
post-radiation, nearly doubling the HF+LF PEG use. This 1day/week group, taken from a
previously completed prophylactic exercise study, was comprised of an exercise group receiving
the same exercises at similar levels to the current study’s HF+LF group, and a group which
performed additional daily swallows as exercise (238 additional saliva swallows per day) (24).
However, this group’s exercise difference does not appear to limit the direct comparison between
this study’s groups because the original study by Virani et al. (24) found no immediate postradiation differences in PEG use between the original study groups. There were noted differences
3 months post-radiation between the original Virani et al. groups; however, some caution should
be used with any future comparison of follow-up data that may be collected from the current
study.
Finally, regarding the PEG outcomes of the current study, it is apparent that, while the
predicative equation finds that approximately 2 weekly SLP-visits result in no PEG, the HF+LF
group does, in fact, have 23.3% PEG use. This continued PEG use illustrates the many possible
factors that may result in PEG use, and highlights that SLP visit frequency is only one of many
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other factors that may be affecting PEG risk. Given that many factors (e.g., nutrition, weight,
toxicity, desire) may change during radiation treatment, having a positive or negative effect on
the potential of PEG use, other factors must be considered. However, the current study’s data
suggest that SLP-patient contact time represents a highly important factors related to PEG use.
Another factor that was apparent in the current study’s comparison of PEG users to non-PEG
users was the relationship with chemotherapy use. The relationship between chemotherapy,
dysphagia has been established previously established and summarized in Table 4.
Chemotherapy alone is not expected to result in dysphagia, but may exacerbate treatment
toxicity. The statistically significant difference between groups, indicating greater chemotherapy
use among PEG users highlighted the likelihood that greater treatment toxicity resulted in PEG
use. In fact, the current study’s HF+LF group rationale for PEG placement was consistent with
toxicity-related factors (e.g., uncontrolled severe nausea) for all 7 PEG placements. In the future,
models including path analysis may also help explain the underlying relationship that may exist
between SLP-patient contact time and PEG outcomes (e.g., impact on adherence to exercise,
nutrition, patient education, use of oral hygiene). At present, path analysis is not possible as these
types of data are not available for the current study’s groups.
FOIS data was examined as both mean data across groups and by using frequency
distribution. Initial examination of the mean data revealed similar FOIS scores across the study
groups. Examination of the distribution of FOIS scores, however, revealed a greater percentage
of subjects who were totally PEG dependent, with no oral intake, in the 1day/week and CTT
groups compared to the HF+LF group. Within the HF+LF only 1 of 7 subjects who received a
PEG was totally PEG dependent. Results of the HF+LF group were similar to the median FOIS
of 5 reported by Carnaby-Mann et al. (132) who also had similar PEG use outcomes compared to
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the HF+LF group of the current study. FOIS levels 4 and 5 represent restrictive diets, but no
feeding tube dependence. In comparison, the 1day/week and CTT both have a median FOIS of 3
representing some feeding tube use, but not total dependence. Hutcheson et al. (14) reported that
maintaining higher diet levels during radiation is important to future diet level or maintenance of
diet level post-radiation. It was reported that, if patients maintained full oral diets during
radiation, they were twice as likely to return to a full oral diet as those using a PEG at any level.
Having partial oral intake resulted in greater likelihood of return to a full oral diet, as well, but
the odds ratio was not significant. This finding highlights the significance of FOIS scores within
the current study. The HF+LF group had 97% of patients consuming full oral or partial oral diet.
While the HF+LF group still experienced PEG use, only 1 of these subjects was completely PEG
dependent increasing the likelihood that more of these subjects will return to and maintain a full
oral diet post-radiation. These findings indicate that higher frequency treatment resulted in
increased maintenance of oral intake, despite PEG use, and increased the likelihood that these
patients will return to full oral diets.
Weight loss during radiation is a constant concern as an indicator of overall nutrition.
Weight loss-related findings have previously been summarized in Table 7. It is often cited a
predictor of PEG tube placement (20, 35, 163, 164). In addition, weight loss and malnutrition are
predictors of overall mortality within the HNC population (155), and thus are important variables
to consider when assessing group characteristics. The treatment site for the current study, Mary
Bird Perkins Cancer Center, sets a 10% weight loss threshold for all HNC patients. Losing 10%
or more of the pre-radiation body weight results in a recommendation of PEG placement.
However, 10 subjects in the current study’s HF+LF group fell below this threshold and not all
received a PEG, and none of the 7 PEGs was placed due to weight loss. Four PEG tubes were
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placed due to poorly controlled severe nausea and vomiting lasting more than 1 week. Two PEGs
were placed due to refusal to maintain a full liquid diet and subjects reporting a horrible mouth
taste/feel. One PEG was placed due to patient reporting severe oral pain. The retrospective nature
of the remaining groups prevented this detailed understanding of group-related PEG tube
placement rationales. However, all groups had a mean weight loss percentage of less than 10%
and no statistical significant differences emerged. The range for the HF+LF group was -19% to
+1.0%, and 33% of subjects lost more than 10% of their pre-radiation weight. This level of
weight loss is again consistent with Carnaby-Mann et al. (132) who reported 28% of subjects lost
more than 10% of their pre-radiation body weight within their exercise group receiving 5 weekly
SLP visits. Within the current study, weight loss means fall within acceptable limits across all
groups and SLP-patient contact time does not appear to directly influence weight loss.
Despite the maintenance of weight seen within study groups the MNA-SF data obtained
in the prospective study groups demonstrated high levels of malnutrition. The levels of
malnutrition illuminated the negative effects of the cancer-related curative treatments. The
MNA-SF accounts for weight loss, diet changes, diagnosis, and BMI. It appears to be
highlighting factors related to risk of malnutrition that weight loss and BMI alone do not account
for alone. These results indicate that previous literature relying on percentage of weight loss or
BMI changes may be underestimating the nutritional risk experienced by chemoradiation
patients.
Quality of Life Outcomes
It was an original intent of this study to assess QOL across all groups. However, as
discussed within the previous chapter, the retrospective nature and EMR-related changes resulted
in no usable QOL data for the CTT group. For the HF+LF and 1day/week groups, MDADI
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patient-generated data were available. Additional SLP-generated QOL measures were obtained
for the HF+LF group, but were not able to be used within this analysis. It has already been
established that a change of 10 points within the composite score of the MDADI represents a
clinically relevant change (264). Analysis revealed no significant difference and scores remained
within a 10-point range between groups and thus also constitute no clinically significant
difference. It is already known that a higher radiation dose is associated with lower QOL scores
using the MDADI (8). As previously discussed in Chapter 6, there was a significant difference in
total radiation dose between the treatment groups. This difference may explain the small
variation in scores resulting in a slightly higher QOL observed within the 1day/week group;
however, it remains non-significant. Based on the lack of any significant findings it does not
appear that SLP-patient contact time influences subject QOL. However, all subjects in the
current study did experience significant declines in QOL, based on MDADI data. This was an
expected outcome and the increased severity across the groups may also be related to the high
proportion of stage III and IV cancers within the study groups. Higher cancer stage, in addition
to the total radiation dose, has been linked to greater decline in QOL, based on the MDADI (78).
This may further explain the lack of between group differences; however, the lack of differences
are consistent with previous studies that did not find differences among QOL, based on MDADI
scores, immediately post-radiation Mann (126, 128, 132).
7.2 +PEG compared to –PEG
Assessment of PEG tube (+PEG) and those who had no PEG tube use (-PEG) revealed a
total of 40 subjects in the +PEG group and 62 in the –PEG group. No differences in total
radiation dose were observed, and both groups had similar ranges of radiation dose. Tumor site
and stage were also not different between the groups. The use of concurrent or neoadjuvant
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chemotherapy was significantly different between the +PEG and –PEG groups, as previously
mentioned. The +PEG group had significantly greater use of chemotherapy. It has already been
determined in previous literature that chemotherapy alone does not result in dysphagia (67, 79,
81). However, chemotherapy may result in more significant toxicity or exacerbate the effects of
radiation (67, 79, 81). This difference in use of chemotherapy did not limit the ability to make
between group comparisons, but rather shed light on the rationale for PEG placement. Within
this study’s HF+LF group all PEG placement had a placement rationale associated with cancerrelated treatment toxicity (e.g., nausea or pain). The between group comparison for +PEG and
–PEG revealed significant differences across post-radiation related physiology, function and
QOL. It is plausible that subjects’ perception of toxicity-related difficulty was influenced by
these underlying toxicity characteristics, and that their reported rationale for PEG placement
represents this perceived toxicity and not the underlying etiology. This finding, along with
previously discussed findings related to ongoing PEG use, despite patients receiving high
frequency SLP-patient contact time, illustrated the need to promote ongoing research to limit the
effects of chemotherapy and radiation-related toxicity.
Physiology
There was no significant difference found between the +PEG and –PEG groups for PAS
mean across bolus types. PAS repeated mean differences for thin and pudding bolus types,
pharyngeal constriction ratio (PCR), and pharyngeal bolus residue ratio (PRR) did show
significant differences, based on PEG use. Repeated measures analysis for thin liquid bolus type
revealed greater risk of aspiration in the +PEG group compared to the -PEG group. For pudding
bolus type, repeated measures analysis revealed the same pattern with the +PEG group having
greater risk of aspiration when compared to the -PEG group. Further investigation using
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frequency data revealed that the +PEG group experienced greater levels of penetration/aspiration
for both thin and pudding compared to the -PEG group. The –PEG group did experience
aspiration for one subject, but it was well controlled with swallowing maneuvers (e.g.,
supraglottic swallow). Overall, aspiration risk was low, despite PEG use, and all patients had
recommendations for thin liquid consumption. One patient did refuse any oral intake due to taste,
and was thus considered fully PEG dependent; however, MBSS findings revealed that this
patient was capable of safe oral intake. Further examination of the count data for aspirationrelated trials revealed only four episodes of aspiration, with pudding bolus type only, in the
+PEG group. Count data for the -PEG group revealed 2 episodes of aspiration for thin bolus type
and 2 episodes of aspiration for pudding bolus type. These data highlight the overall low rate of
aspiration across both the +PEG group and the -PEG. Differences between aspiration rates, based
on bolus type, also highlighted the potential predictive ability of differing bolus types for PEG
placement. The level of aspiration observed using these repeated measures designs was below
the previously reported level of aspiration, ranging up to 50% for patients who experienced postradiation dysphagia (6). Aspiration risks are often cited as a possible primary rationale for PEG
placement (26, 67, 97, 98). In the current study, based on the available prospectively collected
data, there appears to be no clinically relevant difference between the occurrence of aspiration
between PEG users and non-PEG users. In fact, examination of the original raw data revealed
that the 2 occurrences of aspiration for thin liquid bolus type observed in the -PEG group
occurred within the same subject. These data appear to support the finding that other factors,
including radiation-related toxicity, resulted in the PEG placement, rather than observed
significant aspiration risk. These PAS data appear to highlight the increased poor efficiency
observed in subjects who received a PEG. The greater occurrence of penetration that required
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clearance of the airway and/or resulted in observable post-swallow residue demonstrated the
greater changes in swallowing efficiency when compared to non-PEG users. It is important to
remember, however, that these are immediate post-radiation finding. They do not predict the
potential for aspiration risk or dysphagia post-radiation. Recent findings of Hutcheson et al.
(267) reveal that the two-year post-radiation aspiration prevalence is low, 8.6%. Overall
dysphagia rates were reported to persist at 45.3%, and prevalence was highest in subjects
receiving dual or tri-modality treatments (e.g., chemoradiation, or chemoradiation + surgery).
These findings reveal the potential for both underlying physiological deficits and interactions
with the original treatment modality. Any future follow up data from the current study must
account for the original group characteristics and consider the impact of different bolus
materials. The current study appears to be the first to assess different bolus materials using the
repeated method design and highlights the significant impact that accounting for bolus type and
multiple trials have on the analysis outcomes. Using mean data across bolus types yielded
consistent limitations and failed to fully explain the observed between group differences.
The pharyngeal constriction ratio (PCR) was also observed to be significantly different
between the groups (p = .009). The PCR is a measurement of total pharyngeal constriction
observed at the point of maximum constriction during the swallow. A lower PCR indicates a
greater and more efficient constriction when compared to a larger PCR. The mean PCR observed
in non-PEG users was 13.29% compared to 41.9% in the +PEG group, for thin liquid bolus type.
This mean PCR level represents a significant difference in overall swallow-related efficiency
observed in subjects who received a PEG. Simply put, patients did not squeeze the thin liquids
from the pharynx adequately, resulting in residue. Pharyngeal constriction ratio was not
significantly different between these groups based on pudding bolus. This represented an
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interesting difference based on bolus type. It is plausible that underlying sensory changes and the
ability to perceive the bolus weight resulted in the significant lack of constriction observed in
thin, but not pudding bolus types. Another factor may include the bolus size difference, but based
on the data collection methods no specific conclusion can be drawn for the bases of this bolusrelated difference.
Mean data for PCR is available, based on work by Leonard Kendall (99, 252), which
found a PCR level of 3% for a 5ml bolus and 5% for a 20ml bolus. While these bolus sizes are
not directly comparable with the 10 ml thin bolus size used in the current study, they do highlight
the significant changes in PCR levels observed in all prospectively treated subjects. However,
the degree of change observed in subjects who received a PEG placement remains significantly
greater than that of subjects with no PEG. It remains unknown if this significant change in PCR
value attributed to the need for PEG placement, or if the use of PEG paired with a reduced levels
of oral intake, resulted in greater decline of pharyngeal constriction in swallowing efficiency.
Feeding tube use, PEG, has been shown to result in declines of upper esophageal sphincter
function (67). Additionally, as discussed previously in Chapter 3, muscle disuse atrophy
associated with reduced oral intake and use of the swallowing mechanism may possibly result in
greater decline in swallowing-related physiology (67, 105).
Pharyngeal residue ratio (PRR) was also observed to be significantly different between
PEG users and non-PEG users (p = .007). For thin liquid bolus type only, the -PEG group
exhibited a PRR of 2.11% compared to 6.31% for the +PEG group. Pharyngeal residue ratio
illustrates the amount of pharyngeal bolus residue observed after the completion of a swallow
(259). In a normal swallow, no pharyngeal bolus residue is expected. This variable is a newer
swallowing displacement measurement suggested and developed by Leonard (259). While this
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measurement highlights the change in swallowing-related efficiency observed in both non-PEG
users and PEG users, the +PEG users had significantly greater residue levels. Examination of the
range of PRR for both groups also revealed that subjects within the +PEG group experienced up
to 14% residue compared to only 3.4% residue in the most severe -PEG subject. PRR findings
paired with PCR findings highlighted the significance of decreased swallowing efficiency in
PEG users. However, similar to PCR, it is unclear if the higher levels of residue observed in the
+PEG group were evident prior to PEG placement or occurred secondarily. Additionally, PRR
levels were only significant for thin liquid bolus types and not pudding bolus types. The same
pattern was observed in PCR outcomes. It also remains unclear what underlying mechanisms are
contributing to the bolus-related differences in PRR. PRR levels of pudding did increase for
both PEG related groups, with the +PEG group experiencing a greater level of residue compared
to the -PEG group. Thus, a similar pattern was observed, which may reflect a clinical difference
between these groups, despite the lack of significance in the statistical analysis. Clinical
significance related to these displacement measurements is not known at this time, and the
available normative data were based on thin liquids only, limiting further examination of these
data. These findings also highlighted that differing bolus types may yield different outcomes, and
care should be taken when interpreting these physiological measurements.
No other physiological timing or displacement measure was significant between these
groups. Additionally, tongue-to-pallet pressure measurements were obtained across each patient
during the prospective data collection. Data were collected for the anterior and posterior tongue
placements. The percentage of tongue-to-pallet pressure change was measured using the preradiation and post-radiation levels. There were no observable differences between the +PEG
group and the -PEG group. Previous work by Carnaby-Mann et al. (132) has suggested that
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muscle loss of the posterior tongue base is expected during radiation therapy. While there were
no significant differences between patients with or without PEG, there was a noted decline in
posterior tongue-to-pallet pressure. The +PEG group lost 53.19% and the -PEG lost 58.08% of
total tongue-to-pallet pressure during the course of radiation therapy. This difference appears to
constitute a significant clinical decline, and may attribute to overall decreased swallowing
efficiency. However, great care should be taken when trying to interpret these tongue-to-pallet
pressure measurements. These measurements were obtained weekly using the SwallowSTRONG
system, which relied on an intra-oral mouthpiece placement. A recent study, published since the
initiation of the current study’s protocol, illustrates the impact of subject-related mouth pain on
the reliability and validity of these pressure readings (268). This previous study utilized the Iowa
Oral Pressure Instrument, which has a similar intra-oral placed bulb to obtain tongue-to-pallet
pressure measurements. It was suggested that ratings occurring after the fourth week of radiation,
when the pain levels typically increase, should be used with great caution. Within the current
study, significant difficulty was observed when attempting to obtain final tongue-to-pallet
pressure measurements following the completion of radiation. Some subjects refused to perform
the procedure necessary to obtain these measurements, at times, due to the significant mouth pain
they were experiencing. Therefore, while there appears to be a trend of reduced tongue-to-pallet
pressure, there appear to be underlying factors (e.g., pain) other than muscle loss which
contribute to the observed reduced pressure values.
Additionally, there was also an observed decline in anterior tongue-to-palate pressure
across both groups. This pressure measurement did not reach the same degree of decline
compared to the posterior placement, and represented a loss that was approaching 50%. This is
an important finding, despite the potential limitations as discussed above, because it illustrated a
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difference based on placement. The previous work by Carnaby-Mann et al. (132) observed
radiation-related posterior tongue atrophy, which this study has also identified as a structure at
risk during radiation. Work by Lazarus et al. (133, 269) has illustrated the importance of tongue
strength and tongue-based exercise in the dysphagia population. Findings of the current study
suggest that not only does the tongue base atrophy during radiation, but that the more oral and
anterior tongue is also affected. We have already acknowledged the importance of selecting
tongue exercises that are evidence-based, but current findings demonstrate the importance of
assessing the anterior and posterior tongue function/strength.
Functional Outcomes
Functional swallowing outcomes included FOIS, percentage of BMI change, percentage
of weight loss, and nutritional status using the MNA-SF. Only FOIS data were available for all
subjects (n = 102). FOIS scores illustrate the subjects overall diet level, as previously discussed.
Differences between the +PEG group and -PEG group were highly significant (p = ≤.000). This
finding was expected, illustrating the effects of PEG use on FOIS data. FOIS scores 1-3
represent some level of PEG use, while FOIS scores 4-7 represent levels of non-PEG use, so
patients with PEGs will always score lower. The mean FOIS score of the non-PEG users
represented a diet level consistent with intake of a single consistency (e.g., full liquid) or
multiple consistencies requiring special preparation (e.g., liquids and puréed foods). The FOIS
scores of the +PEG group indicated only minimal oral intake, but failed to capture the variations
in oral diet. While there was a decline observed in an overall diet level in both groups, the PEG
dependence in the +PEG group automatically reduced the FOIS level. This measurement fails to
adequately assess the scope of diet and consistency that may be orally consumed by subjects who
maintain oral intake while also using a PEG. Given the low occurrence of aspiration and
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previously reported rationale for PEG placements in the prospectively collected groups, it
appears unlikely that patients are routinely made NPO (nothing by mouth). Therefore, an
additional method of data collection was used to further explore diet-based differences within
these PEG use groups. Other methods of assessment, including the Performance Status Scale for
Head and Neck Cancer Normalcy of Diet (NOD) subsection, used in this current study helped
shed light on further differences in diet level based on these groups. These FOIS-related findings,
however, remain important due to the known relationship between full oral intake during
radiation and post-radiation diet level maintenance (14). NOD data from the original HF and LF
groups (n = 30) revealed that diets in the +PEG group ranged from complete PEG dependence to
intake of thin liquids and puree foods. Non-PEG users were able to maintain diet ranging from
full liquid to soft solids, with over 50% maintaining some form of solid food intake. These
finding demonstrate the importance of varied data collection methods to assess diet across the
HNC population. Findings for NOD also show the greater reduction in diet faced by PEG users
(n = 7). While the underlying physiology causing these differences remains unclear, it is apparent
that patients who receive a PEG exhibit more disruption to their swallow ability.
Subjects’ nutrition levels, based on the MINI Nutritional Assessment Short Form (MINISF) taken from the original HF and LF groups (n = 30), were also significantly different and
continue to highlight the difficulty faced by those using a PEG. Findings indicated a greater
nutritional risk associated with patients who received a PEG. Further assessment of the
nutritional risk data using frequency distribution revealed that 100% of subjects who received a
PEG were considered in a state of malnutrition. This level is compared to 69.5% in a state of
malnutrition and 30.5% at risk for malnutrition in patients who did not receive a PEG. The levels
of malnutrition faced by both groups illuminated the negative effects of the cancer-related
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curative treatments. Nutritional status was remarkably worse in patients who received a PEG.
This malnutrition persisted despite the ability to circumvent the radiation-affected structures.
Furthermore, these patients had access to a dietitian during the entirety of radiation treatment and
were unable to maintain adequate nutrition. The burden of care and associated toxicity appeared
to be overwhelming to many patients. The taste changes and mouth pain they experienced were
only marginally controlled through oral hygiene techniques (baking soda and salt washes,
lidocaine rinses) and pain management (narcotic medications). The current study’s findings are
consistent with previous findings that show continued weight loss or poor retention of weight in
patients using a PEG (165, 168, 172). Additionally, continued malnutrition and weight loss are
associated with greater likelihood of chronic dysphagia and continued PEG use, reduced healing,
and continued muscle atrophy (167, 170, 177). While these are grave concerns for PEG users
these factors cannot be overlooked for all HNC patients.
There were no significant differences between the +PEG and -PEG groups (n = 102) for
percentage of BMI change or percentage of weight loss post-radiation. Lack of significant
findings related to weight loss, paired with the significantly greater risk of malnutrition observed
in patients who received a PEG, are important findings. This finding for weight loss appears
consistent with previous literature which has found that feeding tube use does not appear to
prevent weight loss in patients undergoing radiation for head and neck cancer (165, 170). Within
the current study, the 7 patients who received a PEG were struggling to maintain oral intake
despite to nausea, vomiting, pain, and/or poor desire for available oral intake options. While the
placement of a PEG provided an alternative means to supply nutrition, hydration, and
medications, it did not guarantee weight maintenance or gain. These findings illustrate that while
the PEG may have prevented further decline, including potential death, it was insufficient to
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reverse the patients’ overall nutritional status by the end of radiation treatment. This continued
nutritional risk highlights the importance of further investigation into methodologies to reduce or
eliminate cancer treatment-related toxicities. Despite the reduced number of PEG placements
observed in the higher SLP-patient contact time groups within this study, PEG placements were
still observed. Further reduction of treatment-related toxicity may have the potential to reduce
further PEG placement or improve the overall nutritional status of head and neck cancer patients
immediately post-radiation.
Quality of Life, QOL, Outcomes
Quality-of-life data (QOL) included the MDADI which was available for all groups (n =
102), and NOD, PE, and CFS which were available from the prospective HF and LF groups (n =
30). There was no statistically significant difference between groups, based on MDADI. Both the
+PEG and -PEG groups experienced an overall decline in MDADI measured QOL, and both fell
within a 10-point which groups range indicating no clinically relevant differences. This result
indicated that while subject-reported quality-of-life was reduced, it was not negatively impacted
by feeding tube use. This is consistent with previous findings discussed in this chapter.
The remaining QOL variables were only available for the two prospectively collected
groups. As previously discussed, NOD, which is an SLP-generated quantification of QOL
associated with subject tolerance and acceptance of various diets, may help further explain diet
level based on group differences in subjects using a PEG. The NOD assesses the highest
tolerated diet level, and therefore does not automatically reflect a reduced score resulting from
PEG use. NOD outcomes were highly significant (p = ≤ .000). It has been suggested that scores
below 50 represent a moderate to severe impairment (270). Both groups experienced a decline in
overall NOD level. The -PEG group consumed warm or cold liquids and puréed foods. The
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+PEG group had acceptance of only cold liquids. This difference in tolerated diet highlighted a
difference between those who are PEG dependent and those who maintained normal full oral
intake. This finding also highlights that subjects who received a PEG, but continued some oral
intake, were primarily only accepting cool or cold liquids. Only one of the 7 PEG-dependent
subjects declined to continue any oral intake (full PEG dependence). This patient received a PEG
because he declined to drink Boost, the commonly recommended liquid nutritional supplement
used at the treatment center. This subject’s refusal was based on a reported significant change in
taste and inability to tolerate the taste/flavor of this product or any product supplied by the cancer
center’s dietitian. The remaining 6 subjects were consuming the Boost product, as tolerated, by
mouth. The ability of subjects receiving a PEG to maintain some level of oral intake has
previously been suggested to increase the likelihood that they will return to full oral intake in the
future (14), making the outcome for the +PEG and -PEG groups highly important, despite the
observed group differences. Unfortunately, the level of oral intake based on NOD was not
available for the retrospective groups used in this current study. The oral diet level associated
with PEG users is also not well represented in the current literature, limiting the ability to make
comparisons. This highlights the need for future studies to use multiple methods of data
collection to provide a clearer picture of patients’ diets and eating ability post-radiation.
No significant differences were observed in the remaining variables for public eating
(PE), an additional subtest of the Performance Status Scale for Head and Neck Cancer, and the
Cancer Fatigue Scale (CFS). These data were taken from the original HF and LF groups (n = 30).
While subjects in both the +PEG (n = 7) and –PEG (n = 23) groups exhibited a decline in scores
for PE and an increase in the overall level of fatigue, there appears to be no relationship between
these variables and PEG placement. These declines are consistent with the previously discussed
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decline observed with the MDADI and highlight the significant difficulty faced by all head and
neck cancer patients undergoing radiation with or without chemotherapy. The previous literature
has often discussed patient report of cancer treatment-related fatigue as a potential rationale for
swallowing-related declines (26, 67, 97, 98). However, this current study does not find that
cancer-related fatigue significantly affected subject-related outcomes for feeding tube use.
Overall, feeding tube use appears to be associated with several factors: increased risk of
penetration/aspiration, reduced overall swallowing efficiency associated with reduced
pharyngeal constriction, increased pharyngeal residue, and impaired or reduced desire for dietary
intake. However, feeding tube use does not guarantee the patient’s ability to maintain nutrition or
prevent a state of malnutrition, which is the primary goal of feeding tube placement.
7.3 Assessment of SLP-Patient Contact Time and Exercise Adherence
One secondary goal of the current study was to determine if SLP-patient contact time
would have an effect on subjects’ adherence to the behavioral therapy exercises prescribed
during prophylactic treatment, while undergoing radiation therapy. To assess this relationship,
adherence rates to the prescribed exercise were tracked weekly for both the home-based and
SLP-guided exercises. These weekly data were used to generate mean adherence levels for the
original high-frequency (HF) and original low frequency (LF) groups over the course of
prophylactic swallowing intervention. Findings revealed that the HF group had statistically
significant differences maintaining higher levels of exercise adherence when compared to the LF
group. This difference occurred despite both groups receiving identical swallowing exercise
routines. The only difference occurring between these two groups was the number of SLP visits
received. The HF group did perform two additional days of exercise with the SLP each week;
however, the amount of exercise provided by the SLP per session remained the same despite
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group placement. Additionally, the level of adherence was analyzed based on the proportion of
possible exercise completed, based on group placement. Assessment of these proportional data
eliminated the variations in exercise amounts per groups as a rationale for differences in
adherence levels. The adherence to the SLP-guided exercise for the HF group was 89.96% and
the LF group was 80.61% of the total possible exercise. A wider gap in exercise adherence was
observed in the home-based exercise with the HF group performing 68.07% and the LF group
performing 49.6% of the total recommended home-based exercise. These adherence levels
resulted in a total combined home-based and SLP-based exercise adherence of 79.01% for the
HF group and 64.89% for the LF group. Examination of the weekly percentages of adherence
provided in Figure 8, Chapter 6, shows that the LF group had consistently lower adherence after
the third week of radiation. One plausible rationale for the increased adherence noted in the HF
group is increased opportunity for education or re-education, and motivation from the SLP. The
overall mean combined adherence level in this current study for the HF group is consistent with
the previous adherence level reported by Carnaby-Mann et al. (132). This previously reported
research is supported by the current study’s finding that increasing SLP-patient contact time does
result in increased adherence. Additionally, previous feasibility studies have shown that homebased exercise programs have achieved only 27% adherence, highlighting the greater adherence
achieved in the home-based exercise in the current study (235). A recent study (151) also
highlighted that patients reported poor adherence associated with forgetting to do exercise. This
study was assessing the feasibility and potential impact of a mobile application to interact and
track progress with exercise. One way to ensure that patients do not forget to exercise, and also
ensure accuracy of exercise tracking, is to increase the interaction with the SLP. This is a likely
reason for consistently better adherence in the HF group. Patients cannot forget when being
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actively coached by the SLP, and the data gathered for the analysis of between group differences
may be more consistent. However, the percentage of possible home-based exercise was also
consistently higher in the HF group. This higher adherence may be due to more frequent
reminders or motivation factors. These findings highlight the importance of SLP-patient contact
on adherence to exercise.
Previous work has outlined the factors that may influence patient adherence including
self-efficacy, heath literacy, adequate educational opportunity, and adequate opportunity to
practice (43). These are the motivational factors available to the patients in higher frequency
SLP-patient contact time. Recent preliminary work has demonstrated the potential benefit of
higher frequency interactions and incorporation of these motivating factors into dysphagia
treatment (47). While this work is not directly comparable to the current study because it targets
chronic dysphagia 5 years post-radiation, it does highlight similar findings including improved
swallowing-related outcomes associated with higher frequency/intensity treatment methods. The
authors have yet to publish the related adherence data, so no comparison was made the current
study’s adherence levels.
A comparison of the current study’s levels of adherence to the previously reported
adherence level of the 1day/week group from Virani et al. (24) revealed a contrast in adherence
levels. Mean data of the subjects in the original 1day/week group reveal that subjects never
achieved adherence levels above 80%, and, while declines in adherence did not appear to occur
until after the third week, similar to the current study, these levels of adherence fell more sharply
and further than the current study’s groups did. The mean adherence level for the subjects taken
from Virani et al. (24) appeared to be at or below 30% adherence at the end of treatment for all
exercises. This adherence level is compared to means above 40% for the LF group and above
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50% for the HF group in the current study. Differences in the data collection methodology used
between the current study and the previous study completed by Virani et al. (24) prevented direct
comparison of adherence outcomes. Virani et al. (24) relied on a single patient completed
tracking log and allowed for estimation of completed exercises if patients failed to completed
forms. The current study used both an SLP-completed form and patient-completed form to track
exercise completion. Additionally, for the current study there was a specified amount of exercise
per session for both home and SLP-guided exercise, while Virani et al. recommended 50% or
more during their single weekly SLP visit. Differences in data collection methodologies for
exercise treatment adherence are common in the current available literature (235). Future studies
should strive to track adherence across all exercises and exercise environments to further explain
relationships between treatment factors in adherence outcomes. Despite the inability to make
direct comparisons, the outcomes of this study indicate that exercise adherence is influenced, at
least in part, by the frequency of SLP-patient contact.
7.4 Assessment of Adherence on PEG Use, Physiology, Function, and QOL
An additional goal of the current study, based on adherence, was to explore the potential
implications of adherence level to PEG use, swallowing physiology, function, and QOL. It has
been suggested that increasing subject adherence to prophylactic swallowing exercises may
improve overall post-radiation swallowing outcomes (44, 235). The current study’s author noted
a difference in adherence levels between the HF in the LF groups. However, it has already been
determined that there were no between group differences related to any swallowing outcomes.
While both groups yielded statistically different total adherence levels, it is also noted that they
had similar SLP-guided exercise levels and both groups had greater home-based adherence than
has been reported previously in the literature (24, 235). To further explore the potential impact of
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adherence on swallowing-related outcomes, 2 new groups were developed based on low
adherence and high adherence levels. Previous literature has suggested that levels of adherence at
or above 80% are considered high (41); however, due to the generally high level of observed
adherence in the current study, division using 80% did not yield well-balanced groups. The mean
level of adherence for total combined exercise across all study subjects from the original HF and
LF groups was 88%. Groups were divided into high adherence and low adherence using this 88%
cut off, and this yielded 2 well-balanced groups of 15 subjects each. The HF group had 9 high
adherence patients and 6 low adherence patients. The LF group had 6 high adherence patients
and 9 low adherence patients.
Initial comparison of grouping revealed significant differences in NOD and PE scores.
These results indicated that subjects with the highest adherence achieved a higher diet level,
consuming liquid and puréed foods, compared to a liquid-only diet in the low adherence group.
These results also indicated that high adherence subjects felt comfortable eating in a wider
variety of situations resulting in fewer eating environment-related restrictions compared to low
adherence subjects. These findings suggest that adherence level is related to subjects’ overall diet
level, and related QOL.
No additional statistically significant differences were found among the physiological,
functional, or remaining quality of life variables. Feeding tube use revealed no difference
between the low adherence group, which had 4 PEG placements and the high adherence group,
which had 3 PEG placements. Mean data for diet level (FOIS), weight, nutrition, and aspiration
risk were similar across levels of adherence.
Given that the intent of the current study was to explore not only differences but also
relationships between adherence levels and swallowing-related outcomes, correlation and
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regression were then used to further assess adherence levels’ impact on swallowing. Initial
correlation analysis was performed for all three exercise adherence environments (SLP-based,
home-based, and combined) and feeding tube use, aspiration risk, diet level (FOIS), percentage
of BMI change and weight loss, and QOL variables. Significant correlations were found between
percentage of BMI change, percentage of weight loss, PE, and all exercise adherence
environments. Additionally, NOD was significantly correlated to the SLP-guided adherence.
Based on these findings, linear regression was performed to explore the potential level of
adherence necessary to achieve positive outcomes in weight maintenance, BMI maintenance, PE,
and NOD after radiation. Based on previous findings discussed in this Chapter, the level of
adherence to swallowing exercises appears to have an effect on swallowing outcomes. Subjects
experienced their lowest levels of adherence in the home-based exercise environment. The SLPguided exercise used in this study’s protocol accounted for approximately 50% of the total daily
recommended exercise, and combined SLP-guided and home-based exercise environments
represented 100% of the possible total daily exercise. Thus, 100% adherence would mean that a
subject performed 100% of the recommended exercise load. Based on the wide variation exercise
protocols (14, 24, 25, 34, 36, 39, 47, 51, 126, 128, 132, 152, 153, 154) and findings that suggest
high levels of adherence are related to better post-radiation swallowing performance (14, 132),
linear regression was performed using the combined exercise adherence in the SLP-based
exercise adherence data.
Models were used to develop predictive equations to identify the required level of
exercise adherence necessary to achieve the desired outcomes across weight loss percentage,
percentage of BMI change, NOD, and PE. By determining the level of adherence, which is the
percentage of exercise completed, the desired exercise load is also being predicted. The
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predictive calculations were completed for adherence levels beginning at 50% adherence and
moving up in increments of 10 until 100% adherence was entered into the equation. This output,
available in Chapter 6, Table 40, illustrates an improvement in all correlated variables as
adherence increases. These findings suggested that higher levels of exercise led to the likelihood
of greater swallowing function immediately following radiation. If goals of less than 10% weight
loss and less than 10% change in subjects’ BMI were established, then performing 60% of the
combined SLP-guided and home-based exercise program yields an acceptable outcome,
compared to 70% of the SLP-based-only exercise to accomplish the same outcome. However,
once diet tolerance and public-eating-related QOL were accounted for, the predicted level of
adherence increased. No level of adherence was associated with maintaining a diet of soft and
chewable foods; in fact, 100% adherence to combined SLP-guided and home-based exercise was
required to predict tolerance of a puréed diet. Adherence to 100% of the combined SLP-guided
and home-based exercise resulted in a score of 50.03 for PE representing a willingness to eat in
only select places with select people, and less than a 1% change in BMI or weight. This
predicted result was also the highest PE related score achieved in the prediction model. The
predictive model suggested that anything less than 100% of the total possible exercise would
result in a post-radiation diet consisting of only liquids.
This current study of the first study to assess adherence/exercise load in this manner.
Based on these findings new suggestions related to exercise volume and related adherence can be
made. The best possible outcome, based on the findings of this study, revealed that 100% of
exercise is needed. This finding represents 70 Masako’s, 70 pharyngeal squeeze exercises, and
three repetitions of Shaker exercise daily during the seven weeks of radiation treatment. It
remains unknown what effect increasing the exercise load beyond the current study’s prescribed
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levels would have on anticipated diet levels or related quality of life, if 100% adherence could be
achieved. To prevent weight loss and BMI change greater than 10%, and maintain a full oral diet
(liquids only), 60% of the total possible exercise is required. This amount would represent
approximately 40 repetitions of Masako, 40 repetitions of pharyngeal squeeze exercise, and 2
rounds of Shaker exercise daily over the 7 weeks of radiation. The maximum SLP-based portion
of the exercise in the current study consisted of 40 repetitions of Masako, 40 repetitions of
pharyngeal squeeze exercise, and 1 repetition of Shaker exercise daily, 5 days per week over the
7 weeks of radiation. The predictive models suggested that performing 70% of the SLP-guided
exercise would result in less than 10% change in weight loss and BMI, and in maintaining a full
oral diet (liquids only). This level of exercise would require the completion of approximately 30
repetitions of Masako, 30 repetitions of pharyngeal squeeze exercise, and the continuation of the
single repetition of Shaker exercise, 5 days per week over the 7 weeks of radiation. However,
much is already known about the use of Shaker exercise, and the intensity and volume have been
well-established (51). The current study based the intensity and volume of Shaker exercise on
these previous recommendations. The predicted outcome resulting in maximized oral intake is
based on use of the full recommended exercise protocol, which includes 3 repetitions of Shaker
exercise. The benefits of maximizing oral intake appear to uphold the need for this higher
exercise volume. Therefore, there appears to be no need or rationale for reducing the number of
exercise repetitions used in this study, if maximized diet is the goal of treatment. However, if the
goal is weight or BMI maintenance and diet level is not a primary concern of the patient, it
appears possible to reduce the volume of the Shaker exercise. The treating SLP should educate
HNC patients on the interaction between exercise adherence, the resulting exercise load, and
post-radiation swallowing-physiology-related outcomes.
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7.5 Feasibility of SwallowSTRONG Biofeedback
An initial intent of the current study was to include a third prospective group to explore
the use biofeedback and potential positive outcomes on post-radiation swallowing function.
Before initiation of enrollment into this group, the author had to determine if patients undergoing
chemoradiotherapy for HNC were able to tolerate a biofeedback device that required oral
placement. The initial rationale for the use of the SwallowSTRONG device was based on the
potential of biofeedback to improve adherence to exercise and to determine the potential benefit
of exercising at a targeted tongue pressure (e.g., 60% of maximal ability). In addition, the use of
SwallowSTRONG was chosen over another available biofeedback device, the Iowa Oral
Performance Instrument (IOPI). Both the SwallowSTRONG and IOPI devices can be used for
tongue-palate press exercise and to measure tongue strength in similar ways. However, the
design of the SwallowSTRONG system allows the mouthpiece to be custom molded to fit the
patient’s mouth. This custom molded mouthpiece provides consistent replication of oral
placement and increased consistency of measurement. The IOPI uses a single air-filled bulb
placed within the oral cavity, at the desired locations, for measurements and exercise. This
single-bulb design makes exact replication of placement difficult. For this reason, the
SwallowSTRONG system was chosen over the IOPI.
Previous studies indicated the potential ability for the use of the SwallowSTRONG
device for tongue strengthening in the head and neck cancer population (43). Based on the
following information it was determined that the device might have a positive impact on
swallowing function and that the time needed to benefit from the use of the device was plausible,
indicating the potential feasibility of using it in prophylactic treatment. Rogus-Pila et al. (43)
used SwallowSTRONG with dysphagic patients, which included 14 post-radiation head and neck
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cancer patients from a total n = 51. They used the standard SwallowSTRONG protocol
consisting of 10 repetitions per placement, 3 times daily, 3 days per week, for 8 weeks. They
found improved swallowing-related QOL, improved diet level, and reduced incidence of
pneumonia. This finding demonstrated a potential positive treatment effect on radiation-related
dysphagia, but given the potential for radiation-related oral mucositis and associated pain, the
feasibility of use SwallowSTRONG during prophylactic treatment remained unknown. Fenwich
et al. (182) indicated that mucositis and oral-related pain were associated with a radiation
threshold of 25-38Gy, commonly becoming more severe after week 4 of radiation. This window
of expected absence, or mild, mucositis and associated pain was expected to provide the time
needed for device use during prophylactic intervention. This window of time was based on work
by Burkhead et al. (42) who demonstrated that the muscle building processes of hypertrophy
were measurable in the swallowing muscles after 4-5 weeks of intervention.
Based on these findings it was originally hypothesized that patients would likely tolerate
the device use for the first 4-5 weeks of radiation treatment, allowing for sufficient time to
receive a therapeutic benefit and gather meaningful data. However, based on the high prevalence
of oral mucositis and potential for earlier onset of radiation-related pain, it was noted that
feasibility and tolerance of the intraoral device might be limited. For this reason, another tongue
strengthening exercise (Masako) was included in the current study to ensure that consistently
usable prophylactic exercise was possible.
Despite the published evidence supporting the rationale for the potential feasibility of the
SwallowSTRONG device, the prospective groups (HF and LF) did not tolerate the use of the
device for treatment purposes. The use of the SwallowSTRONG device proved to be nonfeasible as characterized by: 1. limited to no use across all initially enrolled subjects who had
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begun radiation, 2. inability to meet the desired timeline for possible hypertrophy of the tongue
muscle with use of the device (4-5 weeks of use), 3. inability to meet the desired treatment
accuracy (exercising at 60% of maximal ability), and 4. inability to meet the desired exercise
load (120 repetitions per session). The current study’s SwallowSTRONG protocol did differ
from the previously published protocol. Patients still performed 3 sets per day, 3 days per week;
however, only the anterior and posterior placements were targeted during therapy sessions. The
anterior to posterior movement and tongue strength are the most significantly affected during
radiation because of the radiation-related posterior tongue-based atrophy. Therefore, to target
these areas using the same volume of exercise recommended during the standard
SwallowSTRONG protocol, the number of repetitions was increased from 10 to 20. In the
current study, patients’ use of the device for exercise was severely limited, with many subjects
not using it for exercise at all. Frequency of use and participation were assessed and findings
revealed that 27 of 30 subjects attempted the exercise using the device. The mean total number
of sessions attempted was 4.37, with 3.33 complete sessions, and an additional 1.03 sessions
being attempted but incomplete. The mean number of possible sessions was 19.03, but the
optimal number sessions was 21.
The patients within the current study appeared to experience more significant pain earlier
than anticipated based on the published data (31). This difference may be due, in part, to the
exacerbating effects of concurrent treatment chemotherapy. Chemotherapy has been reported to
increase the severity of mucosal reactions. The nausea associated with chemotherapy has also
limited patients’ willingness to hold the intraoral device in the mouth. The two subjects who used
the device for exercise beyond the first two weeks of treatment skipped entire weeks, including
week 3 or 4, and had very limited/inconsistent use afterward before discontinuing use
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completely. No subjects had consistent use of the device. Subjects declined further use related to
the significant pain associated with the device placement inside the mouth, or due to consistent
increased feelings of nausea. Many subjects were willing to attempt additional use of the device
on a subsequent visit, but remained unsuccessful. This resulted in termination of device use. The
reductions in use appear to be consistent with increases in reported pain levels and/or observed
changes in mucositis scores collected from the patients, if pain was the discontinuation-related
factor. Mucositis-related oral pain appeared to be a factor after 2 weeks of intervention as was
nausea which often occurred within the first week of treatment if chemotherapy was given. In
addition to the pain and nausea reported, some subjects also had severe gagging and declined to
continue after the initial attempts.
At the conclusion of the study, rationale for eliminating SwallowSTRONG included oral
pain, which accounted for 56%, nausea and gaging, which accounted for 18% each, and subjects’
general refusal, which accounted for 8%. The pain associated with discontinuation of the device
use occurred sooner than anticipated when originally considering the feasibility of the device
exercise during prophylactic behavioral swallowing intervention. This unexpected lack of device
tolerance might have been due to potentially increased pain levels experienced during use,
associated with the pressure applied by the device on oral tissues during exercise on the affected
oral structures. The level of pain and irritation associated with chemoradiation during the initial
weeks of treatment may be more tolerable when the mouth is empty than when the
SwallowSTRONG device is introduced. As previously discussed in this Chapter, a recent study
published since the initiation of this study’s protocol, illustrated the impact of subject-related
mouth pain on the reliability and validity of these pressure readings (268). The previous study’s
findings suggested that ratings occurring after the fourth week of radiation, when the pain levels
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typically increase, should be used with great caution. Based on the significant difficulty subjects
experienced with the use of the intraoral device, and the findings of the previous article
examining feasibility of a similar intraoral device (268), it was decided that the biofeedback
component of this study was not feasible to pursue. Therefore, an originally planned group using
SwallowSTRONG with biofeedback was eliminated. Given that some subjects did use the
device, while some did not, and that the duration of use did vary among subjects, it was
important to assess if any group-based differences existed relating to the use of the
SwallowSTRONG device. However, no between group differences existed for the percentage of
exercise completion, the percentage of exercise performed, or the duration of use. Additionally,
there were no significant differences between groups based on rationale for discontinuation of
the device.
7.6 Salivary Production During Radiation Therapy With or Without Chemotherapy
The role of salivary production in swallowing physiology and xerostomia as a toxicity
associated with HNC-related dysphagia is well established (30, 81, 101). The HNC-related
complication of mucositis and xerostomia have been previously summarized in Table 9. Salivary
loss is often referred to as one of the most prominent toxicities related to the treatment of head
neck cancer (271). It has been reported that patients report increased swallowing difficulty as
salivary production is reduced (90). Within the current study salivary production was tracked
from the pre-radiation level and then weekly throughout radiation. Saliva loss, or xerostomia, has
been reported to affect 95% of all head neck cancer patients undergoing radiation (30). However,
the degree of salivary loss associated with swallowing-related outcomes including diet level,
feeding tube use, swallowing- related quality of life were unknown. The current study was
seeking to explore these relationships and to determine what level of salivary loss was associated
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with negative swallowing-related outcomes. For the purpose of statistical analysis the degree of
salivary loss was calculated as previously described in Chapter 6.
The initial first step was to determine if any group-based differences existed based on
salivary production following radiation treatment. Statistical analysis revealed no significance
between group differences. It is not surprising that all subjects suffered a large degree of salivary
loss. All subjects within these two groups received a mean total radiation dose of 70Gy.
Radiation dose levels greater than approximately 26Gy have been associated with significant
reductions in salivary production (54). Dirix et al. (271) has reported that a 25% reduction in
salivary function has been given as an arbitrary threshold of clinical significance. He also
discussed that patients exhibited difficulty in mastication, loss of taste, and dysphagia in addition
to reduced swallowing-related QOL scores. Given the lack of group-based differences, the data
of the current study were pooled for the purposes of subsequent correlation and linear regression
analyses to further explore the relationships between degree of salivary loss and diet level.
Initial correlation results between percentage of salivary loss and diet level based on
FOIS scores and NOD scores found that only FOIS was significant (p = .031). Linear regression
was significant and the coefficients of the regression model were used to develop a predictive
equation for FOIS. The purpose of the predictive equation was to identify the percentages of
salivary loss associated with each diet level on the FOIS scale. Findings suggested that a salivary
loss of 74.85% pre-radiation salivary level was associated with feeding tube use; and salivary
loss of 88.68% was associated with complete feeding tube dependence. Additionally, a salivary
loss of 47.18% was associated with the ability to maintain a normal unaltered diet. These
outcomes are significant as they suggest that a non-arbitrary level of 54.1% salivary loss is
associated with initial declines in diet level, based on FOIS scores. Additionally, they suggest
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that, while subjects lost a substantial amount of salivary production over the course of radiation
treatment, they remained in levels associated with ability to maintain oral nutritional intake,
based on mean values.
These data may also suggest that for subjects within the current prospective groups, an
increase in salivary production would provide some benefit toward the advancement of dietary
levels. This finding appears, to the best of the author’s knowledge, to be the first study to track
salivary production weekly across radiation treatment utilizing the Saxon test methodology. The
Saxon test yielded easily obtainable information about subjects’ current salivary flow levels
during the course of their radiation treatment. Based on this new data output provided from the
predictive model discussed within this section, SLPs could assess and counsel patients
undergoing radiation about the potential impacts of xerostomia levels on their diet tolerance. In
addition, future research examining methodologies to protect the patients’ salivary glands and
reduce loss of salivary production while undergoing radiation treatment now have objective
targets by which to measure treatment outcomes.
7.7 Relationship Between Swallowing Function and QOL
The final secondary question addressed in this study is the general relationship between
radiation-related toxicity and swallowing function in QOL. Radiation-related toxicities measured
within the current study included salivary weight, mucositis scale scores, Cancer Fatigue Scale
scores, and pain level. Pain levels were assessed for both swallowing-related pain and general
cancer-related pain. These radiation-related treatment toxicities have the potential to affect
swallowing-related outcomes (31, 101). Salivary loss was already discussed related to FOIS
scores and NOD scores in the previous section, and thus are not addressed here. Significant
correlation relationships were found between salivary loss and feeding tube use, mucositis scores
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and NOD scores, and mucositis scores and PE scores. No other significant correlations were
found. It is important to note that while pain levels did increase across all patients during the
course of radiation for both general pain and swallowing-related pain, the scores did not appear
to affect swallowing function or QOL. Additionally, cancer-related fatigue has been reported as a
significant burden and potential factor related to poor swallowing outcomes following radiation
(31). No such relationship between cancer-related fatigue and swallowing QOL or diet level was
observed. This result indicated that both mucositis and xerostomia may be the most significant
toxicity factors affecting the head and neck cancer population.
Mucositis scale scores were statistically significant for both NOD and PE in the
regression. Post-radiation mucositis scale scores ranged from 9 to 23. Higher scores represent
more significant toxicity. Mucositis, unlike salivary loss is considered a temporary toxicity and
often begins to heal within two weeks following radiation (31). Therefore, while a significant
relationship exists between swallowing-related diet tolerance and eating environment, based on
NOD and PE scores, it can be assumed that it will resolve. Additionally, mucositis did not have a
direct impact on diet level or feeding tube placement.
Regression between loss of saliva production and feeding tube use, PEG use,
demonstrated a significant moderate relationship, immediately following radiation. Due to the
importance of understanding rationales for feeding tube placement, the regression correlation
coefficients were used to create a predictive model to determine the level of salivary loss
associated with PEG use. The resulting equation determined that a salivary loss of 83.25% of the
pre-radiation salivary output was a predictor of potential feeding tube placement. This prediction
appears to support the previous findings related to salivary loss in FOIS scores associated with
feeding tube use. These findings strengthen the argument that substantial losses in salivary
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production associated with radiation therapy have a direct impact on subjects’ tolerance of oral
diet. Protection of salivary function appears to be the most significant next step in providing a
better swallowing-related QOL and improved overall swallowing function for patients who must
undergo radiation organ preservation treatment to cure head and neck cancer. While a complete
elimination of xerostomia is unlikely, the current study’s data suggest that cutting the degree of
salivary loss in half not only reduces the likelihood of PEG placement, but also would result in
greater overall tolerance of oral intake with varied diet consistencies.
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CHAPTER 8. CONCLUSION
8.1 Conclusions and Clinical Implications
In conclusion, higher frequency of SLP-patient contact time, providing prophylactic
behavioral swallowing interventions, resulted in better swallowing-related treatment outcomes
compared to lower frequency of contact time with similar intervention practices. Specifically,
subjects within the current study, who received between three and five weekly visits with the
SLP for the purpose of behavioral swallowing exercise and intervention, outperformed subjects
from the retrospective 1day/week and CTT groups. Benefits of higher frequency contact with the
SLP included increased swallowing physiology (i.e., reduced occurrence of
aspiration/penetration and improved PAS scores) and superior post-radiation swallowing
function (i.e., reduced rates of PEG use immediately post-radiation, higher rates of full oral diet
based on FOIS scores immediately post-radiation). Further examination between PEG users and
non-PEG users revealed improved post-radiation physiology in the non-PEG group. The data
revealed a clinically relevant increase in penetration risk characterized by poor swallowing
efficiency, based on repeated measures design PAS analysis, in the PEG user group.
Additionally, reduced post-radiation swallowing physiology was noted in the PEG user group
based on pharyngeal constriction ratio and pharyngeal residue ratio outcomes. In general, nonPEG users had improved swallowing efficiency when compared to PEG users.
A strong relationship was found between SLP-patient contact time and subsequent
feeding tube use. Coefficient data were used to build an equation and determined that two-day
per week SLP-patient contact time was optimal to minimize risk of feeding tube placement.
Based on these findings, this study has made a new recommendation to change the current
typical treatment recommendation and to provide 2 weekly SLP-patient visits over the course of
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radiation therapy, for a total minimum of 14 visits over 7 the course of radiation. Increased SLPpatient contact time would, in turn, create a healthcare cost savings. Healthcare costs associated
with feeding tube placement use over a period of three months to one year generally ranged
between $517,000 and $636,000 for subjects who received one weekly SLP visit. In contrast,
feeding tube cost for subjects receiving a higher frequency SLP contact are as low as $181,000,
representing a significant savings in addition to the improved QOL and long-term outcome for
these patients. While providing a higher number of SLP visits would require increasing staff, the
healthcare cost savings continue to outweigh the increased staff salary cost. The cost savings
related to feeding tube placement could employ additional SLPs, meeting the increased demand
for behavioral swallowing treatment opportunities and increasing the overall likelihood of
optimal swallowing outcomes of head and neck cancer patients. Additionally, the increased
revenue associated with the higher visit number would further offset the higher salary cost,
further reducing the healthcare dollars spent.
Additional functional outcomes further highlighted differences related to overall diet
level between non-PEG users and PEG users. Results suggested that non-PEG users maintained
higher levels of multiple diet consistencies, based on FOIS scores. Non-PEG users also
maintained higher levels of nutritional stability compared to PEG users, who fell into a state of
malnutrition regardless of PEG placement. PEG placement was also noted to have no effect on
subjects’ weight stability during the course of radiation. Additional QOL data based on NOD
revealed that non-PEG users tolerated a wider variety of foods and liquids, while PEG users were
restricted to complete PEG use or cool liquids only.
Adherence to behavioral treatment exercise is just one factor which may contribute to
improved overall post-radiation swallowing outcomes. The current study did find the difference
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between overall adherence to exercise based on SLP patient contact. Subjects in the higher SLPpatient contact groups performed significantly higher percentages of the behavioral swallowing
exercise compared to the lower frequency 1day/week group. This increased adherence to
exercise observed in the high SLP-contact-time groups resulted in improved normalcy of diet
and public eating scores. Significant relationships were found between adherence levels and
maintenance of BMI level weight level, public eating scores and normalcy of diet. Based on
these findings and predictive equations which were built using significant coefficient data, it was
determined that, while lower percentages of exercise adherence may help maintain weight and
stabilize BMI, 100% adherence of the current study’s exercise program was necessary to
maximize subjects’ diet level. Given the importance of maintaining a full oral diet during
radiation therapy and its relationship with the likelihood of continuing a full oral diet postradiation, there is no rationale for lowering the intensity and volume of the exercise protocol
developed for the study. The completion of 70 repetitions Masako, 70 repetitions of pharyngeal
squeeze exercise, and 3 repetitions Shaker exercise daily over the course of radiation appears key
to maximizing subjects’ post-radiation swallowing performance and optimal swallowing
maintenance.
Additional findings related to the use of biofeedback and tongue pressure measurements
utilizing the SwallowSTRONG system’s intraoral mouthpiece placement revealed the poor
feasibility and limitation of these data collection methodologies during prophylactic behavioral
swallowing intervention. Findings included reduced or no tolerance of the SwallowSTRONG
device or tongue-to-palate exercise, high occurrence of pain and nausea, and undesirable
adherence to the duration of overall treatment time (e.g., 1 to 2 weeks compared to the desired
minimum five weeks). These findings highlighted the poor usability of the SwallowSTRONG
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device for the head and neck cancer population during prophylactic exercise provided during
radiation treatment. This caution does not, however, rule out the potential for future studies to
evaluate the use of the SwallowSTRONG device at different time intervals within the head neck
cancer population. For example, the possible use the device pre-radiation or post-radiation in
patients who experienced persistent dysphagia may be indicated after further evaluation.
Additionally, findings related to differences between the anterior and posterior tongue pressure,
and their differing degree of change during radiation, highlighted the potential importance of
measuring multiple placements and assessing overall decline in tongue strength. Findings
revealed that, while posterior tongue-palate pressure reduced below a clinically relevant level,
the anterior tongue-palate pressure also declined indicating the whole tongue is at risk during
radiation, not only the tongue base.
Findings related to saliva production yielded new objective measurement data related to
salivary loss and diet level or feeding tube use. The current study appears to be the first to have
measured weekly saliva production levels using Saxon test methodology and found significant
relationships between salivary loss and likelihood of feeding tube use and reduced overall diet,
based on FOIS. Until now the clinically relevant level salivary loss has been an arbitrarily
assigned number. New current data developed over the course of this study found specific values
associated with reduced diet level, which are nearly double the previous arbitrary level. This
finding indicates that patients may tolerate a larger degree of salivary loss while maintaining
normal diet levels. This study also established a specific level of salivary loss associated with
complete feeding tube dependence, and a range of salivary loss levels associated with a
combination of feeding tube use and PEG tube dependence. These new data provide objective
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goals by which to measure the effectiveness of methodologies designed to protect and/or restore
salivary function in the head neck cancer population
Further investigation of radiation-related treatment toxicities revealed no relationship
between cancer-related fatigue and cancer-related general and/or swallowing-based pain scores.
Lack of significant findings between these scores and relevant swallowing-related outcomes is an
important finding because these are often cited as potential rationales for reduced swallowing
function, reduced diet level, and/or feeding tube placement. Investigation of toxicities did yield a
relationship between oral mucositis scale scores in the SLP-generated QOL for normalcy of diet
and public eating. These findings highlight an important relationship between the significant
toxicity of mucositis, which occurs in 100% of head and neck cancer patients undergoing
radiation with or without chemotherapy, as it appears to have a significant effect on tolerance of
oral diet and choice of eating environment during radiation treatment. This finding highlighted
the importance of adequate treatments to counteract or prevent mucositis-related deficits to
enable subjects to maintain the highest level of oral intake. This relationship radiation-related
toxicity and oral diet tolerance also highlights the importance of additional future research of
treatments, including pharmaceutical, similar to the previous Gabapentin studies (72, 112),
which have found a beneficial effect on mucositis, despite continued narcotic pain medication,
within the treated subjects. This study’s findings illustrate the importance of mucositis control
and not simple pain control.
8.2 Limitations of the Current Study
Retrospective patient recruitment was the most significant limitation of the current study.
While these retrospective groups were treated at identical facilities using identical treatment
methodologies, and identical behavioral swallowing exercise recommendations, variation in data
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collection methodology minimized the number of direct group comparisons that were available
for analysis. Specifically, the lack of QOL data in the current typical treatment group (CTT)
cohort prevented any comparison of QOL outcomes across all treatment groups. While we know
that higher levels of feeding tube use typically equate to lower overall QOL scores, we are
unable to definitively state that higher SLP-patient contact time affects patient-reported
perceptions related to swallowing-related QOL. In addition, the use of PAS mean data across
bolus types limited the extent of bolus specific analyses across all available study groups. Future
studies should continue to assess PAS data for specific bolus types and across bolus trials to
further explore the potential bolus type based outcomes.
Additionally, it is worth noting that many of the significant outcomes related to the
secondary research questions used to further explain relationships to feeding tube use, adherence
level, and toxicity were available for only 30 subjects. While the current study had a total of 102
subjects, the previous data collection methodologies of both the 1day/week group and CTT
group prevented the analysis of these newer assessment methodologies across all groups. While
this limitation reduced the total number of subjects used in a portion of this study’s analyses, it is
worth noting that statistical analysis prior to the initiation of the study did indicate that two
groups of 15 (total subjects n = 30) would be reasonable to assess between group differences.
Study subjects were also not randomly assigned into the prospective treatment groups,
nor was random assignment used in the selection of subjects in the two retrospective groups.
Randomized clinical trials will always yield the strongest level of statistical analysis. However,
due to the low incidence of head and neck cancer patients and the exclusion of any surgical
techniques beyond biopsy, random assignment was difficult. The alternating assignment into
groups used for the prospective data collection did yield relatively varied groups, which were
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well-matched tumor site, tumor stage, and the subject demographics. The prospective groups
were also well matched, based on the same criteria, to the retrospectively collected subjects.
High occurrence of stage III and IV tumors was also representative of the general head and neck
cancer population. Subjects were also not blinded to the purpose of behavioral swallowing
techniques. It is currently known that prophylactic swallowing intervention appears to have a
beneficial impact on post-radiation swallowing outcomes. Given the importance of self-efficacy
and healthcare knowledge while undergoing such a significant medical treatment, paired with the
knowledge that these interventions may impact swallowing function for the remainder of the
patients’ lives, blinding of subjects to the purpose of these treatments would be unethical.
However, these groups, being well matched and representative of the general head and neck
cancer population receiving organ preservation modalities, yield strength to the validity of the
statistical analyses performed in the current study.
It was the intention of this study to assess the immediate post-radiation swallowing
function, which includes aspiration risk and physiological measures in the head and neck cancer
population. Aspiration risk scores and physiological measurements were obtained during the
modified barium swallow studies. While every attempt was made to obtain these modified
barium swallow studies within three weeks of completion of radiation therapy, three postradiation studies were obtained beyond the three-week interval within six weeks post-radiation.
A similar event occurred with the data collection based on modified barium swallow studies in
the retrospective 1day/week group. Unfortunately, this is not an uncommon occurrence within
the field of dysphagia. This occurrence created undesirable and potentially biasing variation in
the timing of aspiration risk and physiological measurement data collection. Future studies
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should continue to aim to reduce the impact of variations in modified barium swallow study
assessment time.
Adherence to treatment may have also been affected by the treatment methodology. For
the prospective groups and the 1day/week group, treatment was provided by the SLP who was
also the primary investigator of the original studies. These SLPs may have been more motivated
and invested in the patients and their swallowing outcomes than other SLPs not involved directly
with the study. Finally, measurement of adherence used in this study varied from the techniques
used to obtain patient adherence information in other previously published studies. Most notably,
adherence data collected during the SLP visits were obtained directly by the SLP, while homebased exercise was subject reported. In contrast, the total of adherence data in the retrospective
1day/week group was subject reported and other studies providing adherence data failed to report
data collection methodologies completely. This variation in data collection methods limits the
scope of direct comparison and its relationship to swallowing outcomes, as they relate to other
previously completed studies.
8.3 Scope of Future Research
The current study will continue to follow subjects who completed the treatment phase of
this study for follow-up attempts at the 3-month, 6-month, 12-month, 24-month, and 36-month
timeframes. These follow-up timeframes were approved in the initial IRB application and will
help further assess the impact of high-frequency SLP-patient contact time on long-term diet
level, feeding tube use, and swallowing-related QOL outcomes. Initial attempts at follow-ups
have proven difficult, in part due to subjects’ failure to return to their scheduled follow-up
appointment with radiation oncology.
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Future investigations may investigate the use of biofeedback, using tools similar to
SwallowSTRONG or the Iowa Oral Pressure Instrument discussed in this document, to employ
further principles of exercise science and potentially to further optimize behavioral swallowing
interventions. These investigations may take place as pre-treatment, occurring in a sufficient time
period leading up to the start of radiation or occur at an appropriate timeline during the postradiation healing process (e.g., at 3-months or 6-months post-radiation). To date, a preliminary
study utilizing the SwallowSTRONG system has been undertaken at Our Lady of the Lake
Regional Medical Center-Voice Center to assess the potential benefits of this biofeedback device
at 3 months post-radiation.
Additional future research appears warranted to further assess potential mechanisms to
reduce treatment-related toxicities, specifically salivary loss and mucositis. These interventions
may include further or new pharmaceutical studies similar to previous research assessing the
benefits of Gabapentin. They may also include the use of specific oral hygiene regimens, oral
hygiene products, or potentially specifically developed oral nutritional supplements designed for
the head and neck cancer population. In addition to these toxicity-related interventions, further
research appears ongoing related to the genetic biomarkers and underlying etiologies (e.g., HPV)
and may yield additional knowledge about appropriate treatment, management, and prognosis of
specific head and neck cancer variants in the future. The culmination of these future research
outcomes would continue to contribute to the improved care and quality of life of this high-risk
head and neck cancer population.
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Federal Wide Assurance 00002762 Registration # 00000177

Expedited Review Request*
Application for Research Activities Under 45CFR46.110 and 21CFR56.110
To apply for expedited review* provide the following:
1. Demographic Form with attachments (2 copies)
2. Expedited Review Request Form (2 copies) (This form)
3. Full Protocol (2 copies)
4. Informed Consent Document [ for waiver requirements section 12]
(2 copies)
5. Modified Informed Consent [telephone consent, oral script ,etc.
must include all of the elements of informed consent] (2 copies)
6. Attach one set of all tools, questionnaires, surveys, diaries, scripts,
etc.
7. Attach a HIPAA Research Authorization Form or apply for waiver
(section 11)
8. Attach separate forms for HIPAA de-identified form, HIPAA
decedent form, etc. available at Office of Research Services (ORS)
HIPAA website.
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There is an Information Sheet available to assist with the items in this form.
Help is provided in the status bar at the bottom of the document as you tab through the form
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*Expedited Review: All activities must meet the definition of minimal risk “ 46.102(i) Minimal risk means that the
probability and magnitude of harm or discomfort anticipated in research are not greater in and of themselves than those
ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or
tests.”

Only research activities that present no more than minimal risk and involve only procedures listed in one or more of the
qualifying categories may be reviewed through the Expedited Review procedure. The list of Expedited Categories is
provided on the IRB section of the ORS webpage .

It is also available on the US Office of Human Subjects Protection webpage.
hhs.gov/ohrp/humansubjects/guidance/expedited98.htm

The standard requirements for Informed Consent apply to all human subjects’ research. A waiver or alteration may be
requested. See Section 12.

Provide the following information and submit 2 printed copies of this completed form

1. Investigators (state names and departments)
Principal Investigator: Andrew J McWhorter, MD
Co-Investigators: Melda Kunduk, PhD; Mathew Vansant M.S., CCC-SLP, Lindsey Parker M.A., CFSLP

2. Title of Protocol or Proposal: Effects of Pretreatment, Visit Frequency, and Visual Biofeedback on
Swallowing Function During Orga

For Expedited Regulations see the
LSUHSC-NO IRB Information Sheet: “Categories for Expedited Studies ” for
full text of these categories. There are 7 categories for new studies. Indicate in
item 3 the category that you think applies to this proposal.
Additional information is also available at the U.S. Office of Human Research
Protections website hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm#46.110
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3. Expedited Category
State the category(s) that you think applies to this proposal. Check all that apply.

Category 1 Drugs & Medical Devices

Category 2 Blood Samples

Category 3 Biological Specimens Noninvasive Collection

Category 4 Data --Noninvasive Collection

Category 5 Data –Collected for Medical Treatment/Diagnosis
Existing Data Chart Review
Prospective Collection

Category 6 Data –Voice, Video, Digital Recordings

Category 7 Individual or Group Behavior
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Project Abstract [see Information Sheet for Expedited Review
Requests for further guidance] Limit 300 words

For Assistance See Information Sheet to the Expedited Review Request Item 4

State the objectives or the problem, present knowledge relevant to it, the research
hypotheses, and the goal of the proposed study as related to the research question.
Indicate the importance of the research.

4. Project Abstract In this space, provide the brief description of the research. No more than 300 words.
The goal of the proposed study is to prospectively investigate the potential beneficial impact of pretreatment, increased
patient-SLP visit frequency, and the use of visual biofeedback in prophylactic behavioral swallowing interventions for
patients undergoing organ preservation treatment modalities (radiation with or without chemotherapy,
chemoradiotherapy) for head/neck cancer. Chemoradiotherapy is not without risk to swallowing function. Hence, related
swallowing difficulty (dysphagia) and risk of aspiration remains a concern today. Dysphagia may result in altered diet,
declines in nutritional intake, reduced quality of life, interruption to curative cancer treatment, and is linked to overall
morbidity. Currently, there are wide variations in behavioral swallowing treatment methodologies for chemoradiotherapyrelated dysphagia in the head/neck caner population. Patients often fail to maintain adherence and toxicity effects a
contributing factor to both adherence and swallowing function. Behavioral swallowing exercise has proven beneficial, but
knowledge gaps remain for ideal treatment timing and duration, the relationship between toxicity and dysphagia, the
impact of visit frequency with the SLP, and patient related factors of compliance with behavioral swallowing treatment.
To address these knowledge gaps the following research question will be answered: 1. If beginning behavioral swallowing
intervention two weeks prior to the start of radiation treatment (pretreatment), compared to initiating swallowing
interventions when radiation begins, will result in decreased reactive peg placement, improved post-treatment swallow
physiology, diet level, and related quality-of-life; 2. If increased SLP-patient contact time, compared to reduced SLP
contact time, will result in improved treatment compliance; 3. If the use of visual biofeedback, compared to no visual
biofeedback, during tongue-palate pressure swallowing exercise will result in increased treatment accuracy and improved
post-treatment swallow physiology. Resulting data will further increase the knowledge of chemoradiotherapy-related
dysphagia and further optimize the interventions used to treat this dysphagia.
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Project Description
The following items should be addressed as applicable to the study

Study Design
Study Population
Research Procedures and Activities
Potential Risk
Potential Benefit
Safety Precautions
Alternatives

For surveys, questionnaires
Copy of the instrument must be provided with this application
Cover letter or script of oral presentation
For chart/record reviews see the information following this
All Studies Must Include
1. Background
2. Objectives
3. Study Design
4. Study Population Characteristics including Minority Groups
Indicate what information will be collected and if there is a link from the data to
the individual.

For Assistance See Information Sheet to the Expedited Review Request Item 6 “Guide
to Writing the Non-Clinical Project Abstract”
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State the objectives or the problem, present knowledge relevant to it, the research
hypotheses, and the goal of the proposed study as related to the research question.
Indicate the importance of the research.

For Chart Reviews See the Information on the following page.

5. Place the Project Description in this area.
1)

Study Purpose

Specific aims of this study are to investigate the following:

1.
If increased SLP-patient contact time (high contact), compared to reduced SLP contact time (low
contact), will result in improved treatment exercise adherence.
2.
If the use of visual biofeedback, compared to no visual biofeedback, during swallowing exercise
will result in increased treatment accuracy and improved post-treatment swallow physiology and
function.
3.
If beginning evidenced based swallowing exercises two weeks prior to the start of radiation
treatment (pre-treatment), compared to initiating swallowing interventions when radiation begins
(standard treatment), will result in decreased reactive peg placement, improved post-treatment swallow
physiology, diet level, and related quality-of-life (QOL).

Secondary research questions:
1.
Does increased adherence with behavioral intervention result in decreased reactive peg placement,
improved post-treatment swallow physiology, swallow function, and swallowing-related QOL?
2.
How do the use of visual biofeedback and controlled exercise intensity affect the maximal
isometric tongue pressure through chemoradiotherapy?
3.
Are patients undergoing chemoradiotherapy for HNC able to tolerate a biofeedback device that
requires oral placement?
4.

How does salivary weight change during chemoradiotherapy relative to diet level?

5.

Does the level of toxicity correlate to the level of swallowing function and swallowing QOL scores?

Research hypotheses
The research hypotheses for this study, based on previously published literature include:
1.
The high frequency (HF) group will exhibit significantly higher levels of adherence to swallowing
exercise compared to the low frequency (LF) group based on the following:
a.

The percentage (%) of swallowing exercise completed

2.
The visual biofeedback (VB) group will exhibit better swallowing ability post-chemoradiotherapy
than the non-visual biofeedback group (NB) based on the following:
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a.
Physiological outcomes measured by the Penetration Apsiration Scale (PAS) scores, Dynamic
Imaging Grade of Swallowing Toxicity (DIGEST), and maximal upper esophageal sphincter opening
(centimeters, cm), and maximal isometric tongue pressure (kilopascals, kPa)
b.
Functional swallow outcomes measurements: peg tube use, Functional Oral Intake Scale (FOIS),
weight loss percentage, and Mini Nutritional Assessment Short Form (MNA-SF) scores
c.
Quality-of-life: MD Anderson Dysphagia Inventory (MDADI) scores and the Performance Status
Scale Head and Neck (PSS H&N) (normalcy of diet and public eating) scores
3.
The pre-treatment group (PT) will exhibit significantly better swallowing outcomes immediately
post-chemoradiotherapy compared to the standard treatment group in the following areas:
a.
Functional outcomes measured by peg tube use, Functional Oral Intake Scale (FOIS) scores,
weight loss percentage, and Mini Nutritional Assessment Short Form (MNA-SF) tool scores
b.
Physiological outcomes measured by the Penetration Aspiration Scale (PAS), Dynamic Imaging
Grade of Swallowing Toxicity (DIGEST), and maximal upper esophageal sphincter (UES) opening, and
maximal isometric tongue pressure
c.
Quality-of-life measured by the MD Anderson Dysphagia Inventory (MDADI) scores and the
Performance Status Scale Head and Neck (PSS H&N) (normalcy of diet and public eating) score

STUDY POPULATION and RECRUITMENT

Recruitment of Patients into Treatment Groups
Patients with newly diagnosed HNC (oral, pharyngeal, and/or laryngeal cancer) who will begin
radiation therapy with or without chemotherapy between October 1, 2017 and December 31, 2018
(projected dates), at MBPCC, will be referred to the OLOL-Voice Center for a routine baseline
assessment (MBSS). Subsequently, those eligible will be recruited into one of the two main study groups.
The standardized MBSS protocol utilized at OLOLRMC Voice Center (OLOLVC) is described in
Appendix A. MBSS studies will be completed by the co-investigator investigator (M.V.) or a SLP
employed at the OLOLVC as part of routine care. MBSS outcomes and screening of patient medical
history will be used to determine patient eligibility for the study.
If the patient meets eligibility for the study, a short meeting will be held with the patient to recruit
the patient into one of the experimental groups. During this meeting the procedures and objectives of the
study will be explained, which are outlined in the Informed Consent. If the patient has an interest in
participating in the study, the patient will be asked to read the Informed Consent. Once the patient has
agreed to participate in the study, the patient will be asked to sign the IRB approved Informed Consent
along with the LSUHSC Health Insurance Portability and Accountability Act (HIPPA) Statement.

Inclusion Criteria and Exclusion Criteria for Patient-Recruitment:
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Inclusion Criteria
1. Diagnosis of cancers of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx and/or nodal
disease
2. Evidence of functional swallowing abilities assessed using a baseline MBSS study, prior to the initiation
of radiation
3. Without prophylactic PEG tube placement
4. Signed Informed Consent

Exclusion Criteria
1. Dysphagia warranting PEG tube placement prior to the initiation of RT/C
2. Evidence of or reported diminished ability to comprehend and perform therapy tasks, due to any
reasons
3. Patients who will not undergo radiation treatment
4. Pregnancy

Vulnerable Population:

This study does not include a vunerable population.

3) EXPECTED RISKS/BENEFITS

There are no known risks of swallowing therapy administered in head and neck cancer patients.
Therefore this study does not expect to cause any undesirable risks to patients enrolled.

However, when patients perform exercises they may run the risk of biting the tongue, straining the neck,
or feeling tired.

In addition, filling out the M D Anderson Dysphagia Inventory questionnaire or other study related
documents may upset them by increasing awareness of your swallowing-related limitations.
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These risks would be associated with any other swallowing intervention, and therefore do not constitute
any additional or unusual risk.

Although patients will undergo pre and post-radiation therapy Modified Barium Swallow Studies
(MBSS) involving ionizing radiation, but this is no different than the care they would receive if not in this
study, and at the same frequency remains the same. Therefore, this study does not involve any additional
radiation risks.

There may be a risk of aspiration on the MBSS; however silent aspiration is a known complication of
head and neck patients. The MBSS is instrumental in diagnosing the presence of silent aspiration and
hence evidence of aspiration on these tests is only beneficial to patients for early identification and
prevention of possible aspiration pneumonia.

There is the possibility that subjects enrolled in the study will develop oral or pharyngeal soreness and
discomfort during the course of radiation treatments. If this occurs and they can no longer tolerate the
use of the intra-oral device use in the visual biofeedback system, behavioral dysphagia treatments which
do not require an oral device will be used for the completion of their treatment. Treatment would include
the use of tongue-palate presses, without visual biofeedback, to limit any further discomfort. This will
ensure continuity of care.

The expected patient benefits of this study include but are not limited to:

1.
Prevention or reduction in swallowing impairments and subsequent pulmonary complications of
aspiration during and following radiation therapy with or without chemotherapy

2.
Reduction in feeding-tube dependence and the cost associated with tube feeds during and
following radiation therapy with or without chemotherapy

3.
Improvement in swallowing-related quality-of-life during and following radiation therapy with or
without chemotherapy

4) STUDY DESIGN AND ACTIVITIES

Selection of Sample Size and Group Placement
A power analysis for estimated sample size was performed for the main outcome variable, peg tube use or
no peg tube use, for comparison between the treatments. A historical research group was used to
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establish a 35% post radiation peg-use level (1). The following statistical equation was used n =
(Zα/2+Zβ)2 * (p1(1-p1) + p2(1-p2)) / (p1-p2) 2. Analysis revealed recommended sample size of 15 per
group, 60 total, for a power of .80 (effect size) and significance p=.05. This sample size and group design
was reviewed and verified by a statistician in the Department of Experimental Statistics at Louisiana
State University. Additionally, attrition in HNC-related research is a known factor that needs to be
considered when planning sample size (239). To account for possible attrition, recruitment of 17 patients
per group will be planned (total n=66); however, analysis will be performed once 15 participants per
group, per phase, fully complete the treatment portion of this study.
Upon enrollment into the study, patients will be placed into treatment group, based upon phase of the
study. The consecutive enrollment of new patients, as cancer diagnoses are made, means that random
assignment into treatment groups would likely yield unmatched groups for tumor site and tumor stage.
In addition, due to the reported prevalence of stage III and IV tumors at least 50% (2) of the participants
in each group should fall within these stages. This will ensure a clinically relevant sample. To ensure well
matched and clinically representative groups the first 16 patients will be alternately enrolled into each of
the two Phase I groups, and the remaining patients will be enrolled with intent based on tumor site and
tumor stage factors. This enrollment method will increase the likelihood of well-balanced groups. The
same methods will be used to place patients into the Phase II visual biofeedback group and Phase III pretreatment group.

Assessment of Group Differences
The enrollment methods for group placement will be undertaken in an attempt to ensure the balance of
these characteristics within the study groups. However, there is no guarantee of success. To explore
potential group differences between the treatment groups and to explain the potential impact of these
differences on swallowing function, should they occur, a series of statistical analyses will be performed
prior to the main study analyses. Analysis of group characteristics will include age, tumor site and size,
pre-treatment patient QOL measures (MDADI and PSS H&N), function measures (FOIS, DIGEST,
PAS), physiological measures (upper esophageal opening, maximal tongue palate pressure) and pretreatment surgery. If the groups are not well matched and normality of the sample cannot be assumed,
non-parametric statistical analysis will be considered.

Therapeutic Interventions and Rationale
The Phase I study groups are designed to explore the effects of SLP visit frequency. The groups are
divided by SLP visit frequency (High Frequency, HF; Low Frequency, LF). All swallowing treatments
will begin at the start of radiation treatment. The HF group will have a SLP visit frequency of 5 days per
week, and the LF group will receive a SLP visit frequency 3 days per week. Three days per week is the
minimum number of days required to complete the established protocol for tongue-palate press exercises.
Each group will perform tongue-palate press exercises for tongue resistance exercise (without visual
biofeedback), Masako exercise, Shaker exercise, and pharyngeal squeeze exercises. Each group will
perfom these exercsies with the same number of sets, reps, and at the same frequency. The Phase II
group is designed to explore the effects of visual biofeedback (VB). Exercises in this group will only differ
based on the use of SwallowStrong (SWST) and visual biofeedback for the tonuge-palate press exercise.
This group will be matched to either the HF or LF group from Phase I based on the following:
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1.
If the HF group is significantly better than the LF group (based on functional, QOL, or physiology
outcome measures), then the VB group will receive 5 visits per week.
2.
If the LF group performs significantly better than the HF (based on functional, QOL, or
physiology outcome measures), then the VB group will receive 3 SLP visits per week.
3.
If the HF and LF groups do not differ significantly (based on functional, QOL, or physiology
outcome measures), then the biofeedback group will receive 3 SLP visits per week.

The Phase III group is designed to assess the effects of pre-treatment (PT), beginning two weeks prior to
radiation. Exercises in this group will only differ based on the use of pre-treatment. This group will be
compared to either a Phase I or Phase II group based on the following outcomes from Phase II:
1.
If the Phase II VB group is significantly better than the Phase I group (based on functional, QOL,
or physiology outcome measures), then the PT group will receive visual biofeedback and SLP-visits will
match the appropriate group level.
2.
If the Phase I group performs significantly better than the Phase II VB group (based on
functional, QOL, or physiology outcome measures), then the Phase III PT group will receive no visual
biofeedback and SLP-visits will match the appropriate group level.

Exercises:
Pharyngeal squeeze maneuver is considered a valid exercise to improve the muscles of pharyngeal
constriction and laryngeal elevation, and reduced pharyngeal constriction or elevation may increase risk
of aspiration in the HNC population. Shaker exercise is an evidence-based treatment improving
hyolaryngeal excursion and UES function. UES function is diminished or restricted as a result of
radiation, and poor UES function is also predictive of more chronic dysphagia. Generalized weakness is
noted in the tongue as a result of chemoradiotherapy. Tongue resistance exercises are intended to
increase general tongue strength for bolus manipulation and propulsion. Tongue-palate press exercises
using SWST and tongue-palate presses using a tongue depressor offer a valid way to perform the
isometric exercise needed to improve/increase tongue strength. Specific recommendations exist regarding
the level of exercise intensity for this type of intervention (e.g., 60% of maximal effort). While both
exercise methods have reported success, only SWST offers a method to verify that patients are exercising
at the desired intensity during treatment. Additionally, the Masako exercise provides specific
strengthening for the tongue base, which may increase bolus clearance and oral to pharyngeal bolus
transit. It is possible that patients included in this study will not tolerate the intraoral devices (SWST or
tongue depressor) required to complete tongue-palate press exercises due to the pain and toxicity effects
of the cancer treatment modalities. The inclusion of the Masako exercise within the behavioral
swallowing exercise protocol will ensure consistent availability of a targeted tongue strengthening
exercise. The group design is avaliable in Table 2 of the Study Protocol Document included with this IRB
submission.

Group Design:
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Phase I: Within this phase, 30 participants are divided into 2 groups, high frequency (HF) and low
frequency (LF). The HF will receive 5 SLP-visits per week and the LF will receive 3 SLP-visits per week.
All patients will perform tongue-palate press exercises (1 sets of 10 per placement, 40 total; 3 times per
day; 3 days per week), pharyngeal squeeze exercises (7 sets of 10 repetitions; daily), and Shaker exercises
(3 times per day, daily). All exercises are performed at established, evidence-based levels. This group is
designed to provide information regarding the impact of SLP-visit frequency on adherence to the exercise
protocol.

Phase II: Within this phase, the VB group (n=15) will competed the same exercises, as the same levels as
the matched Phase I group. They will differ based on the use of visual biofeedback.

Phase III: Within this phase, the PT group (n-15) will completed the same exercises at the same
frequency and intensity as the matched Phase I or Phase II groups. They will differ based on the start
date and total length of swallowing treatment.

Visual biofeedback has been suggested to provide patients with the ability to verify treatment accuracy
for a prescribed treatment intensity and may improve swallowing outcomes. Increased SLP-patient visit
frequency has also been suggested to increase treatment adherence, and increased adherence may
improve overall swallow-related outcomes. Increased visit SLP-patient visit frequency provides more
opportunities for completion of exercises in the presence of the SLP, more opportunities to motivate the
patient, and more opportunities to answer questions and educate the patient. The Pre-treatment (PT)
group will begin swallowing intervention 2-weeks prior to the start of radiation. Evidence has suggested
that 5-weeks of swallowing therapy is sufficient to develop hypertrophy within the swallowing organs.
Starting 2-weeks prior to radiation may allow a 5-week treatment window before the significant impact
of treatment toxicity appears. It has also been suggested that this pre-treatment may offer additional
protection against the muscle-wasting effects of radiation.Each session will last approximately 45 minutes
and during this treatment session the patient will complete the tongue resistance exercise (SWST or
tongue depressor exercise), and 1-set of the pharyngeal squeeze and Shaker exercise. Once per week, all
patients will complete the needed QOL and functional outcome measures. These will be collected at the
beginning of each week to ensure consistency of data collection across time. The SWST device in the VB
group will automatically collect tongue pressure, and tongue pressure will be captured using IOPI in the
HF and LF groups. While SWST and IOPI are different, they each use the same method to capture
pressure, manometry measured in kilopascals (kPa). Use of SWST to capture pressure measurements of
the HF and LF groups is cost prohibitive, and use of IOPI allows comparison of the measured data.
Following the conclusion of study related swallowing therapy, treatment will be terminated in patients
who do not exhibit dysphagia; whereas patients who exhibit swallowing impairments will be referred to
the OLOLRMC- VC to continue swallowing therapy.

Data Collection and Rationale for Outcome Measures
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The following data will be obtained from the patient’s Electronic Medical Record (EMR): gender,
age in years, tumor site, TNM classification, Tumor stage, previous head/neck surgery excluding biopsy,
cancer treatment plan (radiation or chemoradiation, surgical management), and pre-treatment weight. In
addition, the following will be obtained from MBSS results or by the SLP during the initial/final
swallowing treatment visits as pre/post data:

1)
Functional outcomes: peg tube use and date of placement, Functional Oral Intake Scale (FOIS)
scores, weight loss percentage, and Mini Nutritional Assessment Short Form (MNA-SF) tool scores;

2)
Physiological outcomes: Penetration Aspiration Scale (PAS), Dynamic Imaging Grade of
Swallowing Toxicity (DIGEST), maximal upper esophageal sphincter (UES) opening, maximal
pharyngeal constriction, maximal hyolaryngeal excursion, maximal isometric tongue palate pressure, and
time to airway closure;

3)
Quality-of-life: MD Anderson Dysphagia Inventory (MDADI) scores and the Performance Status
Scale Head and Neck (PSS H&N) (normalcy of diet and public eating) scores;

4)
Compliance/Adherence measurement: percentage of swallowing exercise completed, percentage of
oral hygiene regimens completed, and percentage of oral pain medication use;

5)
Toxicity measurements: salivary weight (Saxon test), mucositis scale (Dische Scale), and the
Fatigue Scale for Cancer

The following will also be assessed weekly or when changes in status occur: peg placement data
(with change), salivary weight (weekly), Dische scores (weekly), fatigue scale (weekly), MNA-SF (weekly),
and QOL measurements (weekly). Weekly data will be collected on a tracking sheet completed by the
SLP.

Rationale for Dependent Measurements

1)

Functional outcome measures:

a)
Peg use: peg dependence indicates a more severe level of dysphagia and is one of only a few
predictors of chronic dysphagia with a reduction in UES function.
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b)
Functional Oral Intake Scale (FOIS): FOIS is a 7-point scale that indicates the level of oral intake
a patient is capable at a given time. It can be used to show change over time, and accounts for patients
using a peg tube while maintaining some level of oral intake. Scores ranging 1-3 indicate non-oral
feeding, 4-6 indicate limited oral feeding, and 7 represents a regular oral diet. Reliability and validity has
been established. In the current study the SLP will assess the FOIS level at baseline, weekly, and posttreatment.

c)
Mini Nutritional Assessment Short Form (MNA-SF) tool: The MNA-SF is a validated nutritional
assessment tool, completed in 4 minutes or less, used to establish is a person is well nourished, at risk of
malnutrition, or malnourished . Due to the risk of malnutrition associated with HNC, and the impact
malnutrition has on overall morbidity, nutritional status should be included.

2)

Physiological Measurements:

a)
Penetration Aspiration Scale (PAS): The PAS is a validity and reliability 8-point scale developed
by Rosenbek and colleagues in 1996 to provide an objective grade for penetration and aspiration. It has
been widely used to assess physiology and aspiration risk in the HNC population. Scores of 6-8 indicate
aspiration, 2-5 indicate penetration, and a score of 1 indicated no penetration or aspiration. The
measurement is assigned by the SLP based on the MBSS data for each bolus type administered. High
percentages of aspiration reported in the HNC population makes this an important outcome measure for
swallowing intervention.

b)
Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Hutcheson and colleagues (2017)
developed Digest, a severity scale, designed to use the PAS levels and pharyngeal residue scale to provide
and objective grade of dysphagia severity in HNC. This scale was developed to meet the universal
framework of the National Cancer Institute’s Common Terminology Criteria for Adverse Events
(CTCAE). It is both reliable and valid, and given the potential benefit of including swallowing efficiency,
along with penetration an aspiration scores, it may offer additional insight into swallowing outcomes in
this unique population.

c)
Maximal upper esophageal sphincter (UES) opening: UES function is highlighted by the available
literature as both an organ at risk and one, which if impaired, is predictive of reduced swallowing ability
and potential chronic dysphagia. Measurement can be obtained from MBSS imaging data using
SwallowTail software (Belldev Medical, Arlington Heights, IL). Emerging software applications, such as
SwallowTail, offer quantification of swallowing timing and displacement events observed during the
MBSS. The SLP will measure maximal UES opening pre- and post-radiation to assess the level of change
among treatment groups.
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d)
Maximal pharyngeal constriction: Reduced pharyngeal constriction has been linked to pharyngeal
residue and increased risk of aspiration in the HNC population, as a result of chemoradiation treatment.
Measurement of maximal pharyngeal constriction will be obtained using SwallowTail software. These
measurements will enable the comparison of pharyngeal constriction ability across the study groups.

e)
Maximal hyolaryngeal excursion: Reduced laryngeal excursion is associated with reduced airway
protection and reduced UES opening in the HNC population during and following chemoradiotherapy.
These measurements, obtained using the SwallowTail software, will further enable the comparison of
hyolaryngeal excursion across the study groups.

f)
Maximal isometric tongue palate pressure: Loss of tongue strength is commonly reported in the
HNC literature and has been correlated to reduced swallow efficiency and safety. Maximal tongue
strength can be used to measure the preventative nature of swallowing exercise on this at-risk organ. It
will also allow investigation of visual biofeedback guided strengthening in the HNC population.

g)
Time to airway closure: Airway closure is important for the prevention of aspiration. Delayed
closure of the laryngeal vestibule (airway closure) is associated with increased risk of aspiration in HNC
patients that receive chemoradiotherapy. Aspiration may also result in peg tube placement. The
measurement of time to airway closure, obtained using SwallowTail software, will allow the comparison
of these timing data across study groups.

3)

Quality-of-life:

a)
MD Anderson Dysphagia Inventory (MDADI) scores: Reduced QOL is a common complaint
associated with dysphagia in this population, and understanding how treatment effects QOL is
important. Chen et.al (2001) originally published the MDADI, a reliable and valid measure quantifying
the patient representation of QOL associated with dysphagia specific to the HNC population. QOL is
measured via global score (single question) and composite score comprised of functional, physical, and
emotional subscales scores. The composite score will be used for this study in order to capture a more
holistic view of the patient’s QOL.

b)
Performance Status Scale Head and Neck (PSS H&N) (normalcy of diet and public eating) scores:
We know that patient reported QOL and SLP rated QOL measures do not correlate significantly, and
patients may report more difficulty than is perceived upon physiological examination. To provide a more
complete illustration of patient performance and ability the PSS H&N, a SLP completed QOL scale, will
be included. List, Ritter-Sterr, and Lansky (2006) reported the measure as reliable and valid. It contains
three subscales quantifying areas related to QOL, each scored separately, including normalcy of diet,
eating in public, and understandability of speech. For the purpose of this study, only the scores assessing
normalcy of diet and eating in public will be used, since the study is not designed to treat or evaluate the
patient’s speech or voice.
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4)

Compliance/Adherence measurement:

a)
Percentage of swallowing exercises completed will be obtained by dividing the total completed by
the total prescribed.

Patients will fill out a tracking for all exercise completed, turned in each week to the SLP. Using
percentage of completion will eliminate problems arising from the differing durations of swallowing
treatment protocols. One goal of this study is to examine how visit frequency may increase compliance,
and how differences in compliance may affect swallowing outcomes. The quantification of adherence
allows these questions to be explored.

5)

Toxicity measurements:

a)
Saxon test: Kohler and Winter (1985) described this simple and cost-effective method to assess
salivary output. The measurement of saliva production is an important toxicity factor in the HNC
population due to the high prevalence of xerostomia and the potential negative impact on patient swallow
perception and physiology.

b)
Dische Scale: The Dische scale for grading severity of mucositis has been validated, and serves as a
reliable way to quantify severity. It accounts for the area involved, edema, bleeding, ulceration, diet, and
pain with a score ranging from 0-24, with higher score representing more severity. Measurement of
mucositis is necessary due to the potential negative impact of this toxicity on swallowing and QOL.

c)
Cancer Fatigue Scale (CFS): Okuyama, Akechi, Kugaya, Okamura, Shima, et al. (2000) developed
the CFS, a reliable and valid 15-item scale, containing three subscales (physical, affective, and cognitive
subscales). The three subscale scores combine to provide an overall measure of fatigue, with scores
ranging from 0-60. A score of 0 represents no fatigue, scores 1 or more represent some level of fatigue,
and higher scores represents greater levels of fatigue. This scale will quantify the level of fatigue
experienced during the treatment process, allowing for group comparison.

Data Analysis

Chi square, a nonparametric statistic, will be used to analysis peg use data, which is dichotomous
frequency data scored as either present or absent. For all other statistics, normality of the population
distribution is assumed within all study groups. However, if non-normal distributions occur, new nonparametric statistics will be chosen.
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Analysis of hypothesis 1 (HF vs. LF) will examine overall adherence. Group differences will be
assessed using t-test.

Analysis of hypothesis 2 will be conducted between the VB and the appropriate Phase I group (HF or
LF). Test statistics will include MANOVA.

Analysis of hypothesis 3 will be conducted between the VB and the appropriate Phase I group (HF or
LF). Test statistics will include MANOVA.

5) REGULATORY REQUIREMENTS

Informed Consent

An informed consent will be obtained from each patient recruited prospectively in the study. The coinvestigator who will also be the treating speech pathologist, will ensure completion of this procedure at
the time of initial patient contact.

Subject Confidentiality

Patients’ confidentiality will be fully maintained. Patients’ data, which will be stored on on a passwordprotected computer at Our Lady of the Lake Regional Medical Center-Voice Center (OLOLRMC-VC).
In addition, this sheet will identify patients based on a randomly assigned identification number only. A
separate excel sheet decoding these identification numbers will also be password-protected on the
computer and will not be used for any reason other than to make initial entries.

Patients’ MBSS which are x-ray videos of their swallows will be stored on the OLOLRMC- VC’s server
as is done typically for any outpatient undergoing this test.

Unanticipated Problems

Although this study has no potential for any risks to patients, any unanticipated problems will be
reported to the IRB in written form immediately. Necessary steps will be taken immediately to resolve
problems.
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6) ALTERNATIVE

The alternative to this study is not to participate. In this case patients would be refered to OLOLRMCVC for swallowing evaluation and treatment, using current best practoices, by the primary investigator,
co-investigator, radiation oncologist, or other provider.
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Category 5
Retrospective Chart Review Research Plan
If your research method will only be the re-interpretation of existing data from medical records fill out the
following information.
The next set of questions will serve as the protocol format for your
chart review study. Complete these questions. Print out this page(s)
and submit with your Expedited Study Application.

Location of the records. State the actual hospital, clinic or office address.

1. What is the purpose of the study?

or the research question

Provide supporting background information from prior studies that will support this study.

2. Describe the source of medical records for chart review
3. The time frame of charts will be from
to
). The time period must precede the application date,

m/d/yyyy Give actual dates (1/1/2008 to 6/31/2008

4. Number of medical records to be used
5. How will you have access to the actual medical records/charts?
6. Will an electronic search be performed for you by medical record specialists?
Yes No
7. Who will actually review the charts?
8. What data items will be collected?
9. Will subject’s name, medical record number, pathology # etc. be collected?
No

Yes

10. If after collecting the data and returning the chart or data source to its appropriate location, you need to
collect any additional data or to verify any of the collected data for a subject, will it be possible for you to
identify and access the source data again based solely on information recorded in your data sheet/database?
No YES
If the answer is yes, provide additional details about encryption and confidentiality.
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11. Data Analysis Plan

12. Attach a bibliography or literature review with the application paperwork.

6. Subjects - Identification, Recruitment, Consenting

No direct subject contact

Number of Subjects: 60 Local

0 National/International

Types of subjects: (check all that apply)
Adults

Children

Vulnerable Populations

Healthy Adults

Newborns

Institutionalized Individuals

Adults 18-64

Children (1-5)

Cognitively/Physically Impaired

Adults 65-100

Children (6-12)

LSUHSC-NO Employees-Staff*

Nursing Home Residents

Adolescents (13-17) LSUHSC-NO Students*

Assisted Living Residents

PRISONERS

Home Visit Requested

Residential Home Visits
For studies that require home visits for surveys or data collection see
LSUHSC-NO Chancellor’s Memorandum 16

LSUHSC-NO Employees/Staff/Students
*IRB policy on enrollment of LSUHSC Employees and Students see
IRB Guidebook section 5.6
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PRISONERS For studies conducted under 45CFR46 Subpart C Call the IRB

7. Recruitment
Use check boxes to indicate how subjects will be identified
Indicate all of the method(s) will be used:
Own Patients
Medical Records
Primary Physician Referrals

Patient Databases

Emergency Room

Newspaper/Radio/TV/Media

Out-Patient Clinics

Email

In-Patients

Internet Sites

Dear Colleague Letters
Dear Patient Letters

Registries
Sponsor Managed “800 numbers”

Fliers and Postings within the School, Hospital, Clinics
OTHER explain: Radiation Oncologist referrals

Permission letters from the sites must be provided with the application

8. Informed Consent Process and Documentation
Waiver of Informed Consent is requested
Waiver of Documentation of Informed Consent is requested

For this research, consent will be obtained from:
Adult Subject
Child with Assent and Parent Permission
Immediate Family Member

The following individuals will provide the informed consent discussion.
1. PI and Co-PIs (names) Melda Kunduk, PhD; Mathew B. Vansant M.S, CCC-SLP
2. Individuals other than the investigators who are authorized to conduct the informed consent discussion:
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None
3. If appropriate how will capacity to give consent be determined?NA
4. Describe the specific location(s) where the informed consent discussion will take place. e.g. bedside, waiting
room, conference room at the clinic, school conference room, coffee shop, library, health fair etc.In an exam
room assigned to co-investigators for swallowing therapy at the Mary Bird Perkins Cancer Center or in an exam
room a the Our Lady of the Lake Regional Medical Center-Voice Center.

Informed Consent is documented through a written form. Written Consent Forms must be developed for
adults and Assent Forms for minor participants who are ages 7-13. Older adolescents can be enrolled
with a form using the style of the adult consent form. Parent Permission forms must be developed for use
with the Assents.

To request a waiver of informed consent see section 12
To request a waiver of documentation see section 13
9. Confidentiality and Anonymity Check all that apply
How will research data be recorded ?
Data Entry Sheet

Computer Database

Other_______(specify)

How will data be stored ?
Computer

Locked File Cabinet Locked Office

Other ____(specify)

How will patient confidentiality be protected?
Coding System

Limiting access to data/specimens

Password protected
Other _______

10. After Completion of Data Collection
Will you keep information/data or video/audio tapes NO
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If yes:
Describe why the information and/or specimens will be retained
Patients' MBSS videos will be retained on the Voice Center's database as this is typical of the standard of care
at the Our Lady of the Lake Regional Medical Center-Voice Center. The procedure would be the same for
patients even if they would not be recruited in the proposed study.
Describe how the confidentiality of the retained information and/or
specimens will be maintained (i.e. encryption, codes, etc)
The excel sheet which contains patient names corresponding to patient numbers will be deleted once all data
have been analyzed, and the study has concluded. At that point only the excel sheet containing information with
random patient identification numbers will be retained. There will not be a possible way of decoding these
identification numbers as the decoding-sheet will be deleted from the computer.

Patients' videos of MBSS will remain on the Voice Center's database which can only be accessed by the
investigators and co-investigators in the study.
State how long research records or specimens will be kept and if they are to be retained will they be stripped of
identifiers at some point. Describe your procedure.
When all data has been analyzed, the microsoft excel sheet containing patient identifiers will be deleted from
the co-investigator's password-protected computers.

MBSS videos stored on the Voice Center's database contain only x-ray videos of patients' swallows. Although
these videos are identified by patients' names, date-of-birth, gender and medical record numbers, there will be
no link to these videos and the study once the excel code sheet is deleted. These videos will not be deleted as
this procedure is part of a routine standard of care. Also if patients develop swallowing impairments in the
future, access to their MBSS videos will be highly beneficial in managing patients' problems.

Not including study staff, who has access to research records that identify subjects(including coded data)
Monitors, FDA, NIH ?
None

Will you have access to, or create a link, which would make it possible to identify subjects?
No
Yes
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Waivers
If a waiver of HIPAA authorization (Item 11) and/or Informed Consent (Item 12) is requested, fill out the
explanation following each item as it applies to this project.

11. Waiver of HIPAA Authorization
Request for Waiver of Authorization Under the HIPAA Privacy Rule
Fill in items 1(a,b,c ) 2, and 3
1. The use or disclosure of protected health information involves no more than minimal risk to the individuals.
The method for ensuring this is to be explained in a, b and c.
a) There is an adequate plan to protect the identifiers from improper use and disclosure
Describe the plan
b) There is an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the
research, unless there is a health or research justification for retaining the identifiers, or such retention is
otherwise required by law
Describe the plan
c) There are adequate written assurances that the protected health information will not be reused or disclosed to
any other person or entity, except as required by law, for authorized oversight of the research project, or for
other research for which the use or disclosure of protected health information would be permitted by this
subpart
.
2. The research could not practicably* be conducted without the alteration or waiver
State the rationale .
3. The research could not practicably* be conducted without access to and use of the protected health
information Describe
12. Waiver of Informed Consent
Request for Waiver of Informed Consent Under the Common Rule
1.

The research involves no more than minimal risk to the subjects

Describe
2.

The waiver or alteration will not adversely affect the rights and welfare of the subjects

Describe
3.

The research could not practicably* be carried out without the waiver or alteration

Describe
4. Whenever appropriate, the subjects will be provided with additional pertinent information after
participation
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Clarify if this will be done

*The test of practicability may be met, for example by
The need for a large number of subjects
A presumed or demonstrated inability to contact subjects for whom contact information may not be accurate
The fact that many of the subjects may have died, or
The fact that a lack of data from a few subjects may make the number of subjects available for the study too few
to make the study valid.

13 . Waiver of Documentation of Informed Consent 45CFR46.117(c)
Choose one of the following and provide information relative to the specific procedures in this protocol:
45CFR46117(c)(1) That the only record linking the subject and the research would be the consent document
and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be
asked whether the subject wants documentation linking the subject with the research, and the subject’s wishes
will govern.
Describe potential harms/risks
Or

45CFR46117(c)(2) That the research presents no more than minimal risk of harm to subjects and involves no
procedures for which written consent is normally required outside of the research context.
Describe procedures

In cases in which the documentation requirement is waived, the IRB may require the investigator to
provide subjects with a written statement regarding the research.

The waiver information is also provided as a separate form WAIVERS
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Print and Submit 2 copies of this form and
2copies of the following :
Demographic Form
HIPAA Authorization
Consent Forms
Assents
Protocol
Site Permission Letter

1 Copy
Tools, survey instruments, assessment forms, rater forms, etc.

Item Inventory List in memo form signed by the PI

Submission Date 9/6/2017
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INFORMED CONSENT FORM

STUDY TITLE:

Effects of Pre-treatment, Visit Frequency, and Visual Biofeedback on
Swallowing Function During Organ Preservation for Head and Neck
Cancer

PERFORMANCE SITE (S):

Mary Bird Perkins Cancer Center
&
Our Lady of the Lake Regional Medical Center

PRINCIPAL INVESTIGATOR:

Andrew McWhorter, MC
7777 Hennessy Blvd., Suite 408
Baton Rouge, Louisiana 70808
United States
Phone: 225-765-5335

CO-INVESTIGATORS:

Melda Kunduk, PhD
&
Mathew B. Vansant, M.S., CCC-SLP
&
Lindsey Parker, M.A., CF-SLP
7777 Hennessy Blvd., Suite 408
Baton Rouge, Louisiana 70808
United States
Phone: 225-765-5335

You may take home an unsigned copy of this consent form to think about or discuss with family or friends
before making your decision. This consent form may contain words that are not clear to you. Please ask the coinvestigator to explain any words or information that you do not understand clearly. Once you sign this consent
form, you will be enrolled in this study.
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PURPOSE OF THE STUDY

The purpose of this research study is to determine if performing swallowing exercises during radiation therapy
with or without chemotherapy will result in reduced aspiration (i.e., choking), reduced feeding-tube dependence
and better swallowing-related quality-of-life at the completion of cancer treatment. Cancer treatments may
result in swallowing problems, as side effects, and subsequent feeding-tube dependence is possible. A proactive
approach to swallowing therapy is currently starting to emerge nationwide to offset these undesirable side
effects of cancer treatment modalities. However, there is limited research data to understand specifics of its
benefits and best delivery methods. Since you will be undergoing radiation therapy with or without
chemotherapy for your cancer diagnosis, you are eligible to participate in this study.

DESCRIPTION OF THE STUDY

Length of Study and Number of Participants

Your treatment portion of the study will last no more than 10 weeks, but no less than 6 weeks. Your radiation
treatments typically last about seven weeks. Your length of swallowing treatment in this study will be based on
the swallowing exercises and group differences used in this study. Group differences are designed to determine
to best starting time for treatment, treatment visit frequency, and swallowing exercises. You will be randomly
placed into a study group. After completing the treatment portion of the study you will be asked to answer
swallowing function and quality of life questions at you 3 month, 6 month, and one year follow-up
appointments, when you return for you appointments at the Mary Bird Perkins Cancer Center. You will also be
asked to answer swallowing function and quality of life questions at 24 and 36-months by phone, or in person.
Sixty participants (60) will be enrolled in this study.

Procedures

You are eligible to participate in this study based on your nature of cancer and results of the baseline Modified
Barium Swallow Study.

This study will be completed in three phases. Phase one participants will begin swallowing treatment when
radiation treatment begins and receive either high or low treatment visit frequency with the speech-language
pathologist (30 participants). Phase two participants (15 participants) will begin swallowing therapy when
radiation begins and receive visual biofeedback regarding their swallowing exercise performance. Phase two
visit frequency will be based on the outcome of the phase one group. Phase three (15 participants) will begin
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swallowing treatment two-weeks prior to the start or radiation treatment. The visit frequency and use of visual
biofeedback will be based on the outcomes of the phase one and phase two groups.

Your speech pathologist will give you a swallowing exercise protocol that you will perform 3-7 times per week.
Each group will perform the same exercises, and all exercise are evidence based for the treatment of swallowing
disorders (dysphagia) associated with head and neck cancer during and after radiation treatment. The number of
days per week is dependent on the specific exercise. Your group placement will also determine the following:

Based on you group placement within the study you may:
1. perform exercise with or without visual feedback;
2. see the speech-language pathologist for 3 or 5 treatment visits per week, just before or after your
radiation treatment;
3. begin swallowing exercises when radiation begins of two-weeks prior to beginning radiation treatment.
You will not be required to make an extra visit to the Mary Bird Perkins Cancer Center/Our Lady of the Lake
Regional Medical Center. During each visit with the speech pathologist, you will perform a portion of your
exercises so that he/she can monitor your progress and identify any problems with the performance of the
exercises. He/she will also be able to answer any swallowing-related questions you may have. Any swallowing
problems that may arise during this period will also be identified, so that they can be managed appropriately.

You will be provided with log sheets to record exercises performed, which you complete every day, to return to
the SLP weekly during a swallowing treatment session.

Each week, your weight and diet will be recorded, saliva weight will be recorded, oral health will be assessed,
and the SLP will ask you a series of swallowing function related questions. In addition, you will fill out a
swallowing related quality-of-life questionnaire and fatigue scale.

At the completion of radiation treatment with or without chemotherapy, your radiation oncologist will refer you
for another routine Modified Barium Swallow Study to identify any problems with the structure and function of
swallowing. This Modified Barium Swallow Study will mark the completion of your treatment portion of this
study. Your study-related swallowing therapy will end at this time. However, if you do suffer any swallowing
problems, the speech pathologist will refer you to the Our Lady of the Lake Regional Medical Center Voice
Center for continuation of swallowing therapy.

To assess the long-term effects of swallowing therapy on swallowing function, you will be requested to fill out
a quality-of-life questionnaire and a swallowing status questionnaire when you return to Mary Bird Perkins
Cancer Center for your 3-month, 6-month, and 12-month follow-up appointments. Additionally, the SLP may
obtain your salivary weight and ask an additional series of swallowing related questions. You will also be asked
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to fill out a quality-of-life questionnaire and a swallowing status questionnaire via telephone call or in person at
24 months and 36 months following the end of treatment.

BENEFITS TO SUBJECTS

Performing swallowing exercises during radiation treatments may result in the following benefits:

a) Prevention or reduction in swallowing impairments and subsequent lung complications of aspiration
during and following cancer treatments.
b) Reduction in feeding-tube dependence during and following cancer treatments.
c) Improvement in swallowing-related quality-of-life during and following cancer treatments.
RISKS TO SUBJECTS

There are no known risks of swallowing therapy.

However, when you perform exercises you may run the risk of biting your tongue, straining the neck or feeling
tired.

In addition, filling out the M D Anderson Dysphagia Inventory questionnaire or other study related documents
may upset you by increasing awareness of your swallowing-related limitations. You may be referred for
counseling services if you or your doctor indicate a need.

ALTERNATIVES TO PARTICIPATION IN THE STUDY

The alternative is to not participate in this study. In addition, if you develop swallowing problems during cancer
treatment, you may be referred for speech pathology services, which are available at the Our Lady of the Lake
Regional Medical Center-Voice Center.

SUBJECT REMOVAL

The investigator or co-investigator may stop you from taking part in this study if at any time if it is believed to be
in your best interest; if you do not follow the study procedures; or if the study is stopped. You could be taken off
the study if your health worsens; if another treatment option appears to be appropriate; or for any other cause
which prevents your continuing in the study as per your radiation oncologist.
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SUBJECT’S RIGHT TO REFUSE TO PARTICIPATE OR WITHDRAW

Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to which you are
otherwise entitled, and you may discontinue participation at any time without penalty or loss of benefits to
which you are otherwise entitled. You may refuse to participate or withdraw from the study at any time without
jeopardizing, in any way, your medical treatment at this institution in the present or future. Tell the researcher if
you are thinking about withdrawing from the study so that you may do so safely. If you decide not to continue
participation in the study you should seek medical advice for alternatives. Should significant new findings take
place during the course of the research that may relate to your willingness to continue participation, that
information will be provided to you.

SUBJECT’S RIGHT TO PRIVACY

If the results of the study are published, the privacy of subjects will be protected and they will not be identified
in any way. Your personal information may be disclosed if required by law.

RELEASE OF INFORMATION

Organizations that may inspect and/or copy your study-related medical records for quality assurance and data
analysis include:





Primary investigator and co-investigators listed on page 1 of this consent form and their staff
Staff at Mary Bird Perkins Cancer Center, Baton Rouge
Institutional Review Board at Our Lady of the Lake Regional Medical Center- Voice Center, Baton
Rouge
 Institutional Review Board at Louisiana State University Health Sciences Center, New Orleans
 Institutional Review Board at Louisiana State University, Baton Rouge
While every effort will be made to maintain your privacy, absolute confidentiality cannot be guaranteed. Records
will be kept private to the extent allowed by law.

FINANCIAL INFORMATION

The swallowing therapy is part of the study and there is no charge for this service. The Modified Barium
Swallow Study is not covered by this study, and is considered part of normal care. You may be responsible for
any co-pay or portion of this study not covered by your health insurance or other related coverage you may
have. You will not be paid for your participation in this research study.
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SIGANTURES

The study has been discussed with me and all my questions have been answered. Additional questions regarding
the study should be directed to Mathew B. Vansant at the number listed on page 1 of this consent form. If I have
questions about subject’s rights, or other concerns, I can contact the Chancellor of the LSU Health Sciences
Center New Orleans at (504) 568-4801 and/or Dennis Landin, Institutional Review Board, (225) 578-8692,
irb@lsu.edu, www.lsu.edu/irb. I agree with the terms above, acknowledge I have been given a copy of the consent
form, and agree to participate in this study. I have not waived any of my legal rights by signing this consent form.

_____________________________________

________________________

Signature of Subject

Date

_____________________________________

________________________

Signature of Principal Investigator

Date

_____________________________________

________________________

Consent Administered by

Date

The study subject has indicated to me that the subject is unable to read. I certify that I have read this consent
form to the subject and explained that by completing the signature line above the subject has agreed to take part.

_____________________________________

_________________

Signature of Reader

Date

Signature of Witness

Date
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INSTITUTIONAL REVIEW BOARD
Health Insurance Portability and Accountability Act (HIPAA) Authorization for
Use and Disclosure of Protected Health Information (PHI) for Research
Purposes
Instructions for Investigators
This form must be reviewed and signed by patients participating in research/clinical trials that require a signed
Informed Consent. These documents should be kept together. A copy of this Authorization and the Informed
Consent must be given to the patient and/or his/her representative.)

Title of Research Project

Sponsor Name & Protocol #, if applicable
Principal Investigator
IRB #

I hereby request and authorize the LSUHSC-NO to use and disclose protected health information from the
record(s) of:
Patient’s Name

Patient’s Address
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Patient’s Birth Date

Specifically, I request and authorize any part of my health information relevant to the research project,
identified above and in the Informed Consent document, to be used and/or disclosed to the Principal
Investigator identified above or his/her designee, in connection with the research project.
I specifically authorize the use and disclosure of the following Protected Health Information. Check A or B.
If B is checked, indicate which document(s) (1 – 14) on page two are being requested.
Complete health record(s) from ─ to (enter specific dates or specific events below).

A.

Complete health record(s) may contain all of the documents listed under B (1-14), as well as other notes or documents
relating to my treatment or hospitalization.
OR

B. One or more of the specific documents listed on page two. . Documents should provide a detailed description of the
particular data requested and period of time for which records are requested (from ─ to: defined as specific
dates or specific events).
11/19/2009
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9.

1.

History and Physical Exam

2.

Hospital Inpatient Records

3.

Clinic/Outpatient Records

4.

Consultation

5.

Laboratory Test Results

6.

Radiology Reports

7.

Pathology Reports

8.

Discharge Summary

Reports

Progress Notes

10. Photographs, Videotapes

11. X-Ray Films/Images, Digital or Other Images
12. Diagnosis and Treatment Codes
13. Complete Billing Record

14. Other (specify)
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I understand that copies of the records indicated above will be:
Used by employees of LSUHSC-NO including treatment providers, and/or other members of its
workforce.
Disclosed to government officials or government agencies, study sponsors, study monitors, or others
responsible for oversight of the research project.
Sent to collaborating researchers outside LSUHSC-NO if and to the extent indicated in the attached
Informed Consent document(s).
I understand that by signing this form, I will allow LSUHSC-NO and its researchers to use or disclose my
health information in connection with the attached Informed Consent and for the purpose of the research that is
described in the Informed Consent. For example, the researchers may need the information to verify that I am
eligible to participate in the study, or to monitor the results, including expected or unexpected side effects or
outcomes. Other University and government officials, safety monitors, and study sponsors may need the
information to ensure that the study is conducted properly. Also, I understand that my health information may
be disclosed to insurance companies or others responsible for my medical bills in order to secure payment.
I understand that any privacy rights not specifically mentioned in this Authorization are contained in the Notice
of Privacy Practices that I received or will receive from the Principal Investigator or at the facility that I attend.
I understand that I may revoke this authorization at any time, except to the extent that LSUHSC-NO has already
relied on the authorization, by sending or transmitting of a facsimile, a written notice to the contact person listed
in the attached Informed Consent document(s).
I understand that if my information already has been included in a research database or registry as described in
the attached Informed Consent document(s), LSUHSC-NO considers itself to have relied on it and, therefore,
my information will not be removed from those repositories.
Unless otherwise revoked, I understand that this authorization:
Will not expire or
Will expire upon

Enter date or event

I understand that if I do not sign this form, I will not be able to participate in the above research study or receive
the study-related interventions, but that LSUHSC-NO cannot otherwise condition treatment on my signing this
form.
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While the research study is in progress, my right to access any research records or results that are maintained by
the facility may be suspended until the research study is over. If my access is denied, I understand that it will be
reinstated at the end of the research study.
I understand the information disclosed by this authorization may be subject to re-disclosure by the recipient and
no longer be protected by the Health Insurance Portability and Accountability Act. The LSUHSC facility, its
employees, officers, and physicians are hereby released from any legal responsibility or liability for disclosure
of the above information to the extent indicated and authorized herein.

I understand that this authorization supersedes any contrary information in any other
documents I have signed related to the attached study.

Signature of Patient or Patient’s Legal Representative

Date

Printed Name of Legal Representative (if any)

Representative’s Authority to Act for Patient (e.g., relationship to patient)

Verification of Representative’s Authority
Viewed driver’s license
Viewed Power of Attorney
Viewed other (specify)
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APPENDIX B. SPEECH LANGUAGE PATHOLOGIST (SLP) DATA TRACKING
FORM Study-Related Data
Pre-Tx

T1

S

Week 1

Week 2

Scores
Week 3

Week 4

Week 5

Week 6

Week 7

T2

E

Patient ID #_______________
Variables

T1

C

S

T2

E

C

Functional Variables:
PEG tube use
Functional Oral Intake Scale
(FOIS)
Mini Nutritional Assessment
Short Form (MNA-SF)
Albumin
Pre-Albumin
Physiological Variables:
PAS Scores Trials
10 ml Thin-PAS
Blended-PAS
Dynamic Imaging Grade of
Swallowing Toxicity (DIGEST)
Safety, Efficiency, Composite
Time to Airway Closure
(SwallowTail)
Total Transit Time
(SwallowTail)
Maximal UES opening
(SwallowTail)
Maximal pharyngeal
constriction (SwallowTail)
Maximal hyolaryngeal
excursion (SwallowTail)
Time to airway closure
(SwallowTail)
Pharyngeal Clearance Ratio
(Swallowtail)
Pharyngeal Residue Ration
(Swallowtail)
Maximal isometric tonguepalate pressure
Quality of Life Variables:
MD Anderson Dysphagia
Inventory (MDADI) scores
Normalcy of Diet- (PSS H&N)
Eating in Public- (PSS H&N)
Adherence Variable:
% of swallowing exercises
completed-With SLP
% of swallowing exercises
completed-Home
% of swallowing exercises
completed-Combined
Toxicity Variables:
Salivary weight (Saxon test)
Mucositis scale score (Dische
Scale)
Cancer Fatigue Scale
General Pain Score
Pain with Swallowing Score
Biometric Variables:
Weight
Height
BMI
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Swallowing Management
Timing

Pre-Treatment

Week 2

Week 3

Week 4

Week 5

Week 6

Week 7

Diet
(General Diet; Specific Abilities)
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________
General Diet:(Liquids)_______________________________
(Solids)________________________________
Water ____Coffee ____Tea ____Soda ____
Pudding ____Mashed Potatoes ____Bread ____Rice ____
Meat ____Fried Chicken ____
Supplement:______________________________________

Complaints
(Reason they Can’t Eat)
If Can’t(N), Reason: Choking
Food Stuck
Other:

If Can’t(N), Reason: Choking
Food Stuck
Other:

If Can’t(N), Reason: Choking
Food Stuck
Other:

If Can’t(N), Reason: Choking
Food Stuck
Other:

If Can’t(N), Reason: Choking
Food Stuck
Other:

If Can’t(N), Reason: Choking
Food Stuck
Other:

If Can’t(N), Reason: Choking
Food Stuck
Other:
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Patient ID # _____________
Swallow-Related Recommendations/Changes
(SLP Plan)

MBSS Aspiration and Residue Data
ID#________________
Pre-treatment
Penetrati
on:

5 ML Thin:

Before/Durin
g/After
Before/Durin
g/After
Before/Durin
g/After
Before/Durin
g/After

Cough/Clear
/Silent
Cough/Clear
/Silent
Cough/Clear
/Silent
Cough/Clear
/Silent

Present /
Absent
Present /
Absent
Present /
Absent
Present /
Absent

Before/Duri
ng/After
Before/Duri
ng/After
Before/Duri
ng/After
Before/Duri
ng/After

Cough/Clea
r/Silent
Cough/Clea
r/Silent
Cough/Clea
r/Silent
Cough/Clea
r/Silent

Mixed:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Mixed:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Mechanical:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Mechanical
:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Cracker:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Cracker:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Nectar:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Nectar:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Honey:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Honey:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

5 ML Thin:

Present /
Absent
Present /
Absent

Before/Durin
g/After
Before/Durin
g/After

Cough/Clear
/Silent
Cough/Clear
/Silent

5 ML Thin:

Present /
Absent
Present /
Absent

Before/Duri
ng/After
Before/Duri
ng/After

Cough/Clea
r/Silent
Cough/Clea
r/Silent

20 ML Thin:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

20 ML Thin:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Pudding:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Pudding:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Mixed:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Mixed:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Mechanical:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Mechanical
:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Cracker:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Cracker:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Nectar:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Nectar:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

Honey:

Present /
Absent

Before/Durin
g/After

Cough/Clear
/Silent

Honey:

Present /
Absent

Before/Duri
ng/After

Cough/Clea
r/Silent

20 ML Thin:
Pudding:

10 ML Thin:

Residue:

Post-Treatment

Present /
Absent
Present /
Absent
Present /
Absent
Present /
Absent

10 ML Thin:

Aspiratio
n:

Patient ID #
______________

Present / Absent

Penetra
tion:

10 ML Thin:
20 ML Thin:
Pudding:

Aspirati
on:

10 ML Thin:

Residue
:

Bolus
Type:

Liquids
:
Thin/T
hick

Solids

Locatio
n:

Oral Cavity
Base of Tongue
Posterior Pharyngeal Wall
Vallecular
Pyriform Sinus
Arytenoids

Both
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5 ML Thin:

Present / Absent
Bolus
Type:

Liquids:
Thin/T
hick

Solids

Locatio
n:

Oral Cavity
Base of Tongue
Posterior Pharyngeal Wall
Vallecular
Pyriform Sinus
Arytenoids

Both

SwallowSTRONG Pressure Data
Pre-treatment

Trials
1

Day 1

2

3

4

5

6

7

8

9

Set 1
2
3

Day 2

Set 1
2
3

Maximal Pressure (mean):_______________________
Day 3

ID#_____________

Set 1
2
3
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10

11

12

13

14

15

16

17

18

19

20

APPENDIX C. FUNCTIONAL ORAL INTAKE SCALE (FOIS)
Functional Oral Intake Scale (FOIS)
1 No oral intake
2 Tube dependent with minimal/inconsistent oral intake
3 Tube supplements with consistent oral intake
4 Total oral intake of a single consistency
5 Total oral intake of multiple consistencies requiring special preparation
6 Total oral intake with no special preparation, but must avoid specific foods or liquid items
7 Total oral intake with no restrictions
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APPENDIX D. MINI NUTRITIONAL ASSESSMENT SHORT FORM (MNA-SF)
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APPENDIX E. PENETRATION ASPIRATION SCALE (PAS)
Penetration Aspiration Scale
Condition
NEITHER
PENETRATION

ASPIRATION

Consistency

Score Description
1
Material does not enter airway
2
Material enters airway, but remains above vocal folds;
Ejected from airway; no stasis
3
Material remains above vocal folds; visible stasis remains
4
Material contacts vocal folds, but is ejected; no stasis
5
Material contacts vocal folds, and is not ejected; visible stasis remains
6
Material passes glottis, but is ejected from airway;
No visible subglottic stasis
7
Material passes glottis, but is not ejected from airway; visible
Subglottic stasis despite patient’s response
8
Material passes glottis, and is not ejected; visible subglottic stasis;
Absent patient response

Score Comments

Patient number_________________________________
Date of VFSS_______________
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APPENDIX F. DYNAMIC IMAGING GRADE OF SWALLOWING TOXICITY
(DIGEST)

303

APPENDIX G. MD ANDERSON DYSPHAGIA INVENTORY (MDADI)
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APPENDIX H. PERFORMANCE STATUS SCALE HEAD AND NECK (PSS H&N)
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APPENDIX I. Patient Tracking Form
Patient:
Pharyngeal
Squeeze

Masako Exercise
(Tongue Hold)

Tongue-Palate
Exercise

Shaker (neck)
Exercise

Date: /
Monday
Reps:

/
Tuesday
Reps:

/
Wednesday
Reps:

/
Thursday
Reps:

Sets:

Sets:

Sets:

Reps:

Reps:

Sets:

Friday
Reps:

/
Saturday
Reps:

/
Sunday
Reps:

Sets:

Sets:

Sets:

Sets:

Reps:

Reps:

Reps:

Reps:

Reps:

Sets:

Sets:

Sets:

Sets:

Sets:

Sets:

Reps:

Reps:

Reps:

Reps:

Reps:

Reps:

Reps:

Sets:

Sets:

Sets:

Sets:

Sets:

Sets:

Sets:

Part 1:

Part 1:

Part 1:

Part 1:

Part 1:

Part 1:

Part 1:

Part 2:

Part 2:

Part 2:

Part 2:

Part 2:

Part 2:

Part 2:
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APPENDIX J. SAXON TEST
Saxon Test for Saliva Production
Supplies:
1. 10 cm gauze, folded to a 5x5 cm square
2. Scale for measurement in grams (gm)
Protocol:
1.
2.
3.
4.

Place the dry gauze in a sterile, dry, container and obtain a pre-chewed weight.
Instruct the patient chew the gauze for exactly 2 minutes.
Place the chewed gauze into the same container and obtain a post-chewed weight.
Subtract the pre- and post-chewed weights to obtain the salivary weight.
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APPENDIX K. CANCER FATIGUE SCALE (CFS)
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